[{"Element":"<div class=\"WordSection1\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX I<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <b><span lang=\"EN-GB\" style='font-size:16.0pt;font-family:\"Arial\",sans-serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <h1 style=\"margin:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'>1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/h1> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco 150 mg film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif;color:black'>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each film\u2011coated tablet contains 150 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each film\u2011coated tablet contains 167.2 mg of lactose monohydrate.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL FORM<\/span><\/h1> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Film\u2011coated tablet (tablet)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Light blue, capsule\u2011shaped film\u2011coated tablets, printed with \u201cV 150\u201d in black ink on one side and plain on the other<\/span><span lang=\"EN-GB\"> (16.5 mm x 8.4 mm in modified tablet shape).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif;text-transform:uppercase'>4.       <\/span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CLINICAL PARTICULARS<\/span><\/h1> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Kalydeco tablets are indicated: <\/span><\/p> <p class=\"labeltext\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an <i>R117H CFTR<\/i> mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (<i>CFTR)<\/i> gene: <i>G551D<\/i>, <i>G1244E<\/i>, <i>G1349D<\/i>, <i>G178R<\/i>, <i>G551S<\/i>, <i>S1251N<\/i>, <i>S1255P<\/i>, <i>S549N<\/i> or <i>S549R<\/i> (see sections 4.4 and 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:justify;text-justify: inter-ideograph;line-height:normal;text-autospace:none\"> <\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in; text-autospace:none\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>In a combination regimen with tezacaftor 100 mg\/ivacaftor 150 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the <i>F508del <\/i>mutation or who are heterozygous for the <i>F508del<\/i> mutation and have one of the following mutations in the <i>CFTR<\/i> gene: <i>P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A\u2192G, S945L, S977F, R1070W, D1152H, 2789+5G\u2192A, 3272\u201126A\u2192G, <\/i>and<i> 3849+10kbC\u2192T<\/i>.<\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace: none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-.25in; text-autospace:none\"><a name=\"_Hlk36013910\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>In a combination regimen with ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the <i>F508del<\/i> mutation in the <i>CFTR<\/i> gene or heterozygous for <i>F508del<\/i> in the <i>CFTR<\/i> gene with a minimal function (MF) mutation (see section 5.1).<\/a><\/p> <p class=\"MsoListParagraphCxSpLast\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2     Posology and method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient's genotype is unknown, an accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in the <i>CFTR<\/i> gene (see section 4.1). The phase of the poly\u2011T variant identified with the <i>R117H<\/i> mutation should be determined in accordance with local clinical recommendations.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><a name=\"paragraph00000061\"><\/a><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Adults<\/span><span style=\"font-size:11.0pt\">, adolescents and children aged 6 years and older <\/span><span style=\"font-size:11.0pt\">should be dosed according to Table 1. <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Table 1: Dosing recommendations<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"margin-left:-.25pt;border-collapse:collapse;border:none\" width=\"626\"> <tr style=\"height:16.25pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;padding:   0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\"> <\/span><\/b><\/p> <\/td> <td style=\"width:233.9pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"312\"> <p align=\"center\" class=\"labeltext\" style=\"text-align:center;page-break-after:   avoid\"><b><span style=\"font-size:11.0pt\">Morning<\/span><\/b><\/p> <\/td> <td style=\"width:122.3pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"163\"> <p align=\"center\" class=\"labeltext\" style=\"text-align:center;page-break-after:   avoid\"><b><span style=\"font-size:11.0pt\">Evening<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Ivacaftor as monotherapy<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:16.25pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">6 years and older, \u226525 kg<\/span><\/p> <\/td> <td style=\"width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"312\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <td style=\"width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"163\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Ivacaftor in combination with tezacaftor\/ivacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"312\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One tezacaftor 100 mg\/ivacaftor 150 mg tablet<\/span><\/p> <\/td> <td style=\"width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"163\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"312\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">Two ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablets<\/span><\/p> <\/td> <td style=\"width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"163\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\">The <span style=\"font-size: 11.0pt\">morning and evening dose should be taken approximately 12 hours apart with fat-containing food (see Method of administration).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">Missed dose<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">Patients receiving ivacaftor in a combination regimen should not take more than one dose of either medicine at the same time.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Concomitant use of CYP3A inhibitors<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When co-administered with moderate or strong inhibitors of CYP3A, either as monotherapy or<\/span> in a combination regimen with tezacaftor\/ivacaftor<span lang=\"EN-GB\" style=\"font-size:11.0pt\"> or ivacaftor\/tezacaftor\/elexacaftor<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">, the dose <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">should be reduced (see Table 2 for the recommended dose). Dosing intervals<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> should be <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">modified<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> according to <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">clinical response and tolerability (see sections<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> 4.4 and 4.5).<\/span><\/p> <p class=\"labeltext\"> <\/p> <p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Table 2: Dosing recommendations for concomitant use with moderate or strong CYP3A inhibitors<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <thead> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <\/td> <td style=\"width:215.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:    avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Moderate CYP3A inhibitors<\/span><\/b><\/p> <\/td> <td style=\"width:197.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:    avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Strong CYP3A inhibitors<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td colspan=\"3\" style=\"width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor as   monotherapy<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6 years and   older,<br\/>   \u226525 kg<\/span><\/p> <\/td> <td style=\"width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet   of ivacaftor 150 mg once daily. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet   of ivacaftor 150 mg twice a week, approximately 3 to 4 days apart.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in a   combination regimen with tezacaftor\/ivacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years   and older<\/span><\/p> <\/td> <td style=\"width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Alternate each morning:<\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:20.5pt;text-indent:   -.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">one tablet of tezacaftor 100 mg\/ivacaftor 150 mg   on the first day<\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:20.5pt;text-indent:-.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">one tablet of ivacaftor 150 mg   on the next day<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Continue alternating tablets each day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet   of tezacaftor 100 mg\/ivacaftor 150 mg twice a week, approximately 3   to 4 days apart.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in   a combination regimen with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years   and older<\/span><\/p> <\/td> <td style=\"width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Alternate each morning:   <\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:20.5pt;text-indent:   -.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">two tablets of ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   on the first day <\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:20.5pt;text-indent:-.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">one tablet of ivacaftor 150 mg   on the next day <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Continue alternating tablets each day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Two morning dose   tablets of ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   twice a week, approximately 3 to 4 days apart.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"labeltext\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i>Elderly<\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i> <\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Very limited data are available for elderly patients treated with ivacaftor (administered as monotherapy or in a combination regimen). No dose adjustment specific to this patient population is required (see section 5.2).<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.4 and 5.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltextheading\"><a name=\"_Hlk46222749\"><\/a><a name=\"_Hlk45278269\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/a><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">No dose adjustment is necessary for ivacaftor as monotherapy or in a combination regimen in patients with mild hepatic impairment (Child\u2011Pugh Class A). <\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">For patients with moderate hepatic impairment (Child\u2011Pugh Class B) <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">the dose <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">of ivacaftor as monotherapy <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">should be reduced <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">to 150 mg once daily. <\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">For patients with severe hepatic impairment (Child-Pugh Class C), the dose of ivacaftor as monotherapy should be reduced to 150 mg every other day or less frequently. <\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">For use as an evening dose in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor see Table 3 for dosing regimen<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\"> recommendations<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">. <\/span><\/p> <p class=\"labeltextheading\" style=\"page-break-after:auto\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt;color:black\">Table 3: Recommendations for patients with moderate or severe hepatic impairment <\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:104.54%;border-collapse:collapse;border:none\" width=\"104%\"> <tr> <td style=\"width:13.42%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:49.26%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"49%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Moderate (Child-Pugh Class B)<\/span><\/b><\/p> <\/td> <td style=\"width:37.32%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Severe (Child-Pugh Class C)<\/span><\/b><\/p> <\/td> <\/tr> <\/table> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\" width=\"633\"> <tr> <td colspan=\"3\" style=\"width:474.65pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"633\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor as   monotherapy<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6 years and   older,<br\/>   \u226525 kg<\/span><\/p> <\/td> <td style=\"width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning   tablet of ivacaftor 150 mg once daily. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use is not   recommended unless the benefits are expected to outweigh the risks. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">In such cases,   take one morning tablet of ivacaftor 150 mg every other day or less   frequently. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dosing interval   should be modified according to clinical response and tolerability. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:474.65pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"633\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in a combination regimen with   tezacaftor\/ivacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet of tezacaftor 100 mg\/ivacaftor 150 mg   once daily.<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use is not recommended unless the benefits are   expected to outweigh the risks. <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">In such cases, take one morning tablet of tezacaftor 100 mg\/ivacaftor 150 mg   once daily or less frequently. <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dosing interval should be modified according to   clinical response and tolerability. <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:474.65pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"633\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in   a combination regimen with ivacaftor\/tezacaftor\/elexacaftor <\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years   and older<\/span><\/p> <\/td> <td style=\"width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use not   recommended.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use should only   be considered when there is a clear medical need and the benefits are   expected to outweigh the risks.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">If used:   alternate each day between two   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablets and one   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablet.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Should not be   used.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No morning   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg dose.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and efficacy of ivacaftor monotherapy in children aged less than 4 months have not been established. No data are available.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">An appropriate dose for children under 6 years of age and weighing less than 25 kg cannot be achieved with ivacaftor tablets.<\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Limited data are available in patients less than 6 years of age with an <i>R117H <\/i>mutation in the <i>CFTR <\/i>gene. Available data in patients aged <\/span><span style=\"font-size:11.0pt\">6 years<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> and older are described in sections 4.8, 5.1, and 5.2.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The safety and efficacy of ivacaftor in a combination regimen with tezacaftor\/ivacaftor and ivacaftor\/tezacaftor\/elexacaftor in children aged less than 12 years have not been established. No data are available.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">For oral use. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be instructed to swallow the tablets whole. The tablets should not be chewed, crushed, or broken before swallowing because there are no clinical data currently available to support other methods of administration.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Ivacaftor tablets should be taken with fat\u2011containing food.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Food or drink containing grapefruit should be avoided during treatment (see section 4.5).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.3       Contraindications<\/span><\/h2> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.4       Special warnings and precautions for use<\/span><\/h2> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Only patients with CF who had a <i>G551D<\/i>, <i>G1244E<\/i>, <i>G1349D<\/i>, <i>G178R<\/i>, <i>G551S<\/i>, <i>S1251N<\/i>, <i>S1255P<\/i>, <i>S549N<\/i>, <i>S549R<\/i> gating (class III), <i>G970R<\/i> <\/span>or <i>R117H <\/i><span lang=\"EN-GB\">mutation in at least one allele of the <i>CFTR<\/i> gene were included in studies 1, 2, 5 and 6 (see section 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\">In study 5, four patients with the <i>G970R<\/i> mutation were included. In three of four patients the change in the sweat chloride test was &lt; 5 mmol\/L and this group did not demonstrate a clinically relevant improvement in FEV<sub>1<\/sub> after 8 weeks of treatment. Clinical efficacy in patients with the <i>G970R<\/i> mutation of the <i>CFTR<\/i> gene could not be established (see section 5.1).<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\">Efficacy results from a phase 2 study in patients with CF who are homozygous for the <i>F508del <\/i>mutation in the <i>CFTR<\/i> gene showed no statistically significant difference in FEV<sub>1<\/sub> over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Less evidence of a positive effect of ivacaftor has been shown for patients with an <i>R117H\u20117T<\/i> mutation associated with less severe disease in study 6 (see section 5.1). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span style=\"text-decoration:  none\"> <\/span><\/u><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">Ivacaftor in a combination regimen with tezacaftor\/ivacaftor should not be prescribed in patients with CF <\/span><span style=\"font-size:11.0pt\">who are heterozygous for the <i>F508del<\/i> mutation and have a second <i>CFTR<\/i> mutation not listed in section 4.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span style=\"text-decoration:  none\"> <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Effect on liver function tests<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor as monotherapy and in combination regimens with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3 months during the first year of treatment and annually thereafter. For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. In the event of significant elevations of transaminases (e.g., patients with ALT or AST &gt; 5 x the upper limit of normal (ULN), or ALT or AST &gt; 3 x ULN with bilirubin &gt; 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><a name=\"_Hlk45278421\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Use of ivacaftor, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor, is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks. Patients with severe hepatic impairment should not be treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor. (See Table 3 and sections 4.2 and 5.2). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For patients with moderate hepatic impairment, use of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor is not recommended. Treatment should only be considered when there is a clear medical need and the benefits are expected to outweigh the risks. If used, it should be used with caution at a reduced dose (see Table 3 and sections 4.2 and 5.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Caution is recommended while using ivacaftor, <\/span><span style=\"font-size:11.0pt\">either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor,<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> in patients with severe renal impairment or end\u2011stage renal disease (see sections 4.2 and 5.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients after organ transplantation<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Rash events <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The incidence of rash events with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor was higher in females than in males<\/span>, particularly in females taking hormonal contraceptives<span lang=\"EN-GB\">. A role for hormonal contraceptives in the occurrence of rash cannot be excluded. For patients taking hormonal contraceptives who develop rash, interrupting treatment with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor and hormonal contraceptives should be considered. Following the resolution of rash, it should be considered if resuming ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor without hormonal contraceptives is appropriate. If rash does not recur, resumption of hormonal contraceptives can be considered (see section 4.8).<i> <\/i><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Interactions with medicinal products<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">CYP3A inducers<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Exposure to ivacaftor is significantly decreased and exposures to elexacaftor and tezacaftor are expected to decrease by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, co-administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) with strong CYP3A inducers is not recommended (see section 4.5). <\/span><\/p> <p class=\"labeltext\"> <\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inhibitors<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Exposure to ivacaftor, tezacaftor and elexacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see Table 2 and sections 4.2 and 4.5).<\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cases of non\u2011congenital lens opacities\/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor and ivacaftor-containing regimens. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow\u2011up ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment<\/span><span lang=\"EN-GB\">, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor (see section 5.3).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Lactose content<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose\u2011galactose malabsorption should not take this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium content<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Interaction with other medicinal products and other forms of interaction<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P\u2011gp and a potential inhibitor of CYP2C9. <i>In vitro<\/i> studies showed that ivacaftor is not a substrate for P\u2011gp. <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Medicinal products affecting the pharmacokinetics of ivacaftor, tezacaftor and\/or elexacaftor<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inducers<\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Co\u2011administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ivacaftor<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> or ivacaftor\/tezacaftor\/elexacaftor<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">)<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> with strong <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John\u2019s wort (<i>Hypericum perforatum<\/i>), is not recommended (see section 4.4).<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustment is recommended when ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is used with moderate or weak CYP3A inducers. <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inhibitors<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is recommended for co\u2011administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).<\/span><\/p> <p class=\"labeltext\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).<\/span><\/p> <p class=\"labeltext\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, see section 4.2).<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Potential for ivacaftor to interact with transporters<\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in vitro<\/i>. Due to its high intrinsic permeability and low likelihood of being excreted intact, co-administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1\u2011IVA, while any potential changes in M6\u2011IVA exposures are not expected to be clinically relevant. <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ciprofloxacin<\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is co\u2011administered with ciprofloxacin.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Medicinal products affected by ivacaftor, tezacaftor and\/or elexacaftor<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and\/or P\u2011gp, and\/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">CYP2C9 substrates<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during co\u2011administration of warfarin with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Digoxin and other P\u2011gp substrates<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with digoxin, a sensitive P\u2011gp substrate, increased digoxin exposure by 1.3\u2011fold, consistent with weak inhibition of P\u2011gp by ivacaftor. Administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) may increase systemic exposure of medicinal products that are sensitive substrates of P\u2011gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly<\/span><span style=\"font-size:11.0pt\"> with<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> digoxin or other substrates of P\u2011gp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A substrates <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5\u2011fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co\u2011administered with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hormonal contraceptives<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) has been studied with an oestrogen\/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral contraceptives is necessary.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p> <p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">Interaction studies have only been performed in adults.<\/span><\/p> <p style=\"margin:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6    Fertility, pregnancy and lactation<\/span><\/b><\/p> <p style=\"margin:0in;page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"margin-left:28.1pt;text-indent:-28.1pt;page-break-after: avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pregnancy<\/span><\/u><\/p> <p class=\"labeltext\" style=\"margin-left:28.1pt;text-indent:-28.1pt;page-break-after: avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:  none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women. Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of ivacaftor during pregnancy.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">It is unknown whether ivacaftor and\/or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of ivacaftor into the milk of lactating female rats. As such, a risk to the newborns\/infants cannot be excluded. A decision must be made whether to discontinue breast\u2011feeding or to discontinue\/abstain from ivacaftor therapy taking into account the benefit of breast\u2011feeding for the child and the benefit of therapy for the woman.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3).<\/span><\/p> <p style=\"margin:0in\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore,<\/span><span lang=\"EN-GB\"> patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8     <a name=\"_Hlk36070162\">Undesirable effects<\/a><\/span><\/b><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Summary of the safety profile<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">The most common adverse reactions experienced by patients aged 6 years and older who received ivacaftor are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">dizziness (9.2%), <\/span><span style=\"font-size:11.0pt\">rash (12.8%<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">) and <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bacteria<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span style=\"font-size:11.0pt\">in <\/span><span style=\"font-size:11.0pt\">sputum (12.8%).<\/span><span style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Transaminase elevations occurred in 12.8% of ivacaftor-treated patients versus 11.5% of placebo\u2011treated patients.<\/span><\/p> <p class=\"labeltext\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).<\/span><\/p> <p class=\"labeltext\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).<\/span><\/p> <p class=\"labeltext\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><a name=\"_Hlk45279317\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Tabulated list of adverse reactions<\/span><\/u><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Table 4 reflects the adverse reactions observed with ivacaftor monotherapy in clinical trials (placebo-controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. Additional adverse reactions observed with ivacaftor in a combination regimen with tezacaftor\/ivacaftor and\/or in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor are also provided in Table 4. The frequency of adverse reactions is defined as follows: very common (\u2265 1\/10); common (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare (&lt; 1\/10,000); not known (cannot be estimated from the available data). <span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.3pt;text-indent:-40.3pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 4: Adverse reactions in patients treated with ivacaftor monotherapy and\/or in a combination regimen<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.18%;margin-left:-.25pt;border-collapse:collapse;border:none\" width=\"99%\"> <thead> <tr style=\"page-break-inside:avoid;height:15.5pt\"> <td style=\"width:34.06%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">System organ class<\/span><\/b><\/p> <\/td> <td style=\"width:35.94%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"35%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Adverse reactions<\/span><\/b><\/p> <\/td> <td style=\"width:30.0%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"4\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Infections and infestations<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Upper respiratory tract infection<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nasopharyngitis<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Influenza <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rhinitis<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hypoglycaemia <\/span><sup><span lang=\"EN-GB\" style='font-family:   \"Arial\",sans-serif'>\u2020<\/span><\/sup><span lang=\"EN-GB\"> <\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"2\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Nervous system disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Headache<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Dizziness<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"6\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ear and labyrinth disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ear pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear discomfort<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tinnitus<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tympanic membrane   hyperaemia<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vestibular   disorder<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear congestion<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"7\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Oropharyngeal pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nasal   congestion<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Abnormal   breathing <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rhinorrhoea <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Sinus   congestion<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharyngeal   erythema<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Wheezing <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"5\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Abdominal pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Abdominal pain   upper <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Flatulence <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nausea <sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"3\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DA\">Hepatobiliary disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Transaminase elevations<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Alanine aminotransferase increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Aspartate aminotransferase increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"3\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Rash<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Acne <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pruritus <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"5\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Breast mass<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Breast   inflammation<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gynaecomastia<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple   disorder<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"3\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Investigations<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Bacteria in sputum<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Blood creatine phosphokinase increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Blood pressure increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">uncommon <\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with tezacaftor\/ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style='font-size:9.0pt; font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Transaminase elevations <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">During the 48-week placebo\u2011controlled studies 1 and 2 of ivacaftor as monotherapy in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5 or &gt; 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor\u2011treated patients and 1.0%, 1.9% and 8.7% in placebo\u2011treated patients, respectively. Two patients, one on placebo and one on ivacaftor permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN. No ivacaftor\u2011treated patients experienced a transaminase elevation &gt; 3 x ULN associated with elevated total bilirubin &gt; 1.5 x ULN. In ivacaftor\u2011treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations &gt; 5 x ULN. In all instances where dosing was interrupted for elevated transaminases<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor\/ivacaftor, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor\/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor\/ivacaftor experienced a transaminase elevation &gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">During the 24-week, placebo-controlled, phase 3 study of ivacaftor\/tezacaftor\/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor\/tezacaftor\/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor treated patients and 4.0% in placebo-treated patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Rash events<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Rash events, generally mild to moderate in severity, have been observed with the use of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor and occurred more frequently in female-treated patients (16.3%) and in those taking hormonal contraceptives (20.5%). See section 4.4.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Increased creatine phosphokinase <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Generally transient and asymptomatic increases in <\/span><span lang=\"EN-CA\">creatine phosphokinase were observed in patients treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor, which did not lead to treatment discontinuation.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Increased blood pressure<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">An increase from baseline in mean systolic and diastolic blood pressure of 3.5 mmHg and 1.9 mmHg, respectively was observed in patients treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The safety data of ivacaftor as monotherapy were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, <\/span><span lang=\"EN-GB\">19 patients between 12 months to less than 24 months of age, <\/span><span lang=\"EN-GB\">34 patients between 2 to less than 6 years of age,<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety profile of ivacaftor (as monotherapy or in a combination regimen) is generally consistent among paediatric patients and is also consistent with adult patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients <\/span><span lang=\"EN-GB\">aged 6 to less than <\/span><span lang=\"EN-GB\">24 months) are described in Table 5. In the placebo controlled studies<\/span><span lang=\"EN-GB\">, the incidence of transaminase elevations <\/span><span lang=\"EN-GB\">were similar between treatment with ivacaftor (15.0%)<\/span><span lang=\"EN-GB\"> and <\/span><span lang=\"EN-GB\">placebo (14.6%). Across all populations, <\/span>peak LFT elevations <span lang=\"EN-GB\">returned to baseline levels following interruption, and <\/span>in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully <span lang=\"EN-GB\">(see section 4.4). <\/span>Cases suggestive of positive rechallenge were observed<span lang=\"EN-GB\">. In study 7 <\/span><span lang=\"EN-GB\">ivacaftor was permanently discontinued in one patient. <\/span><span lang=\"EN-GB\">In study 8 <\/span><span lang=\"EN-GB\">no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).<\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:12.0pt\"><b><span lang=\"EN-GB\">Table 5: Transaminase elevations in patients 4 months to &lt; 12 years treated with ivacaftor as monotherapy<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"margin-left:6.85pt;border-collapse:collapse;border:none\"> <tr style=\"height:28.95pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">n<\/span><\/b><\/p> <\/td> <td style=\"width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 3 x ULN <\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt;5 x ULN<\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 8 x ULN<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.0%   (6)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2 to &lt;6 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 to &lt;24 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.8%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">9.1%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4 to &lt;6 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:  none\"> <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style=\"background: lightgrey\">the national reporting system listed in <\/span><\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span lang=\"EN-GB\" style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.9       Overdose<\/span><\/h2> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>5.       PHARMACOLOGICAL PROPERTIES<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.5pt;text-indent:-28.5pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Pharmacodynamic properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Other respiratory system products, ATC code: <\/span><span lang=\"EN-GB\">R07AX02<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is a potentiator of the CFTR protein, i.e., <i>in vitro<\/i> ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channel\u2011open probability compared to normal CFTR. Ivacaftor also potentiated the channel\u2011open probability of R117H\u2011CFTR, which has both low channel\u2011open probability (gating) and reduced channel current amplitude (conductance). The <i>G970R <\/i>mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to <i>in vivo <\/i>pharmacodynamic response (e.g., sweat chloride) or clinical benefit. <\/span><span lang=\"EN-GB\">The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacodynamic effects<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor as monotherapy<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In studies 1 and 2 in patients with the <i>G551D <\/i>mutation in one allele of the <i>CFTR<\/i> gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was \u201148 mmol\/L [95% CI \u201151, \u201145] and \u201154 mmol\/L [95% CI \u201162, \u201147], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.<\/span><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In study 5, part 1 in patients who had a non\u2011<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of \u201149 mmol\/L (95% CI \u201157, \u201141) through 8 weeks of treatment. However, in patients with the <i>G970R<\/i>\u2011<i>CFTR<\/i> mutation, the mean (SD) absolute change in sweat chloride at week 8 was \u20116.25 (6.55) mmol\/L. Similar results to part 1 were seen in part 2 of the study. <\/span><span style=\"font-size:11.0pt\">At the 4\u2011week follow\u2011up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre\u2011treatment levels.<\/span><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In study 6 in patients aged 6 years or older with CF who had an <i>R117H<\/i> mutation in the <i>CFTR<\/i> gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was \u201124 mmol\/L (95% CI \u201128, \u201120). In subgroup analyses by age, the treatment difference was -21.87 mmol\/L (95% CI: -26.46, -17.28) in patients aged 18 years or older, and -27.63 mmol\/L (95% CI: -37.16, -18.10) in patients aged 6-11 years. <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Two patients 12 to 17<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">years of age were enrolled in this study.<\/span><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Ivacaftor in a combination regimen with tezacaftor\/ivacaftor<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"><br\/> <\/span><\/i><span lang=\"EN-GB\">In patients homozygous for the <i>F508del <\/i>mutation, the treatment difference between ivacaftor in combination with tezacaftor\/ivacaftor and placebo in mean absolute change from baseline in sweat chloride through week 24, was \u201110.1 mmol\/L (95% CI: \u201111.4, \u20118.8<span style=\"color:black\">).<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients heterozygous for the <i>F508del <\/i>mutation and a second mutation associated with residual CFTR<i> <\/i>activity, the treatment difference in mean absolute change from baseline in sweat chloride through week 8 was \u20119.5 mmol\/L (95% CI: \u201111.7, \u20117.3) between tezacaftor\/ivacaftor and placebo, and \u20114.5 mmol\/L (95% CI: \u20116.7, \u20112.3) between ivacaftor and placebo.<\/span><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">In patients with an <i>F508del<\/i> mutation on one allele and a mutation on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor\/ivacaftor, the treatment difference between ivacaftor\/tezacaftor\/elexacaftor and placebo for mean absolute change in sweat chloride from baseline through week 24 was \u201141.8 mmol\/L (95% CI: -44.4, -39.3).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In patients homozygous for the <i>F508del <\/i>mutation, the treatment difference between ivacaftor\/tezacaftor\/elexacaftor and tezacaftor\/ivacaftor for mean absolute change in sweat chloride from baseline at week 4 was \u201145.1 mmol\/L (95% CI: -50.1, -40.1).<\/span><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Clinical efficacy and safety<\/span><\/u><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor as monotherapy<\/span><\/i><\/p> <p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Study 1 and 2: studies in patients with CF with G551D gating mutations<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p> <p class=\"labeltext\" style=\"margin-right:-1.85pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The efficacy of ivacaftor has been evaluated in two phase 3 randomised, double\u2011blind, placebo\u2011controlled, multi\u2011centre studies of clinically stable patients with CF who had the <i>G551D<\/i> mutation in the <i>CFTR<\/i> gene on at least 1 allele and had FEV<sub>1<\/sub> \u2265 40% predicted.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the <i>F508del<\/i> mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol\/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV<sub>1<\/sub> was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the <i>F508del<\/i> mutation in the second allele. At baseline, mean predicted FEV<sub>1<\/sub> was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV<sub>1<\/sub> less than 70% predicted at baseline.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV<sub>1<\/sub> through 24 weeks of treatment.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV<sub>1<\/sub> (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV<sub>1<\/sub> were rapid in onset (day 15) and durable through 48 weeks.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients with baseline predicted FEV<sub>1 <\/sub>greater than 90% in study 2 was 6.9 percentage points (\u20113.8, 17.6).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The results for clinically relevant secondary endpoints are shown in Table 6.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 6: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2<\/span><\/b><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.82%;margin-left:5.45pt;border-collapse:collapse\" width=\"98%\"> <thead> <tr style=\"height:10.5pt\"> <td rowspan=\"2\" style=\"width:27.12%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"bottom\" width=\"27%\"> <p class=\"MsoNormal\" style=\"margin-left:55.0pt;line-height:normal;page-break-after:    avoid\"><b><span lang=\"EN-GB\">Endpoint<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:34.82%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"34%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:38.06%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"38%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:28.25pt\"> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:14.64%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:17.88%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in CFQ-R<\/span><\/b><sup><span lang=\"EN-GB\">b<\/span><\/sup><b><span lang=\"EN-GB\"> respiratory domain score   (points)<\/span><\/b><sup><span lang=\"EN-GB\">c<\/span><\/sup><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(4.7, 11.4)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">6.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.4, 13.5)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1092<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.6<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(5.3, 11.9)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">5.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.6, 11.8)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1354<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Relative risk of pulmonary exacerbation<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.40<\/span><sup><span lang=\"EN-GB\">d<\/span><\/sup><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0016<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.46<sup>d<\/sup><\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0012<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in body weight (kg)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.8, 3.7)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.9, 2.9)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0004<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.7<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.1)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.2)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0002<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in BMI (kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.94<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.62, 1.26)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.81<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.34, 1.28)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0008<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.93<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.48, 1.38)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.09<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.51, 1.67)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0003<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.05pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean change from baseline in z\u2011scores<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2011for\u2011age   z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.04, 0.62)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0260<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.39<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.24, 0.53)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">BMI\u2011for\u2011age z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.002, 0.65)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0490<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.45<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.26, 0.65)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"tablefootnote\" style=\"margin-top:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">CI: confidence interval; NA: not analysed due to low incidence of events<\/span><\/p> <p class=\"tablefootnote\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment difference = effect of ivacaftor \u2013 effect of placebo<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     CFQ\u2011R: Cystic Fibrosis Questionnaire\u2011Revised is a disease\u2011specific, health\u2011related quality\u2011of\u2011life measure for CF.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">c<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Study 1 data were pooled from CFQ\u2011R for adults\/adolescents and CFQ\u2011R for children 12 to 13 years of age; Study 2 data were obtained from CFQ\u2011R for children 6 to 11 years of age.<\/span><\/p> <p align=\"left\" class=\"tabletextcenterjustified\" style=\"margin-top:0in;margin-right: 0in;margin-bottom:0in;margin-left:.2in;text-align:left;text-indent:-.2in; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">d<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Hazard ratio for time to first pulmonary exacerbation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">e<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     In subjects under 20 years of age (CDC growth charts)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Study 5: study in patients with CF with non\u2011G551D gating mutations<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 5 was a phase 3, two\u2011part, randomised, double\u2011blind, placebo\u2011controlled, crossover study (part 1) followed by a 16\u2011week open\u2011label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a <i>G970R<\/i> or non\u2011<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene (<i>G178R<\/i>, <i>S549N<\/i>, <i>S549R<\/i>, <i>G551S<\/i>, <i>G1244E<\/i>, <i>S1251N<\/i>, <i>S1255P<\/i> or <i>G1349D<\/i>).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat\u2011containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4\u2011 to 8\u2011week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to part 1 placebo\/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor\/placebo treatment sequence.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Thirty\u2011nine patients (mean age 23 years) with baseline FEV<sub>1<\/sub><\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">\u2265 40% predicted (mean FEV<sub>1<\/sub> 78% predicted [range: 43% to 119%]) were enrolled. Sixty\u2011two percent (24\/39) of them carried the <i>F508del<\/i>\u2011<i>CFTR<\/i> mutation in the second allele. <\/span><span style=\"font-size:11.0pt\">A total of 36 patients continued into part 2 (18 per treatment sequence).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 1 of study 5, the mean FEV<sub>1<\/sub> percent predicted at baseline in placebo\u2011treated patients was 79.3% while in ivacaftor\u2011treated patients this value was 76.4%. The mean overall post\u2011baseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week<\/span><span lang=\"EN-GB\"> 8 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 7.5% in the ivacaftor period and \u20113.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P &lt; 0.0001).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQ\u2011R through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV<sub>1<\/sub> at week 8) is shown in Table 7. Based on clinical (percent predicted FEV<sub>1<\/sub>) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the <i>G970R<\/i> mutation could not be established.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 7: Effect of ivacaftor for efficacy variables in the overall population and for specific <i>CFTR<\/i> mutations<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.84%;margin-left:5.35pt;border-collapse:collapse;border:none\" width=\"98%\"> <tr> <td colspan=\"2\" style=\"width:32.6%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change in percent   predicted FEV<sub>1<\/sub><\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:33.66%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">BMI<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <td style=\"width:33.66%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">CFQ-R respiratory domain score   (points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:32.6%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Through week<\/span><\/b><span lang=\"EN-GB\"> <\/span><b><span lang=\"EN-GB\">8<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:33.66%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">At week<\/span><\/b><span lang=\"EN-GB\"> <\/span><b><span lang=\"EN-GB\">8<\/span><\/b><\/p> <\/td> <td style=\"width:33.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Through week<\/span><\/b><span lang=\"EN-GB\"> <\/span><b><span lang=\"EN-GB\">8<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"5\" style=\"width:99.92%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"99%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><span lang=\"EN-GB\">All patients (N = 39)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (95% CI) change   from baseline ivacaftor vs placebo\u2011treated patients:<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:32.6%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">10.7 (7.3, 14.1)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:33.66%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.66 (0.34, 0.99)<\/span><\/p> <\/td> <td style=\"width:33.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">9.6 (4.5, 14.7)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"5\" style=\"width:99.92%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"99%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><b><span lang=\"EN-GB\">Patients grouped under mutation   types (n)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (minimum, maximum) change from baseline for   ivacaftor\u2011treated patients at week 8<sup>*<\/sup>:<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td rowspan=\"2\" style=\"width:16.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"16%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Mutation (n)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Absolute   change in sweat chloride (mmol\/L)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Absolute   change in percent predicted FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"2\" style=\"width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">At week<\/span><\/b><span lang=\"EN-GB\"> <b>8<\/b><\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">At week<\/span><\/b><span lang=\"EN-GB\"> <b>8<\/b><\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.4pt\"> <td style=\"width:16.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"16%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><i><span lang=\"PT\">G1244E<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G1349D<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G178R<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G551S<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G970R<sup>#<\/sup><\/span><\/i><sup><span lang=\"PT\"> <\/span><\/sup><span lang=\"PT\">(4)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"EN-GB\">S1251N <\/span><\/i><span lang=\"EN-GB\">(8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"EN-GB\">S1255P<\/span><\/i><span lang=\"EN-GB\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"EN-GB\">S549N<\/span><\/i><span lang=\"EN-GB\">   (6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">S549R<\/span><\/i><span lang=\"EN-GB\"> (4)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span style='font-family:\"MS Mincho\"'>\u2011<\/span><span lang=\"EN-GB\">55 (-75, -34)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-80 (-82, -79)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-53 (-65, -35)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-68<sup><span style=\"position:relative;   top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-6 (-16, -2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-54 (-84, -7)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-78 (-82, -74)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-74 (-93, -53)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-61<sup><span style=\"position:relative;   top:-3.0pt\">\u2020\u2020<\/span><\/sup> (-71, -54)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">20 (3, 36)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">3<sup><span style=\"position:relative;   top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">3 (-1, 5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">9 (-20, 21)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">3 (-1, 8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">11 (-2, 20)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">5 (-3, 13)<\/span><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"112\"><\/td> <td style=\"border:none\" width=\"116\"><\/td> <td style=\"border:none\" width=\"177\"><\/td> <td style=\"border:none\" width=\"58\"><\/td> <td style=\"border:none\" width=\"235\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Statistical testing was not performed due to small numbers for individual mutations.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Reflects results from the one patient with the <i>G551S<\/i> mutation with data at the 8\u2011week time point.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">    n = 3 for the analysis of absolute change in sweat chloride.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">#<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> following 16 weeks (patients randomised to the ivacaftor\/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the follow\u2011up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1 <\/sub>from<sub> <\/sub>part 2 week 16 was \u20115.9% (9.4%). For patients randomised to the placebo\/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV<sub>1<\/sub> after the additional 16 weeks of treatment with ivacaftor. At the follow up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> from part 2 week 16 was \u20117.4% (5.5%).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study 3: study in patients with CF with the F508del mutation in the CFTR gene<\/span><\/u><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 3 (part A) was a 16\u2011week, 4:1 randomised, double\u2011blind, placebo\u2011controlled, parallel\u2011group phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the <i>F508del<\/i> mutation in the <i>CFTR<\/i> gene and who had FEV<sub>1<\/sub> \u2265 40% predicted.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The mean absolute change from baseline through week 16 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and \u20110.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI \u20110.6, 4.1); this difference was not statistically significant (P = 0.15).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Study 4: open\u2011label extension study<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">In study 4 patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo\/ivacaftor group and at least 144 weeks for patients in the ivacaftor\/ivacaftor group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One hundred and forty\u2011four (144) patients from study 1 were rolled over in study 4, 67 in the placebo\/ivacaftor group and 77 in the ivacaftor\/ivacaftor group. Forty\u2011eight (48) patients from study 2 were rolled over in study 4, 22 in the placebo\/ivacaftor group and 26 in the ivacaftor\/ivacaftor group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Table 8 shows the results of the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> for both groups of patients. For patients in the placebo\/ivacaftor group baseline percent predicted FEV<sub>1<\/sub> is that of study 4 while for patients in the ivacaftor\/ivacaftor group the baseline value is that of studies 1 and 2.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Table 8: Effect of ivacaftor on percent predicted FEV<\/span><\/b><sub>1<\/sub><b><span style=\"font-size:11.0pt\"> in study 4<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:.05in;border-collapse:collapse;border:none\"> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Original study and treatment group<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration of ivacaftor treatment (weeks)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:46.44%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"46%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change from baseline in   percent predicted FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">N<\/span><\/b><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean (SD)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">77<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (8.3)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">72<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (10.8)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">67<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20111.2 (7.8)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">55<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.5 (11.2)<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">26<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.2 (15.7)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">25<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.3 (12.4)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">22<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20110.6 (10.1)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">21<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.5 (11.5)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment occurred during blinded, controlled, 48\u2011week phase 3 study.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt; position:relative;top:-3.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size: 9.0pt;position:relative;top:-3.0pt\">     <\/span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Change from prior study baseline after 48 weeks of placebo treatment.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> is compared from study 4 baseline for patients in the ivacaftor\/ivacaftor group (n = 72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> was 0.0% (9.05), while for patients in the ivacaftor\/ivacaftor group (n = 25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor\/ivacaftor group maintained the improvement seen at week<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48 of the initial study (day<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">0 through week 48) in percent predicted FEV<sub>1<\/sub> through week 144. There were no additional improvements in study 4 (week 48 through week 144).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients in the placebo\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events\/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events\/year across day<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1 to week<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48, and 0.67 events\/year across weeks<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48 to 96). For patients in the ivacaftor\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events\/year across day 1 to week 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events\/year across day<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1 to week<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48 and 0.77 events\/year across weeks 48 to 96.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients who rolled over from study 2 the number of events was, overall, low.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u>Study 6: study in patients with CF with an R117H mutation in the CFTR gene<\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span style=\"text-decoration:none\"> <\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the <i>F508del<\/i> mutation in the second allele. The confirmed <i>R117H <\/i>poly\u2011T variant was <i>5T <\/i>in 38 patients<i> <\/i>and <i>7T <\/i>in 16 patients. At baseline, mean predicted FEV<sub>1<\/sub> was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI \u20111.1, 5.4).<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">A pre\u2011planned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV<sub>1<\/sub> through week 24 of 4.5 percentage points in the ivacaftor group versus \u20110.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">In a subgroup analysis in patients with a confirmed <i>R117H\u20115T <\/i>genetic variant, the difference in the mean absolute change from baseline through week<span lang=\"EN-GB\"> <\/span>24 in percent predicted FEV<sub>1<\/sub> between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed <i>R117H\u20117T <\/i>genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI \u20118.1, 8.5).<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_Hlk37921752\"><span lang=\"EN-GB\">For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQ\u2011R respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).<\/span><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Ivacaftor in a combination regimen with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The efficacy and safety of ivacaftor in a combination regimen with tezacaftor\/ivacaftor in patients with CF aged 12 years and older was assessed in two clinical studies; a 24 week, randomised, double\u2011blind, placebo\u2011controlled study with 504 patients who were homozygous for the <i>F508del <\/i>mutation; and a randomised, double\u2011blind, placebo\u2011controlled and ivacaftor controlled, 2 period, 3 treatment, 8\u2011week crossover study with 244 patients who were heterozygous for the <i>F508del<\/i> mutation and a second mutation associated with residual <i>CFTR <\/i>activity. The long-term safety and efficacy of the combination regimen was also assessed in both patient populations in a 96-week open-label, rollover, long-term extension study. Refer to the Summary of Product Characteristics of tezacaftor\/ivacaftor for additional data.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The efficacy and safety of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor in patients aged 12 years and older was demonstrated in two, phase 3 studies, randomised, double blind, placebo-controlled (heterozygous <i>F508del<\/i> patients, n=403) and active-controlled (homozygous <i>F508del<\/i> patients, n=107) of 24 and 4 weeks of duration, respectively. Heterozygous <i>F508del<\/i> patients had a minimal function mutation on the second allele defined as one that either leads to <\/span><span lang=\"EN-GB\">no CFTR protein being produced (e.g. Class I) or a CFTR protein that does not function to transport chloride and is unlikely to respond to other CFTR modulators (tezacaftor, ivacaftor or the combination of both). Homozygous <i>F508del<\/i> patients received tezacaftor\/ivacaftor and ivacaftor regimen during a 4-week open-label run-in period and were then randomised and dosed to receive ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor during a 4-week double-blind treatment period. Patients from both studies were eligible to enter an open\u2011label, rollover, 96-week study. Refer to the Summary of Product Characteristics of ivacaftor\/tezacaftor\/elexacaftor for additional data.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (\u00b1 SD) for AUC and C<sub>max<\/sub> were 10600 (5260) ng*hr\/mL and 768 (233) ng\/mL, respectively. After every 12\u2011hour dosing, steady\u2011state plasma concentrations of ivacaftor were reached by days<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\">Absorption<\/span><\/u><\/p> <p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food, the exposure of ivacaftor increased approximately 2.5\u2011 to 4\u2011fold. When co-administered with tezacaftor and elexacaftor, the increase in AUC was similar (approximately 3\u2011fold and 2.5-to 4-fold respectively). Therefore, ivacaftor, administered as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, should be administered with fat\u2011containing food. The median (range) t<sub>max<\/sub> is approximately 4.0 (3.0; 6.0) hours in the fed state.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ivacaftor granules (2 x 75 mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0\u2011\u221e<\/sub> and 0.918 (0.750, 1.12) for C<sub>max<\/sub>. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1\u2011acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (\u00b1 SD) apparent volume of distribution was 353 L (122) .<\/span><\/p> <p class=\"labeltext\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Biotransformation<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is extensively metabolised in humans. <i>In vitro<\/i> and <i>in vivo<\/i> data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one\u2011sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one\u2011fiftieth the potency of ivacaftor and is not considered pharmacologically active.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">The effect of the CYP3A4*22 heterozygous genotype on tezacaftor, ivacaftor and elexacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose-adjustment of tezacaftor, ivacaftor or elexacaftor is considered necessary. The effect in CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half\u2011life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL\/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (\u00b1 SD) CL\/F for a single 150 mg dose was 17.3 (8.4) L\/hr in healthy subjects.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Linearity\/non\u2011linearity<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltextheading\"><a name=\"_Hlk45278559\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/a><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child\u2011Pugh Class B, score 7 to 9) had similar ivacaftor C<sub>max<\/sub> (mean [\u00b1 SD] of 735 [331] ng\/mL) but an approximately two\u2011fold increase in ivacaftor AUC<sub>0-\u221e<\/sub> (mean [\u00b1 SD] of 16800 [6140] ng*hr\/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady\u2011state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady\u2011state C<sub>min<\/sub> values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\">In subjects with moderately impaired hepatic function (Child Pugh Class B, score 7 to 9), ivacaftor AUC increased approximately by 50% following multiple doses for 10 days of either tezacaftor and ivacaftor or of ivacaftor, tezacaftor and elexacaftor. <\/p> <p class=\"MsoNormal\"> <\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor has not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">For guidance on appropriate use and dose modification see Table 3 in section 4.2.<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Renal impairment<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor <\/span>or with <span lang=\"EN-GB\" style=\"font-size:11.0pt\">ivacaftor\/tezacaftor\/elexacaftor. In a human pharmacokinetic study with ivacaftor monotherapy, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustments are recommended for mild and moderate renal impairment. Caution is recommended when administering ivacaftor, either as monotherapy or in a combination with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor, to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.2 and 4.4).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Race<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gender<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The pharmacokinetic parameters of ivacaftor, either as monotherapy or in combination with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, are similar in males and females.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Elderly<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Clinical studies of ivacaftor monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">The pharmacokinetic parameters of ivacaftor in combination with tezacaftor in the elderly patients (65\u201172 years) are comparable to those in younger adults. No patients aged 65 years and older were included in the clinical studies of ivacaftor\/tezacaftor\/elexacaftor and therefore it cannot be <\/span>determined whether pharmacokinetic parameters are similar or not to those in younger adults<span lang=\"EN-GB\">.<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\">Paediatric population<\/span><\/u><\/p> <p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 9.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b>Table 9: Mean (SD) ivacaftor exposure by age group<\/b><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:101.48%;margin-left:5.35pt;border-collapse:collapse\" width=\"101%\"> <tr style=\"height:23.9pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;padding:   0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"55%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b>Age group<\/b><\/p> <\/td> <td style=\"width:14.96%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b>Dose<\/b><\/p> <\/td> <td style=\"width:13.1%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b>C<sub>min, ss<\/sub> (ng\/mL)<\/b><\/p> <\/td> <td style=\"width:16.2%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"16%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b><span lang=\"PT\">AUC<\/span><sub><span lang=\"EN-GB\">\u03c4<\/span><\/sub><\/b><b><sub><span lang=\"PT\">, ss<\/span><\/sub><\/b><b><span lang=\"PT\"> (ng*h\/mL)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"55%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">6 months   to less than 12 months (5 kg to &lt; 7 kg)<span class=\"MsoCommentReference\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> <\/span><\/span><sup>*<\/sup><\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"14%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">25 mg   q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">336<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"16%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">5410<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"55%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">6 months   to less than 12 months (7 kg to &lt; 14 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"14%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">50 mg   q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">508 (252)<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"16%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">9140 (4200)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 months to less than 24 months (7 kg to   &lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">440 (212)<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">9050 (3050)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 months to less than 24 months (<\/span><span style=\"font-size:11.0pt;font-family:SimSun\">\u2265<\/span><span style=\"font-size:11.0pt\"> 14 kg to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">451 (125)<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">9600 (1800)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">2\u2011   to 5\u2011year-olds (&lt; 14 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">50 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">577   (317)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">10500   (4260)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">2\u2011 to 5\u2011year-olds (\u2265 14 kg   to &lt; 25 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">75 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">629 (296)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">11300 (3820)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">6\u2011 to 11\u2011year-olds <sup>\u2020<\/sup>   (\u2265 14 kg to &lt; 25 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">75 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">641 (329)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">10760 (4470)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">6\u2011 to 11\u2011year-olds <sup>\u2020<\/sup>   (\u2265 25 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">150 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">958 (546)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">15300 (7340)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">12\u2011 to 17\u2011year-olds   <\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">150 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">564 (242)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">9240 (3420)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Adults   (\u2265 18 years old) <\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">150 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">701   (317)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">10700   (4100)<\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span style=\"font-size:9.0pt\">*<\/span><\/sup><span style=\"font-size:9.0pt\">     Values based on data from a single patient; standard deviation not reported.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt; position:relative;top:-3.0pt\">\u2020<\/span><\/sup><span style=\"font-size:9.0pt\">     Exposures in 6\u2011 to 11\u2011year\u2011olds are predictions based on simulations from the population PK model using data obtained for this age group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The pharmacokinetic parameters of ivacaftor in combination with tezacaftor and with tezacaftor\/elexacaftor in adolescent patients (12 to 17-year-olds) are similar to that of adult patients (see Table 10).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b>Table 10: Mean (SD) of ivacaftor exposure when used in combination with tezacaftor and in combination with tezacaftor\/elexacaftor, by age group<\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:467.55pt;border-collapse:collapse;border:none\" width=\"623\"> <tr style=\"height:26.55pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;padding:   0in 0in 0in 0in;height:26.55pt\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Age group<\/span><\/b><\/p> <\/td> <td style=\"width:27.28%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 0in 0in 0in;height:26.55pt\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <\/td> <td style=\"width:31.84%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 0in 0in 0in;height:26.55pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Ivacaftor Mean (SD)<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">AUC<sub>0-12h<\/sub>,ss (ng*h\/mL)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\"><span lang=\"EN-GB\">Adolescent patients (12 to &lt;18 years) <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\"><span lang=\"EN-GB\">n = 97<\/span><\/p> <\/td> <td rowspan=\"2\" style=\"width:27.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"PT\">tezacaftor 100 mg qd\/ <br\/>   ivacaftor 150 mg q12h<\/span><\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">11400 (5500)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">Adult patients (\u2265 18 years)<\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\"><span lang=\"EN-GB\">n = 389<\/span><\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">11400 (4140)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">Adolescent patients (12 to &lt;18 years)<\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">n = 69<\/p> <\/td> <td rowspan=\"2\" style=\"width:27.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\">elexacaftor 200 mg qd\/<br\/>   tezacaftor 100 mg qd\/<br\/>   ivacaftor 150 mg q12h<\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\">10600 (3350)<\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">Adult patients (\u226518 years)<\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">n = 186<\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\">12100 (4170)<\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy and fertility<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The No\u2011Observed\u2011Adverse\u2011Effect\u2011Level (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Peri\u2011 and post\u2011natal development<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level of approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile animal studies<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7\u2011week old rats, nor in 3.5 to 5\u2011month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL PARTICULARS<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Tablet core<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cellulose, microcrystalline<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hypromellose acetate succinate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Sodium laurilsulfate (E487)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Silica, colloidal anhydrous<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Magnesium stearate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"IT\">Tablet film coat<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"IT\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Polyvinyl alcohol<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Titanium dioxide (E171)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PT\">Macrogol (PEG 3350)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PT\">Talc<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PT\">Indigo carmine aluminium lake (E132)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Carnauba wax<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u>Printing ink<\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Shellac<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Iron oxide black (E172)<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Propylene glycol (E1520)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Ammonia solution, concentrated<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">4 years.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The film-coated tablets are packed in a thermoform (PolyChloroTriFluoroEthylene [PCTFE]\/foil) blister or a High-Density PolyEthylene (HDPE) bottle with <\/span><span lang=\"EN-GB\">a polypropylene child-resistant closure, foil-lined induction seal and molecular sieve<\/span><span lang=\"EN-GB\"> desiccant.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The following pack sizes are available:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt; font-family:Symbol\">-<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Blister card pack containing 28 film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt; font-family:Symbol\">-<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Blister pack containing 56 film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:8.0pt;font-family:Symbol\">-<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Bottle containing 56 film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Not all pack sizes may be marketed<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6    Special precautions for disposal and other handling<\/span><\/b><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>7.       MARKETING AUTHORISATION HOLDER<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/001<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/002<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/005<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of first authorisation: 23 July 2012<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of latest renewal: 28 April 2017<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>10.     DATE OF REVISION OF THE TEXT<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>http:\/\/www.ema.europa.eu<\/u>.<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 25 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Excipient with known effect<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 36.6 mg of lactose monohydrate.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 50 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Excipient with known effect<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 73.2 mg of lactose monohydrate.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 75 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Excipient with known effect<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 109.8 mg of lactose monohydrate.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL FORM<\/span><\/h1> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">White to off\u2011white granules approximately 2 mm in diameter.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif;text-transform:uppercase'>4.       <\/span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CLINICAL PARTICULARS<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an <i>R117H CFTR<\/i> mutation or one of the following gating (class III) mutations in the <i>CFTR<\/i> gene: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N <\/i>or<i> S549R<\/i> (see sections 4.4 and 5.1).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.2     Posology and method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. <\/span>If the patient's genotype is unknown, an <span lang=\"EN-GB\">accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in at least one allele of the <i>CFTR<\/i> gene (see section 4.1). The phase of the poly-T variant identified with the <i>R117H <\/i>mutation should be determined in accordance with local clinical recommendation.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Infants aged at least 4 months, toddlers, children, adolescents and adults should be dosed according to Table 1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 1: Dosing recommendations for patients aged 4 months and older<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.0%;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Age<\/span><\/b><\/p> <\/td> <td style=\"width:21.68%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Weight<\/span><\/b><\/p> <\/td> <td style=\"width:36.18%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <\/td> <td style=\"width:20.46%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Total daily dose<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">4 months to less than 6 months<\/span><\/p> <\/td> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\">5 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">25 mg granules taken orally every 12 hours with fat-containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td rowspan=\"4\" style=\"width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">6 months and older<\/span><\/p> <\/td> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\">5 kg to   &lt; 7 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">25 mg granules taken orally every 12 hours with fat\u2011containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 7 kg to &lt; 14 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg granules taken orally every 12 hours with fat\u2011containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">100 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 14 kg to   &lt; 25 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">75 mg granules taken orally every 12 hours with fat\u2011containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">150 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.7pt\"> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 25 kg<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:56.64%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">See Kalydeco   tablets SmPC for further details.<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><span class=\"s10\"><span lang=\"EN-GB\"> <\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span class=\"s10\"><i><span lang=\"EN-GB\">Missed dose<\/span><\/i><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span class=\"s10\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span class=\"s10\"><span lang=\"EN-GB\">If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.<\/span><\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">Concomitant use of CYP3A inhibitors<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">When co-administered with strong inhibitors of CYP3A in patients aged 6 months and older, the <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ivacaftor dose should be reduced to one sachet (ivacaftor 25 mg for patients 5 kg to &lt; 7 kg; ivacaftor 50 mg for patients 7 kg to &lt; 14 kg; ivacaftor 75 mg for patients 14 kg to &lt; 25 kg) twice a week <\/span><span style=\"font-size:11.0pt\">(see sections 4.4 and 4.5).<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">When co-administered with moderate inhibitors of CYP3A in patients aged 6 months and older,<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> the ivacaftor dose is as above recommended but administered once daily <\/span><span style=\"font-size:11.0pt\">(see sections 4.4 and 4.5).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Due to the variability in maturation of the cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended when co-administered with moderate or strong inhibitors of CYP3A in patients aged 4 months to less than 6 months, unless the benefits outweigh the risks. In such cases, the recommended dose is one packet of 25 mg granules twice weekly or less frequently (see sections 4.4 and 4.5). Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.4 and 5.2).<\/span><\/p> <p class=\"labeltextheading\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltextheading\"><span style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/p> <p class=\"labeltextheading\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustment is necessary for patients aged 6 months and older with mild hepatic impairment (Child\u2011Pugh Class A). For patients aged 6 months and older with moderate hepatic impairment (Child\u2011Pugh Class B), a <\/span><span style=\"font-size:11.0pt\">reduced dose of one sachet (ivacaftor 25 mg for patients 5 kg to &lt; 7 kg; ivacaftor 50 mg for patients 7 kg to &lt; 14 kg; ivacaftor 75 mg for patients 14 kg to &lt; 25 kg) once daily is recommended. There is no experience of the use of ivacaftor in patients aged 6 months and older with severe hepatic impairment (Child-Pugh Class C); therefore, its use is not recommended unless the benefits outweigh the risks. In such cases, the starting dose should be as above recommended, administered <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">every other day<\/span><span style=\"font-size:11.0pt\">. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).<\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">Due to variability in maturation of cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended in patients aged 4 months to less than 6 months with hepatic impairment, unless the benefits outweigh the risks. In such cases, the recommended dose is one sachet (ivacaftor 25 mg) once daily or less frequently. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).<\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\"> <\/span><\/i><\/b><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">The safety and efficacy of ivacaftor in children aged less than 4 months have not been established. No data are available.<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">Limited data are available in patients less than 6 years of age with an <i>R117H<\/i> mutation in the <i>CFTR<\/i> gene. Available data in patients aged 6 years and older are described in sections 4.8, 5.1 and 5.2.<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">For oral use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Each sachet is for single use only.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules should be mixed with 5 mL of age\u2011appropriate soft food or liquid and<\/span><span lang=\"EN-GB\"> completely and immediately consumed. <\/span>Food or liquid should be at room temperature or below. <span lang=\"EN-GB\">If not immediately consumed, the mixture has been shown to be stable for one hour and therefore should be ingested during this period. A fat\u2011containing meal or snack should be consumed just before or just after dosing.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Food or drink containing grapefruit should be avoided during treatment (see section 4.5).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.3       Contraindications<\/span><\/h2> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.4       Special warnings and precautions for use<\/span><\/h2> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Only patients with CF who had a <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N<\/i> or <i>S549R<\/i> gating (class III) or <i>G970R<\/i> mutation in at least one allele of the <i>CFTR<\/i> gene were included in studies 1, 2, 5 and 7 (see section<\/span><span lang=\"EN-GB\"> 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Less evidence of a positive effect of ivacaftor has been shown for patients with an <i>R117H-7T<\/i> mutation associated with less severe disease in study 6 (see section 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In study 5, four patients with the <i>G970R<\/i> mutation were included. In three of four patients the change in the sweat chloride test was &lt; 5<\/span><span lang=\"EN-GB\"> mmol\/L and this group did not demonstrate a clinically relevant improvement in FEV<sub>1<\/sub> after 8 weeks of treatment. Clinical efficacy in patients with the <i>G970R<\/i> mutation of the <i>CFTR<\/i> gene could not be established (see section 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Efficacy results from a phase 2 study in patients with CF who are homozygous for the <i>F508del <\/i>mutation in the <i>CFTR<\/i> gene showed no statistically significant difference in FEV<sub>1<\/sub> over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.<\/span><\/p> <p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Effect on liver function tests<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor monotherapy. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3<\/span><span style=\"font-size:11.0pt\"> <\/span><span style=\"font-size:11.0pt\">months during the first year of treatment and annually thereafter. <\/span><span style=\"font-size:11.0pt\">For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. <\/span><span style=\"font-size:11.0pt\">In the event of significant elevations of transaminases (e.g., patients with ALT or AST &gt; 5 x the upper limit of normal (ULN), or ALT or AST &gt; 3 x ULN with bilirubin &gt; 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Use of ivacaftor is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks (see sections 4.2 and 5.2). No safety data are available in infants aged 4 to less than 12 months of age with moderate or severe hepatic impairment treated with ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Caution is recommended while using ivacaftor in patients with severe renal impairment or end\u2011stage renal disease (see sections 4.2 and 5.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients after organ transplantation<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Interactions with medicinal products<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inducers<\/span><\/i><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Exposure to ivacaftor is significantly decreased by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">co-administration <\/span><span style=\"font-size:11.0pt\">of ivacaftor <\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">with strong CYP3A inducers is not recommended<\/span><span style=\"font-size:11.0pt\"> (see section 4.5).<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inhibitors <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Exposure to ivacaftor is increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see sections 4.2 and 4.5). No safety data are available in infants aged 4 to less than 12 months of age who are treated with ivacaftor and moderate or strong CYP3A inhibitors (see sections 4.2 and 4.5).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cases of non\u2011congenital lens opacities\/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow\u2011up ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Lactose content<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose\u2011galactose malabsorption should not take this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium content<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.5pt;text-indent:-28.5pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Interaction with other medicinal products and other forms of interaction<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P\u2011gp and a potential inhibitor of CYP2C9. <\/span><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> studies showed that ivacaftor is not a substrate for P\u2011gp. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Medicinal products affecting the pharmacokinetics of ivacaftor<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inducers<\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Co\u2011administration of ivacaftor with strong CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John\u2019s wort (<i>Hypericum perforatum<\/i>), is not recommended (see section 4.4).<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inhibitors<\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is a sensitive CYP3A substrate. Co\u2011administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the <\/span><span style=\"font-size:11.0pt\">ivacaftor dose <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">is recommended for co\u2011administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the <\/span><span style=\"font-size:11.0pt\">ivacaftor dose is recommended <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co-administration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (see section 4.2).<\/span><\/p> <p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Potential for ivacaftor to interact with transporters<\/span><\/u><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in vitro<\/i>. Due to its high intrinsic permeability and low likelihood of being excreted intact, co\u2011administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1\u2011IVA, while any potential changes in M6\u2011IVA exposures are not expected to be clinically relevant. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Ciprofloxacin<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Co-administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor is co\u2011administered with ciprofloxacin.<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Medicinal products affected by ivacaftor<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and\/or P\u2011gp, and\/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">CYP2C9 substrates<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during co\u2011administration of warfarin with ivacaftor. Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Digoxin and other P\u2011gp substrates<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with digoxin, a sensitive P\u2011gp substrate, increased digoxin exposure by 1.3\u2011fold, consistent with weak inhibition of P\u2011gp by ivacaftor. Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of P\u2011gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly<\/span><span style=\"font-size:11.0pt\"> with<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> digoxin or other substrates of P\u2011gp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.<\/span><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A substrates <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5\u2011fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co-administered with ivacaftor. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hormonal contraceptives<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor has been studied with an oestrogen\/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive.<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Therefore, no dose adjustment of oral contraceptives is necessary.<\/span><\/p> <p style=\"margin:0in\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p> <p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">Interaction studies have only been performed in adults.<i> <\/i><\/span><\/p> <p style=\"margin:0in\"><b><span style=\"font-size:11.0pt\"> <\/span><\/b><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.6       Fertility, pregnancy and lactation<\/span><\/h2> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Pregnancy<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women.<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable avoid the use of ivacaftor during pregnancy.<\/span><\/p> <p class=\"labeltext\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">It is unknown whether ivacaftor and\/or its metabolites are excreted in human milk. <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Available pharmacokinetic data in animals have shown excretion of <\/span><span style=\"font-size:11.0pt\">ivacaftor into the milk of lactating female rats. <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">As such, a risk to the newborns\/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue\/abstain from ivacaftor therapy taking into account the benefit of breast\u2011feeding for the child and the benefit of therapy for the woman.<\/span><\/p> <p class=\"labeltext\"> <\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3)<\/span>.<\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore, patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/b><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Summary of the safety profile<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The most common adverse reactions experienced by patients aged 6 years and older are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and bacteria in sputum (12.8%).<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">Transaminase elevations occurred in 12.8% of ivacaftor\u2011treated patients versus 11.5% of placebo-treated patients.<\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).<\/span><\/p> <p class=\"labeltext\"><u><span style=\"font-size:11.0pt\"><span style=\"text-decoration:  none\"> <\/span><\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Tabulated list of adverse reactions<\/span><\/u><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Table 2 reflects the adverse reactions observed with ivacaftor in clinical trials (placebo\u2011controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. The frequency of adverse reactions is defined as follows: very common (\u2265 1\/10); common (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare (&lt; 1\/10,000); not known (cannot be estimated from the available data). <\/span><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b>Table 2: Adverse reactions in ivacaftor\u2011treated patients aged 4 months and older<\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:95.28%;margin-left:5.45pt;border-collapse:collapse;border:none\" width=\"95%\"> <thead> <tr style=\"page-break-inside:avoid;height:12.55pt\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:12.55pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">System organ class<\/span><\/b><\/p> <\/td> <td style=\"width:33.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b>Adverse reactions<\/b><\/p> <\/td> <td style=\"width:33.72%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"NL-BE\">Frequency <\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td rowspan=\"3\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Infections and   infestations<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Upper   respiratory tract infection<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nasopharyngitis<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.35pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rhinitis <\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nervous system   disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Headache<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Dizziness<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td rowspan=\"6\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear and   labyrinth disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear discomfort<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tinnitus<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tympanic   membrane hyperaemia<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vestibular   disorder<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear congestion<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td rowspan=\"4\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Oropharyngeal pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Nasal congestion<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Sinus congestion <\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:16.6pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharyngeal   erythema<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:18.75pt\"> <td rowspan=\"2\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gastrointestinal   disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Abdominal pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:18.75pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:18.75pt\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DA\">Hepatobiliary   disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Transaminase   elevations<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Skin and   subcutaneous tissue disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rash<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"5\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Reproductive   system and breast disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Breast mass<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Breast   inflammation<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gynaecomastia<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple   disorder<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:16.6pt\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Investigations<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Bacteria in   sputum<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Transaminase elevations<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">During the 48\u2011week placebo\u2011controlled studies 1 and 2 in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5 or &gt; 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor-treated patients and 1.0%, 1.9% and 8.7% in placebo-treated patients, respectively. Two patients, one on placebo and one on ivacaftor, permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN. No ivacaftor\u2011treated patients experienced a transaminase elevation &gt; 3 x ULN associated with elevated total bilirubin &gt; 1.5 x ULN. In ivacaftor-treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations &gt; 5 x ULN. In all instances where dosing was interrupted for elevated transaminases and <\/span><span lang=\"EN-GB\">subsequently resumed, ivacaftor<\/span><span lang=\"EN-GB\"> dosing was able to be resumed successfully (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor\/ivacaftor, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor\/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor\/ivacaftor experienced a transaminase elevation &gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. <\/span><\/p> <p class=\"MsoNormal\"> <\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">During the 24-week, placebo-controlled, phase 3 study of ivacaftor\/tezacaftor\/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor\/tezacaftor\/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor treated patients and 4.0% in placebo-treated patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The safety data of ivacaftor were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, 19 patients between 12 months to less than 24 months of age, 34 patients between 2 to less than 6 years of age, 61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety profile is generally consistent among paediatric patients aged 4 months and older and is also consistent with adult patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients aged 6 to less than 24 months) are described in Table 3. <\/span><span lang=\"EN-GB\">In the placebo controlled studies, the incidence of transaminase elevations were similar between treatment with ivacaftor (15.0%) and placebo<\/span>(14.6%)<span lang=\"EN-GB\">Across all populations, <\/span>peak LFT <span lang=\"EN-GB\">elevations <\/span>returned to baseline levels following interruption, and in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4). Cases suggestive of positive rechallenge were observed. In study 7 <span lang=\"EN-GB\">ivacaftor was permanently discontinued in one patient. In study 8 <\/span><span lang=\"EN-GB\">no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).<\/span><\/p> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:12.0pt\"><b><span lang=\"EN-GB\">Table 3: Transaminase elevations in patients 4 months to &lt; 12 years treated with ivacaftor as monotherapy<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"margin-left:6.85pt;border-collapse:collapse;border:none\"> <tr style=\"height:28.95pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">n<\/span><\/b><\/p> <\/td> <td style=\"width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 3 x ULN <\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt;5 x ULN<\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 8 x ULN<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.0%   (6)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2 to &lt;6 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 to &lt;24 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.8%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">9.1%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4 to &lt;6 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style=\"background: lightgrey\">the national reporting system listed in <\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a>.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.9       Overdose<\/span><\/h2> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'>5.       PHARMACOLOGICAL PROPERTIES<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.5pt;text-indent:-28.5pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Pharmacodynamic properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Other respiratory system products, ATC code: <\/span>R07AX02<\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is a potentiator of the CFTR protein, i.e., <i>in vitro<\/i> ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channel\u2011open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance). The <i>G970R <\/i>mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data). <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to <i>in vivo <\/i>pharmacodynamic response (e.g., sweat chloride) or clinical benefit. <\/span><span lang=\"EN-GB\">The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacodynamic effects<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In studies 1 and 2 in patients with the <i>G551D <\/i>mutation in one allele of the <i>CFTR<\/i> gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was \u201148 mmol\/L [95% CI \u201151, \u201145] and \u201154 mmol\/L [95% CI \u201162, \u201147], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 5, part 1 in patients who had a non-<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of \u201149 mmol\/L (95% CI \u201157, \u201141) through 8 weeks of treatment. However, in patients with the <i>G970R<\/i>\u2011<i>CFTR<\/i> mutation, the mean (SD) absolute change in sweat chloride at week 8 was \u20116.25 (6.55) mmol\/L. Similar results to part 1 were seen in part 2 of the study. At the 4\u2011week follow\u2011up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre\u2011treatment levels.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 6 in patients aged 6 years or older with CF who had an <i>R117H<\/i> mutation in the <i>CFTR<\/i> gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was \u201124 mmol\/L (95% CI \u201128, \u201120). In subgroup analyses by age, the treatment difference was \u201121.87 mmol\/L (95% CI: \u201126.46, \u201117.28) in patients aged 18 years or older, and \u201127.63 mmol\/L (95% CI: \u201137.16, \u201118.10) in patients aged 6\u201111 years. Two patients 12 to 17 years of age were enrolled in this study.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 7 in patients aged 2 to less than 6 years with a gating mutation on at least 1 allele of the <i>CFTR<\/i> gene administered either 50 mg or 75 mg of ivacaftor twice daily, the mean absolute change from baseline in sweat chloride was \u201147 mmol\/L (95% CI \u201158, \u201136) at week 24.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 8 in patients with CF aged less than 24 months, the mean absolute change from baseline in sweat chloride was -65.1 mmol\/L (95% CI \u201174.1, \u201156.0) at week 24. Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.<\/span><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Clinical efficacy and safety<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 1 and 2: studies in patients with CF with G551D gating mutations<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The efficacy of ivacaftor has been evaluated in two phase 3 randomised, double\u2011blind, placebo\u2011controlled, multi\u2011centre studies of clinically stable patients with CF who had the <i>G551D<\/i> mutation in the <i>CFTR<\/i> gene on at least 1 allele and had FEV<sub>1<\/sub> <\/span><span style=\"font-family: SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 40% predicted.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the <i>F508del<\/i> mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol\/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV<sub>1<\/sub> was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the <i>F508del<\/i> mutation in the second allele. At baseline, mean predicted FEV<sub>1<\/sub> was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV<sub>1<\/sub> less than 70% predicted at baseline.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV<sub>1<\/sub> through 24 weeks of treatment.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV<sub>1<\/sub> (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV<sub>1<\/sub> were rapid in onset (day 15) and durable through 48 weeks.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients with baseline predicted FEV<sub>1 <\/sub>greater than 90% in study 2 was 6.9 percentage points (\u20113.8, 17.6).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The results for clinically relevant secondary endpoints are shown in Table 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 4: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2<\/span><\/b><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.82%;margin-left:5.45pt;border-collapse:collapse\" width=\"98%\"> <thead> <tr style=\"height:10.5pt\"> <td rowspan=\"2\" style=\"width:27.12%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"bottom\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Endpoint<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:34.82%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:38.06%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"38%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:28.25pt\"> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:14.64%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:17.88%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in CFQ-R<\/span><\/b><sup><span lang=\"EN-GB\">b<\/span><\/sup><b><span lang=\"EN-GB\"> respiratory domain score   (points)<\/span><\/b><sup><span lang=\"EN-GB\">c<\/span><\/sup><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(4.7, 11.4)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">6.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.4, 13.5)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1092<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.6<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(5.3, 11.9)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">5.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.6, 11.8)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1354<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Relative risk of pulmonary exacerbation<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.40<\/span><sup><span lang=\"EN-GB\">d<\/span><\/sup><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0016<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.46<sup>d<\/sup><\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0012<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in body weight (kg)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.8, 3.7)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.9, 2.9)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0004<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.7<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.1)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.2)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0002<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in BMI (kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.94<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.62, 1.26)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.81<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.34, 1.28)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0008<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.93<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.48, 1.38)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.09<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.51, 1.67)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0003<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.05pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean change from baseline in z\u2011scores<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2011for\u2011age   z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.04, 0.62)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0260<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.39<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.24, 0.53)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">BMI\u2011for\u2011age z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.002, 0.65)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0490<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.45<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.26, 0.65)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">CI: confidence interval; NA: not analysed due to low incidence of events <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment difference = effect of ivacaftor \u2013 effect of placebo<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     CFQ-R: Cystic Fibrosis Questionnaire-Revised is a disease-specific, health-related quality-of-life measure for CF.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">c<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Study 1 data were pooled from CFQ-R for adults\/adolescents and CFQ-R for children 12 to 13 years of age; Study 2 data were obtained from CFQ-R for children 6 to 11 years of age.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">d<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Hazard ratio for time to first pulmonary exacerbation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">e<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     In subjects under 20 years of age (CDC growth charts)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 5: study in patients with CF with non-G551D gating mutations<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 5 was a phase 3, two\u2011part, randomised, double\u2011blind, placebo-controlled, crossover study (part 1) followed by a 16\u2011week open\u2011label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a <i>G970R<\/i> or non\u2011<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene (<i>G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P<\/i> or<i> G1349D<\/i>).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat-containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4- to 8\u2011week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to the part 1 placebo\/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor\/placebo treatment sequence.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Thirty-nine patients (mean age 23 years) with baseline FEV<sub>1<\/sub> <\/span><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">40% predicted (mean FEV<sub>1<\/sub> 78% predicted [range: 43% to 119%]) were enrolled. Sixty\u2011two percent (24\/39) of them carried the <i>F508del<\/i>-<i>CFTR<\/i> mutation in the second allele. A total of 36 patients continued into part 2 (18 per treatment sequence).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 1 of study 5, the mean FEV<sub>1<\/sub> percent predicted at baseline in placebo-treated patients was 79.3% while in ivacaftor\u2011treated patients this value was 76.4%. The mean overall post\u2011baseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week 8 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 7.5% in the ivacaftor period and \u20113.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) <\/span><span lang=\"EN-GB\">(P &lt; 0.0001).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQ\u2011R through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV<sub>1<\/sub> at week 8) is shown in Table 5. Based on clinical (percent predicted FEV<sub>1<\/sub>) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the <i>G970R<\/i> mutation could not be established.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 5: Effect of ivacaftor for efficacy variables in the overall population and for specific <i>CFTR<\/i> mutations<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:454.0pt;margin-left:5.35pt;border-collapse:collapse;border:none\" width=\"605\"> <tr> <td colspan=\"2\" style=\"width:147.75pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"197\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change in percent   predicted FEV<sub>1<\/sub><\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:152.5pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"203\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">BMI<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <td style=\"width:153.75pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">CFQ-R respiratory domain score   (points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:147.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"197\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Through week 8<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:152.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"203\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">At week 8<\/span><\/b><\/p> <\/td> <td style=\"width:153.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Through week 8<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"5\" style=\"width:454.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">All patients (N = 39)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (95% CI) change from baseline ivacaftor vs.   placebo-treated patients:<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:147.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"197\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.7 (7.3, 14.1)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:152.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"203\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.66 (0.34, 0.99)<\/span><\/p> <\/td> <td style=\"width:153.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.6 (4.5, 14.7)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Patients grouped under mutation types (n)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (minimum, maximum) change from baseline for   ivacaftor-treated patients <br\/>   at week 8*:<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td rowspan=\"2\" style=\"width:18.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"bottom\" width=\"18%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">Mutation (n)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">Absolute change in sweat chloride   (mmol\/L)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">Absolute change in percent predicted   FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"2\" style=\"width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">At week 8<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">At week 8<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:88.5pt\"> <td style=\"width:18.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:88.5pt\" valign=\"top\" width=\"18%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><i><span lang=\"PT\">G1244E<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G1349D<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G178R<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G551S<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G970R<sup>#<\/sup><\/span><\/i><span lang=\"PT\"> (4)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"EN-GB\">S1251N <\/span><\/i><span lang=\"EN-GB\">(8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"EN-GB\">S1255P<\/span><\/i><span lang=\"EN-GB\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"EN-GB\">S549N<\/span><\/i><span lang=\"EN-GB\"> (6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><i><span lang=\"EN-GB\">S549R<\/span><\/i><span lang=\"EN-GB\">   (4)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:88.5pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-55 (-75, -34)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-80 (-82, -79)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-53 (-65, -35)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-68<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-6 (-16, -2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-54 (-84, -7)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-78 (-82, -74)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-74 (-93, -53)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-61<span style=\"position:relative;top:-3.0pt\">\u2020\u2020<\/span> (-71, -54)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:88.5pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">20 (3, 36)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">3<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">3 (-1, 5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9 (-20, 21)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">3 (-1, 8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">11 (-2, 20)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">5 (-3, 13)<\/span><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"113\"><\/td> <td style=\"border:none\" width=\"123\"><\/td> <td style=\"border:none\" width=\"123\"><\/td> <td style=\"border:none\" width=\"123\"><\/td> <td style=\"border:none\" width=\"124\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Statistical testing was not performed due to small numbers for individual mutations.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Reflects results from the one patient with the <i>G551S<\/i> mutation with data at the 8-week time point.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">    n = 3 for the analysis of absolute change in sweat chloride.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">#        <\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> following 16 weeks (patients randomised to the ivacaftor\/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the follow\u2011up visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1 <\/sub>from<sub> <\/sub>part 2 week 16 was \u20115.9% (9.4%). For patients randomised to the placebo\/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV<sub>1<\/sub> after the additional 16 weeks of treatment with ivacaftor. At the follow up visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> from part 2 week 16 was \u20117.4% (5.5%).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 3: study in patients with CF with the F508del mutation in the CFTR gene<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 3 (part A) was a 16\u2011week, 4:1 randomised, double\u2011blind, placebo\u2011controlled, parallel\u2011group phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the <i>F508del<\/i> mutation in the <i>CFTR<\/i> gene and who had FEV<sub>1<\/sub> \u2265 40% predicted.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The mean absolute change from baseline through week 16 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and \u20110.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI \u20110.6, 4.1); this difference was not statistically significant (P = 0.15).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 4: open-label extension study<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">In study 4, patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo\/ivacaftor group and at least 144 weeks for patients in the ivacaftor\/ivacaftor group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One hundred and forty\u2011four (144) patients from study 1 were rolled over in study 4, 67 in the placebo\/ivacaftor group and 77 in the ivacaftor\/ivacaftor group. Forty\u2011eight (48) patients from study 2 were rolled over in study 4, 22 in the placebo\/ivacaftor group and 26 in the ivacaftor\/ivacaftor group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Table<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">6 shows the results of the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> for both groups of patients. For patients in the placebo\/ivacaftor group baseline percent predicted FEV<sub>1<\/sub> is that of study 4 while for patients in the ivacaftor\/ivacaftor group the baseline value is that of studies<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">1 and 2.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 6: Effect of ivacaftor on percent predicted FEV<\/span><\/b><sub><span lang=\"EN-GB\">1<\/span><\/sub><b><span lang=\"EN-GB\"> in study 4<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"24%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Original study and treatment group<\/span><\/b><\/p> <\/td> <td rowspan=\"2\" style=\"width:27.72%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration of ivacaftor treatment (weeks)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:47.56%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change from baseline in   percent predicted FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">N<\/span><\/b><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Mean (SD)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">77<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (8.3)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">72<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (10.8)<\/span><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">67<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20111.2 (7.8)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">55<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.5 (11.2)<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">26<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.2 (15.7)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">25<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.3 (12.4)<\/span><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">22<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20110.6 (10.1)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">21<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.5 (11.5)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment occurred during blinded, controlled, 48-week phase 3 study.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Change from prior study baseline after 48 weeks of placebo treatment.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">When the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> is compared from study 4 baseline for patients in the ivacaftor\/ivacaftor group (n<\/span><span lang=\"EN-GB\"> = <\/span><span lang=\"EN-GB\">72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> was 0.0% (9.05), while for patients in the ivacaftor\/ivacaftor group (n<\/span><span lang=\"EN-GB\"> = <\/span><span lang=\"EN-GB\">25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor\/ivacaftor group maintained the improvement seen at <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 of the initial study (<\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 0 through <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48) in percent predicted FEV<sub>1<\/sub> through <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 144. There were no additional improvements in study 4 (<\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 through <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 144).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For patients in the placebo\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events\/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events\/year across <\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 1 to <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48, and 0.67 events\/year across <\/span><span lang=\"EN-GB\">weeks<\/span><span lang=\"EN-GB\"> 48 to 96). For patients in the ivacaftor\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events\/year across <\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 1 to <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events\/year across <\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 1 to <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 and 0.77 events\/year across <\/span><span lang=\"EN-GB\">weeks<\/span><span lang=\"EN-GB\"> 48 to 96.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For patients who rolled over from study 2 the number of events was, overall, low.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Study 6: study in patients with CF with an R117H mutation in the CFTR gene<\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i> <\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\">Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the <i>F508del<\/i> mutation in the second allele. The confirmed <i>R117H <\/i>poly\u2011T variant was <i>5T <\/i>in 38 patients<i> <\/i>and <i>7T <\/i>in 16 patients. At baseline, mean predicted FEV<sub>1<\/sub> was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI \u20111.1, 5.4).<\/p> <p class=\"MsoNormal\"> <\/p> <p class=\"MsoNormal\">A pre\u2011planned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV<sub>1<\/sub> through week 24 of 4.5 percentage points in the ivacaftor group versus \u20110.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).<\/p> <p class=\"MsoNormal\"> <\/p> <p class=\"MsoNormal\">In a subgroup analysis in patients with a confirmed <i>R117H\u20115T <\/i>genetic variant, the difference in the mean absolute change from baseline through week<span lang=\"EN-GB\"> <\/span>24 in percent predicted FEV<sub>1<\/sub> between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed <i>R117H\u20117T <\/i>genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI \u20118.1, 8.5).<\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQ\u2011R respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 7: study in paediatric patients <\/span><span lang=\"EN-GB\">with CF <\/span><\/i><i><span lang=\"EN-GB\">aged 2 to less than 6<\/span><span lang=\"EN-GB\"> years with G551D or another gating mutation<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetic profile, safety and efficacy of ivacaftor in 34 patients aged 2 to less than 6 years with CF who had a <i>G551D<\/i>, <i>G1244E<\/i>, <i>G1349D<\/i>,<i> G178R<\/i>,<i> G551S<\/i>,<i> S1251N<\/i>,<i> S1255P<\/i>,<i> S549N<\/i> or<i> S549R<\/i><i> <\/i>mutation in the <i>CFTR<\/i> gene were assessed in a 24\u2011week uncontrolled study with ivacaftor (patients weighing less than 14 kg received ivacaftor 50 mg and patients weighing 14 kg or more received ivacaftor 75 mg). Ivacaftor was administered orally every 12 hours with fat\u2011containing food in addition to their prescribed CF therapies.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients in study 7 were aged 2 to less than 6 years (mean age 3 years). Twenty\u2011six patients out of the 34 enrolled (76.5%) had a <i>CFTR<\/i> genotype <i>G551D\/F508del<\/i> with only 2 patients with a non\u2011<i>G551D<\/i> mutation (<i>S549N<\/i>). The mean (SD) sweat chloride at baseline (n = 25) was 97.88 mmol\/L (14.00). The mean (SD) faecal elastase\u20111 value at baseline (n = 27) was 28 \u00b5g\/g (95).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary endpoint of safety was evaluated through week 24 (see section 4.8). Secondary and exploratory efficacy endpoints evaluated were absolute change from baseline in sweat chloride through 24 weeks of treatment, absolute change from baseline in weight, body mass index (BMI) and stature (supported by weight, BMI and stature z-scores) at 24 weeks of treatment, and measures of pancreatic function such as faecal elastase\u20111. Data on percent predicted FEV<sub>1<\/sub> (exploratory endpoint) were available for 3 patients in the ivacaftor 50 mg group and 17 patients in the 75 mg dosing group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/s><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The mean (SD) overall (both ivacaftor dosing groups combined) absolute change from baseline in BMI at week 24 was 0.32 kg\/m<sup>2<\/sup> (0.54) and the mean (SD) overall change in BMI\u2011for\u2011age z\u2011score was 0.37 (0.42). The mean (SD) overall change in stature-for-age z-score was \u20110.01 (0.33). The mean (SD) overall change from baseline in faecal elastase\u20111 (n = 27) was 99.8 \u00b5g\/g (138.4). Six patients with initial levels below 200 \u00b5g\/g achieved, at week 24, a level of \u2265 200 \u00b5g\/g. The mean (SD) overall change in percent predicted FEV<sub>1 <\/sub>from baseline at week 24 (exploratory endpoint) was 1.8 (17.81).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 8: study in paediatric patients <\/span><span lang=\"EN-GB\">with CF <\/span><\/i><i><span lang=\"EN-GB\">aged less than 24 months<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetic profile, safety, and efficacy of ivacaftor in patients with CF aged 6 months to less than 24 months were assessed in a completed cohort of patients in an on-going 24\u2011week, open\u2011label, phase 3 clinical study in patients aged less than 24 months (study 8).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Part B of study 8 enrolled 19 patients aged 12 months to less than 24 months (mean age 15.2 months at baseline), with 18 patients completing the 24\u2011week treatment period, 11 patients aged 6 months to less than 12 months (mean age 9.0 months at baseline) with all 11 patients completing the 24\u2011week treatment period, and 6 patients aged 4 months to less than 6 months (mean age 4.5 months at baseline) with all 6 patients completing the 24\u2011week treatment period. Patients received ivacaftor 25 mg, 50 mg or 75 mg according to their age and weight at each study visit (see section 4.2). Ivacaftor was administered orally every 12 hours with fat<\/span><span lang=\"EN-GB\" style='font-family:\"MS Mincho\"'>\u2011<\/span><span lang=\"EN-GB\">containing food. Patients continued on their prescribed standard\u2011of\u2011care CF therapies.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part B of study 8 the primary endpoint of safety was evaluated through 24 weeks (see section 4.8). Secondary endpoints were evaluation of pharmacokinetics and the absolute change from baseline in sweat chloride through 24 weeks of treatment (see Pharmacodynamic effects). Tertiary endpoints included efficacy measures such as faecal elastase\u20111 and growth parameters.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For patients aged 4 months to less than 24 months, with both baseline and week 24 values available, mean (SD) weight\u2011for\u2011age, length\u2011for\u2011age, and weight\u2011for\u2011length z\u2011scores are provided in Table 7.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 7: Effect of ivacaftor on growth parameters in patients aged 4 months to less than 24 months with baseline and week 24 values<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableGrid1\" style=\"border-collapse:collapse;border:none\" width=\"601\"> <tr> <td rowspan=\"2\" style=\"width:126.9pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Parameter<\/span><\/b><\/p> <\/td> <td rowspan=\"2\" style=\"width:.75in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Number of patients<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:1.75in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Baseline<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:2.0in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"192\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change at week 24<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Mean<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(SD)<\/span><\/b><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Median<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(min, max)<\/span><\/b><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Mean<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(SD)<\/span><\/b><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Median<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(min, max)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2013for\u2011age   z\u2011score<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">35<\/span><\/p> <\/td> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.17 (0.85)<\/span><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.20<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-1.92, 1.79]<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.53)<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.26<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-0.54, 1.63]<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Length\u2011for\u2011age   z\u2011score<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.06 (1.03) <\/span><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.12<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-1.99, 2.79]<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.32<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.92)<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.47<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-1.81, 3.38]<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2011for\u2011length   z\u2011score<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.24 (1.01)<\/span><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.26<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">[-1.72, 2.16]<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.24<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">(0.98)<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.29<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">[-2.04, 2.22]<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients aged 4 months to less than 24 months, with both baseline and week 24 values available, 18 patients were pancreatic insufficient at baseline (defined as faecal elastase-1 &lt; 200 \u00b5g\/g) with mean (SD) faecal elastase\u20111 values at baseline and week 24 of 25.5 \u00b5g\/g (27.6) and 253.6 \u00b5g\/g (128.3), respectively (mean [SD] absolute change 228.41 \u00b5g\/g [128.3]). Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.2       Pharmacokinetic properties<\/span><\/h2> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (\u00b1 SD) for AUC and C<sub>max<\/sub> were 10600 (5260) ng*hr\/mL and 768 (233) ng\/mL, respectively. After every 12\u2011hour dosing, steady-state plasma concentrations of ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food the exposure of ivacaftor increased approximately 2.5- to 4\u2011fold. Therefore, ivacaftor should be administered with fat\u2011containing food. The median (range) t<sub>max <\/sub>is approximately 4.0 (3.0; 6.0) hours in the fed state.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ivacaftor granules (2 x 75<\/span><span lang=\"EN-GB\"> mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0-\u221e<\/sub> and 0.918 (0.750, 1.12) for C<sub>max<\/sub>. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1\u2011acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor 150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (\u00b1 SD) apparent volume of distribution was 353 L (122) .<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is extensively metabolised in humans. <i>In vitro<\/i> and <i>in vivo<\/i> data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one\u2011sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one\u2011fiftieth the potency of ivacaftor and is not considered pharmacologically active.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The effect of the CYP3A4*22 heterozygous genotype on ivacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose adjustment of ivacaftor is considered necessary. The effect of CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half\u2011life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL\/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (\u00b1SD) CL\/F for a single 150 mg dose was 17.3 (8.4) L\/hr in healthy subjects.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Linearity\/non\u2011linearity<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had similar ivacaftor C<sub>max<\/sub> (mean [\u00b1 SD] of 735 [331] ng\/mL) but an approximately two-fold increase in ivacaftor AUC<sub>0-<\/sub><\/span><sub><span style=\"font-family:SimSun\">\u221e<\/span><\/sub><span lang=\"EN-GB\"> (mean [\u00b1 SD] of 16800 [6140] ng*hr\/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady-state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady-state C<sub>min<\/sub> values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. Based on these results, a modified regimen of Kalydeco monotherapy is recommended for patients with moderate hepatic impairment (see section 4.2)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor have not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. The use of Kalydeco in patients with severe hepatic impairment is therefore not recommended unless the benefits outweigh the risks (see section 4.2 and section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No dose adjustment is considered necessary for patients with mild hepatic impairment.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment. In a human pharmacokinetic study, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No dose adjustments are recommended for mild and moderate renal impairment. However, caution is recommended when administering ivacaftor to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end-stage renal disease (see sections 4.2 and 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Race<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Gender<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetic parameters of ivacaftor are similar in males and females.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Clinical studies of ivacaftor as monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 8. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal\"><b><span lang=\"EN-GB\">Table 8: Mean (SD) ivacaftor exposure by age group<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.66%;margin-left:5.45pt;border-collapse:collapse;border:none\" width=\"99%\"> <thead> <tr style=\"height:13.7pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"56%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Age group<\/span><\/b><\/p> <\/td> <td style=\"width:15.24%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <\/td> <td style=\"width:12.34%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">C<sub>min, ss<\/sub> (ng\/mL)<\/span><\/b><\/p> <\/td> <td style=\"width:15.68%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"PT\">AUC<\/span><sub><span lang=\"EN-GB\">\u03c4<\/span><\/sub><\/b><b><sub><span lang=\"PT\">,ss<\/span><\/sub><\/b><b><span lang=\"PT\"> (ng*h\/mL)<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4 months to less than 6 months (<\/span><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\">5 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">25 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">371 (183)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6480 (2520)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 months to less than 12 months   (5 kg to &lt; 7 kg) <sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">25 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">336<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5410<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 months to less than 12 months   (7 kg to &lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">508 (252)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9140 (4200)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 months to less than   24 months (7 kg to &lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">440 (212)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9050 (3050)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 months to less than   24 months (<\/span><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 14 kg to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">451 (125)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9600 (1800)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2- to 5-year-olds (&lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">577 (317)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10500 (4260)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2- to 5-year-olds (\u2265 14 kg   to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">629 (296)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">11300 (3820)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6- to 11-year-olds <sup>\u2020<\/sup> (\u2265 14 kg   to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">641 (329)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10760 (4470)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6- to 11-year-olds <sup>\u2020<\/sup> (\u2265 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">150 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">958 (546)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">15300 (7340)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12- to 17-year-olds<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">150 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">564 (242)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9240 (3420)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adults (\u2265 18 years old)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">150 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">701 (317)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10700 (4100)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><sup>       <\/sup><span style=\"font-size:9.0pt\">Values based on data from a single patient; standard deviation not reported.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;position:relative; top:-3.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Exposures in 6\u2011 to 11\u2011year\u2011olds are predictions based on simulations from the population PK model using data obtained for this age group.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy and fertility<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The No\u2011Observed\u2011Adverse\u2011Effect\u2011Level (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Peri\u2011 and post\u2011natal development<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile animal studies<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7\u2011week old rats, nor in 3.5 to 5\u2011month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL PARTICULARS<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Silica, colloidal anhydrous<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hypromellose acetate succinate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Magnesium stearate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Mannitol<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Sucralose<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Sodium laurilsulfate (E487)<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">6.3       Shelf life<\/span><\/h2> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Once mixed, the mixture has been shown to be stable for one hour.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">The granules are packed in a Biaxially Oriented Polyethylene Terephthalate\/Polyethylene\/Foil\/Polyethylene (BOPET\/PE\/Foil\/PE) sachet.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pack size of 56 sachets (contains 4 individual wallets with 14 sachets per wallet)<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and other handling<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>7.       MARKETING AUTHORISATION HOLDER<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/003<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/004<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/006<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of first authorisation: 23 July 2012<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of latest renewal: 28 April 2017<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>10.     DATE OF REVISION OF THE TEXT<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>http:\/\/www.ema.europa.eu.<\/u><\/span><\/p> <u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/u> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p> <p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'>Annex II<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE <\/span><\/b><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/b><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\" style=\"text-transform:none\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">C.      OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\" style=\"text-transform:none;font-weight:normal\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman Bold\"; text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"TitleB\"><span lang=\"EN-GB\">A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Name and address of the manufacturer(s) responsible for batch release<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Almac Pharma Services (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Finnabair Industrial Estate<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dundalk<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Co. Louth<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">A91 P9KD<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Almac Pharma Services Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Seagoe Industrial Estate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Craigavon<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Co. Armagh BT63 5UA<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">United Kingdom<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.<\/span><\/p> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/p> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'>Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).<\/span><\/p> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">C.      Other conditions and requirements of the Marketing Authorisation<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom: 0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Periodic safety update reports (PSURs)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.85pt;line-height:normal\"><span lang=\"EN-GB\">The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001\/83\/EC and any subsequent updates published on the European medicines web-portal.<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p> <p class=\"TitleB\"><span lang=\"EN-GB\">D.      Conditions or restrictions with regard to the safe and effective use of the medicinal product<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"NormalAgency\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Risk management plan (RMP)<\/span><\/b><\/p> <p class=\"NormalAgency\"><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><span lang=\"EN-GB\">An updated RMP should be submitted:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom: 0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">At the request of the European Medicines Agency;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom: 0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit\/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p> <p class=\"NormalAgency\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Obligation to conduct post-authorisation measures<\/span><\/b><\/p> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; layout-grid-mode:line'> <\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif; layout-grid-mode:line'>The MAH shall complete, within the stated timeframe, the below measures:<\/span><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif; layout-grid-mode:line'> <\/span><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableGrid1\" style=\"border-collapse:  collapse;border:none\"> <tr> <td style=\"width:3.75in;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"360\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;   font-family:\"Times New Roman\",serif;layout-grid-mode:line'>Description<\/span><\/b><\/p> <\/td> <td style=\"width:189.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;   font-family:\"Times New Roman\",serif;layout-grid-mode:line'>Due date<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:3.75in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"360\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Long-term effectiveness study to compare disease progression among   children with CF who have a specified CFTR gating mutation and are aged 2   through 5 years at the time of Kalydeco treatment initiation versus disease progression   among concurrent matched cohort of children with CF who have never received   Kalydeco treatment.<\/span><\/p> <\/td> <td style=\"width:189.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\">Interim analysis 1: December 2017<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\">Interim analysis 2: December 2019<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Interim analysis 3: December 2021<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Final report: December 2023<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:28.3pt;text-align:center; line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.3pt;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX III<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif; color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal;background:white\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Outer carton<\/span><span lang=\"EN-GB\"> FOR BLISTER \u2013 56-TABLET PACK<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each tablet contains 150 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"left\" class=\"TitleA\" style=\"margin-left:.5in;text-align:left;text-indent: -.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">56 tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Oral use <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">Take with fat-containing food. <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\">Do not break, chew or dissolve the tablets.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.         OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.         SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/002<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span style=\"background:lightgrey\">2D barcode carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">PC<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">SN<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"color:black\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"> <\/p> <b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt; font-family:\"Times New Roman\",serif'>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">BLISTERS \u2013 56\u2011TABLET PACK<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         NAME OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin:0in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Outer carton<\/span><span lang=\"EN-GB\"> FOR BLISTER CARD \u2013 28\u2011TABLET PACK <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each tablet contains 150 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">28 tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Oral use <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor has told you to.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">Take with fat-containing food.<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\">Do not break, chew or dissolve the tablets.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Insert tab below to close<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Open<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.         OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.         SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/005<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt;color:black\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:lightgrey\">2D barcode carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"color:black\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt;color:black\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">PC<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">SN<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">NN<\/span><\/p> <b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin:0in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif; color:black;text-transform:uppercase'>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black;text-transform:uppercase\">BLISTER<\/span><span lang=\"EN-GB\" style=\"color:black\"> CARD \u2013 28-TABLET PACK <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">Kalydeco 150 mg film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">2.         STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">Each Kalydeco tablet contains 150 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p align=\"left\" class=\"TitleA\" style=\"margin-left:.5in;text-align:left;text-indent: -.5in\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">7 tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"color:black\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Oral use <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor has told you to.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">Take with fat-containing food.<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\">Do not break, chew or dissolve the tablets.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\">Mon. Tue. Wed. Thu. Fri. Sat. Sun.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.         OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.         SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/005<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">BLISTERS \u2013 28-TABLET PACK<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         NAME OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vertex<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin:0in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Outer carton<\/span><span lang=\"EN-GB\"> FOR BOTTLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each tablet contains 150 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">56 tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Oral use<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><b> <\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">Take with fat-containing food.<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\">Do not break, chew or dissolve the tablets.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.         OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">8.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/001<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span style=\"background:lightgrey\">2D barcode carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">PC<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">SN<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"color:black\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin:0in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">BOTTLE LABEL<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 150 mg film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each tablet contains 150 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">56 tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Oral use<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/001<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt; font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Outer carton<\/span><span lang=\"EN-GB\"> FOR SACHET<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules contains 25 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"background:lightgrey\">Granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">56 sachets<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">4 individual wallets with 14 sachets per wallet<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Oral use<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><b><span lang=\"EN-GB\">Instructions for use<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mix the entire content of a sachet with 5 mL of age\u2011appropriate soft food or liquid that is at or below room temperature and consume it completely.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Use within one hour after mixing, just before or after a fat\u2011containing meal or snack.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lift here to open<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.         OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">8.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">9.         SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/006<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 25 mg granules<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\"><span style=\"background:lightgrey\">2D barcode carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">PC<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; text-autospace:none\">SN<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">NN<\/p> <b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt; font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">WALLET<\/span><span lang=\"EN-GB\"> FOR SACHET<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules contains 25 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"background:lightgrey\">Granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">14 sachets<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Oral use<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><b><span lang=\"EN-GB\">Instructions for use<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mix the entire content of a sachet with 5 mL of age-appropriate soft food or liquid that is at or below room temperature and consume it completely. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Use within one hour after mixing, just before or after a fat-containing meal or snack.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Use all 7 days\u2019 doses before starting a new wallet.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Morning<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Evening<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Mon. Tue. Wed. Thu. Fri. Sat. Sun.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/006<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt; font-family:\"Times New Roman\",serif'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">SACHETS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 25 mg granules<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Oral use<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         METHOD OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Vertex Pharmaceuticals (Ireland) Limited<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin:0in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Outer carton<\/span><span lang=\"EN-GB\"> FOR SACHET<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules contains 50 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"background:lightgrey\">Granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">56 sachets<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">4 individual wallets with 14 sachets per wallet<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Oral use<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mix the entire content of a sachet with 5 mL of age-appropriate soft food or liquid that is at or below room temperature and consume it completely.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Use within one hour after mixing, just before or after a fat\u2011containing meal or snack.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lift here to open<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.      SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.      EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"> <\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/003<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 50 mg granules<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span style=\"background:lightgrey\">2D barcode carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">PC<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">SN<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">NN<\/p> <b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt; font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">WALLET<\/span><span lang=\"EN-GB\"> FOR SACHET<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules contains 50 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"background:lightgrey\">Granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">14 sachets<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Oral use<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mix the entire content of a sachet with 5 mL of age-appropriate soft food or liquid that is at or below room temperature and consume it completely. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Use within one hour after mixing, just before or after a fat-containing meal or snack.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Use all 7 days\u2019 doses before starting a new wallet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Morning<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Evening<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Mon. Tue. Wed. Thu. Fri. Sat. Sun.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.         OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">8.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.         SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/003<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin:0in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">SACHETS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 50 mg granules<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Oral use<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Vertex Pharmaceuticals (Ireland) Limited<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin:0in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">Outer carton<\/span><span lang=\"EN-GB\"> FOR SACHET<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules contains 75 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"background:lightgrey\">Granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">56 sachets<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">4 individual wallets with 14 sachets per wallet<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Oral use<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mix the entire content of a sachet with 5 mL of age-appropriate soft food or liquid that is at or below room temperature and consume it completely.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Use within one hour after mixing, just before or after a fat\u2011containing meal or snack.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lift here to open<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.      SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.      EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"> <\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/004<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 75 mg granules<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span style=\"background:lightgrey\">2D barcode carrying the unique identifier included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin:0in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\">PC<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">SN<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"color:black\">NN<\/span><\/p> <b><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif; color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt; font-family:\"Times New Roman\",serif'>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">WALLET<\/span><span lang=\"EN-GB\"> FOR SACHET<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         STATEMENT OF ACTIVE SUBSTANCE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules contains 75 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Contains lactose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         PHARMACEUTICAL FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span style=\"background:lightgrey\">Granules in sachet<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">14 sachets<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         METHOD AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Read the package leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Oral use<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b>Instructions for use<\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mix the entire content of a sachet with 5 mL of age-appropriate soft food or liquid that is at or below room temperature and consume it completely.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Use within one hour after mixing, just before or after a fat-containing meal or snack.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Use all 7 days\u2019 doses before starting a new wallet.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Morning<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Evening<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Mon. Tue. Wed. Thu. Fri. Sat. Sun.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">7.         OTHER SPECIAL WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">8.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.         SPECIAL STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">10.       SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">11.       NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <p class=\"MsoNormalIndent\" style=\"margin-bottom:0in;text-indent:-.5in\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">12.       MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EU\/1\/12\/782\/004<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">13.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">14.       GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">15.       INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">16.       INFORMATION IN BRAILLE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h2 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;border:none;padding:0in\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">18.       UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA<\/span><\/h2> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"> <\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <h1 style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in; text-indent:-.5in;line-height:normal;border:none;padding:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/h1> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">SACHETS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">1.         NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Kalydeco 75 mg granules<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Oral use<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">2.         METHOD OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">3.         EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">4.         BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">5.         CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; border:none;padding:0in\"><b><span lang=\"EN-GB\">6.         OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\">Vertex Pharmaceuticals (Ireland) Limited<\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Verdana\",sans-serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/u> <p class=\"No-numheading3Agency\" style=\"margin:0in;page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif;text-transform:uppercase'> <\/span><\/p> <p class=\"TitleB\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\" style=\"font-weight:normal\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Package leaflet: Information for the patient<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal; background:white\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Kalydeco 150 mg film-coated tablets<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">What is in this leaflet<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\">1.   What Kalydeco is and what it is used for<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">2.   What you need to know before you take Kalydeco<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">3.   How to take Kalydeco<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">4.   Possible side effects<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">5.   How to store Kalydeco<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">6.   Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">What Kalydeco is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">Kalydeco contains the active ingredient ivacaftor. Ivacaftor acts at the level of the cystic fibrosis transmembrane conductance regulator (CFTR), a protein that forms a channel at the cell surface that allows the movement of particles such as chloride in and out of the cell. Due to mutations in the <i>CFTR<\/i> gene (see below), chloride movement is reduced in those with cystic fibrosis (CF). Ivacaftor helps certain abnormal CFTR proteins open more often to improve chloride movement in and out of the cell.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><a name=\"_Hlk46239356\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Kalydeco tablets are indicated: <\/span><\/a><\/p> <p class=\"labeltext\" style=\"margin-left:28.35pt;text-indent:-.25in;page-break-after: avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">As monotherapy for patients aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an <i>R117H<\/i><\/span><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CFTR<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> mutation or one of the following gating mutations in the <i>CFTR<\/i> gene: <i>G551D<\/i>, <i>G1244E<\/i>, <i>G1349D<\/i>, <i>G178R<\/i>, <i>G551S<\/i>, <i>S1251N<\/i>, <i>S1255P<\/i>, <i>S549N<\/i> or <i>S549R<\/i>.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in; text-autospace:none\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>In combination with tezacaftor\/ivacaftor tablets for patients aged 12 years and older with CF who have two <i>F508del <\/i>mutations in the <i>CFTR <\/i>gene (homozygous for the <i>F508del <\/i>mutation) or who have an <i>F508del <\/i>mutation and certain other second mutations (heterozygous for the <i>F508del<\/i> mutation). If you have been prescribed Kalydeco to be taken with tezacaftor\/ivacaftor, read the tezacaftor\/ivacaftor package leaflet. It contains important information about how to take these two medicines.<\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace: none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>In combination with ivacaftor\/tezacaftor\/elexacaftor tablets for patients aged 12 years and over with CF who are homozygous for the <i>F508del <\/i>mutation in the <i>CFTR<\/i> gene or heterozygous for <i>F508del<\/i> in the <i>CFTR<\/i> gene with a minimal function (MF) mutation. A minimal function mutation is defined as one that results either in no CFTR protein being produced or a CFTR protein that does not function, and which is unlikely to respond to ivacaftor alone and tezacaftor\/ivacaftor. If you have been prescribed Kalydeco to be taken with ivacaftor\/tezacaftor\/elexacaftor, read the ivacaftor\/tezacaftor\/elexacaftor package leaflet. It contains important information about how to take these two medicines.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:0in;text-indent:0in;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">What you need to know before you take Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Do not take Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>if you are allergic to ivacaftor or any of the other ingredients of this medicine (listed in section 6).<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-.25in; page-break-after:avoid\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>Talk to your doctor if you have liver problems or have previously had them. Your doctor may need to adjust your dose.<\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>Increased liver enzymes in the blood have been seen in some people receiving Kalydeco (alone or in combination with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). Tell your doctor right away if you have any of these symptoms, which may be a sign of liver problems:<\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Pain or discomfort in the upper right stomach (abdominal) area<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Yellowing of the skin or the white part of the eyes<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Loss of appetite<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nausea or vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Dark urine<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:.25in;margin-bottom:.0001pt;line-height:normal\"><span lang=\"EN-GB\">Your doctor will do some blood tests to check your liver before and during treatment, particularly during the first year and especially if your blood tests showed high liver enzymes in the past.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:.25in;margin-bottom:.0001pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>Talk to your doctor if you have kidney problems or have previously had them.<\/p> <p class=\"MsoNormal\" style=\"margin-left:10.35pt\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>Kalydeco (alone or in combination with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is not recommended if you have undergone an organ transplant.<\/p> <p class=\"MsoNormal\" style=\"margin-left:10.35pt\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>Talk to your doctor if you are using hormonal contraception \u2013 for example, women using the contraceptive pill. This may mean you are more likely to get a rash while taking Kalydeco in combination with ivacaftor\/tezacaftor\/elexacaftor.<\/p> <p class=\"MsoNormal\" style=\"margin-left:10.35pt\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>Abnormality of the eye lens (cataract) without any effect on vision has been noted in some children and adolescents treated with Kalydeco (alone or in combination with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). Your doctor may perform some eye examinations prior to and during treatment.<\/p> <p class=\"MsoNormal\" style=\"margin-left:10.35pt\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>Kalydeco (alone or in combination with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) should only be used if you have one of the mutations in the <i>CFTR<\/i> gene indicated in section 1 (What Kalydeco is and what it is used for).<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Children and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Do not give this medicine to children under 4 months of age as it is not known if ivacaftor is safe and effective in these children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not give this medicine in combination with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor to children under 12 years of age as it is not known if they are safe and effective for them.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Other medicines and Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Some medicines can affect how Kalydeco works or make side effects more likely. In particular, tell your doctor if you are taking any of the medicines listed below. Your doctor may decide to adjust your dose or that you need extra check-ups.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Antifungal medicines<\/b> (used for the treatment of fungal infections). These include fluconazole, itraconazole, ketoconazole, posaconazole, and voriconazole.<\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent: -.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Antibiotic medicines<\/b> (used for the treatment of bacterial infections). These include clarithromycin, erythromycin, rifabutin, rifampicin, and telithromycin .<\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent: -.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Epilepsy<\/b><b> medicines<\/b> (used for the treatment of epileptic seizures). These include carbamazepine, phenobarbital, and phenytoin. <\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent: -.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Herbal medicines.<\/b> These include St. John\u2019s wort (Hypericum perforatum).<\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent: -.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Immunosuppressants<\/b> (used after an organ transplantation). These include ciclosporin, everolimus, sirolimus, and tacrolimus, . <\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent: -.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Cardiac glycosides<\/b> (used for the treatment of some heart conditions). These include digoxin.<\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent: -.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Anticoagulant medicines<\/b> (used to prevent blood clots). These include warfarin. <\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-left:28.35pt;text-indent: -.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Medicines for diabetes.<\/b> These include glimepiride and glipizide. <\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b>Medicines for lowering blood pressure.<\/b> These include verapamil.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Kalydeco with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Avoid food or drink containing grapefruit during treatment with Kalydeco as they may increase the side effects of Kalydeco by increasing the amount of ivacaftor in your body.<\/span><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. <\/span>It may be better to avoid using Kalydeco during pregnancy, if possible, and <span lang=\"EN-GB\">your doctor will help you decide what is best for you and your child.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is unknown whether ivacaftor is excreted in human milk. If you plan to breast-feed, ask your doctor for advice before taking Kalydeco.<\/span><span lang=\"EN-GB\" style='font-size:10.5pt;font-family:\"TimesNewRoman\",serif'> <\/span>Your doctor will decide whether to recommend that you stop breast-feeding or for you to stop ivacaftor therapy. Your doctor will take into account the benefit of breast-feeding for the child and the benefit of therapy for you.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco can make you dizzy. If you feel dizzy, do not drive, cycle or use machines.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Important information about the contents of Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Kalydeco contains lactose. <\/span><\/b><span lang=\"EN-GB\">If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><b><span lang=\"EN-GB\">Kalydeco<\/span><span lang=\"EN-GB\"> contains less than 1 mmol sodium<\/span><\/b><span lang=\"EN-GB\"> (23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">How to take Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Always take this medicine exactly as your doctor has told you to. Check with your doctor if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Your doctor will determine which medicine and dose is right for you.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco dosing recommendations are provided in Table 1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 1: Dosing recommendations<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"width:469.6pt;border-collapse:collapse;border:none\" width=\"626\"> <tr style=\"height:16.25pt\"> <td style=\"width:148.2pt;border:solid windowtext 1.0pt;padding:   0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"198\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\"> <\/span><\/b><\/p> <\/td> <td style=\"width:192.35pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"256\"> <p align=\"center\" class=\"labeltext\" style=\"text-align:center;page-break-after:   avoid\"><b><span style=\"font-size:11.0pt\">Morning<\/span><\/b><\/p> <\/td> <td style=\"width:129.05pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"172\"> <p align=\"center\" class=\"labeltext\" style=\"text-align:center;page-break-after:   avoid\"><b><span style=\"font-size:11.0pt\">Evening<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Kalydeco as monotherapy<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:16.25pt\"> <td style=\"width:148.2pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"198\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">6 years and older, \u226525 kg<\/span><\/p> <\/td> <td style=\"width:192.35pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"256\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One Kalydeco 150 mg tablet<\/span><\/p> <\/td> <td style=\"width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"172\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One Kalydeco 150 mg tablet<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Kalydeco in combination with tezacaftor\/ivacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td style=\"width:148.2pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"198\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:192.35pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"256\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One tezacaftor 100 mg\/ivacaftor 150 mg tablet<\/span><\/p> <\/td> <td style=\"width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"172\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One Kalydeco 150 mg tablet<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Kalydeco in combination with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td style=\"width:148.2pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"198\"> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:192.35pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"256\"> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">Two ivacaftor 75 mg\/tezacaftor   50 mg\/elexacaftor 100 mg tablets<\/span><\/p> <\/td> <td style=\"width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"172\"> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">One Kalydeco 150 mg   tablet<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Take the tablets morning and evening doses approximately 12 hours apart with food that contains fat. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">You must keep using all other medicines you use, unless your doctor tells you to stop using any.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you have liver problems, either moderate or severe, your doctor may need to reduce the dose of your tablets, because your liver will not clear the medicine as fast as in people who have normal liver function.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Use in children<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Other forms of this medicine (granules in sachet) are more suitable for children under 6 years of age; ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">This medicine is for oral use. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Swallow the tablet whole. Do not break, chew or dissolve the tablets. Take Kalydeco tablets with food that contains fat.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Meals or snacks that contain fat include those prepared with butter or oils or those containing eggs. Other fat-containing foods are:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Cheese, whole milk, whole-milk dairy products, yogurt, chocolate<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Meats, oily fish<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Avocados, hummus, soy-based products (tofu)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nuts, fat-containing nutritional bars or drinks<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:12.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you take more Kalydeco than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">You may experience side effects, including those mentioned in section 4 below. If so, contact your doctor or pharmacist to ask for advice. If possible, have your medicine and this leaflet with you.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">If you forget to take Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Take the missed dose if less than 6 hours have passed since the time you missed the dose. Otherwise, wait until your next scheduled dose as you normally would. Do not take a double dose to make up for a forgotten dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">If you stop taking Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Take Kalydeco for as long as your doctor recommends. Do not stop unless your doctor advises you to. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><a name=\"_Hlk45322707\"><b><span lang=\"EN-GB\">4.         Possible side effects<\/span><\/b><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Serious side effects <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Stomach (abdominal) ache and increased liver enzymes in the blood. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Possible signs of liver problems<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Increased liver enzymes in the blood are common in patients with CF. These may be signs of liver problems: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Pain or discomfort in the upper right area of the stomach (abdominal) area<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Yellowing of the skin or white part of the eyes<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Loss of appetite<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nausea or vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Dark urine<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><b><span lang=\"EN-GB\">Tell<\/span><\/b><b><span lang=\"EN-GB\"> your doctor straight away<\/span><\/b><span lang=\"EN-GB\"> if you get any of these.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common<\/span><\/b><span lang=\"EN-GB\"> side effects (may affect more than 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Upper respiratory tract infection (the common cold), including sore throat and nasal congestion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Headache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Dizziness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Diarrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Stomach or abdominal pain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Changes in the type of bacteria in mucus<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Increased liver enzymes (signs of stress on the liver)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Rash <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Common<\/span><\/b><span lang=\"EN-GB\"> side effects (may affect up to 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Runny nose<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Ear pain, ear discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Ringing in the ears<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Redness inside the ear<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Inner ear disorder (<\/span><span lang=\"EN-GB\">feeling dizzy or spinning<\/span><span lang=\"EN-GB\">)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Sinus problems (sinus congestion)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Redness in the throat<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Breast mass<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Feeling sick (nausea)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Flu<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Low blood sugar (hypoglycaemia)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Abnormal breathing (shortness of breath or difficulty breathing)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Wind (flatulence)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Spots (acne)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Itchy skin <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Increased creatine phosphokinase (sign of muscle breakdown) seen in blood tests<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Uncommon<\/span><\/b><span lang=\"EN-GB\"> side effects (may affect up to 1 in 100 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Ear congestion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Breast inflammation <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Enlargement of the breast in males<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nipple changes or pain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Wheezing<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Increased blood pressure<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Additional side effects in children and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Side effects seen in children and adolescents are similar to those observed in adults. However, increased liver enzymes in the blood are more frequently seen in young children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via <span style=\"background:lightgrey\">the national reporting system listed in <\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a>. By reporting side effects you can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.5in;text-indent:-.5in;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>                   <\/span><\/span><\/b><b><span lang=\"EN-GB\">How to store Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicine does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">What Kalydeco contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">The active substance is ivacaftor. Each film\u2011coated tablet contains 150 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The other ingredients are:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-13.5pt;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Tablet core: cellulose microcrystalline, lactose monohydrate, hypromellose acetate succinate, croscarmellose sodium, sodium laurilsulfate (E487), silica, colloidal anhydrous, and magnesium stearate.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-13.5pt;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Coating:<i> <\/i>polyvinyl alcohol, titanium dioxide (E171), macrogol (PEG 3350), talc, indigo carmine aluminium lake (E132) and carnauba wax.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-13.5pt;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Printing ink: <\/span><span lang=\"EN-GB\">shellac, iron oxide black (E172), propylene glycol (E1520) and ammonia solution, concentrated.<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:0in\">See the end of section 2 - Important information about the contents of Kalydeco.<\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Kalydeco looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco 150 mg film-coated tablets are light blue, capsule\u2011shaped, 16.5 mm x 8.4 mm, and printed with \u201cV 150\u201d in black ink on one side and plain on the other.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco is available in the following pack sizes:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Blister card pack containing 28 film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Blister pack containing 56 film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Bottle containing 56 film\u2011coated tablets<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><a name=\"OLE_LINK2\"><\/a><a name=\"OLE_LINK3\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Tel: +353 (0)1 761 7299<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Almac Pharma Services (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Finnabair Industrial Estate<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dundalk<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Co. Louth<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">A91 P9KD<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Almac Pharma Services Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Seagoe Industrial Estate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Craigavon<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">County Armagh<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">BT63 5UA<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">United Kingdom<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">This leaflet was last revised in<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Detailed information on this medicine is available on the European Medicines Agency website: <a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a>. There are also links to other websites about rare diseases and treatments.<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"margin-right:-.1pt;text-align:center; line-height:normal\"><b><span lang=\"EN-GB\">Package leaflet: Information for the patient<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal; background:white\"><span lang=\"EN-GB\"> <\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">ivacaftor<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before your child starts taking this medicine because it contains important information for your child.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family: Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">If you have any further questions, ask your child\u2019s doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">This medicine has been prescribed for your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as your child\u2019s.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">If your child gets any side effects, talk to your child\u2019s doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">What is in this leaflet<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\">1.   What Kalydeco is and what it is used for<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">2.   What you need to know before your child takes Kalydeco<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">3.   How to take Kalydeco<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">4.   Possible side effects<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">5.   How to store Kalydeco<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height: normal\"><span lang=\"EN-GB\">6.   Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\">1.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">What Kalydeco is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">Kalydeco contains the active ingredient ivacaftor. <\/span>Ivacaftor acts at the level of the cystic fibrosis transmembrane conductance regulator (CFTR), a protein that forms a channel at the cell surface that allows the movement of particles such as chloride in and out of the cell. Due to mutations in the <i>CFTR <\/i>gene (see below), chloride movement is reduced in those with cystic fibrosis (CF). Ivacaftor helps certain abnormal CFTR proteins open more often to improve chloride movement in and out of the cell.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"labeltext\"><span style=\"font-size:11.0pt\">Kalydeco granules are indicated for the treatment of babies and children aged 4 months and older and weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an<\/span><i><span style=\"font-size:11.0pt\"> <\/span><\/i><i><span style=\"font-size:11.0pt\">R117H CFTR<\/span><\/i><span style=\"font-size:11.0pt\"> mutation or one of the following gating mutations in the <i>CFTR<\/i> gene: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N <\/i>or<i> S549R<\/i>.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">2.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">What you need to know before your child takes Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Do not take Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt; font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">if your child is allergic to ivacaftor or any of the other ingredients of this medicine (listed in section 6).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Talk to your child\u2019s doctor if your child has liver problems or has had them previously. Your child\u2019s doctor may need to adjust your child\u2019s dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Increased liver enzymes in the blood have been seen in some people receiving Kalydeco. Tell your child\u2019s doctor right away if your child has any of these symptoms, which may be a sign of liver problems:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt; font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Pain or discomfort in the upper right stomach (abdominal) area<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt; font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Yellowing of the skin or the white part of the eyes<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt; font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Loss of appetite<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt; font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nausea or vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:42.55pt;text-indent:-.25in;line-height: normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt; font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Dark urine<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.25in;line-height:normal\"><span lang=\"EN-GB\">Your child\u2019s doctor will do some blood tests to check your child\u2019s liver before and during treatment, particularly during the first year and <\/span><span lang=\"EN-GB\">especially if blood tests showed high liver enzymes in the past.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.25in;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Talk to your child\u2019s doctor if you have been told your child has kidney problems or has previously had them. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Kalydeco is not recommended for patients who have undergone an organ transplant.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Abnormality of the eye lens (cataract) without any effect on vision has been noted in some children and adolescents during treatment. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\">Your child\u2019s doctor may perform some eye examinations prior to and during treatment with ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Children<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Do not give this medicine to children under 4 months of age as it is not known if ivacaftor is safe and effective in these children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Other medicines and Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Tell your child\u2019s doctor or pharmacist if your child is using, has recently used or might use any other medicines. Some medicines can affect how Kalydeco works or make side effects more likely. In particular, tell your child\u2019s doctor if your child is taking any of the medicines listed below. Your child\u2019s doctor may decide to adjust your child\u2019s dose or if extra check-ups are needed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Antifungal medicines<\/span><\/b><span lang=\"EN-GB\"> (used for the treatment of fungal infections). These include fluconazole, itraconazole, ketoconazole, posaconazole, and voriconazole.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Antibiotic medicines <\/span><\/b><span lang=\"EN-GB\">(used for the treatment of bacterial infections). These include, clarithromycin, erythromycin, rifabutin, rifampicin and telithromycin.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Epilepsy<\/span><\/b><b><span lang=\"EN-GB\"> medicines<\/span><\/b><span lang=\"EN-GB\"> (used for the treatment of epileptic seizures or fits). These include carbamazepine, phenobarbital, and phenytoin.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Herbal medicines<\/span><\/b><span lang=\"EN-GB\">. These include St. John\u2019s wort (<i>Hypericum perforatum<\/i>).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Immunosuppressants<\/span><\/b><span lang=\"EN-GB\"> (used after an organ transplantation). These include ciclosporin, everolimus, sirolimus, and tacrolimus. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Cardiac glycosides<\/span><\/b><span lang=\"EN-GB\"> (used for the treatment of some heart conditions). These include digoxin.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Anticoagulant medicines<\/span><\/b><span lang=\"EN-GB\"> (used to prevent blood clots). These include warfarin.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Medicines for diabetes<\/span><\/b><span lang=\"EN-GB\">. These include glimepiride and glipizide.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Medicines for lowering blood pressure<\/span><\/b><span lang=\"EN-GB\">. These include verapamil.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Kalydeco with food and drink<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Avoid giving your child food or drink containing grapefruit during treatment with Kalydeco as they may increase <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">the side effects of Kalydeco by increasing the amount of ivacaftor in <\/span><span style=\"font-size:11.0pt\">your child\u2019s body.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco can make your child dizzy. If your child feels dizzy, it is advised that your child does not ride his\/her bike or do anything else that needs his\/her full attention.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Important information about the contents of Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Kalydeco contains lactose. <\/span><\/b><span lang=\"EN-GB\">If you have been told by your child\u2019s doctor that your child has an intolerance to some sugars, contact your child\u2019s doctor before your child takes this medicine.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><b><span lang=\"EN-GB\">Kalydeco<\/span><span lang=\"EN-GB\"> contains less than 1 mmol sodium <\/span><\/b><span lang=\"EN-GB\">(23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.65pt;text-indent:-28.65pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">How to take Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Always give your child this medicine exactly as your child\u2019s doctor has told you to. Check with your child\u2019s doctor if you are not sure.<\/span><\/p> <p class=\"s15\" style=\"margin:0in\"><span class=\"s10\"> <\/span><\/p> <p class=\"s15\" style=\"margin:0in\"><span class=\"s10\"><span style=\"font-size:11.0pt\">Your child\u2019s doctor will determine the correct dose for your child.<\/span><\/span><span style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Your child must keep using all other medicines, unless your child\u2019s doctor tells him\/her to stop using any.<\/span><\/p> <p class=\"s15\" style=\"margin:0in\"><span class=\"s10\"><span style=\"font-size:11.0pt\"> <\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco dosing recommendations are provided in Table 1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 1: Dosing recommendations for children aged 4 months and older<\/span><\/b><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr style=\"height:11.45pt\"> <td style=\"width:93.3pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.45pt\" valign=\"top\" width=\"124\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Age<\/span><\/b><\/p> <\/td> <td style=\"width:101.35pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.45pt\" valign=\"top\" width=\"135\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Weight<\/span><\/b><\/p> <\/td> <td style=\"width:171.75pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.45pt\" valign=\"top\" width=\"229\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <\/td> <td style=\"width:81.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.45pt\" valign=\"top\" width=\"109\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Total daily dose<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td style=\"width:93.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"124\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">4 months to less than 6 months<\/span><\/p> <\/td> <td style=\"width:101.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"135\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">5 kg or more<\/span><\/p> <\/td> <td style=\"width:171.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"229\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">One sachet of 25 mg granules taken orally every 12 hours   with fat\u2011containing food<\/span><\/p> <\/td> <td style=\"width:81.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"109\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td rowspan=\"4\" style=\"width:93.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"124\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">6 months and older<\/span><\/p> <\/td> <td style=\"width:101.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"135\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">5 kg to less than 7 kg<\/span><\/p> <\/td> <td style=\"width:171.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"229\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">One Kalydeco sachet of 25 mg granules taken orally every   12 hours with fat\u2011containing food<\/span><\/p> <\/td> <td style=\"width:81.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"109\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.75pt\"> <td style=\"width:101.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.75pt\" valign=\"top\" width=\"135\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">7 kg to less   than 14 kg<\/span><\/p> <\/td> <td style=\"width:171.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.75pt\" valign=\"top\" width=\"229\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One Kalydeco sachet   of 50 mg granules taken orally every 12 hours with fat-containing food <\/span><\/p> <\/td> <td style=\"width:81.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.75pt\" valign=\"top\" width=\"109\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">100 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:11.45pt\"> <td style=\"width:101.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.45pt\" valign=\"top\" width=\"135\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">14 kg to   less than 25 kg<\/span><\/p> <\/td> <td style=\"width:171.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.45pt\" valign=\"top\" width=\"229\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One Kalydeco sachet   of 75 mg granules taken orally every 12 hours with fat-containing food <\/span><\/p> <\/td> <td style=\"width:81.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.45pt\" valign=\"top\" width=\"109\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">150 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:16.95pt\"> <td style=\"width:101.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.95pt\" valign=\"top\" width=\"135\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">25 kg or   more<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:253.7pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.95pt\" valign=\"top\" width=\"338\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Please refer   to Kalydeco tablets Package Leaflet<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">If your child has liver problems<\/span><\/b><span lang=\"EN-GB\">, your child\u2019s doctor may need to reduce the dose of Kalydeco as your child\u2019s liver will not clear the medicine as fast as in children who have normal liver function.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Moderate liver problems in children 6 months of age or older:<\/span><\/b><span lang=\"EN-GB\"> the dose may be reduced to one half of the indicated dose in the table above, that is one sachet once daily.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Severe liver problems in children 6 months of age or older:<\/span><\/b><span lang=\"EN-GB\"> the use is not recommended but your child\u2019s doctor will decide if it is appropriate for your child to use this medicine in which case the dose (as indicated in the table above) must be reduced to one sachet every other day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><a name=\"_Hlk36546718\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Liver problems in children between 4 months and 6 months of age:<\/span><\/b><\/a><span lang=\"EN-GB\"> the use is not recommended but your child\u2019s doctor will decide if it is appropriate for your child to use<a name=\"_Hlk36546744\"> and <\/a>what dose your child should have.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Kalydeco is for oral use.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Each sachet is for single use only.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Giving Kalydeco to your child:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Hold sachet of granules with cut line on top.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Shake sachet gently to settle contents.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Tear or cut sachet open along cut line.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Mix the entire content of a sachet with 5 mL of age-appropriate soft food or liquid. Food or liquid should be at room temperature or below. Some examples of age-appropriate soft foods or liquids include pur\u00e9ed fruits or vegetables, yogurt, applesauce, water, milk, <\/span><span lang=\"EN-GB\">breast milk, infant formula, <\/span><span lang=\"EN-GB\">or juice.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Once mixed, give the product to your child immediately. If this is not possible, give it within the following hour after mixing. Ensure that the mixture is completely and immediately consumed.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">A fat-containing meal or snack should be given to your child just before or just after dosing (some examples are provided below).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><i><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/i><\/b><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:0in;page-break-after:avoid\">Meals or snacks that contain fat include those prepared with butter or oils or those containing eggs. Other fat-containing foods are:<\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Cheese, whole milk, whole-milk dairy products, yogurt, <\/span><span lang=\"EN-GB\">breast milk, infant formula,<\/span><span lang=\"EN-GB\"> chocolate<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Meats, oily fish<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Avocados, hummus, soy-based products (tofu)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nuts, fat-containing nutritional bars or drinks<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If your child takes more Kalydeco than he\/she should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Your child may experience side effects, including those mentioned in section 4 below. If so, contact your child\u2019s doctor or pharmacist to ask for advice. If possible, have your child\u2019s medicine and this leaflet with you.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">If you forget to give your child Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Give the missed dose if less than 6 hours have passed since the time your child missed the dose. Otherwise, wait until your child\u2019s next scheduled dose as you normally would. Do not give your child a double dose to make up for a forgotten dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">If you stop giving your child Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Give Kalydeco to your child for as long as your child\u2019s doctor recommends. Do not stop unless your child\u2019s doctor advises you to. If you have any further questions on the use of this medicine, ask your child\u2019s doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\">4.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><b><span lang=\"EN-GB\">Serious side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">Stomach (abdominal) ache and increased liver enzymes in the blood. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Possible signs of liver problems<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Increased liver enzymes in the blood are common in patients with CF. These may be signs of liver problems: <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Pain or discomfort in the upper right area of the stomach (abdominal) area<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Yellowing of the skin or white part of the eyes<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Loss of appetite<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nausea or vomiting<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Dark urine<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">Tell your child\u2019s doctor straight away if he\/she gets any of these.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common<\/span><\/b><span lang=\"EN-GB\"> side effects (may affect more than 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt; font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Upper respiratory tract infection (the common cold), including sore throat and nasal congestion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Headache<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Dizziness<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Diarrhoea<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Rash<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Changes in the type of bacteria in mucus<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common<\/span><\/b><span lang=\"EN-GB\"> side effects (may affect up to 1 in 10 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Runny nose<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Ear pain, ear discomfort<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Ringing in the ears<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Redness inside the ear<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Inner ear disorder (feeling dizzy or spinning)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Sinus congestion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Redness in the throat<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Breast mass<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Uncommon<\/span><\/b><span lang=\"EN-GB\"> side effects (may affect up to 1 in 100 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Ear congestion<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Breast inflammation<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Enlargement of the breast in males<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Nipple changes or pain<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Additional side effects in children and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Side effects seen in children and adolescents are similar to those observed in adults. However, increased liver enzymes in the blood are more frequently seen in young children. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">If your child gets any side effects, talk to your child\u2019s doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via <span style=\"background:lightgrey\">the national reporting system listed in <\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a>. By reporting side effects you can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.4in;text-indent:-.4in;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\">5.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">How to store Kalydeco<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicine does not require any special storage conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Once mixed, the mixture has been shown to be stable for one hour.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal; page-break-after:avoid\"><b><span lang=\"EN-GB\">6.<span style='font:7.0pt \"Times New Roman\"'>              <\/span><\/span><\/b><b><span lang=\"EN-GB\">Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">What Kalydeco contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:.25in;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet:<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The active substance is ivacaftor. Each sachet contains 25 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><u><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet:<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The active substance is ivacaftor. Each sachet contains 50 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><u><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet:<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The active substance is ivacaftor. Each sachet contains 75 mg of ivacaftor.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">The other ingredients are: silica, colloidal anhydrous, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sucralose and sodium laurilsulfate <\/span><span lang=\"EN-GB\">(E487)<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:.25in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:0in\">See the end of section 2 - Important information about the contents of Kalydeco.<\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:0in\"> <\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">What Kalydeco looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet are white to off-white granules.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet are white to off-white granules.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet are white to off-white granules.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">The granules are supplied in sachets.<\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Pack size of 56 sachets (contains 4 individual wallets with 14 sachets per wallet)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Tel: +353 (0)1 761 7299<\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Almac Pharma Services (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Finnabair Industrial Estate<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dundalk<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Co. Louth<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">A91 P9KD<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Almac Pharma Services Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Seagoe Industrial Estate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Craigavon<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">County Armagh<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">BT63 5UA<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:lightgrey\">United Kingdom<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">This leaflet was last revised in <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\">Detailed information on this medicine is available on the European Medicines Agency website: <a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a>. There are also links to other websites about rare diseases and treatments.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><a name=\"page_total_master4\"><\/a><a name=\"page_total\"><\/a><span lang=\"EN-GB\"> <\/span><\/p> <\/div>","ID":"41a55993-df84-4176-b094-22b5447b9115","Styles":"None","Classes":"['WordSection1']","Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ","ParentId":"53cdb429-99a0-4599-b80e-4ad3a2725d38"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"6d4a43a1-ea11-43be-b6ef-d253f7f5a00e","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"4474ec26-95f3-4fe5-bd6d-5f5e9735be8d","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"e2c1d38f-be6c-4c17-b760-03a64a3537bb","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"4abbc825-36c5-4834-8a1b-330d20c47bff","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"bf4df8be-4f8f-4a6b-8073-18ddb33aa879","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"3adb1de3-88b1-4a30-b6e5-f3bb2aa73aae","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"1db252fa-2cea-4325-af17-3b5c768692a6","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"ba495aef-409a-4054-b87d-33fe1207ed64","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"309fa223-9674-4eb2-aeb1-f504be614ac2","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"49ec7973-82a6-47cb-8bd5-58adeb60e250","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"5b08c6e2-1189-41b3-88ee-f94cb82e4b5d","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"35096670-bb25-4c4f-9b88-c7c61985e6ce","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"80b604b9-2a27-42c8-9dd2-45e342f095c4","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"cabcf366-5630-4206-8b97-7286001f2bf3","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"0cfb6061-b17f-4035-b362-2294005676e4","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"729700c4-07f2-4a46-8106-5b560bfd478d","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"4f230b11-7b6f-40dd-80a2-0681d6d0c225","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"d945bf97-8bc4-4672-8688-f194dd6dc7c7","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"f13ad0d8-0a5d-477a-8b95-bfffebf6fa3f","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"3cab91f2-cb72-4193-b1cc-19ec8cddbf3f","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"6effdc49-c915-4a05-8931-d3e95de7a4b4","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"e66136c3-0e59-4224-86bb-2ae80dae5eda","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"21385977-c096-46dc-bccb-b7d8c0d08544","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX I<\/span><\/b><\/p>","ID":"8a0be25c-c5ac-49de-83d2-e6477dd17b97","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":"ANNEX I","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"952ead5d-df9f-4148-a6fb-6b6a1d91dc21","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p>","ID":"d5f421d5-0dc2-4eb5-bd4f-dfeaaed36946","Styles":"None","Classes":"['TitleA']","Text":"SUMMARY OF PRODUCT CHARACTERISTICS","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"8a685911-a2d1-4fb0-9354-0d170dbc0f57","Styles":"text-align:center;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"1f75a93a-6592-40f7-aded-dbb12e031ff6","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:16.0pt;font-family:\"Arial\",sans-serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"c15b2f90-a09e-48ae-ae82-b7d44fe7347b","Styles":"None","Classes":"None","Text":"","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<span lang=\"EN-GB\" style='font-size:16.0pt;font-family:\"Arial\",sans-serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"ca57231f-78a9-4bf1-a51f-9b01ab07495c","Styles":"font-size:16.0pt;font-family:\"Arial\",sans-serif","Classes":"None","Text":" ","ParentId":"c15b2f90-a09e-48ae-ae82-b7d44fe7347b"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"0bc94d85-fd1b-4113-b7f1-9bd1d0719e02","Styles":"page-break-before:always","Classes":"None","Text":"","ParentId":"ca57231f-78a9-4bf1-a51f-9b01ab07495c"},{"Element":"<h1 style=\"margin:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'>1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/h1>","ID":"ecd47757-4dfb-405f-a2bc-66a5f931b6be","Styles":"margin:0in","Classes":"None","Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"440de72c-4af5-40c2-8b3a-0ca79296927d","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco 150 mg film\u2011coated tablets<\/span><\/p>","ID":"c3bcb91a-32d0-4de2-997e-f9546d48b648","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Kalydeco 150 mg film\u2011coated tablets","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9d1f4ce3-4107-4f50-9121-d7f7d3ce74e4","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"68e401df-02c0-41a0-912f-1c06e6cfa4c7","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif;color:black'>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/h1>","ID":"c5437b82-c375-4a72-a6e9-e21e24360a56","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"2.       QUALITATIVE AND QUANTITATIVE COMPOSITION","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1ec30ef6-aaac-4e62-b16e-658bf76de940","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each film\u2011coated tablet contains 150 mg of ivacaftor.<\/span><\/p>","ID":"ce5518ff-e394-437e-9bd5-c91760bbdd75","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each film\u2011coated tablet contains 150 mg of ivacaftor.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"67e9fe56-928b-4d80-bb62-b07323a5b491","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><\/p>","ID":"5414a058-0a78-4413-876c-573dc20babd8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Excipient with known effect","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"fa571260-ea54-4f98-bcdc-95f1f9c66de2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each film\u2011coated tablet contains 167.2 mg of lactose monohydrate.<\/span><\/p>","ID":"8a431f85-b799-4611-83d6-b46878041c43","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each film\u2011coated tablet contains 167.2 mg of lactose monohydrate.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"57d836f6-e76e-40f7-af3c-65ce22f40c21","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p>","ID":"e9e6560c-0e15-4d6e-9a2f-724f19a3b7b4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"For the full list of excipients, see section 6.1.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"683ef1a0-3c2b-4171-b2f8-d5a4dba350ce","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"04edc21c-6451-42c3-bf13-a04321866bde","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL FORM<\/span><\/h1>","ID":"3f895d6a-f534-478e-9edd-40a64295983b","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"3.       PHARMACEUTICAL FORM","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"0cc9339e-d294-4f95-aff3-b7e98cae0773","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Film\u2011coated tablet (tablet)<\/span><\/p>","ID":"ec65fa9b-8345-4f35-9b8a-cae967705be2","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":"Film\u2011coated tablet (tablet)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d1ca468c-2adb-431c-b1a8-a521f44dcd3a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Light blue, capsule\u2011shaped film\u2011coated tablets, printed with \u201cV 150\u201d in black ink on one side and plain on the other<\/span><span lang=\"EN-GB\"> (16.5 mm x 8.4 mm in modified tablet shape).<\/span><\/p>","ID":"928db921-7937-469b-ab12-a59e3a4ba796","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Light blue, capsule\u2011shaped film\u2011coated tablets, printed with \u201cV 150\u201d in black ink on one side and plain on the other (16.5 mm x 8.4 mm in modified tablet shape).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2d558401-e40f-4ead-9397-cefda8d5ddc5","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b861c92e-278e-4e75-8b5d-379595f66e3a","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif;text-transform:uppercase'>4.       <\/span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CLINICAL PARTICULARS<\/span><\/h1>","ID":"8b964289-f2cb-49c4-9693-4c42afa6c431","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"4.       CLINICAL PARTICULARS","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4476129b-9c4a-4f3a-9aaa-43818f400242","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p>","ID":"0183e6dc-5ac3-48ff-8667-df8390e85fd8","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.1     Therapeutic indications","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b1ca9f54-a41d-42d1-81fb-42cbae4c05b1","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Kalydeco tablets are indicated: <\/span><\/p>","ID":"be2dd65e-50fb-408c-8fff-2caae21da65f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Kalydeco tablets are indicated: ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-left:28.35pt;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an <i>R117H CFTR<\/i> mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (<i>CFTR)<\/i> gene: <i>G551D<\/i>, <i>G1244E<\/i>, <i>G1349D<\/i>, <i>G178R<\/i>, <i>G551S<\/i>, <i>S1251N<\/i>, <i>S1255P<\/i>, <i>S549N<\/i> or <i>S549R<\/i> (see sections 4.4 and 5.1).<\/span><\/p>","ID":"8e1581bf-de17-45b7-a1ba-bf57039dbc6f","Styles":"margin-left:28.35pt;text-indent:-.25in","Classes":"['labeltext']","Text":"\u00b7         As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:justify;text-justify: inter-ideograph;line-height:normal;text-autospace:none\"> <\/p>","ID":"3b6cb219-886d-4cec-985a-b1cb56c38f73","Styles":"margin-left:28.35pt;text-align:justify;text-justify:\ninter-ideograph;line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-.25in; text-autospace:none\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>In a combination regimen with tezacaftor 100 mg\/ivacaftor 150 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the <i>F508del <\/i>mutation or who are heterozygous for the <i>F508del<\/i> mutation and have one of the following mutations in the <i>CFTR<\/i> gene: <i>P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A\u2192G, S945L, S977F, R1070W, D1152H, 2789+5G\u2192A, 3272\u201126A\u2192G, <\/i>and<i> 3849+10kbC\u2192T<\/i>.<\/p>","ID":"b733d28c-d57e-4e87-9d78-3caf7b36e804","Styles":"margin-left:28.35pt;text-indent:-.25in;\ntext-autospace:none","Classes":"['MsoListParagraph']","Text":"\u00b7         In a combination regimen with tezacaftor 100 mg\/ivacaftor 150 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A\u2192G, S945L, S977F, R1070W, D1152H, 2789+5G\u2192A, 3272\u201126A\u2192G, and 3849+10kbC\u2192T.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace: none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e8f63d12-6f2a-4c94-b253-b1d3b7b0719c","Styles":"margin-left:28.35pt;line-height:normal;text-autospace:\nnone","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-.25in; text-autospace:none\"><a name=\"_Hlk36013910\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span>In a combination regimen with ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the <i>F508del<\/i> mutation in the <i>CFTR<\/i> gene or heterozygous for <i>F508del<\/i> in the <i>CFTR<\/i> gene with a minimal function (MF) mutation (see section 5.1).<\/a><\/p>","ID":"90f83bd3-39af-434d-9b49-62264ac4e1e6","Styles":"margin-left:28.35pt;text-indent:-.25in;\ntext-autospace:none","Classes":"['MsoListParagraphCxSpFirst']","Text":"\u00b7         In a combination regimen with ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation in the CFTR gene or heterozygous for F508del in the CFTR gene with a minimal function (MF) mutation (see section 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoListParagraphCxSpLast\"> <\/p>","ID":"87dd67d4-f0f0-42de-a927-cf912fda81bc","Styles":"None","Classes":"['MsoListParagraphCxSpLast']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2     Posology and method of administration<\/span><\/b><\/p>","ID":"c3dfefdb-74e8-4677-8fde-62ef52021637","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.2     Posology and method of administration","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c3e8be9d-6cce-4f8c-aaf0-026ebf3791e5","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient's genotype is unknown, an accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in the <i>CFTR<\/i> gene (see section 4.1). The phase of the poly\u2011T variant identified with the <i>R117H<\/i> mutation should be determined in accordance with local clinical recommendations.<\/span><\/p>","ID":"e3d16dc3-8abd-4e49-8553-46fb9d55689a","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\nnone","Classes":"['MsoNormal']","Text":"Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient's genotype is unknown, an accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in the CFTR gene (see section 4.1). The phase of the poly\u2011T variant identified with the R117H mutation should be determined in accordance with local clinical recommendations.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none\"><a name=\"paragraph00000061\"><\/a><span lang=\"EN-GB\"> <\/span><\/p>","ID":"38091715-2fa1-4007-b964-d796937f110f","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"d249c9a8-a432-4fe4-8a6f-9323aa3c8fcc","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Posology","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"fe849afd-494e-4236-befa-772d8bce6f3a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Adults<\/span><span style=\"font-size:11.0pt\">, adolescents and children aged 6 years and older <\/span><span style=\"font-size:11.0pt\">should be dosed according to Table 1. <\/span><\/p>","ID":"f406fac1-f934-4abe-82e1-2f88e2c60b12","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Adults, adolescents and children aged 6 years and older should be dosed according to Table 1. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p>","ID":"e27a55c7-4dcf-4791-8593-4006be358cc4","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Table 1: Dosing recommendations<\/span><\/b><\/p>","ID":"8034c6b1-74fc-4f3f-b87d-ce5c9398ca6d","Styles":"margin-bottom:6.0pt;page-break-after:avoid","Classes":"['labeltext']","Text":"Table 1: Dosing recommendations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"margin-left:-.25pt;border-collapse:collapse;border:none\" width=\"626\"> <tr style=\"height:16.25pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;padding:   0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\"> <\/span><\/b><\/p> <\/td> <td style=\"width:233.9pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"312\"> <p align=\"center\" class=\"labeltext\" style=\"text-align:center;page-break-after:   avoid\"><b><span style=\"font-size:11.0pt\">Morning<\/span><\/b><\/p> <\/td> <td style=\"width:122.3pt;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"163\"> <p align=\"center\" class=\"labeltext\" style=\"text-align:center;page-break-after:   avoid\"><b><span style=\"font-size:11.0pt\">Evening<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Ivacaftor as monotherapy<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:16.25pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">6 years and older, \u226525 kg<\/span><\/p> <\/td> <td style=\"width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"312\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <td style=\"width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt\" width=\"163\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Ivacaftor in combination with tezacaftor\/ivacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"312\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One tezacaftor 100 mg\/ivacaftor 150 mg tablet<\/span><\/p> <\/td> <td style=\"width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"163\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td colspan=\"3\" style=\"width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"626\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><b><span style=\"font-size:   11.0pt\">Ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:15.3pt\"> <td style=\"width:113.4pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"151\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:233.9pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"312\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">Two ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablets<\/span><\/p> <\/td> <td style=\"width:122.3pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt\" width=\"163\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">One ivacaftor 150 mg tablet<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"993cd6d2-9c2c-451e-bb12-fe005b0655dc","Styles":"margin-left:-.25pt;border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Text":"       Morning   Evening     Ivacaftor as monotherapy     6 years and older, \u226525 kg   One ivacaftor 150 mg tablet   One ivacaftor 150 mg tablet     Ivacaftor in combination with tezacaftor\/ivacaftor     12 years and older   One tezacaftor 100 mg\/ivacaftor 150 mg tablet   One ivacaftor 150 mg tablet     Ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor     12 years and older   Two ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablets   One ivacaftor 150 mg tablet   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"a7334c7c-57a9-4d5f-8ffa-3cace24c035b","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\">The <span style=\"font-size: 11.0pt\">morning and evening dose should be taken approximately 12 hours apart with fat-containing food (see Method of administration).<\/span><\/p>","ID":"68e321fb-d497-4651-99e5-230bdf6aa1e6","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"The morning and evening dose should be taken approximately 12 hours apart with fat-containing food (see Method of administration).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"735b5a67-84c3-46ed-9bf0-176bd5ac3444","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">Missed dose<\/span><\/i><\/p>","ID":"bddda4d7-ca77-4f7d-856d-881ef531352e","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Missed dose","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p>","ID":"57447102-6658-4af0-947d-4d714e8f8a6b","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.<\/span><\/p>","ID":"9b81333b-7670-42eb-ac5b-ad96f2f67f90","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"a7004e8a-b8ad-43f2-a2dd-6e478c770aa1","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">Patients receiving ivacaftor in a combination regimen should not take more than one dose of either medicine at the same time.<\/span><\/p>","ID":"1854231b-f3db-4d6a-a071-217919a26bdf","Styles":"None","Classes":"['labeltext']","Text":"Patients receiving ivacaftor in a combination regimen should not take more than one dose of either medicine at the same time.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"d7d864bc-4d5c-4ee5-b0a9-87c3eb3125f7","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Concomitant use of CYP3A inhibitors<\/span><\/i><\/p>","ID":"2b9b991d-3f29-4208-b6a1-de80b7679a74","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Concomitant use of CYP3A inhibitors","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"41d22326-ed9b-4c67-bf57-c9a34b742eeb","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When co-administered with moderate or strong inhibitors of CYP3A, either as monotherapy or<\/span> in a combination regimen with tezacaftor\/ivacaftor<span lang=\"EN-GB\" style=\"font-size:11.0pt\"> or ivacaftor\/tezacaftor\/elexacaftor<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">, the dose <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">should be reduced (see Table 2 for the recommended dose). Dosing intervals<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> should be <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">modified<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> according to <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">clinical response and tolerability (see sections<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> 4.4 and 4.5).<\/span><\/p>","ID":"ea1f0ea9-ebd3-40e6-8ce0-d47631db829e","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"When co-administered with moderate or strong inhibitors of CYP3A, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, the dose should be reduced (see Table 2 for the recommended dose). Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"> <\/p>","ID":"090418ce-b36d-4f33-8bdb-47a4d07c95ee","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Table 2: Dosing recommendations for concomitant use with moderate or strong CYP3A inhibitors<\/span><\/b><\/p>","ID":"3e146e90-6bce-4ed0-97b2-a35e95c3c29c","Styles":"margin-bottom:6.0pt;page-break-after:avoid","Classes":"['labeltext']","Text":"Table 2: Dosing recommendations for concomitant use with moderate or strong CYP3A inhibitors","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\"> <thead> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <\/td> <td style=\"width:215.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:    avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Moderate CYP3A inhibitors<\/span><\/b><\/p> <\/td> <td style=\"width:197.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:    avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Strong CYP3A inhibitors<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr> <td colspan=\"3\" style=\"width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor as   monotherapy<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6 years and   older,<br\/>   \u226525 kg<\/span><\/p> <\/td> <td style=\"width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet   of ivacaftor 150 mg once daily. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet   of ivacaftor 150 mg twice a week, approximately 3 to 4 days apart.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in a   combination regimen with tezacaftor\/ivacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years   and older<\/span><\/p> <\/td> <td style=\"width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Alternate each morning:<\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:20.5pt;text-indent:   -.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">one tablet of tezacaftor 100 mg\/ivacaftor 150 mg   on the first day<\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:20.5pt;text-indent:-.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">one tablet of ivacaftor 150 mg   on the next day<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Continue alternating tablets each day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet   of tezacaftor 100 mg\/ivacaftor 150 mg twice a week, approximately 3   to 4 days apart.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in   a combination regimen with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:40.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"54\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years   and older<\/span><\/p> <\/td> <td style=\"width:215.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"288\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Alternate each morning:   <\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:20.5pt;text-indent:   -.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">two tablets of ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   on the first day <\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:20.5pt;text-indent:-.25in\"><span style=\"font-size:10.0pt\">-<span style='font:7.0pt \"Times New Roman\"'>            <\/span><\/span><span style=\"font-size:10.0pt\">one tablet of ivacaftor 150 mg   on the next day <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Continue alternating tablets each day.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:2.5pt\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:197.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"264\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Two morning dose   tablets of ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   twice a week, approximately 3 to 4 days apart.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"500d131a-9533-4700-8d92-e42d62fe2b5f","Styles":"border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Text":"        Moderate CYP3A inhibitors   Strong CYP3A inhibitors      Ivacaftor as   monotherapy     6 years and   older,   \u226525 kg   One morning tablet   of ivacaftor 150 mg once daily.    No evening dose.   One morning tablet   of ivacaftor 150 mg twice a week, approximately 3 to 4 days apart.   No evening dose.     Ivacaftor in a   combination regimen with tezacaftor\/ivacaftor     12 years   and older   Alternate each morning: -            one tablet of tezacaftor 100 mg\/ivacaftor 150 mg   on the first day -            one tablet of ivacaftor 150 mg   on the next day Continue alternating tablets each day.   No evening dose.   One morning tablet   of tezacaftor 100 mg\/ivacaftor 150 mg twice a week, approximately 3   to 4 days apart.   No evening dose.     Ivacaftor in   a combination regimen with ivacaftor\/tezacaftor\/elexacaftor     12 years   and older   Alternate each morning:    -            two tablets of ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   on the first day  -            one tablet of ivacaftor 150 mg   on the next day  Continue alternating tablets each day.   No evening dose.   Two morning dose   tablets of ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   twice a week, approximately 3 to 4 days apart.   No evening dose.   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"eceb59a8-6a9d-4f0c-a93a-cf43d6ee9a09","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p>","ID":"baaa1edf-4252-4415-87ab-f609f3e26996","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Special populations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5c2e1083-c198-4cf3-990f-c78f2dd8b83b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i>Elderly<\/i><\/p>","ID":"9c693bd1-0385-404e-b101-12149a15a7b8","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Elderly","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i> <\/i><\/p>","ID":"8c7045ed-e51b-4990-b870-2104a4acc5a5","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\">Very limited data are available for elderly patients treated with ivacaftor (administered as monotherapy or in a combination regimen). No dose adjustment specific to this patient population is required (see section 5.2).<\/p>","ID":"76ec40c5-df95-4157-9592-ba140b2e5ec5","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Very limited data are available for elderly patients treated with ivacaftor (administered as monotherapy or in a combination regimen). No dose adjustment specific to this patient population is required (see section 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"53fc4de2-7a73-470d-a8f0-0e8f25c683e4","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"32f5bc86-8598-4558-b3ac-2d579ccaac79","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Renal impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"ca03610e-9165-4cc0-9dea-fef3f2586519","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.4 and 5.2).<\/span><\/p>","ID":"573f038c-0876-4b72-bf13-77dacb8634ea","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.4 and 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b726474f-34d6-45a9-a733-fb5d36b4552a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><a name=\"_Hlk46222749\"><\/a><a name=\"_Hlk45278269\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/a><\/p>","ID":"4e445052-cb49-4869-bdd3-f5b8b027fbbd","Styles":"None","Classes":"['labeltextheading']","Text":"Hepatic impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"9fc03c0b-47fa-4a41-b58a-7682b10c746a","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">No dose adjustment is necessary for ivacaftor as monotherapy or in a combination regimen in patients with mild hepatic impairment (Child\u2011Pugh Class A). <\/span><\/p>","ID":"2929f5cb-4798-4177-8fa9-287392bdc7f0","Styles":"None","Classes":"['labeltextheading']","Text":"No dose adjustment is necessary for ivacaftor as monotherapy or in a combination regimen in patients with mild hepatic impairment (Child\u2011Pugh Class A). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p>","ID":"7826d297-9d61-4f19-ad5f-4a95392b96bc","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">For patients with moderate hepatic impairment (Child\u2011Pugh Class B) <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">the dose <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">of ivacaftor as monotherapy <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">should be reduced <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">to 150 mg once daily. <\/span><\/p>","ID":"5dbea742-a509-4750-8c1f-59c17396994a","Styles":"None","Classes":"['labeltextheading']","Text":"For patients with moderate hepatic impairment (Child\u2011Pugh Class B) the dose of ivacaftor as monotherapy should be reduced to 150 mg once daily. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p>","ID":"534fe269-fa43-4652-8676-ae8426aca1b9","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">For patients with severe hepatic impairment (Child-Pugh Class C), the dose of ivacaftor as monotherapy should be reduced to 150 mg every other day or less frequently. <\/span><\/p>","ID":"4ca9f8b8-e52d-4164-94f6-76c4f1416cd9","Styles":"None","Classes":"['labeltextheading']","Text":"For patients with severe hepatic impairment (Child-Pugh Class C), the dose of ivacaftor as monotherapy should be reduced to 150 mg every other day or less frequently. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p>","ID":"e83424c3-879f-44b9-b802-6b59b5f21a30","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\">For use as an evening dose in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor see Table 3 for dosing regimen<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\"> recommendations<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style:normal\">. <\/span><\/p>","ID":"8feb029d-adb1-4384-97e7-22f942e48822","Styles":"None","Classes":"['labeltextheading']","Text":"For use as an evening dose in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor see Table 3 for dosing regimen recommendations. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\" style=\"page-break-after:auto\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"35d057e7-c83d-465b-b75d-95778dda929e","Styles":"page-break-after:auto","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt;color:black\">Table 3: Recommendations for patients with moderate or severe hepatic impairment <\/span><\/b><\/p>","ID":"3c7cbfd6-6467-4eb1-a23c-6acfda89dc0c","Styles":"margin-bottom:6.0pt;page-break-after:avoid","Classes":"['labeltext']","Text":"Table 3: Recommendations for patients with moderate or severe hepatic impairment ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:104.54%;border-collapse:collapse;border:none\" width=\"104%\"> <tr> <td style=\"width:13.42%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:49.26%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"49%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Moderate (Child-Pugh Class B)<\/span><\/b><\/p> <\/td> <td style=\"width:37.32%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"37%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Severe (Child-Pugh Class C)<\/span><\/b><\/p> <\/td> <\/tr> <\/table>","ID":"341ad8c7-e88a-411f-8546-80e3d3abf9e5","Styles":"width:104.54%;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"       Moderate (Child-Pugh Class B)   Severe (Child-Pugh Class C)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none\" width=\"633\"> <tr> <td colspan=\"3\" style=\"width:474.65pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"633\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor as   monotherapy<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6 years and   older,<br\/>   \u226525 kg<\/span><\/p> <\/td> <td style=\"width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning   tablet of ivacaftor 150 mg once daily. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use is not   recommended unless the benefits are expected to outweigh the risks. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">In such cases,   take one morning tablet of ivacaftor 150 mg every other day or less   frequently. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dosing interval   should be modified according to clinical response and tolerability. <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:474.65pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"633\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in a combination regimen with   tezacaftor\/ivacaftor<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years and older<\/span><\/p> <\/td> <td style=\"width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">One morning tablet of tezacaftor 100 mg\/ivacaftor 150 mg   once daily.<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use is not recommended unless the benefits are   expected to outweigh the risks. <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">In such cases, take one morning tablet of tezacaftor 100 mg\/ivacaftor 150 mg   once daily or less frequently. <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Dosing interval should be modified according to   clinical response and tolerability. <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"3\" style=\"width:474.65pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"633\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ivacaftor in   a combination regimen with ivacaftor\/tezacaftor\/elexacaftor <\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:62.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"83\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">12 years   and older<\/span><\/p> <\/td> <td style=\"width:235.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"314\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use not   recommended.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Use should only   be considered when there is a clear medical need and the benefits are   expected to outweigh the risks.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">If used:   alternate each day between two   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablets and one   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablet.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <td style=\"width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"236\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Should not be   used.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No morning   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg dose.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">No evening dose.<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"e77c82ae-fb04-410e-8b6d-334f668443e0","Styles":"border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Text":"   Ivacaftor as   monotherapy     6 years and   older,   \u226525 kg   One morning   tablet of ivacaftor 150 mg once daily.    No evening dose.   Use is not   recommended unless the benefits are expected to outweigh the risks.    In such cases,   take one morning tablet of ivacaftor 150 mg every other day or less   frequently.    Dosing interval   should be modified according to clinical response and tolerability.    No evening dose.     Ivacaftor in a combination regimen with   tezacaftor\/ivacaftor     12 years and older   One morning tablet of tezacaftor 100 mg\/ivacaftor 150 mg   once daily.   No evening dose.   Use is not recommended unless the benefits are   expected to outweigh the risks.    In such cases, take one morning tablet of tezacaftor 100 mg\/ivacaftor 150 mg   once daily or less frequently.    Dosing interval should be modified according to   clinical response and tolerability.    No evening dose.     Ivacaftor in   a combination regimen with ivacaftor\/tezacaftor\/elexacaftor      12 years   and older   Use not   recommended. Use should only   be considered when there is a clear medical need and the benefits are   expected to outweigh the risks.   If used:   alternate each day between two   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablets and one   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg   tablet.   No evening dose.   Should not be   used.   No morning   ivacaftor 75 mg\/tezacaftor 50 mg\/elexacaftor 100 mg dose.   No evening dose.   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> <\/span><\/p>","ID":"abbf6243-eb4a-4430-a141-3ef350711352","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"e873d6f1-7006-4b2d-bb3b-a4745839dee4","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"f7e679f9-9554-44e1-8221-8709a021f693","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and efficacy of ivacaftor monotherapy in children aged less than 4 months have not been established. No data are available.<\/span><\/p>","ID":"ea7e9ec7-f1ad-4ac2-8e8c-24e87e162334","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The safety and efficacy of ivacaftor monotherapy in children aged less than 4 months have not been established. No data are available.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"54da5b2a-d177-46c6-8f5e-32c79867b578","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\">An appropriate dose for children under 6 years of age and weighing less than 25 kg cannot be achieved with ivacaftor tablets.<\/p>","ID":"0cc87c6c-dcef-472e-8d81-05eb0457e244","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"An appropriate dose for children under 6 years of age and weighing less than 25 kg cannot be achieved with ivacaftor tablets.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"f47e258a-503e-40fe-a070-9b64ee10e331","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Limited data are available in patients less than 6 years of age with an <i>R117H <\/i>mutation in the <i>CFTR <\/i>gene. Available data in patients aged <\/span><span style=\"font-size:11.0pt\">6 years<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> and older are described in sections 4.8, 5.1, and 5.2.<\/span><\/p>","ID":"0046f085-9e05-4637-a0d1-c9137992e567","Styles":"None","Classes":"['labeltext']","Text":"Limited data are available in patients less than 6 years of age with an R117H mutation in the CFTR gene. Available data in patients aged 6 years and older are described in sections 4.8, 5.1, and 5.2.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"8ab02d1f-b695-4468-a6cc-081c946ee7e8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The safety and efficacy of ivacaftor in a combination regimen with tezacaftor\/ivacaftor and ivacaftor\/tezacaftor\/elexacaftor in children aged less than 12 years have not been established. No data are available.<\/span><\/p>","ID":"1ee48d0f-a2fc-4f92-b8a2-60390953d4f0","Styles":"None","Classes":"['labeltext']","Text":"The safety and efficacy of ivacaftor in a combination regimen with tezacaftor\/ivacaftor and ivacaftor\/tezacaftor\/elexacaftor in children aged less than 12 years have not been established. No data are available.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"22bbf4f9-7b93-493e-8d92-f99412791976","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p>","ID":"1a176904-922a-475f-9429-9ce7c21fd2ef","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Method of administration","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"4f60006a-b5da-4a2c-8f47-f6b20050ee56","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">For oral use. <\/span><\/p>","ID":"ea44a498-b05e-491d-8b82-500dd1672bdd","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\nnone","Classes":"['MsoNormal']","Text":"For oral use. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6b213c90-1dbe-4eaf-8504-299279f8167e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be instructed to swallow the tablets whole. The tablets should not be chewed, crushed, or broken before swallowing because there are no clinical data currently available to support other methods of administration.<\/span><\/p>","ID":"7cb23523-17d4-4e7f-84af-aeede1cfdf58","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":"Patients should be instructed to swallow the tablets whole. The tablets should not be chewed, crushed, or broken before swallowing because there are no clinical data currently available to support other methods of administration.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"208363d8-b2f8-4d64-820f-ba72800b75c0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Ivacaftor tablets should be taken with fat\u2011containing food.<\/span><\/p>","ID":"103aa004-349a-4467-88f0-98cb1640abbd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":"Ivacaftor tablets should be taken with fat\u2011containing food.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e0a0d185-358c-4e9e-8ae6-1501021d959c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Food or drink containing grapefruit should be avoided during treatment (see section 4.5).<\/span><\/p>","ID":"b28910e0-32f7-45e3-8b8a-791ba1f13205","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":"Food or drink containing grapefruit should be avoided during treatment (see section 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1f76078a-1851-427a-ae45-c94aa03f5e0a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.3       Contraindications<\/span><\/h2>","ID":"9a42b421-385f-4f40-bc34-c2694415d75d","Styles":"margin:0in","Classes":"None","Text":"4.3       Contraindications","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4dbe61cb-5f98-4d0b-aab3-7615470d86f5","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\nnone","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"d70301e5-f937-4e08-937c-5833d721c6ae","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":"Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"8ddd3fe1-2ee0-4a22-b900-48ac44e10d6e","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.4       Special warnings and precautions for use<\/span><\/h2>","ID":"cdce1f37-ea72-47f5-8339-5cad38737198","Styles":"margin:0in","Classes":"None","Text":"4.4       Special warnings and precautions for use","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"ab5fca04-bb51-48cf-9009-99b36ba4881e","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Only patients with CF who had a <i>G551D<\/i>, <i>G1244E<\/i>, <i>G1349D<\/i>, <i>G178R<\/i>, <i>G551S<\/i>, <i>S1251N<\/i>, <i>S1255P<\/i>, <i>S549N<\/i>, <i>S549R<\/i> gating (class III), <i>G970R<\/i> <\/span>or <i>R117H <\/i><span lang=\"EN-GB\">mutation in at least one allele of the <i>CFTR<\/i> gene were included in studies 1, 2, 5 and 6 (see section 5.1).<\/span><\/p>","ID":"48ed9c2e-c22e-4036-a9c0-17f9fda10118","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":"Only patients with CF who had a G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R gating (class III), G970R or R117H mutation in at least one allele of the CFTR gene were included in studies 1, 2, 5 and 6 (see section 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d47ea670-f208-4d5c-b8fa-1516cd7df721","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\">In study 5, four patients with the <i>G970R<\/i> mutation were included. In three of four patients the change in the sweat chloride test was &lt; 5 mmol\/L and this group did not demonstrate a clinically relevant improvement in FEV<sub>1<\/sub> after 8 weeks of treatment. Clinical efficacy in patients with the <i>G970R<\/i> mutation of the <i>CFTR<\/i> gene could not be established (see section 5.1).<\/span><\/p>","ID":"f068ea8f-02fe-4dcb-bf7a-e3344e4ca915","Styles":"margin:0in","Classes":"['MsoNormalIndent']","Text":"In study 5, four patients with the G970R mutation were included. In three of four patients the change in the sweat chloride test was < 5 mmol\/L and this group did not demonstrate a clinically relevant improvement in FEV1 after 8 weeks of treatment. Clinical efficacy in patients with the G970R mutation of the CFTR gene could not be established (see section 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b3a9b161-4b45-4b28-9c33-f58114b1ebf1","Styles":"margin:0in","Classes":"['MsoNormalIndent']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\">Efficacy results from a phase 2 study in patients with CF who are homozygous for the <i>F508del <\/i>mutation in the <i>CFTR<\/i> gene showed no statistically significant difference in FEV<sub>1<\/sub> over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.<\/span><\/p>","ID":"d4d7659a-3a7c-4f9d-bcdb-7737f09ea30a","Styles":"margin:0in","Classes":"['MsoNormalIndent']","Text":"Efficacy results from a phase 2 study in patients with CF who are homozygous for the F508del mutation in the CFTR gene showed no statistically significant difference in FEV1 over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"baf0d16e-848c-4260-876e-29a95e2a5d8d","Styles":"margin:0in","Classes":"['MsoNormalIndent']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Less evidence of a positive effect of ivacaftor has been shown for patients with an <i>R117H\u20117T<\/i> mutation associated with less severe disease in study 6 (see section 5.1). <\/span><\/p>","ID":"61d0ae07-3c0b-4e29-8e17-128a4c7402b0","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Less evidence of a positive effect of ivacaftor has been shown for patients with an R117H\u20117T mutation associated with less severe disease in study 6 (see section 5.1). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span style=\"text-decoration:  none\"> <\/span><\/u><\/p>","ID":"95dbf993-2c97-4b12-a36f-568dc7b027b7","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">Ivacaftor in a combination regimen with tezacaftor\/ivacaftor should not be prescribed in patients with CF <\/span><span style=\"font-size:11.0pt\">who are heterozygous for the <i>F508del<\/i> mutation and have a second <i>CFTR<\/i> mutation not listed in section 4.1.<\/span><\/p>","ID":"9f405790-2129-40b1-bb1d-c112f71eaf64","Styles":"None","Classes":"['labeltext']","Text":"Ivacaftor in a combination regimen with tezacaftor\/ivacaftor should not be prescribed in patients with CF who are heterozygous for the F508del mutation and have a second CFTR mutation not listed in section 4.1.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span style=\"text-decoration:  none\"> <\/span><\/u><\/p>","ID":"2d7f9a0f-62aa-4307-83f2-adb861401119","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Effect on liver function tests<\/span><\/u><\/p>","ID":"ac2aad56-f0c5-49d8-98fd-509911acdb66","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Effect on liver function tests","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"91068cd5-a936-406f-a288-b068f1d1c575","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor as monotherapy and in combination regimens with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3 months during the first year of treatment and annually thereafter. For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. In the event of significant elevations of transaminases (e.g., patients with ALT or AST &gt; 5 x the upper limit of normal (ULN), or ALT or AST &gt; 3 x ULN with bilirubin &gt; 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).<\/span><\/p>","ID":"d8bd17ff-0c43-4550-ab82-e2fdf8a959e7","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":"Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor as monotherapy and in combination regimens with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3 months during the first year of treatment and annually thereafter. For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. In the event of significant elevations of transaminases (e.g., patients with ALT or AST > 5 x the upper limit of normal (ULN), or ALT or AST > 3 x ULN with bilirubin > 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"157b136b-a2d7-4aeb-8d24-746628dbc091","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><a name=\"_Hlk45278421\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/a><\/p>","ID":"e21d573a-7ef9-4147-a902-a15f440540bd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Hepatic impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"e49094ba-7447-4d25-8ad4-b8a9c12214c2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Use of ivacaftor, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor, is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks. Patients with severe hepatic impairment should not be treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor. (See Table 3 and sections 4.2 and 5.2). <\/span><\/p>","ID":"50efd2fe-8ab0-4081-8789-9a0bf85cd382","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Use of ivacaftor, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor, is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks. Patients with severe hepatic impairment should not be treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor. (See Table 3 and sections 4.2 and 5.2). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"8519d6a6-ceae-4c3c-8620-77093bb710c2","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For patients with moderate hepatic impairment, use of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor is not recommended. Treatment should only be considered when there is a clear medical need and the benefits are expected to outweigh the risks. If used, it should be used with caution at a reduced dose (see Table 3 and sections 4.2 and 5.2).<\/span><\/p>","ID":"184ec066-e896-4add-9a92-546173242237","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"For patients with moderate hepatic impairment, use of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor is not recommended. Treatment should only be considered when there is a clear medical need and the benefits are expected to outweigh the risks. If used, it should be used with caution at a reduced dose (see Table 3 and sections 4.2 and 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"f9418b90-7797-4055-b79e-fa7824317804","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"957a41bd-00cd-40cb-b0ea-cfe970f3ae20","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Renal impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"3a0b005d-9a07-4e71-8e90-f642c0d4d5de","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Caution is recommended while using ivacaftor, <\/span><span style=\"font-size:11.0pt\">either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor,<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> in patients with severe renal impairment or end\u2011stage renal disease (see sections 4.2 and 5.2).<\/span><\/p>","ID":"e6a434de-9755-4fce-8270-ed34caec9eee","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Caution is recommended while using ivacaftor, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, in patients with severe renal impairment or end\u2011stage renal disease (see sections 4.2 and 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6210670a-b5bc-4b36-9ab9-c43439db2bc5","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients after organ transplantation<\/span><\/u><\/p>","ID":"1c4317d7-1a3d-44e2-9a6e-0153b5b1b880","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Patients after organ transplantation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"051a04ea-11c0-4d30-84fe-8a4d44cd2ac7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.<\/span><\/p>","ID":"3a3e9470-7f6e-4471-a8f2-b8c88348f965","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"25df3dd2-d715-4790-ad00-f52f5c6b3f79","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Rash events <\/span><\/u><\/p>","ID":"0c6bc512-db16-47fa-ae7c-cfa9fb4f6dfa","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Rash events ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5ae1436f-2b84-4441-9223-c81cda3f2d45","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The incidence of rash events with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor was higher in females than in males<\/span>, particularly in females taking hormonal contraceptives<span lang=\"EN-GB\">. A role for hormonal contraceptives in the occurrence of rash cannot be excluded. For patients taking hormonal contraceptives who develop rash, interrupting treatment with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor and hormonal contraceptives should be considered. Following the resolution of rash, it should be considered if resuming ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor without hormonal contraceptives is appropriate. If rash does not recur, resumption of hormonal contraceptives can be considered (see section 4.8).<i> <\/i><\/span><\/p>","ID":"09fa7d7c-8344-4888-b387-5fe077516fc3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The incidence of rash events with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor was higher in females than in males, particularly in females taking hormonal contraceptives. A role for hormonal contraceptives in the occurrence of rash cannot be excluded. For patients taking hormonal contraceptives who develop rash, interrupting treatment with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor and hormonal contraceptives should be considered. Following the resolution of rash, it should be considered if resuming ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor without hormonal contraceptives is appropriate. If rash does not recur, resumption of hormonal contraceptives can be considered (see section 4.8). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"22dc816a-a54c-4be6-8efb-1dedfdd5be6c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Interactions with medicinal products<\/span><\/u><\/p>","ID":"56c85482-bd84-45c5-8f6d-5ea13b3769a4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Interactions with medicinal products","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"eaab263d-b53b-47ac-a895-2a64f65d74dc","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">CYP3A inducers<\/span><\/i><\/p>","ID":"cd10d606-26d3-4c8b-af80-6f7fe9740fac","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"CYP3A inducers","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"f07e110d-904b-48ea-a2fa-8ed08baae383","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Exposure to ivacaftor is significantly decreased and exposures to elexacaftor and tezacaftor are expected to decrease by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, co-administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) with strong CYP3A inducers is not recommended (see section 4.5). <\/span><\/p>","ID":"94ef863e-3f31-4620-a243-795680102c2b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Exposure to ivacaftor is significantly decreased and exposures to elexacaftor and tezacaftor are expected to decrease by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, co-administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) with strong CYP3A inducers is not recommended (see section 4.5). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"> <\/p>","ID":"c3c9c195-9700-4be0-8fea-13d4f54c097f","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inhibitors<\/span><\/i><\/p>","ID":"98053f87-1ba9-4ff2-b213-f01acb6236b1","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"CYP3A inhibitors","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p>","ID":"befb9086-eaac-4724-8e71-2e4b720c12fe","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Exposure to ivacaftor, tezacaftor and elexacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see Table 2 and sections 4.2 and 4.5).<\/span><\/p>","ID":"12f4fc37-7f3d-4293-80bb-d2c3dd21b100","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Exposure to ivacaftor, tezacaftor and elexacaftor are increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see Table 2 and sections 4.2 and 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"> <\/p>","ID":"cb8c78fe-d8d5-4e51-a609-951fda1ec966","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"a246fa81-0195-403b-a266-f2ad968312ad","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"1aa6f25f-d9b5-44a3-a63f-7276a65fc7b4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cases of non\u2011congenital lens opacities\/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor and ivacaftor-containing regimens. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow\u2011up ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment<\/span><span lang=\"EN-GB\">, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor (see section 5.3).<\/span><\/p>","ID":"24c24743-966d-45ab-a68d-c6cd6295375b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Cases of non\u2011congenital lens opacities\/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor and ivacaftor-containing regimens. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow\u2011up ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor (see section 5.3).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"382e0d76-fa39-459d-b4b8-3ad6dc347070","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Lactose content<\/span><\/u><\/p>","ID":"74cfdac8-5b52-448a-9326-43e0bb9a60bf","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Lactose content","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"c2099efc-c06c-4acc-b4ad-09833636b4b0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose\u2011galactose malabsorption should not take this medicine.<\/span><\/p>","ID":"914bb1e8-ac5b-4837-9d18-c15ca31f1669","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose\u2011galactose malabsorption should not take this medicine.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7b0a178e-8be2-48c2-a89c-718957066e0c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium content<\/span><\/u><\/p>","ID":"0162d05f-9fc7-4bb9-abc7-4769612a5560","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Sodium content","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"7846a084-b920-4c5c-a88f-5c3cef5d5e89","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.<\/span><\/p>","ID":"6f8d82ea-7537-4c47-a6a0-86df8ec8cfbf","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"250ffc6b-ffad-4a1d-82f2-d89c2ea02067","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Interaction with other medicinal products and other forms of interaction<\/span><\/b><\/p>","ID":"6a72cb41-ea95-4a61-8bba-d6be126e04bf","Styles":"margin-left:28.1pt;text-indent:-28.1pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.5          Interaction with other medicinal products and other forms of interaction","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"98328546-d127-45c1-91d0-664e2a8353e4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P\u2011gp and a potential inhibitor of CYP2C9. <i>In vitro<\/i> studies showed that ivacaftor is not a substrate for P\u2011gp. <\/span><\/p>","ID":"aa505c01-93b4-4e4a-b336-72931578f2cd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P\u2011gp and a potential inhibitor of CYP2C9. In vitro studies showed that ivacaftor is not a substrate for P\u2011gp. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"55147640-50f3-419c-9a19-2c8b6f005c07","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Medicinal products affecting the pharmacokinetics of ivacaftor, tezacaftor and\/or elexacaftor<\/span><\/u><\/p>","ID":"706ff1cf-3a6c-4cfc-aeaa-ca0bf48eaa9a","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Medicinal products affecting the pharmacokinetics of ivacaftor, tezacaftor and\/or elexacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"cb8ff843-3107-4b3e-85d2-73f53a6ccbc0","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inducers<\/span><\/i><\/p>","ID":"046c3fa8-d592-4a01-8171-1f5621a193cb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"CYP3A inducers","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"227d902b-d1a6-4599-843b-0a453991d29f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Co\u2011administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ivacaftor<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> or ivacaftor\/tezacaftor\/elexacaftor<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">)<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> with strong <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John\u2019s wort (<i>Hypericum perforatum<\/i>), is not recommended (see section 4.4).<\/span><\/p>","ID":"32b67876-ee9e-44cd-8409-cd1211439bda","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Co\u2011administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Co\u2011administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) with strong CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John\u2019s wort (Hypericum perforatum), is not recommended (see section 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"429105fd-aeff-40c5-9b9e-ec97c0f162b3","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustment is recommended when ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is used with moderate or weak CYP3A inducers. <\/span><\/p>","ID":"e150b757-8ba0-4c62-b400-743007ad9c29","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":"No dose adjustment is recommended when ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is used with moderate or weak CYP3A inducers. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"71292f5a-22cc-4486-9647-0bcf4f7c557a","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inhibitors<\/span><\/i><\/p>","ID":"f74ddb20-14ef-4b1e-a85e-1a02f7b79a58","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"CYP3A inhibitors","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"f3c2dd0f-7a41-4009-bdee-2331cf81db02","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is recommended for co\u2011administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).<\/span><\/p>","ID":"c656104e-4914-4845-b78d-e5c2f3b9fa90","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is recommended for co\u2011administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"c6c51ad0-9e25-4c95-add4-1c8912fc88d9","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).<\/span><\/p>","ID":"de5eb9e0-042c-4120-9ac9-0d6d555eb7c2","Styles":"None","Classes":"['labeltext']","Text":"Co\u2011administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"98c38e43-f3a4-469b-b6dd-a577b35a57ea","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, see section 4.2).<\/span><\/p>","ID":"032addfb-2306-4937-99ea-4086ede9ccde","Styles":"None","Classes":"['labeltext']","Text":"Co\u2011administration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, see section 4.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"e0040bf1-7fd2-48f3-b1de-3f220e489691","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Potential for ivacaftor to interact with transporters<\/span><\/i><\/p>","ID":"da46c9f1-60ee-41c0-8041-7c27d87b6f1e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Potential for ivacaftor to interact with transporters","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"10941d98-1b89-4f90-b7d1-297d14cdc1d6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in vitro<\/i>. Due to its high intrinsic permeability and low likelihood of being excreted intact, co-administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1\u2011IVA, while any potential changes in M6\u2011IVA exposures are not expected to be clinically relevant. <\/span><\/p>","ID":"74fd1a33-7b0d-49b4-ae9c-7f22b5fa6bcb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"In vitro studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP in vitro. Due to its high intrinsic permeability and low likelihood of being excreted intact, co-administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1\u2011IVA, while any potential changes in M6\u2011IVA exposures are not expected to be clinically relevant. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"0af8c2ec-4c6d-41d4-9aba-10839fb8c846","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ciprofloxacin<\/span><\/i><\/p>","ID":"564b024f-b55c-45d3-ab8f-b21a66810dbd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Ciprofloxacin","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"be60d3e0-ee46-4238-b197-81b613eefeb1","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is co\u2011administered with ciprofloxacin.<\/span><\/p>","ID":"cdc5986e-ad73-452f-b00b-a8f3c4725df5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Co\u2011administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) is co\u2011administered with ciprofloxacin.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"1c2895bd-5c21-4c2d-be1b-c16e52263dc1","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Medicinal products affected by ivacaftor, tezacaftor and\/or elexacaftor<\/span><\/u><\/p>","ID":"ecffe7f1-ea2a-42ab-a058-c244a145fd5f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Medicinal products affected by ivacaftor, tezacaftor and\/or elexacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"89d5af13-88ec-4bd1-b2d8-1f2f04b4b196","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and\/or P\u2011gp, and\/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.<\/span><\/p>","ID":"b95f8bae-3d53-4d59-b9b1-4f1804a5bc8a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and\/or P\u2011gp, and\/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"559a5be9-bafc-40bd-9745-239f62c0f57b","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">CYP2C9 substrates<\/span><\/i><\/p>","ID":"dbd82cca-86cc-4098-a9e3-01402b271ed3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"CYP2C9 substrates","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"b6422584-6441-487e-8193-b704465d52ff","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during co\u2011administration of warfarin with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.<\/span><\/p>","ID":"74179285-cb7a-453f-9b6e-4b61ea586aa1","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during co\u2011administration of warfarin with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"473aa1e7-56bf-4503-abe4-befd92647058","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Digoxin and other P\u2011gp substrates<\/span><\/i><\/p>","ID":"38565006-fac8-4f8c-95c4-5c3e89a4cbd9","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Digoxin and other P\u2011gp substrates","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"e1b03362-d3d8-4427-a87a-23db907244de","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with digoxin, a sensitive P\u2011gp substrate, increased digoxin exposure by 1.3\u2011fold, consistent with weak inhibition of P\u2011gp by ivacaftor. Administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) may increase systemic exposure of medicinal products that are sensitive substrates of P\u2011gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly<\/span><span style=\"font-size:11.0pt\"> with<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> digoxin or other substrates of P\u2011gp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.<\/span><\/p>","ID":"18fb4c5e-bcab-4965-aeb3-362e7a2379ae","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Co\u2011administration with digoxin, a sensitive P\u2011gp substrate, increased digoxin exposure by 1.3\u2011fold, consistent with weak inhibition of P\u2011gp by ivacaftor. Administration of ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) may increase systemic exposure of medicinal products that are sensitive substrates of P\u2011gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly with digoxin or other substrates of P\u2011gp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"c9222ba3-fe89-459b-b916-b4cda45fca08","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A substrates <\/span><\/i><\/p>","ID":"e4b2afec-f27b-4569-bddc-d057371c6e17","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"CYP3A substrates ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"0b5cdfae-0bb6-4475-9677-c68834ef5fc6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5\u2011fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co\u2011administered with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). <\/span><\/p>","ID":"49167467-9ab4-403d-8a7c-6761a4280056","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Co\u2011administration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5\u2011fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co\u2011administered with ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"a02f829b-ba53-4497-b8e3-502486d8e2d9","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hormonal contraceptives<\/span><\/i><\/p>","ID":"8a036475-6b0a-480b-84b2-dbfd98b1bc54","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Hormonal contraceptives","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"f8a806d0-8cb1-4a6a-8c61-8bf7d4d360d4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) has been studied with an oestrogen\/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral contraceptives is necessary.<\/span><\/p>","ID":"92c65c98-7256-4951-8a1b-7c4e59bf1b57","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Ivacaftor (as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor) has been studied with an oestrogen\/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral contraceptives is necessary.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"bfa43991-fe86-481a-8080-9bfa8de68a9c","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p>","ID":"12179c22-6d13-4ffc-a561-b992ac4a87db","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"0730805c-3cad-4e24-b080-c2c0c1bf055a","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">Interaction studies have only been performed in adults.<\/span><\/p>","ID":"f8e76064-2206-4d91-9a2a-461e84ebd43f","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":"Interaction studies have only been performed in adults.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"10fa2d23-74d0-4e18-8cd0-9473c0abc71a","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6    Fertility, pregnancy and lactation<\/span><\/b><\/p>","ID":"ee091e0c-6aa7-4714-9997-5b59cac487a7","Styles":"margin-left:28.1pt;text-indent:-28.1pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.6    Fertility, pregnancy and lactation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"abde01cc-1fa1-4606-8d1a-81dca16ca820","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-left:28.1pt;text-indent:-28.1pt;page-break-after: avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pregnancy<\/span><\/u><\/p>","ID":"10da29db-3449-4813-8cb4-783fa5a23487","Styles":"margin-left:28.1pt;text-indent:-28.1pt;page-break-after:\navoid","Classes":"['labeltext']","Text":"Pregnancy","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-left:28.1pt;text-indent:-28.1pt;page-break-after: avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:  none\"> <\/span><\/span><\/u><\/p>","ID":"376a6c8a-5e92-4054-a3b3-3d761e42a9f2","Styles":"margin-left:28.1pt;text-indent:-28.1pt;page-break-after:\navoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women. Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of ivacaftor during pregnancy.<\/span><\/p>","ID":"82bb109b-3fb7-4e51-bba4-50baff0699a4","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women. Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of ivacaftor during pregnancy.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7b746cb2-6d91-4ea5-a065-d07c69f41921","Styles":"margin:0in","Classes":"['MsoNormalIndent']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding<\/span><\/u><\/p>","ID":"16e4c207-dedc-42c5-aa2a-b5c4208454e2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Breast\u2011feeding","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"494356a0-1ffe-432e-93f3-b60a45b547a9","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">It is unknown whether ivacaftor and\/or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of ivacaftor into the milk of lactating female rats. As such, a risk to the newborns\/infants cannot be excluded. A decision must be made whether to discontinue breast\u2011feeding or to discontinue\/abstain from ivacaftor therapy taking into account the benefit of breast\u2011feeding for the child and the benefit of therapy for the woman.<\/span><\/p>","ID":"6fda1e6b-a8b7-4668-a337-2fe8bd89ff75","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"It is unknown whether ivacaftor and\/or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of ivacaftor into the milk of lactating female rats. As such, a risk to the newborns\/infants cannot be excluded. A decision must be made whether to discontinue breast\u2011feeding or to discontinue\/abstain from ivacaftor therapy taking into account the benefit of breast\u2011feeding for the child and the benefit of therapy for the woman.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2c171df8-4439-4dbe-b558-62d643843d04","Styles":"margin:0in","Classes":"['MsoNormalIndent']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"8174cbb7-c7ec-46e8-a998-96ec0c6ce939","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":"Fertility","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"891f494d-009a-442f-9a2e-46e1ec3138f1","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3).<\/span><\/p>","ID":"fdf2edf5-090e-47fd-97da-15f3c12d14a7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"d6b86eea-8f68-4e55-a8e5-32acbd98f58a","Styles":"margin:0in","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p>","ID":"efef6a90-9ec9-413a-967e-c2cb3e732078","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.7     Effects on ability to drive and use machines","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5fbc10fb-e7da-4d76-a263-1aac3201af96","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore,<\/span><span lang=\"EN-GB\"> patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.<\/span><\/p>","ID":"19d21779-48df-47a4-89b2-6ce3157637ce","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore, patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ac54c99b-cd11-4f9e-bb89-2e6a00c89106","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8     <a name=\"_Hlk36070162\">Undesirable effects<\/a><\/span><\/b><\/p>","ID":"28877e86-6b4e-4e0b-8f33-a3ec8772562f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.8     Undesirable effects","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"cee5b431-5ff4-4660-b652-780135cc6e9c","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Summary of the safety profile<\/span><\/u><\/p>","ID":"3100937b-cb63-4a14-a7a0-0577ebcfa17d","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Summary of the safety profile","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"2bb3ab57-0ed0-431c-ab89-85060a3b72c2","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">The most common adverse reactions experienced by patients aged 6 years and older who received ivacaftor are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">dizziness (9.2%), <\/span><span style=\"font-size:11.0pt\">rash (12.8%<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">) and <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">bacteria<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span style=\"font-size:11.0pt\">in <\/span><span style=\"font-size:11.0pt\">sputum (12.8%).<\/span><span style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Transaminase elevations occurred in 12.8% of ivacaftor-treated patients versus 11.5% of placebo\u2011treated patients.<\/span><\/p>","ID":"02893bb1-5a3c-4f62-8122-e81efa3624b5","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"The most common adverse reactions experienced by patients aged 6 years and older who received ivacaftor are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and bacteria in sputum (12.8%). Transaminase elevations occurred in 12.8% of ivacaftor-treated patients versus 11.5% of placebo\u2011treated patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"34ed5e4a-d7f3-4541-8512-0d135072589b","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).<\/span><\/p>","ID":"f1c175fa-74f4-41ed-a61c-7e62baa506fa","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"b3811433-bde2-4669-88cb-1e537a49c897","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).<\/span><\/p>","ID":"a0d8b964-1cbc-4347-ac60-8b32ee5daee9","Styles":"None","Classes":"['labeltext']","Text":"Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"09c011e6-6338-4f46-a798-7646cf3c02b5","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><a name=\"_Hlk45279317\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Tabulated list of adverse reactions<\/span><\/u><\/a><\/p>","ID":"9562a743-265e-444b-b0ae-e4e3e29aa360","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Tabulated list of adverse reactions","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"92a46780-c2cd-466c-b68c-8099aa260a17","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Table 4 reflects the adverse reactions observed with ivacaftor monotherapy in clinical trials (placebo-controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. Additional adverse reactions observed with ivacaftor in a combination regimen with tezacaftor\/ivacaftor and\/or in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor are also provided in Table 4. The frequency of adverse reactions is defined as follows: very common (\u2265 1\/10); common (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare (&lt; 1\/10,000); not known (cannot be estimated from the available data). <span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<\/span><\/p>","ID":"5708273e-deb5-436b-8cc8-a37faf962db0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Table 4 reflects the adverse reactions observed with ivacaftor monotherapy in clinical trials (placebo-controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. Additional adverse reactions observed with ivacaftor in a combination regimen with tezacaftor\/ivacaftor and\/or in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor are also provided in Table 4. The frequency of adverse reactions is defined as follows: very common (\u2265 1\/10); common (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare (< 1\/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ae069e05-e966-4e58-a8b8-2ebbe125e690","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.3pt;text-indent:-40.3pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 4: Adverse reactions in patients treated with ivacaftor monotherapy and\/or in a combination regimen<\/span><\/b><\/p>","ID":"a52bdaca-248a-49e2-b9c9-128f15cbc298","Styles":"margin-top:0in;margin-right:0in;margin-bottom:6.0pt;\nmargin-left:40.3pt;text-indent:-40.3pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 4: Adverse reactions in patients treated with ivacaftor monotherapy and\/or in a combination regimen","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.18%;margin-left:-.25pt;border-collapse:collapse;border:none\" width=\"99%\"> <thead> <tr style=\"page-break-inside:avoid;height:15.5pt\"> <td style=\"width:34.06%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">System organ class<\/span><\/b><\/p> <\/td> <td style=\"width:35.94%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"35%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Adverse reactions<\/span><\/b><\/p> <\/td> <td style=\"width:30.0%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"30%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"4\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Infections and infestations<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Upper respiratory tract infection<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nasopharyngitis<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Influenza <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rhinitis<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hypoglycaemia <\/span><sup><span lang=\"EN-GB\" style='font-family:   \"Arial\",sans-serif'>\u2020<\/span><\/sup><span lang=\"EN-GB\"> <\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"2\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Nervous system disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Headache<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Dizziness<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"6\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ear and labyrinth disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ear pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear discomfort<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tinnitus<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tympanic membrane   hyperaemia<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vestibular   disorder<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear congestion<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"7\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Oropharyngeal pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nasal   congestion<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Abnormal   breathing <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rhinorrhoea <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Sinus   congestion<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharyngeal   erythema<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Wheezing <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"5\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Abdominal pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Abdominal pain   upper <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Flatulence <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nausea <sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"3\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DA\">Hepatobiliary disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Transaminase elevations<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Alanine aminotransferase increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Aspartate aminotransferase increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"3\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Rash<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Acne <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pruritus <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common <\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"5\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Breast mass<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Breast   inflammation<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gynaecomastia<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple   disorder<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple pain<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td rowspan=\"3\" style=\"width:34.06%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Investigations<\/span><\/p> <\/td> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Bacteria in sputum<\/span><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Blood creatine phosphokinase increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:.2in\"> <td style=\"width:35.94%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"35%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Blood pressure increased <\/span><sup><span lang=\"EN-GB\" style='font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><\/p> <\/td> <td style=\"width:30.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:.2in\" valign=\"top\" width=\"30%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">uncommon <\/span><\/p> <\/td> <\/tr> <\/table>","ID":"5b22ff6b-22e0-4d4f-a206-2fc3bbfb680a","Styles":"width:99.18%;margin-left:-.25pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"    System organ class   Adverse reactions   Frequency      Infections and infestations   Upper respiratory tract infection   very common     Nasopharyngitis   very common     Influenza \u2020   common      Rhinitis   common     Metabolism and nutrition disorders   Hypoglycaemia \u2020    common      Nervous system disorders   Headache   very common     Dizziness   very common     Ear and labyrinth disorders   Ear pain   common     Ear discomfort   common     Tinnitus   common     Tympanic membrane   hyperaemia   common     Vestibular   disorder   common     Ear congestion   uncommon     Respiratory, thoracic and mediastinal disorders   Oropharyngeal pain   very common     Nasal   congestion   very common     Abnormal   breathing \u2020   common      Rhinorrhoea \u2020   common      Sinus   congestion   common     Pharyngeal   erythema   common     Wheezing \u2020   uncommon     Gastrointestinal disorders   Abdominal pain   very common     Diarrhoea   very common     Abdominal pain   upper \u2020   common     Flatulence \u2020   common      Nausea *   common     Hepatobiliary disorders   Transaminase elevations   very common     Alanine aminotransferase increased \u2020   common     Aspartate aminotransferase increased \u2020   common      Skin and subcutaneous tissue disorders   Rash   very common     Acne \u2020   common     Pruritus \u2020   common      Reproductive system and breast disorders   Breast mass   common     Breast   inflammation   uncommon     Gynaecomastia   uncommon     Nipple   disorder   uncommon     Nipple pain   uncommon     Investigations   Bacteria in sputum   very common     Blood creatine phosphokinase increased \u2020   common     Blood pressure increased \u2020   uncommon    ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with tezacaftor\/ivacaftor<\/span><\/p>","ID":"7bf8964e-54cc-444d-997c-4e5a0dcee401","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"* Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with tezacaftor\/ivacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style='font-size:9.0pt; font-family:\"Arial\",sans-serif'>\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/p>","ID":"b6990a79-0779-413a-899f-0bb94768156a","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"\u2020 Adverse reaction and frequency reported from clinical studies with ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"c04ce24f-1153-4bbc-aa2d-252a7d357053","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p>","ID":"e4094778-96ce-4695-ac88-7dfbfb7a3e5b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Description of selected adverse reactions","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"60a8e748-c0ed-4005-9f48-e13d745904a2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Transaminase elevations <\/span><\/i><\/p>","ID":"334bfb78-d098-4a17-8209-5912fddb3c78","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Transaminase elevations ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"211b3516-b991-464a-b487-3aee76ccec1b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">During the 48-week placebo\u2011controlled studies 1 and 2 of ivacaftor as monotherapy in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5 or &gt; 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor\u2011treated patients and 1.0%, 1.9% and 8.7% in placebo\u2011treated patients, respectively. Two patients, one on placebo and one on ivacaftor permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN. No ivacaftor\u2011treated patients experienced a transaminase elevation &gt; 3 x ULN associated with elevated total bilirubin &gt; 1.5 x ULN. In ivacaftor\u2011treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations &gt; 5 x ULN. In all instances where dosing was interrupted for elevated transaminases<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).<\/span><\/p>","ID":"4b11f39b-1dc2-4810-b0b8-034a81fc8174","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"During the 48-week placebo\u2011controlled studies 1 and 2 of ivacaftor as monotherapy in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) > 8, > 5 or > 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor\u2011treated patients and 1.0%, 1.9% and 8.7% in placebo\u2011treated patients, respectively. Two patients, one on placebo and one on ivacaftor permanently discontinued treatment for elevated transaminases, each > 8 x ULN. No ivacaftor\u2011treated patients experienced a transaminase elevation > 3 x ULN associated with elevated total bilirubin > 1.5 x ULN. In ivacaftor\u2011treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations > 5 x ULN. In all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"744856b1-3e8f-40dd-8617-2e1b9f895132","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor\/ivacaftor, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor\/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor\/ivacaftor experienced a transaminase elevation &gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. <\/span><\/p>","ID":"d8f1fbcc-36e5-49ab-99e9-5fc114c2eb27","Styles":"None","Classes":"['MsoNormal']","Text":"During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor\/ivacaftor, the incidence of maximum transaminase (ALT or AST) > 8, > 5, or > 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor\/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor\/ivacaftor experienced a transaminase elevation >3 x ULN associated with elevated total bilirubin >2 x ULN. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"a163f110-02d5-48e0-950b-ba94d26bba45","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">During the 24-week, placebo-controlled, phase 3 study of ivacaftor\/tezacaftor\/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor\/tezacaftor\/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor treated patients and 4.0% in placebo-treated patients.<\/span><\/p>","ID":"e8dad0ea-4466-4724-b9fa-d1759289abc0","Styles":"None","Classes":"['MsoNormal']","Text":"During the 24-week, placebo-controlled, phase 3 study of ivacaftor\/tezacaftor\/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor\/tezacaftor\/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor treated patients and 4.0% in placebo-treated patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"e6371bf5-2eed-4c81-939c-44fd5d8c040e","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Rash events<\/span><\/i><\/p>","ID":"e5a1b010-3643-4d97-8eb4-a911fd4d85fb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Rash events","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"456f8a9f-c0f2-47ce-af8b-3ec630ceef97","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Rash events, generally mild to moderate in severity, have been observed with the use of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor and occurred more frequently in female-treated patients (16.3%) and in those taking hormonal contraceptives (20.5%). See section 4.4.<\/span><\/p>","ID":"b91be445-22b2-4227-addd-c42bba98049f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Rash events, generally mild to moderate in severity, have been observed with the use of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor and occurred more frequently in female-treated patients (16.3%) and in those taking hormonal contraceptives (20.5%). See section 4.4.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1e220527-b22f-4672-929d-488035252411","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Increased creatine phosphokinase <\/span><\/i><\/p>","ID":"f78d6d7d-a940-44d5-808f-910b8ec68fc8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Increased creatine phosphokinase ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"cb70efd6-e05f-4024-9597-0a70b68be6c7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Generally transient and asymptomatic increases in <\/span><span lang=\"EN-CA\">creatine phosphokinase were observed in patients treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor, which did not lead to treatment discontinuation.<\/span><\/p>","ID":"7b51905c-1857-4191-8167-7ab48c26242c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Generally transient and asymptomatic increases in creatine phosphokinase were observed in patients treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor, which did not lead to treatment discontinuation.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"567d8f39-788b-42c4-aef1-b0d0a2f6ae48","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Increased blood pressure<\/span><\/i><\/p>","ID":"ef7e4643-260b-4f7b-8ad6-3c0aadc22f71","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Increased blood pressure","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"d8fe63ee-992e-4187-94b5-b600ae5b8dad","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">An increase from baseline in mean systolic and diastolic blood pressure of 3.5 mmHg and 1.9 mmHg, respectively was observed in patients treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor. <\/span><\/p>","ID":"41107084-1425-4e9f-b41c-ec7cd4387ecd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"An increase from baseline in mean systolic and diastolic blood pressure of 3.5 mmHg and 1.9 mmHg, respectively was observed in patients treated with ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7ce2ab3b-cb34-444c-8384-a2a1483ebbc4","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"fb950675-2ce7-4774-b51e-206862a2147e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c4ed58a1-94b6-42fe-88c8-76214c89e77d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The safety data of ivacaftor as monotherapy were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, <\/span><span lang=\"EN-GB\">19 patients between 12 months to less than 24 months of age, <\/span><span lang=\"EN-GB\">34 patients between 2 to less than 6 years of age,<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age. <\/span><\/p>","ID":"4f225685-5809-4c81-b83a-7fdf01d2bd60","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The safety data of ivacaftor as monotherapy were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, 19 patients between 12 months to less than 24 months of age, 34 patients between 2 to less than 6 years of age, 61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e7e1ba66-9f50-4155-95de-c2150e26eee6","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety profile of ivacaftor (as monotherapy or in a combination regimen) is generally consistent among paediatric patients and is also consistent with adult patients.<\/span><\/p>","ID":"c8a30ce2-199e-49ca-bc59-c1aa78ad3c1e","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The safety profile of ivacaftor (as monotherapy or in a combination regimen) is generally consistent among paediatric patients and is also consistent with adult patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"892f707a-e0a9-4cc8-ba23-dfd938365723","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients <\/span><span lang=\"EN-GB\">aged 6 to less than <\/span><span lang=\"EN-GB\">24 months) are described in Table 5. In the placebo controlled studies<\/span><span lang=\"EN-GB\">, the incidence of transaminase elevations <\/span><span lang=\"EN-GB\">were similar between treatment with ivacaftor (15.0%)<\/span><span lang=\"EN-GB\"> and <\/span><span lang=\"EN-GB\">placebo (14.6%). Across all populations, <\/span>peak LFT elevations <span lang=\"EN-GB\">returned to baseline levels following interruption, and <\/span>in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully <span lang=\"EN-GB\">(see section 4.4). <\/span>Cases suggestive of positive rechallenge were observed<span lang=\"EN-GB\">. In study 7 <\/span><span lang=\"EN-GB\">ivacaftor was permanently discontinued in one patient. <\/span><span lang=\"EN-GB\">In study 8 <\/span><span lang=\"EN-GB\">no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).<\/span><\/p>","ID":"2253bf57-83e9-4384-9148-4245170a7018","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients aged 6 to less than 24 months) are described in Table 5. In the placebo controlled studies, the incidence of transaminase elevations were similar between treatment with ivacaftor (15.0%) and placebo (14.6%). Across all populations, peak LFT elevations returned to baseline levels following interruption, and in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4). Cases suggestive of positive rechallenge were observed. In study 7 ivacaftor was permanently discontinued in one patient. In study 8 no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"6e435945-3f71-4265-9f2d-9191c943362c","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:12.0pt\"><b><span lang=\"EN-GB\">Table 5: Transaminase elevations in patients 4 months to &lt; 12 years treated with ivacaftor as monotherapy<\/span><\/b><\/p>","ID":"a29030bd-9ee3-40a6-955a-49fd1bc193ea","Styles":"margin-bottom:12.0pt","Classes":"['MsoNormal']","Text":"Table 5: Transaminase elevations in patients 4 months to < 12 years treated with ivacaftor as monotherapy","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"margin-left:6.85pt;border-collapse:collapse;border:none\"> <tr style=\"height:28.95pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">n<\/span><\/b><\/p> <\/td> <td style=\"width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 3 x ULN <\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt;5 x ULN<\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 8 x ULN<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.0%   (6)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2 to &lt;6 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 to &lt;24 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.8%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">9.1%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4 to &lt;6 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"f9a41f3d-dbe4-4081-b6b0-de4d17a51a2b","Styles":"margin-left:6.85pt;border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Text":"       n   % of Patients > 3 x ULN    % of Patients >5 x ULN   % of Patients > 8 x ULN     6 to <12 years   40   15.0%   (6)   2.5%   (1)   2.5%   (1)     2 to <6 years   34   14.7%   (5)   14.7%   (5)   14.7%   (5)     12 to <24 months   18   27.8%   (5)   11.1%   (2)   11.1%   (2)     6 to <12 months   11   9.1%   (1)   0.0%   (0)   0.0%   (0)     4 to <6 months   6   0.0%   (0)   0.0%   (0)   0.0%   (0)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"text-decoration:  none\"> <\/span><\/u><\/p>","ID":"974a706c-a68b-4fb8-8bae-0ce5362ea261","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","ID":"5573395a-2b37-4c23-b2d6-e08c8947ffed","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Reporting of suspected adverse reactions","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"80e44be5-f8d7-4f53-9890-2b12811a5093","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style=\"background: lightgrey\">the national reporting system listed in <\/span><\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span lang=\"EN-GB\" style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a><span lang=\"EN-GB\">.<\/span><\/p>","ID":"453593d1-7805-4ee1-a776-92f375726e7d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7f486c87-c255-464b-9027-789b7a0293dd","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.9       Overdose<\/span><\/h2>","ID":"44377d08-6b89-4308-b9ef-a6a275463a46","Styles":"margin:0in","Classes":"None","Text":"4.9       Overdose","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"81257da0-28e1-45ca-a586-0bf4406cd74b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.<\/span><\/p>","ID":"4de96938-efd9-44ff-ae79-877f084f186b","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ace39d15-bc2e-4f16-ae7d-3a75b49921b4","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"26a61a49-6042-4790-a3d4-2d2919aa6a1d","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>5.       PHARMACOLOGICAL PROPERTIES<\/span><\/h1>","ID":"58dd05b9-7a49-4fa5-9352-95d1bde1da86","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"f487d95b-cde9-48ee-9547-a4b4d0501af2","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.5pt;text-indent:-28.5pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Pharmacodynamic properties<\/span><\/b><\/p>","ID":"ca17d4d1-c714-400f-91fb-9c6375b6d447","Styles":"margin-left:28.5pt;text-indent:-28.5pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"5.1          Pharmacodynamic properties","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"3f409092-48d5-4c5b-93b2-ab9718ea9fef","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Other respiratory system products, ATC code: <\/span><span lang=\"EN-GB\">R07AX02<\/span><\/p>","ID":"659ae99a-58da-4576-8b97-3bca82e46e3d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Pharmacotherapeutic group: Other respiratory system products, ATC code: R07AX02","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7dc6bea8-a38c-47bc-bca6-ea550ee10acc","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"54e26913-3c7e-444c-b16f-2b9b98f759d4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Mechanism of action","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"efdbb55e-b6d4-4786-95b4-ac7aa1a5164d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is a potentiator of the CFTR protein, i.e., <i>in vitro<\/i> ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channel\u2011open probability compared to normal CFTR. Ivacaftor also potentiated the channel\u2011open probability of R117H\u2011CFTR, which has both low channel\u2011open probability (gating) and reduced channel current amplitude (conductance). The <i>G970R <\/i>mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data).<\/span><\/p>","ID":"6048aaae-1579-4b32-960a-f9e099758a0f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channel\u2011open probability compared to normal CFTR. Ivacaftor also potentiated the channel\u2011open probability of R117H\u2011CFTR, which has both low channel\u2011open probability (gating) and reduced channel current amplitude (conductance). The G970R mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d0cb6cc1-d017-4dd7-8b57-907dbe5b67c6","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to <i>in vivo <\/i>pharmacodynamic response (e.g., sweat chloride) or clinical benefit. <\/span><span lang=\"EN-GB\">The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.<\/span><\/p>","ID":"9fc6d300-afd9-49fa-b6e2-c0f42f134fd2","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In vitro responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to in vivo pharmacodynamic response (e.g., sweat chloride) or clinical benefit. The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"b05da1d5-3ce2-4988-ad62-be08f9c785fb","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacodynamic effects<\/span><\/u><\/p>","ID":"3bfc8c8a-07c3-4874-8bf5-4e6873e01c42","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Pharmacodynamic effects","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"c5c65f94-6af9-41fd-b7d6-02d6c7362d16","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor as monotherapy<\/span><\/i><\/p>","ID":"5b5df9bf-a2fc-476e-adc8-c7336deeda5f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Ivacaftor as monotherapy","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"00fe403f-11ec-42ce-9f9d-8c8d1cf4c5b7","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In studies 1 and 2 in patients with the <i>G551D <\/i>mutation in one allele of the <i>CFTR<\/i> gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was \u201148 mmol\/L [95% CI \u201151, \u201145] and \u201154 mmol\/L [95% CI \u201162, \u201147], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.<\/span><\/p>","ID":"960462d9-f0f1-4d97-a6ec-deed35162973","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"In studies 1 and 2 in patients with the G551D mutation in one allele of the CFTR gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was \u201148 mmol\/L [95% CI \u201151, \u201145] and \u201154 mmol\/L [95% CI \u201162, \u201147], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"018e7767-6e40-4378-b87b-21f2faf39fd8","Styles":"margin-bottom:0in","Classes":"['documenttext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In study 5, part 1 in patients who had a non\u2011<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of \u201149 mmol\/L (95% CI \u201157, \u201141) through 8 weeks of treatment. However, in patients with the <i>G970R<\/i>\u2011<i>CFTR<\/i> mutation, the mean (SD) absolute change in sweat chloride at week 8 was \u20116.25 (6.55) mmol\/L. Similar results to part 1 were seen in part 2 of the study. <\/span><span style=\"font-size:11.0pt\">At the 4\u2011week follow\u2011up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre\u2011treatment levels.<\/span><\/p>","ID":"6780a336-87b9-43b3-8df9-1be5645b60c0","Styles":"margin-bottom:0in","Classes":"['documenttext']","Text":"In study 5, part 1 in patients who had a non\u2011G551D gating mutation in the CFTR gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of \u201149 mmol\/L (95% CI \u201157, \u201141) through 8 weeks of treatment. However, in patients with the G970R\u2011CFTR mutation, the mean (SD) absolute change in sweat chloride at week 8 was \u20116.25 (6.55) mmol\/L. Similar results to part 1 were seen in part 2 of the study. At the 4\u2011week follow\u2011up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre\u2011treatment levels.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"610a106e-3d85-42c8-b584-f399621c0fb2","Styles":"margin-bottom:0in","Classes":"['documenttext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In study 6 in patients aged 6 years or older with CF who had an <i>R117H<\/i> mutation in the <i>CFTR<\/i> gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was \u201124 mmol\/L (95% CI \u201128, \u201120). In subgroup analyses by age, the treatment difference was -21.87 mmol\/L (95% CI: -26.46, -17.28) in patients aged 18 years or older, and -27.63 mmol\/L (95% CI: -37.16, -18.10) in patients aged 6-11 years. <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Two patients 12 to 17<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">years of age were enrolled in this study.<\/span><\/p>","ID":"86d1d3c4-b236-4ed7-ab65-8a07c9e8b446","Styles":"margin-bottom:0in","Classes":"['documenttext']","Text":"In study 6 in patients aged 6 years or older with CF who had an R117H mutation in the CFTR gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was \u201124 mmol\/L (95% CI \u201128, \u201120). In subgroup analyses by age, the treatment difference was -21.87 mmol\/L (95% CI: -26.46, -17.28) in patients aged 18 years or older, and -27.63 mmol\/L (95% CI: -37.16, -18.10) in patients aged 6-11 years. Two patients 12 to 17 years of age were enrolled in this study.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"0f1eb3bb-ea35-488c-ae4b-65ee7d506d3b","Styles":"margin-bottom:0in","Classes":"['documenttext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Ivacaftor in a combination regimen with tezacaftor\/ivacaftor<\/span><\/i><\/p>","ID":"575a1881-87a8-42b6-b4cc-7e65a0f64c0d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor in a combination regimen with tezacaftor\/ivacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"><br\/> <\/span><\/i><span lang=\"EN-GB\">In patients homozygous for the <i>F508del <\/i>mutation, the treatment difference between ivacaftor in combination with tezacaftor\/ivacaftor and placebo in mean absolute change from baseline in sweat chloride through week 24, was \u201110.1 mmol\/L (95% CI: \u201111.4, \u20118.8<span style=\"color:black\">).<\/span><\/span><\/p>","ID":"dd9a0f72-aea6-40de-ac96-8a69fd9935cd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" In patients homozygous for the F508del mutation, the treatment difference between ivacaftor in combination with tezacaftor\/ivacaftor and placebo in mean absolute change from baseline in sweat chloride through week 24, was \u201110.1 mmol\/L (95% CI: \u201111.4, \u20118.8).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e2e418c3-38a3-431e-8ffc-76e03e74db41","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients heterozygous for the <i>F508del <\/i>mutation and a second mutation associated with residual CFTR<i> <\/i>activity, the treatment difference in mean absolute change from baseline in sweat chloride through week 8 was \u20119.5 mmol\/L (95% CI: \u201111.7, \u20117.3) between tezacaftor\/ivacaftor and placebo, and \u20114.5 mmol\/L (95% CI: \u20116.7, \u20112.3) between ivacaftor and placebo.<\/span><\/p>","ID":"9dbca4bf-2950-4759-ac63-5d728a014023","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In patients heterozygous for the F508del mutation and a second mutation associated with residual CFTR activity, the treatment difference in mean absolute change from baseline in sweat chloride through week 8 was \u20119.5 mmol\/L (95% CI: \u201111.7, \u20117.3) between tezacaftor\/ivacaftor and placebo, and \u20114.5 mmol\/L (95% CI: \u20116.7, \u20112.3) between ivacaftor and placebo.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"ae13d345-3c8d-4571-8f01-fd691a065496","Styles":"margin-bottom:0in","Classes":"['documenttext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/i><\/p>","ID":"7cf544e4-b878-47ef-9f0d-a337a7c0e97e","Styles":"margin-bottom:0in;page-break-after:avoid","Classes":"['documenttext']","Text":"Ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"24f249bc-2934-4be2-b79f-c521d5b20b19","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">In patients with an <i>F508del<\/i> mutation on one allele and a mutation on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor\/ivacaftor, the treatment difference between ivacaftor\/tezacaftor\/elexacaftor and placebo for mean absolute change in sweat chloride from baseline through week 24 was \u201141.8 mmol\/L (95% CI: -44.4, -39.3).<\/span><\/p>","ID":"74f61fc0-745b-4dd5-9b01-e9eb00a27730","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"In patients with an F508del mutation on one allele and a mutation on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor\/ivacaftor, the treatment difference between ivacaftor\/tezacaftor\/elexacaftor and placebo for mean absolute change in sweat chloride from baseline through week 24 was \u201141.8 mmol\/L (95% CI: -44.4, -39.3).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"fe77de84-a16e-4c0b-83c7-db8acb7482a8","Styles":"text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In patients homozygous for the <i>F508del <\/i>mutation, the treatment difference between ivacaftor\/tezacaftor\/elexacaftor and tezacaftor\/ivacaftor for mean absolute change in sweat chloride from baseline at week 4 was \u201145.1 mmol\/L (95% CI: -50.1, -40.1).<\/span><\/p>","ID":"aa0432b3-5a08-4881-813d-35c874862456","Styles":"text-autospace:none","Classes":"['MsoNormal']","Text":"In patients homozygous for the F508del mutation, the treatment difference between ivacaftor\/tezacaftor\/elexacaftor and tezacaftor\/ivacaftor for mean absolute change in sweat chloride from baseline at week 4 was \u201145.1 mmol\/L (95% CI: -50.1, -40.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"b760a2ad-026a-4091-8b80-388b69c7d143","Styles":"margin-bottom:0in","Classes":"['documenttext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Clinical efficacy and safety<\/span><\/u><\/p>","ID":"0a616b78-d58a-4786-83b0-af3aea53693f","Styles":"margin-bottom:0in;page-break-after:avoid","Classes":"['documenttext']","Text":"Clinical efficacy and safety","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"8ea9bd74-8526-4581-a4e7-ba0f2e38bddb","Styles":"margin-bottom:0in;page-break-after:avoid","Classes":"['documenttext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor as monotherapy<\/span><\/i><\/p>","ID":"43aa24a9-9ff2-48c3-8e8b-408e897d7916","Styles":"margin-bottom:0in;page-break-after:avoid","Classes":"['documenttext']","Text":"Ivacaftor as monotherapy","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"documenttext\" style=\"margin-bottom:0in;page-break-after:avoid\"><i><span style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"d9cd5016-6b79-4401-9453-ca7d7776ca2d","Styles":"margin-bottom:0in;page-break-after:avoid","Classes":"['documenttext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Study 1 and 2: studies in patients with CF with G551D gating mutations<\/span><\/u><\/i><\/p>","ID":"5b34600b-c2ea-49d1-b60b-ae30dd712e4e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 1 and 2: studies in patients with CF with G551D gating mutations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p>","ID":"be3298bc-a66d-493f-b834-8bb75282474c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-right:-1.85pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The efficacy of ivacaftor has been evaluated in two phase 3 randomised, double\u2011blind, placebo\u2011controlled, multi\u2011centre studies of clinically stable patients with CF who had the <i>G551D<\/i> mutation in the <i>CFTR<\/i> gene on at least 1 allele and had FEV<sub>1<\/sub> \u2265 40% predicted.<\/span><\/p>","ID":"fd7a82ba-b14b-4932-bbc4-6197dfb9ca47","Styles":"margin-right:-1.85pt;page-break-after:avoid","Classes":"['labeltext']","Text":"The efficacy of ivacaftor has been evaluated in two phase 3 randomised, double\u2011blind, placebo\u2011controlled, multi\u2011centre studies of clinically stable patients with CF who had the G551D mutation in the CFTR gene on at least 1 allele and had FEV1 \u2265 40% predicted.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"10a9c7fb-b9cb-4090-b448-9b9f8b6f2703","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.<\/span><\/p>","ID":"324848f8-c982-40f5-ab9c-ca51f222fbd8","Styles":"None","Classes":"['labeltext']","Text":"Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"5e7515b4-0603-459f-b166-20f6a3393db6","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the <i>F508del<\/i> mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol\/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV<sub>1<\/sub> was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).<\/span><\/p>","ID":"6ee06ed9-37c2-47b4-a30e-27836ecddfd6","Styles":"None","Classes":"['labeltext']","Text":"Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the F508del mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol\/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV1 was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"8e8cec56-03cf-449d-b0ae-6997ffdcf21a","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the <i>F508del<\/i> mutation in the second allele. At baseline, mean predicted FEV<sub>1<\/sub> was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV<sub>1<\/sub> less than 70% predicted at baseline.<\/span><\/p>","ID":"524903b5-0c08-4a40-bd06-3386744b0321","Styles":"None","Classes":"['labeltext']","Text":"Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the F508del mutation in the second allele. At baseline, mean predicted FEV1 was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV1 less than 70% predicted at baseline.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"277258e0-6cb3-4fb6-b8d3-c9b0caf60b44","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV<sub>1<\/sub> through 24 weeks of treatment.<\/span><\/p>","ID":"b9b52cbe-3d01-48f8-92e6-cfc7f538bd7c","Styles":"None","Classes":"['labeltext']","Text":"The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV1 through 24 weeks of treatment.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"ee3839c7-805d-41f2-b2d5-3fb6dbe2fea3","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV<sub>1<\/sub> (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV<sub>1<\/sub> were rapid in onset (day 15) and durable through 48 weeks.<\/span><\/p>","ID":"c287fe0d-2e99-4e5e-9707-08cd73a043e3","Styles":"None","Classes":"['labeltext']","Text":"The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV1 from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV1 from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV1 (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV1 were rapid in onset (day 15) and durable through 48 weeks.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"7c1dde83-d2a7-4a75-932b-2b3ceb9848f2","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients with baseline predicted FEV<sub>1 <\/sub>greater than 90% in study 2 was 6.9 percentage points (\u20113.8, 17.6).<\/span><\/p>","ID":"ce76e5e9-2523-43cc-bc9e-30c8762a6290","Styles":"None","Classes":"['labeltext']","Text":"The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV1 from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV1 from baseline through week 24 in patients with baseline predicted FEV1 greater than 90% in study 2 was 6.9 percentage points (\u20113.8, 17.6).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"43212696-b41f-4f78-b03f-2335f751aaaa","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The results for clinically relevant secondary endpoints are shown in Table 6.<\/span><\/p>","ID":"eecf4194-b7ac-4eff-9e7c-2990950f2fcb","Styles":"None","Classes":"['labeltext']","Text":"The results for clinically relevant secondary endpoints are shown in Table 6.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"92744ebd-d0bc-4bed-b8b6-f0af1c5ce922","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Table 6: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2<\/span><\/b><\/p>","ID":"d1a4a73a-c7e6-4f67-9657-daeee9704848","Styles":"margin-bottom:6.0pt;page-break-after:avoid","Classes":"['labeltext']","Text":"Table 6: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.82%;margin-left:5.45pt;border-collapse:collapse\" width=\"98%\"> <thead> <tr style=\"height:10.5pt\"> <td rowspan=\"2\" style=\"width:27.12%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"bottom\" width=\"27%\"> <p class=\"MsoNormal\" style=\"margin-left:55.0pt;line-height:normal;page-break-after:    avoid\"><b><span lang=\"EN-GB\">Endpoint<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:34.82%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"34%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:38.06%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"38%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:28.25pt\"> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:14.64%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:17.88%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in CFQ-R<\/span><\/b><sup><span lang=\"EN-GB\">b<\/span><\/sup><b><span lang=\"EN-GB\"> respiratory domain score   (points)<\/span><\/b><sup><span lang=\"EN-GB\">c<\/span><\/sup><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(4.7, 11.4)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">6.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.4, 13.5)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1092<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.6<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(5.3, 11.9)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">5.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.6, 11.8)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1354<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Relative risk of pulmonary exacerbation<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.40<\/span><sup><span lang=\"EN-GB\">d<\/span><\/sup><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0016<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.46<sup>d<\/sup><\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0012<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in body weight (kg)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.8, 3.7)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.9, 2.9)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0004<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.7<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.1)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.2)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0002<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in BMI (kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.94<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.62, 1.26)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.81<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.34, 1.28)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0008<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.93<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.48, 1.38)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.09<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.51, 1.67)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0003<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.05pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean change from baseline in z\u2011scores<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2011for\u2011age   z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.04, 0.62)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0260<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.39<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.24, 0.53)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">BMI\u2011for\u2011age z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.002, 0.65)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0490<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.45<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.26, 0.65)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"a7bd4e3b-896b-43d6-9c4f-bcf45b996a87","Styles":"width:98.82%;margin-left:5.45pt;border-collapse:collapse","Classes":"['MsoNormalTable']","Text":"    Endpoint   Study 1   Study 2     Treatment differencea (95% CI)   P value   Treatment differencea (95% CI)   P value      Mean absolute change from baseline in CFQ-Rb respiratory domain score   (points)c     Through week   24   8.1 (4.7, 11.4)   < 0.0001   6.1 (\u20111.4, 13.5)   0.1092     Through week   48   8.6 (5.3, 11.9)   < 0.0001   5.1 (\u20111.6, 11.8)   0.1354     Relative risk of pulmonary exacerbation     Through week 24   0.40d   0.0016   NA   NA     Through week 48   0.46d   0.0012   NA   NA     Mean absolute change from baseline in body weight (kg)     At week   24   2.8 (1.8, 3.7)   < 0.0001   1.9 (0.9, 2.9)   0.0004     At week   48   2.7 (1.3, 4.1)   0.0001   2.8 (1.3, 4.2)   0.0002     Mean absolute change from baseline in BMI (kg\/m2)     At week 24   0.94 (0.62, 1.26)   < 0.0001   0.81 (0.34, 1.28)   0.0008     At week 48   0.93 (0.48, 1.38)   < 0.0001   1.09 (0.51, 1.67)   0.0003     Mean change from baseline in z\u2011scores     Weight\u2011for\u2011age   z\u2011score at week 48e   0.33 (0.04, 0.62)   0.0260   0.39 (0.24, 0.53)   < 0.0001     BMI\u2011for\u2011age z\u2011score at week 48e   0.33 (0.002, 0.65)   0.0490   0.45 (0.26, 0.65)   < 0.0001   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"tablefootnote\" style=\"margin-top:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">CI: confidence interval; NA: not analysed due to low incidence of events<\/span><\/p>","ID":"fd63951a-27c8-4311-a015-11014a6f4c8e","Styles":"margin-top:6.0pt;page-break-after:avoid","Classes":"['tablefootnote']","Text":"CI: confidence interval; NA: not analysed due to low incidence of events","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"tablefootnote\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment difference = effect of ivacaftor \u2013 effect of placebo<\/span><\/p>","ID":"477b5d07-cb14-405b-9fa4-064a59279e72","Styles":"margin-left:.2in;text-indent:-.2in;page-break-after:\navoid","Classes":"['tablefootnote']","Text":"a     Treatment difference = effect of ivacaftor \u2013 effect of placebo","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     CFQ\u2011R: Cystic Fibrosis Questionnaire\u2011Revised is a disease\u2011specific, health\u2011related quality\u2011of\u2011life measure for CF.<\/span><\/p>","ID":"6ddf0152-6946-46b1-ab88-cfb1fc43e181","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"b     CFQ\u2011R: Cystic Fibrosis Questionnaire\u2011Revised is a disease\u2011specific, health\u2011related quality\u2011of\u2011life measure for CF.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">c<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Study 1 data were pooled from CFQ\u2011R for adults\/adolescents and CFQ\u2011R for children 12 to 13 years of age; Study 2 data were obtained from CFQ\u2011R for children 6 to 11 years of age.<\/span><\/p>","ID":"0029b6bc-1f96-46b0-baf2-d858504b916a","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"c     Study 1 data were pooled from CFQ\u2011R for adults\/adolescents and CFQ\u2011R for children 12 to 13 years of age; Study 2 data were obtained from CFQ\u2011R for children 6 to 11 years of age.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"left\" class=\"tabletextcenterjustified\" style=\"margin-top:0in;margin-right: 0in;margin-bottom:0in;margin-left:.2in;text-align:left;text-indent:-.2in; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">d<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Hazard ratio for time to first pulmonary exacerbation<\/span><\/p>","ID":"46ad36d6-ab63-43ab-a8bf-27bff576f94b","Styles":"margin-top:0in;margin-right:\n0in;margin-bottom:0in;margin-left:.2in;text-align:left;text-indent:-.2in;\npage-break-after:avoid","Classes":"['tabletextcenterjustified']","Text":"d     Hazard ratio for time to first pulmonary exacerbation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">e<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     In subjects under 20 years of age (CDC growth charts)<\/span><\/p>","ID":"8a040c80-e6ac-427d-a8b9-dedd58297b55","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"e     In subjects under 20 years of age (CDC growth charts)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"3a0ab2fa-7359-4792-9b0c-8ebab0f0dc66","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Study 5: study in patients with CF with non\u2011G551D gating mutations<\/span><\/u><\/i><\/p>","ID":"b0b508ac-2301-4389-8de6-d12513f10235","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 5: study in patients with CF with non\u2011G551D gating mutations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p>","ID":"308348ef-03e4-4d04-ae62-a8e49080f664","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 5 was a phase 3, two\u2011part, randomised, double\u2011blind, placebo\u2011controlled, crossover study (part 1) followed by a 16\u2011week open\u2011label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a <i>G970R<\/i> or non\u2011<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene (<i>G178R<\/i>, <i>S549N<\/i>, <i>S549R<\/i>, <i>G551S<\/i>, <i>G1244E<\/i>, <i>S1251N<\/i>, <i>S1255P<\/i> or <i>G1349D<\/i>).<\/span><\/p>","ID":"2c45824f-ef38-4839-9a28-7d8523abc415","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 5 was a phase 3, two\u2011part, randomised, double\u2011blind, placebo\u2011controlled, crossover study (part 1) followed by a 16\u2011week open\u2011label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a G970R or non\u2011G551D gating mutation in the CFTR gene (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"22536848-0483-4b0c-b5da-f4d33601f088","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat\u2011containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4\u2011 to 8\u2011week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to part 1 placebo\/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor\/placebo treatment sequence.<\/span><\/p>","ID":"1d33d5f1-e533-494b-bae0-697c3c2c9d77","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat\u2011containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4\u2011 to 8\u2011week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to part 1 placebo\/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor\/placebo treatment sequence.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"c6d57f10-f9d2-4ffe-8a39-e73df6a625d0","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Thirty\u2011nine patients (mean age 23 years) with baseline FEV<sub>1<\/sub><\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">\u2265 40% predicted (mean FEV<sub>1<\/sub> 78% predicted [range: 43% to 119%]) were enrolled. Sixty\u2011two percent (24\/39) of them carried the <i>F508del<\/i>\u2011<i>CFTR<\/i> mutation in the second allele. <\/span><span style=\"font-size:11.0pt\">A total of 36 patients continued into part 2 (18 per treatment sequence).<\/span><\/p>","ID":"f5547788-430f-4247-a8ca-c177f198a0d7","Styles":"None","Classes":"['labeltext']","Text":"Thirty\u2011nine patients (mean age 23 years) with baseline FEV1 \u2265 40% predicted (mean FEV1 78% predicted [range: 43% to 119%]) were enrolled. Sixty\u2011two percent (24\/39) of them carried the F508del\u2011CFTR mutation in the second allele. A total of 36 patients continued into part 2 (18 per treatment sequence).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"c57dda32-34b9-48a5-be05-539a9d6aa2ca","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 1 of study 5, the mean FEV<sub>1<\/sub> percent predicted at baseline in placebo\u2011treated patients was 79.3% while in ivacaftor\u2011treated patients this value was 76.4%. The mean overall post\u2011baseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week<\/span><span lang=\"EN-GB\"> 8 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 7.5% in the ivacaftor period and \u20113.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P &lt; 0.0001).<\/span><\/p>","ID":"d1cf8189-9a9f-42f5-b252-fbb318acaaef","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In part 1 of study 5, the mean FEV1 percent predicted at baseline in placebo\u2011treated patients was 79.3% while in ivacaftor\u2011treated patients this value was 76.4%. The mean overall post\u2011baseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week 8 in percent predicted FEV1 (primary efficacy endpoint) was 7.5% in the ivacaftor period and \u20113.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P < 0.0001).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"95212a3c-14cf-478a-b673-3465d4f58d92","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQ\u2011R through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV<sub>1<\/sub> at week 8) is shown in Table 7. Based on clinical (percent predicted FEV<sub>1<\/sub>) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the <i>G970R<\/i> mutation could not be established.<\/span><\/p>","ID":"6220f15f-9626-4b3e-82e6-17240c1c4ea5","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQ\u2011R through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV1 at week 8) is shown in Table 7. Based on clinical (percent predicted FEV1) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the G970R mutation could not be established.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"472105cd-032d-4858-99d5-9122b578fede","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 7: Effect of ivacaftor for efficacy variables in the overall population and for specific <i>CFTR<\/i> mutations<\/span><\/b><\/p>","ID":"0c45aa76-2e3b-4c8b-b650-9529c0497ff0","Styles":"margin-top:0in;margin-right:0in;margin-bottom:6.0pt;\nmargin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 7: Effect of ivacaftor for efficacy variables in the overall population and for specific CFTR mutations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.84%;margin-left:5.35pt;border-collapse:collapse;border:none\" width=\"98%\"> <tr> <td colspan=\"2\" style=\"width:32.6%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change in percent   predicted FEV<sub>1<\/sub><\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:33.66%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">BMI<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <td style=\"width:33.66%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">CFQ-R respiratory domain score   (points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:32.6%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Through week<\/span><\/b><span lang=\"EN-GB\"> <\/span><b><span lang=\"EN-GB\">8<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:33.66%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">At week<\/span><\/b><span lang=\"EN-GB\"> <\/span><b><span lang=\"EN-GB\">8<\/span><\/b><\/p> <\/td> <td style=\"width:33.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Through week<\/span><\/b><span lang=\"EN-GB\"> <\/span><b><span lang=\"EN-GB\">8<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"5\" style=\"width:99.92%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"99%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><span lang=\"EN-GB\">All patients (N = 39)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (95% CI) change   from baseline ivacaftor vs placebo\u2011treated patients:<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:32.6%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">10.7 (7.3, 14.1)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:33.66%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.66 (0.34, 0.99)<\/span><\/p> <\/td> <td style=\"width:33.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">9.6 (4.5, 14.7)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"5\" style=\"width:99.92%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"99%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><b><span lang=\"EN-GB\">Patients grouped under mutation   types (n)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (minimum, maximum) change from baseline for   ivacaftor\u2011treated patients at week 8<sup>*<\/sup>:<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td rowspan=\"2\" style=\"width:16.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"16%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Mutation (n)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;   text-autospace:none\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Absolute   change in sweat chloride (mmol\/L)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Absolute   change in percent predicted FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"2\" style=\"width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">At week<\/span><\/b><span lang=\"EN-GB\"> <b>8<\/b><\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">At week<\/span><\/b><span lang=\"EN-GB\"> <b>8<\/b><\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.4pt\"> <td style=\"width:16.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"16%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><i><span lang=\"PT\">G1244E<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G1349D<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G178R<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G551S<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"PT\">G970R<sup>#<\/sup><\/span><\/i><sup><span lang=\"PT\"> <\/span><\/sup><span lang=\"PT\">(4)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"EN-GB\">S1251N <\/span><\/i><span lang=\"EN-GB\">(8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"EN-GB\">S1255P<\/span><\/i><span lang=\"EN-GB\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><i><span lang=\"EN-GB\">S549N<\/span><\/i><span lang=\"EN-GB\">   (6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><i><span lang=\"EN-GB\">S549R<\/span><\/i><span lang=\"EN-GB\"> (4)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:41.9%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span style='font-family:\"MS Mincho\"'>\u2011<\/span><span lang=\"EN-GB\">55 (-75, -34)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-80 (-82, -79)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-53 (-65, -35)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-68<sup><span style=\"position:relative;   top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-6 (-16, -2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-54 (-84, -7)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-78 (-82, -74)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-74 (-93, -53)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">-61<sup><span style=\"position:relative;   top:-3.0pt\">\u2020\u2020<\/span><\/sup> (-71, -54)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:41.98%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.4pt\" valign=\"top\" width=\"41%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">20 (3, 36)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">3<sup><span style=\"position:relative;   top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">3 (-1, 5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">9 (-20, 21)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">3 (-1, 8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">11 (-2, 20)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">5 (-3, 13)<\/span><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"112\"><\/td> <td style=\"border:none\" width=\"116\"><\/td> <td style=\"border:none\" width=\"177\"><\/td> <td style=\"border:none\" width=\"58\"><\/td> <td style=\"border:none\" width=\"235\"><\/td> <\/tr> <\/table>","ID":"7634f017-4968-4a1b-ba77-256b94c7d153","Styles":"width:98.84%;margin-left:5.35pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"   Absolute change in percent   predicted FEV1   BMI (kg\/m2)   CFQ-R respiratory domain score   (points)     Through week 8   At week 8   Through week 8     All patients (N = 39) Results shown as mean (95% CI) change   from baseline ivacaftor vs placebo\u2011treated patients:     10.7 (7.3, 14.1)   0.66 (0.34, 0.99)   9.6 (4.5, 14.7)     Patients grouped under mutation   types (n) Results shown as mean (minimum, maximum) change from baseline for   ivacaftor\u2011treated patients at week 8*:     Mutation (n)     Absolute   change in sweat chloride (mmol\/L)   Absolute   change in percent predicted FEV1 (percentage points)     At week 8   At week 8     G1244E (5) G1349D (2) G178R (5) G551S (2) G970R# (4) S1251N (8) S1255P (2) S549N   (6) S549R (4)   \u201155 (-75, -34) -80 (-82, -79) -53 (-65, -35) -68\u2020 -6 (-16, -2) -54 (-84, -7) -78 (-82, -74) -74 (-93, -53) -61\u2020\u2020 (-71, -54)   8 (-1, 18) 20 (3, 36) 8 (-1, 18) 3\u2020 3 (-1, 5) 9 (-20, 21) 3 (-1, 8) 11 (-2, 20) 5 (-3, 13)          ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Statistical testing was not performed due to small numbers for individual mutations.<\/span><\/p>","ID":"ae504498-bec9-4496-a192-aa13919e49a9","Styles":"margin-top:6.0pt;margin-right:0in;margin-bottom:0in;\nmargin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"*     Statistical testing was not performed due to small numbers for individual mutations.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Reflects results from the one patient with the <i>G551S<\/i> mutation with data at the 8\u2011week time point.<\/span><\/p>","ID":"5b667f44-18e1-4ffc-858c-b91498d4c4f8","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"\u2020     Reflects results from the one patient with the G551S mutation with data at the 8\u2011week time point.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">    n = 3 for the analysis of absolute change in sweat chloride.<\/span><\/p>","ID":"fbbf6a52-342c-4196-a899-50cd4f0a4d89","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"\u2020\u2020    n = 3 for the analysis of absolute change in sweat chloride.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">#<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface<\/span><\/p>","ID":"aed0989e-3ccc-404d-a991-f04a9344996d","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"#     Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"10c80e5d-68bf-4516-a73b-c30daea20d42","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> following 16 weeks (patients randomised to the ivacaftor\/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the follow\u2011up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1 <\/sub>from<sub> <\/sub>part 2 week 16 was \u20115.9% (9.4%). For patients randomised to the placebo\/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV<sub>1<\/sub> after the additional 16 weeks of treatment with ivacaftor. At the follow up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> from part 2 week 16 was \u20117.4% (5.5%).<\/span><\/p>","ID":"e810c654-5743-4bab-b948-74eda5e2feba","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV1 following 16 weeks (patients randomised to the ivacaftor\/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the follow\u2011up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV1 from part 2 week 16 was \u20115.9% (9.4%). For patients randomised to the placebo\/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV1 after the additional 16 weeks of treatment with ivacaftor. At the follow up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV1 from part 2 week 16 was \u20117.4% (5.5%).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"53e6e2ae-95f0-40bf-88f4-90550606fe10","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Study 3: study in patients with CF with the F508del mutation in the CFTR gene<\/span><\/u><\/i><\/p>","ID":"6c1c85cd-bf88-4f6f-bd4a-96efeb4626a7","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Study 3: study in patients with CF with the F508del mutation in the CFTR gene","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p>","ID":"6966ae1c-c1f6-41dc-ad31-d0dad8fbee1a","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 3 (part A) was a 16\u2011week, 4:1 randomised, double\u2011blind, placebo\u2011controlled, parallel\u2011group phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the <i>F508del<\/i> mutation in the <i>CFTR<\/i> gene and who had FEV<sub>1<\/sub> \u2265 40% predicted.<\/span><\/p>","ID":"94ec4692-678e-47e9-a30d-0d88d539260e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 3 (part A) was a 16\u2011week, 4:1 randomised, double\u2011blind, placebo\u2011controlled, parallel\u2011group phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the F508del mutation in the CFTR gene and who had FEV1 \u2265 40% predicted.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"740bcef0-79fe-4c09-a8f5-c52a6b32f7bf","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The mean absolute change from baseline through week 16 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and \u20110.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI \u20110.6, 4.1); this difference was not statistically significant (P = 0.15).<\/span><\/p>","ID":"3d2dd1d2-e8aa-49ad-a8bf-555aea20860b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The mean absolute change from baseline through week 16 in percent predicted FEV1 (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and \u20110.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI \u20110.6, 4.1); this difference was not statistically significant (P = 0.15).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c2de54c0-7322-4ade-8497-8467692d2ad0","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Study 4: open\u2011label extension study<\/span><\/u><\/i><\/p>","ID":"dc9df325-a707-468a-9629-c007eb8fe4b8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 4: open\u2011label extension study","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p>","ID":"f5ec0f71-df8b-40f1-a20b-359c36762909","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">In study 4 patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo\/ivacaftor group and at least 144 weeks for patients in the ivacaftor\/ivacaftor group.<\/span><\/p>","ID":"f1fef3e2-ee84-486d-a3a8-0631140c0a1e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"In study 4 patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo\/ivacaftor group and at least 144 weeks for patients in the ivacaftor\/ivacaftor group.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"f374ca69-38c0-49b1-9295-2fa7c27d7395","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One hundred and forty\u2011four (144) patients from study 1 were rolled over in study 4, 67 in the placebo\/ivacaftor group and 77 in the ivacaftor\/ivacaftor group. Forty\u2011eight (48) patients from study 2 were rolled over in study 4, 22 in the placebo\/ivacaftor group and 26 in the ivacaftor\/ivacaftor group.<\/span><\/p>","ID":"43470637-dc04-45a8-ba8b-ff10faa53635","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"One hundred and forty\u2011four (144) patients from study 1 were rolled over in study 4, 67 in the placebo\/ivacaftor group and 77 in the ivacaftor\/ivacaftor group. Forty\u2011eight (48) patients from study 2 were rolled over in study 4, 22 in the placebo\/ivacaftor group and 26 in the ivacaftor\/ivacaftor group.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"10da0012-71da-4801-a223-746709accce8","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Table 8 shows the results of the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> for both groups of patients. For patients in the placebo\/ivacaftor group baseline percent predicted FEV<sub>1<\/sub> is that of study 4 while for patients in the ivacaftor\/ivacaftor group the baseline value is that of studies 1 and 2.<\/span><\/p>","ID":"0081c832-8537-4318-994b-4f6425a3f71b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Table 8 shows the results of the mean (SD) absolute change in percent predicted FEV1 for both groups of patients. For patients in the placebo\/ivacaftor group baseline percent predicted FEV1 is that of study 4 while for patients in the ivacaftor\/ivacaftor group the baseline value is that of studies 1 and 2.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"e93738e2-47ab-4e18-8e42-7050c2c38b19","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span style=\"font-size:11.0pt\">Table 8: Effect of ivacaftor on percent predicted FEV<\/span><\/b><sub>1<\/sub><b><span style=\"font-size:11.0pt\"> in study 4<\/span><\/b><\/p>","ID":"7932037c-ef4e-4133-a418-dba1640e59f5","Styles":"margin-bottom:6.0pt;page-break-after:avoid","Classes":"['labeltext']","Text":"Table 8: Effect of ivacaftor on percent predicted FEV1 in study 4","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:.05in;border-collapse:collapse;border:none\"> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Original study and treatment group<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration of ivacaftor treatment (weeks)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:46.44%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"46%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change from baseline in   percent predicted FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">N<\/span><\/b><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean (SD)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">77<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (8.3)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">72<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (10.8)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">67<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20111.2 (7.8)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">55<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.5 (11.2)<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">26<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.2 (15.7)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">25<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.3 (12.4)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">22<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20110.6 (10.1)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:21.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:31.62%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">21<\/span><\/p> <\/td> <td style=\"width:31.6%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.5 (11.5)<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"4c562d4f-8cb3-4627-af8c-34e19f73dbb8","Styles":"margin-left:.05in;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"   Original study and treatment group   Duration of ivacaftor treatment (weeks)   Absolute change from baseline in   percent predicted FEV1 (percentage points)             N   Mean (SD)     Study 1     Ivacaftor   48*   77   9.4 (8.3)         144   72   9.4 (10.8)     Placebo   0*   67   \u20111.2 (7.8)\u2020         96   55   9.5 (11.2)     Study 2     Ivacaftor   48*   26   10.2 (15.7)         144   25   10.3 (12.4)     Placebo   0*   22   \u20110.6 (10.1)\u2020         96   21   10.5 (11.5)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment occurred during blinded, controlled, 48\u2011week phase 3 study.<\/span><\/p>","ID":"a0f7b630-1fa1-4a50-a394-6a7e8c9b1b09","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"*     Treatment occurred during blinded, controlled, 48\u2011week phase 3 study.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt; position:relative;top:-3.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size: 9.0pt;position:relative;top:-3.0pt\">     <\/span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Change from prior study baseline after 48 weeks of placebo treatment.<\/span><\/p>","ID":"4469043d-a38c-4a5f-9610-841f78ccdf11","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"\u2020     Change from prior study baseline after 48 weeks of placebo treatment.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"835cc105-a914-4887-84c3-abf155b9223e","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">When the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> is compared from study 4 baseline for patients in the ivacaftor\/ivacaftor group (n = 72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> was 0.0% (9.05), while for patients in the ivacaftor\/ivacaftor group (n = 25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor\/ivacaftor group maintained the improvement seen at week<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48 of the initial study (day<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">0 through week 48) in percent predicted FEV<sub>1<\/sub> through week 144. There were no additional improvements in study 4 (week 48 through week 144).<\/span><\/p>","ID":"f7d4f383-456f-46ca-a565-e742a8d1d665","Styles":"None","Classes":"['labeltext']","Text":"When the mean (SD) absolute change in percent predicted FEV1 is compared from study 4 baseline for patients in the ivacaftor\/ivacaftor group (n = 72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV1 was 0.0% (9.05), while for patients in the ivacaftor\/ivacaftor group (n = 25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor\/ivacaftor group maintained the improvement seen at week 48 of the initial study (day 0 through week 48) in percent predicted FEV1 through week 144. There were no additional improvements in study 4 (week 48 through week 144).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"43e5130c-69a4-4882-b45f-57a109315e53","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients in the placebo\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events\/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events\/year across day<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1 to week<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48, and 0.67 events\/year across weeks<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48 to 96). For patients in the ivacaftor\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events\/year across day 1 to week 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events\/year across day<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">1 to week<\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">48 and 0.77 events\/year across weeks 48 to 96.<\/span><\/p>","ID":"616614cf-f1b3-4078-b54d-02f8e3d41297","Styles":"None","Classes":"['labeltext']","Text":"For patients in the placebo\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events\/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events\/year across day 1 to week 48, and 0.67 events\/year across weeks 48 to 96). For patients in the ivacaftor\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events\/year across day 1 to week 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events\/year across day 1 to week 48 and 0.77 events\/year across weeks 48 to 96.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"5740ed02-316f-4f31-b99a-97da55ef90d5","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">For patients who rolled over from study 2 the number of events was, overall, low.<\/span><\/p>","ID":"f6ed3fd7-3c1e-446d-960d-db5b014b6b33","Styles":"None","Classes":"['labeltext']","Text":"For patients who rolled over from study 2 the number of events was, overall, low.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"c9e5ab8b-a333-4d23-8a9b-548d444480b3","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u>Study 6: study in patients with CF with an R117H mutation in the CFTR gene<\/u><\/i><\/p>","ID":"a09394f8-bdcf-4fcc-9c51-0ca65ef5bfb6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 6: study in patients with CF with an R117H mutation in the CFTR gene","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span style=\"text-decoration:none\"> <\/span><\/u><\/i><\/p>","ID":"ec4e7708-80be-4c15-bc39-d179de67b105","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the <i>F508del<\/i> mutation in the second allele. The confirmed <i>R117H <\/i>poly\u2011T variant was <i>5T <\/i>in 38 patients<i> <\/i>and <i>7T <\/i>in 16 patients. At baseline, mean predicted FEV<sub>1<\/sub> was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI \u20111.1, 5.4).<\/p>","ID":"a8623293-5d75-4991-8ec2-7198f71eff30","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the F508del mutation in the second allele. The confirmed R117H poly\u2011T variant was 5T in 38 patients and 7T in 16 patients. At baseline, mean predicted FEV1 was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV1 (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI \u20111.1, 5.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"a774935d-278c-4c91-879c-ad76279547ae","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\">A pre\u2011planned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV<sub>1<\/sub> through week 24 of 4.5 percentage points in the ivacaftor group versus \u20110.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).<\/p>","ID":"69d56980-0b3f-4441-8442-03eafd853936","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"A pre\u2011planned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV1 through week 24 of 4.5 percentage points in the ivacaftor group versus \u20110.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"bddfa623-0cb5-45c4-a29d-9ab88c808b7d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\">In a subgroup analysis in patients with a confirmed <i>R117H\u20115T <\/i>genetic variant, the difference in the mean absolute change from baseline through week<span lang=\"EN-GB\"> <\/span>24 in percent predicted FEV<sub>1<\/sub> between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed <i>R117H\u20117T <\/i>genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI \u20118.1, 8.5).<\/p>","ID":"fd67841c-ec6b-48a6-b61a-3853ff222d1d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In a subgroup analysis in patients with a confirmed R117H\u20115T genetic variant, the difference in the mean absolute change from baseline through week 24 in percent predicted FEV1 between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed R117H\u20117T genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI \u20118.1, 8.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"01f54d0d-3314-44de-8d37-5ed0534ff88d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_Hlk37921752\"><span lang=\"EN-GB\">For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQ\u2011R respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).<\/span><\/a><\/p>","ID":"bd9488ec-ccaa-49be-9937-dab474d9e55a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQ\u2011R respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"7aa5b862-db60-44cb-a96b-090f9ccc991a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Ivacaftor in a combination regimen with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor<\/span><\/i><\/p>","ID":"ceb8cd92-4cd7-4c0f-92fa-de53ec8f7d95","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor in a combination regimen with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"07c58484-93f4-4d1a-90f8-e9a114d60c41","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The efficacy and safety of ivacaftor in a combination regimen with tezacaftor\/ivacaftor in patients with CF aged 12 years and older was assessed in two clinical studies; a 24 week, randomised, double\u2011blind, placebo\u2011controlled study with 504 patients who were homozygous for the <i>F508del <\/i>mutation; and a randomised, double\u2011blind, placebo\u2011controlled and ivacaftor controlled, 2 period, 3 treatment, 8\u2011week crossover study with 244 patients who were heterozygous for the <i>F508del<\/i> mutation and a second mutation associated with residual <i>CFTR <\/i>activity. The long-term safety and efficacy of the combination regimen was also assessed in both patient populations in a 96-week open-label, rollover, long-term extension study. Refer to the Summary of Product Characteristics of tezacaftor\/ivacaftor for additional data.<\/span><\/p>","ID":"4ae303cb-c8c3-451c-a795-deda6a4e927a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The efficacy and safety of ivacaftor in a combination regimen with tezacaftor\/ivacaftor in patients with CF aged 12 years and older was assessed in two clinical studies; a 24 week, randomised, double\u2011blind, placebo\u2011controlled study with 504 patients who were homozygous for the F508del mutation; and a randomised, double\u2011blind, placebo\u2011controlled and ivacaftor controlled, 2 period, 3 treatment, 8\u2011week crossover study with 244 patients who were heterozygous for the F508del mutation and a second mutation associated with residual CFTR activity. The long-term safety and efficacy of the combination regimen was also assessed in both patient populations in a 96-week open-label, rollover, long-term extension study. Refer to the Summary of Product Characteristics of tezacaftor\/ivacaftor for additional data.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"c5938a4b-af0e-44ec-80f8-20eddaf0b494","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The efficacy and safety of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor in patients aged 12 years and older was demonstrated in two, phase 3 studies, randomised, double blind, placebo-controlled (heterozygous <i>F508del<\/i> patients, n=403) and active-controlled (homozygous <i>F508del<\/i> patients, n=107) of 24 and 4 weeks of duration, respectively. Heterozygous <i>F508del<\/i> patients had a minimal function mutation on the second allele defined as one that either leads to <\/span><span lang=\"EN-GB\">no CFTR protein being produced (e.g. Class I) or a CFTR protein that does not function to transport chloride and is unlikely to respond to other CFTR modulators (tezacaftor, ivacaftor or the combination of both). Homozygous <i>F508del<\/i> patients received tezacaftor\/ivacaftor and ivacaftor regimen during a 4-week open-label run-in period and were then randomised and dosed to receive ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor during a 4-week double-blind treatment period. Patients from both studies were eligible to enter an open\u2011label, rollover, 96-week study. Refer to the Summary of Product Characteristics of ivacaftor\/tezacaftor\/elexacaftor for additional data.<\/span><\/p>","ID":"a24cefb4-1375-4dab-9999-86f49c3dbcf4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The efficacy and safety of ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor in patients aged 12 years and older was demonstrated in two, phase 3 studies, randomised, double blind, placebo-controlled (heterozygous F508del patients, n=403) and active-controlled (homozygous F508del patients, n=107) of 24 and 4 weeks of duration, respectively. Heterozygous F508del patients had a minimal function mutation on the second allele defined as one that either leads to no CFTR protein being produced (e.g. Class I) or a CFTR protein that does not function to transport chloride and is unlikely to respond to other CFTR modulators (tezacaftor, ivacaftor or the combination of both). Homozygous F508del patients received tezacaftor\/ivacaftor and ivacaftor regimen during a 4-week open-label run-in period and were then randomised and dosed to receive ivacaftor in combination with ivacaftor\/tezacaftor\/elexacaftor during a 4-week double-blind treatment period. Patients from both studies were eligible to enter an open\u2011label, rollover, 96-week study. Refer to the Summary of Product Characteristics of ivacaftor\/tezacaftor\/elexacaftor for additional data.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"a9c40145-f2a7-447c-ba1b-9759e8b1a96b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"d7d03284-e36e-4067-a376-fca3466c0881","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"4bbd0134-98d8-49b5-9ad1-cf4c32c584de","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).<\/span><\/p>","ID":"2e64615c-b9c7-4301-91cc-7749763b1c2d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"31d21ef9-dfc8-4662-bea9-0031b114a004","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/b><\/p>","ID":"b2ace7c1-1c69-479b-94d6-7355681a6912","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"5.2     Pharmacokinetic properties","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c93ec2aa-1ce6-43fc-a520-59181757deba","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.<\/span><\/p>","ID":"94e249b3-ab4e-4ce2-9e14-f71fc0bc18a7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5aaaaa41-30dc-4936-8a67-9a6bb48d4651","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (\u00b1 SD) for AUC and C<sub>max<\/sub> were 10600 (5260) ng*hr\/mL and 768 (233) ng\/mL, respectively. After every 12\u2011hour dosing, steady\u2011state plasma concentrations of ivacaftor were reached by days<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.<\/span><\/p>","ID":"adce7f1a-c171-4cb1-9c13-4385e1b18876","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (\u00b1 SD) for AUC and Cmax were 10600 (5260) ng*hr\/mL and 768 (233) ng\/mL, respectively. After every 12\u2011hour dosing, steady\u2011state plasma concentrations of ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5ce10305-7a97-4e8a-8fa3-83dedcc4be22","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\">Absorption<\/span><\/u><\/p>","ID":"51b157cd-2eba-4459-a737-7fcaa0f95ba6","Styles":"None","Classes":"['labeltextheading']","Text":"Absorption","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"fcb50555-54cd-40ed-9520-c3fbddbc0815","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food, the exposure of ivacaftor increased approximately 2.5\u2011 to 4\u2011fold. When co-administered with tezacaftor and elexacaftor, the increase in AUC was similar (approximately 3\u2011fold and 2.5-to 4-fold respectively). Therefore, ivacaftor, administered as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, should be administered with fat\u2011containing food. The median (range) t<sub>max<\/sub> is approximately 4.0 (3.0; 6.0) hours in the fed state.<\/span><\/p>","ID":"9ea4220b-7909-4b86-86b4-ef42deb31bb6","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food, the exposure of ivacaftor increased approximately 2.5\u2011 to 4\u2011fold. When co-administered with tezacaftor and elexacaftor, the increase in AUC was similar (approximately 3\u2011fold and 2.5-to 4-fold respectively). Therefore, ivacaftor, administered as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, should be administered with fat\u2011containing food. The median (range) tmax is approximately 4.0 (3.0; 6.0) hours in the fed state.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"902d5806-af7a-4785-86c5-483c6f251a52","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ivacaftor granules (2 x 75 mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0\u2011\u221e<\/sub> and 0.918 (0.750, 1.12) for C<sub>max<\/sub>. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.<\/span><\/p>","ID":"c8927cc2-c14c-4876-945b-1bfb36b00997","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Ivacaftor granules (2 x 75 mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC0\u2011\u221e and 0.918 (0.750, 1.12) for Cmax. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"3a86d79e-fd00-438c-ba1f-66b89249d7c8","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"977d2a95-27b9-42fe-a61e-b7f388135fc4","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Distribution","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"b199d46c-f3eb-40b4-b538-39970dc6ee93","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1\u2011acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (\u00b1 SD) apparent volume of distribution was 353 L (122) .<\/span><\/p>","ID":"f6f2d266-b775-4b56-8077-87435bb52f54","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1\u2011acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (\u00b1 SD) apparent volume of distribution was 353 L (122) .","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"d0772c63-709e-4ef1-bc0a-19b4d26e6107","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Biotransformation<\/span><\/u><\/p>","ID":"310a4882-6a26-4920-92d3-547b1d5a7ac8","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Biotransformation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p>","ID":"01476efe-5279-4cff-a158-50f007f79812","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is extensively metabolised in humans. <i>In vitro<\/i> and <i>in vivo<\/i> data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one\u2011sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one\u2011fiftieth the potency of ivacaftor and is not considered pharmacologically active.<\/span><\/p>","ID":"89ee0b31-73e5-4f4a-a62a-079e194da7e4","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Ivacaftor is extensively metabolised in humans. In vitro and in vivo data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one\u2011sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one\u2011fiftieth the potency of ivacaftor and is not considered pharmacologically active.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"23698fe3-1b7e-4f9b-8423-345259d30c11","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">The effect of the CYP3A4*22 heterozygous genotype on tezacaftor, ivacaftor and elexacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose-adjustment of tezacaftor, ivacaftor or elexacaftor is considered necessary. The effect in CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.<\/span><\/p>","ID":"99b2722b-6339-4b09-a91d-8b08b267b7ba","Styles":"None","Classes":"['labeltext']","Text":"The effect of the CYP3A4*22 heterozygous genotype on tezacaftor, ivacaftor and elexacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose-adjustment of tezacaftor, ivacaftor or elexacaftor is considered necessary. The effect in CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4961215a-629d-42c0-9c04-a9c8423a7956","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"0a845050-6146-4d20-9977-9c84267cfa77","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Elimination","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"247de960-62a8-4451-a940-c08f3de90471","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half\u2011life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL\/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (\u00b1 SD) CL\/F for a single 150 mg dose was 17.3 (8.4) L\/hr in healthy subjects.<\/span><\/p>","ID":"28cccc1b-62db-4510-bae4-d064c0e70cbc","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half\u2011life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL\/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (\u00b1 SD) CL\/F for a single 150 mg dose was 17.3 (8.4) L\/hr in healthy subjects.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"265e0e00-d1a2-448c-a820-48dc7dbfb94e","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Linearity\/non\u2011linearity<\/span><\/u><\/p>","ID":"2580a89a-66a0-43ae-bc7d-2e818a22dfe1","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Linearity\/non\u2011linearity","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"763a545a-12b1-48c1-929e-0e8631a34693","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.<\/span><\/p>","ID":"6d983664-9b79-41b6-b172-b72e4b3bc09f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"321332e7-37c4-46e5-a303-4adfa3b7a9df","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p>","ID":"b5f272bc-9749-4808-a435-d3eba11d46ab","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Special populations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"8050d2b9-6685-493c-8f70-1385d167cf1e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><a name=\"_Hlk45278559\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/a><\/p>","ID":"f7c96687-77e2-4eed-9567-0794c3e5e110","Styles":"None","Classes":"['labeltextheading']","Text":"Hepatic impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"1d88a499-3aa0-4de1-b411-4b53e1642c62","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child\u2011Pugh Class B, score 7 to 9) had similar ivacaftor C<sub>max<\/sub> (mean [\u00b1 SD] of 735 [331] ng\/mL) but an approximately two\u2011fold increase in ivacaftor AUC<sub>0-\u221e<\/sub> (mean [\u00b1 SD] of 16800 [6140] ng*hr\/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady\u2011state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady\u2011state C<sub>min<\/sub> values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. <\/span><\/p>","ID":"4c300454-5054-4dac-afe3-ddfa9ea1cbdf","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child\u2011Pugh Class B, score 7 to 9) had similar ivacaftor Cmax (mean [\u00b1 SD] of 735 [331] ng\/mL) but an approximately two\u2011fold increase in ivacaftor AUC0-\u221e (mean [\u00b1 SD] of 16800 [6140] ng*hr\/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady\u2011state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady\u2011state Cmin values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"1e554201-a3bf-444f-9daa-83c044da557f","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\">In subjects with moderately impaired hepatic function (Child Pugh Class B, score 7 to 9), ivacaftor AUC increased approximately by 50% following multiple doses for 10 days of either tezacaftor and ivacaftor or of ivacaftor, tezacaftor and elexacaftor. <\/p>","ID":"14ae370e-18aa-421e-ab06-e8bb1faf2e94","Styles":"None","Classes":"['MsoNormal']","Text":"In subjects with moderately impaired hepatic function (Child Pugh Class B, score 7 to 9), ivacaftor AUC increased approximately by 50% following multiple doses for 10 days of either tezacaftor and ivacaftor or of ivacaftor, tezacaftor and elexacaftor. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"> <\/p>","ID":"77eeabc1-55b6-4ee4-a881-5f65215656ed","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor has not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. <\/span><\/p>","ID":"bff03738-9343-434c-af2a-c2d74ea638c3","Styles":"None","Classes":"['labeltext']","Text":"The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor has not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"9079e323-469d-4e00-82a5-ce1d85cb280c","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">For guidance on appropriate use and dose modification see Table 3 in section 4.2.<\/span><\/p>","ID":"00fbaea1-804c-4b38-9345-d13e8264b63d","Styles":"None","Classes":"['labeltext']","Text":"For guidance on appropriate use and dose modification see Table 3 in section 4.2.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"c3e42fac-7244-453b-a3de-981d88bc5e88","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Renal impairment<\/span><\/i><\/p>","ID":"160f234b-d374-47b1-a52a-350a62fbcb22","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Renal impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"65426e15-76b0-46e3-94da-5f46034e0884","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor <\/span>or with <span lang=\"EN-GB\" style=\"font-size:11.0pt\">ivacaftor\/tezacaftor\/elexacaftor. In a human pharmacokinetic study with ivacaftor monotherapy, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). <\/span><\/p>","ID":"8581b258-f17a-4d58-986a-50956198c212","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment, either as monotherapy or in a combination regimen with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor. In a human pharmacokinetic study with ivacaftor monotherapy, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"da0f1ef9-74a9-4ecc-8a0d-787e10267977","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustments are recommended for mild and moderate renal impairment. Caution is recommended when administering ivacaftor, either as monotherapy or in a combination with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor, to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.2 and 4.4).<\/span><\/p>","ID":"78f4983c-1cb8-46c9-b64f-e9d101b1db68","Styles":"None","Classes":"['labeltext']","Text":"No dose adjustments are recommended for mild and moderate renal impairment. Caution is recommended when administering ivacaftor, either as monotherapy or in a combination with tezacaftor\/ivacaftor or with ivacaftor\/tezacaftor\/elexacaftor, to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.2 and 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"3ab1de49-c5be-4f7a-9b65-95e6671a0f40","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Race<\/span><\/i><\/p>","ID":"cc5362ce-4615-4585-a2e9-48257124f7fa","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Race","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"bcc1d1c5-37dd-43ec-b612-118824e2136f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.<\/span><\/p>","ID":"0b2e7840-caab-4bd0-9e97-a8028d6edb1e","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"5fbd3587-6c3b-4508-a6aa-c7562f6cb637","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gender<\/span><\/i><\/p>","ID":"4f9bcec6-c829-4230-a844-f86ea870b079","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Gender","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"ca839a83-b250-4d47-a4b4-8fa6fbf1b7f8","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The pharmacokinetic parameters of ivacaftor, either as monotherapy or in combination with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, are similar in males and females.<\/span><\/p>","ID":"5b749a42-ddf1-4f0e-a933-7782b5f5e95f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"The pharmacokinetic parameters of ivacaftor, either as monotherapy or in combination with tezacaftor\/ivacaftor or ivacaftor\/tezacaftor\/elexacaftor, are similar in males and females.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"639474db-27b3-4b5a-9d43-197f71a15c62","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Elderly<\/span><\/i><\/p>","ID":"fd6d2f36-0c1f-4c2f-957b-57b281382de3","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Elderly","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"f18aa3c2-6f7f-4515-a5c6-c943dab77999","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Clinical studies of ivacaftor monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.<\/span><\/p>","ID":"76976234-3baf-4a64-ae2b-e2aad231dc15","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Clinical studies of ivacaftor monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"4b99bd50-8009-459a-adf9-6f5a8e0aa092","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">The pharmacokinetic parameters of ivacaftor in combination with tezacaftor in the elderly patients (65\u201172 years) are comparable to those in younger adults. No patients aged 65 years and older were included in the clinical studies of ivacaftor\/tezacaftor\/elexacaftor and therefore it cannot be <\/span>determined whether pharmacokinetic parameters are similar or not to those in younger adults<span lang=\"EN-GB\">.<\/span><\/p>","ID":"80e4bdb9-e3a2-437a-a00c-2fc84ffdd82b","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":"The pharmacokinetic parameters of ivacaftor in combination with tezacaftor in the elderly patients (65\u201172 years) are comparable to those in younger adults. No patients aged 65 years and older were included in the clinical studies of ivacaftor\/tezacaftor\/elexacaftor and therefore it cannot be determined whether pharmacokinetic parameters are similar or not to those in younger adults.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"96e7bbc1-e290-4972-b237-0c09b488296b","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\">Paediatric population<\/span><\/u><\/p>","ID":"ecd0d3a9-ee8b-42a9-9f74-12102b1b1299","Styles":"None","Classes":"['labeltextheading']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt; font-style:normal\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"ebad6423-efba-4341-aa20-1305a0544efb","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 9.<\/p>","ID":"ce2082fc-3142-48e4-b5e0-8cac1f4fe255","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 9.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"c05391e8-2d99-4bc2-b348-8c0a1e8c8892","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b>Table 9: Mean (SD) ivacaftor exposure by age group<\/b><\/p>","ID":"c59e3249-c71b-4007-830d-19bb1ff33438","Styles":"margin-bottom:6.0pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 9: Mean (SD) ivacaftor exposure by age group","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:101.48%;margin-left:5.35pt;border-collapse:collapse\" width=\"101%\"> <tr style=\"height:23.9pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;padding:   0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"55%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b>Age group<\/b><\/p> <\/td> <td style=\"width:14.96%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b>Dose<\/b><\/p> <\/td> <td style=\"width:13.1%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b>C<sub>min, ss<\/sub> (ng\/mL)<\/b><\/p> <\/td> <td style=\"width:16.2%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt\" width=\"16%\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-bottom:6.0pt;text-align:center;   line-height:normal;page-break-after:avoid\"><b><span lang=\"PT\">AUC<\/span><sub><span lang=\"EN-GB\">\u03c4<\/span><\/sub><\/b><b><sub><span lang=\"PT\">, ss<\/span><\/sub><\/b><b><span lang=\"PT\"> (ng*h\/mL)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"55%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">6 months   to less than 12 months (5 kg to &lt; 7 kg)<span class=\"MsoCommentReference\"><span lang=\"EN-GB\" style=\"font-size:8.0pt\"> <\/span><\/span><sup>*<\/sup><\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"14%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">25 mg   q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">336<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"16%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">5410<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"55%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">6 months   to less than 12 months (7 kg to &lt; 14 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"14%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\">50 mg   q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">508 (252)<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" width=\"16%\"> <p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><span lang=\"EN-GB\">9140 (4200)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 months to less than 24 months (7 kg to   &lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">440 (212)<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">9050 (3050)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">12 months to less than 24 months (<\/span><span style=\"font-size:11.0pt;font-family:SimSun\">\u2265<\/span><span style=\"font-size:11.0pt\"> 14 kg to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">451 (125)<\/span><\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:   11.0pt\">9600 (1800)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">2\u2011   to 5\u2011year-olds (&lt; 14 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">50 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">577   (317)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">10500   (4260)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">2\u2011 to 5\u2011year-olds (\u2265 14 kg   to &lt; 25 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">75 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">629 (296)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">11300 (3820)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">6\u2011 to 11\u2011year-olds <sup>\u2020<\/sup>   (\u2265 14 kg to &lt; 25 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">75 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">641 (329)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">10760 (4470)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">6\u2011 to 11\u2011year-olds <sup>\u2020<\/sup>   (\u2265 25 kg)<\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">150 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">958 (546)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">15300 (7340)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">12\u2011 to 17\u2011year-olds   <\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">150 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">564 (242)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal\">9240 (3420)<\/p> <\/td> <\/tr> <tr style=\"height:19.0pt\"> <td style=\"width:55.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"55%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Adults   (\u2265 18 years old) <\/p> <\/td> <td style=\"width:14.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"14%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">150 mg q12h<\/p> <\/td> <td style=\"width:13.1%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">701   (317)<\/p> <\/td> <td style=\"width:16.2%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:19.0pt\" valign=\"top\" width=\"16%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">10700   (4100)<\/p> <\/td> <\/tr> <\/table>","ID":"a44f25ff-a492-4b88-abe8-b9a8bfd46e4b","Styles":"width:101.48%;margin-left:5.35pt;border-collapse:collapse","Classes":"['MsoNormalTable']","Text":"   Age group   Dose   Cmin, ss (ng\/mL)   AUC\u03c4, ss (ng*h\/mL)     6 months   to less than 12 months (5 kg to < 7 kg) *   25 mg   q12h   336   5410     6 months   to less than 12 months (7 kg to < 14 kg)   50 mg   q12h   508 (252)   9140 (4200)     12 months to less than 24 months (7 kg to   < 14 kg)   50 mg q12h   440 (212)   9050 (3050)     12 months to less than 24 months (\u2265 14 kg to < 25 kg)   75 mg q12h   451 (125)   9600 (1800)     2\u2011   to 5\u2011year-olds (< 14 kg)   50 mg q12h   577   (317)   10500   (4260)     2\u2011 to 5\u2011year-olds (\u2265 14 kg   to < 25 kg)   75 mg q12h   629 (296)   11300 (3820)     6\u2011 to 11\u2011year-olds \u2020   (\u2265 14 kg to < 25 kg)   75 mg q12h   641 (329)   10760 (4470)     6\u2011 to 11\u2011year-olds \u2020   (\u2265 25 kg)   150 mg q12h   958 (546)   15300 (7340)     12\u2011 to 17\u2011year-olds      150 mg q12h   564 (242)   9240 (3420)     Adults   (\u2265 18 years old)    150 mg q12h   701   (317)   10700   (4100)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span style=\"font-size:9.0pt\">*<\/span><\/sup><span style=\"font-size:9.0pt\">     Values based on data from a single patient; standard deviation not reported.<\/span><\/p>","ID":"d7de3c7e-0fa3-4ffc-8a67-3cc228ea2c55","Styles":"margin-top:6.0pt;margin-right:0in;margin-bottom:0in;\nmargin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"*     Values based on data from a single patient; standard deviation not reported.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt; position:relative;top:-3.0pt\">\u2020<\/span><\/sup><span style=\"font-size:9.0pt\">     Exposures in 6\u2011 to 11\u2011year\u2011olds are predictions based on simulations from the population PK model using data obtained for this age group.<\/span><\/p>","ID":"797786a8-f51e-4f08-b5ef-39b479c2eb0a","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"\u2020     Exposures in 6\u2011 to 11\u2011year\u2011olds are predictions based on simulations from the population PK model using data obtained for this age group.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"609d0f14-a030-4ce5-8802-00db8d4661bc","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The pharmacokinetic parameters of ivacaftor in combination with tezacaftor and with tezacaftor\/elexacaftor in adolescent patients (12 to 17-year-olds) are similar to that of adult patients (see Table 10).<\/span><\/p>","ID":"a7b4645f-42d7-45b2-8f57-b9441ce85488","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The pharmacokinetic parameters of ivacaftor in combination with tezacaftor and with tezacaftor\/elexacaftor in adolescent patients (12 to 17-year-olds) are similar to that of adult patients (see Table 10).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"55597caf-24c0-4b85-9c24-062ec2ed977d","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b>Table 10: Mean (SD) of ivacaftor exposure when used in combination with tezacaftor and in combination with tezacaftor\/elexacaftor, by age group<\/b><\/p>","ID":"26b27118-eeec-4a26-9f32-7119ba55e2f5","Styles":"margin-bottom:6.0pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 10: Mean (SD) of ivacaftor exposure when used in combination with tezacaftor and in combination with tezacaftor\/elexacaftor, by age group","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:467.55pt;border-collapse:collapse;border:none\" width=\"623\"> <tr style=\"height:26.55pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;padding:   0in 0in 0in 0in;height:26.55pt\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Age group<\/span><\/b><\/p> <\/td> <td style=\"width:27.28%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 0in 0in 0in;height:26.55pt\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <\/td> <td style=\"width:31.84%;border:solid windowtext 1.0pt;border-left:   none;padding:0in 0in 0in 0in;height:26.55pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Ivacaftor Mean (SD)<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">AUC<sub>0-12h<\/sub>,ss (ng*h\/mL)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\"><span lang=\"EN-GB\">Adolescent patients (12 to &lt;18 years) <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\"><span lang=\"EN-GB\">n = 97<\/span><\/p> <\/td> <td rowspan=\"2\" style=\"width:27.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"PT\">tezacaftor 100 mg qd\/ <br\/>   ivacaftor 150 mg q12h<\/span><\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">11400 (5500)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">Adult patients (\u2265 18 years)<\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\"><span lang=\"EN-GB\">n = 389<\/span><\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">11400 (4140)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">Adolescent patients (12 to &lt;18 years)<\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">n = 69<\/p> <\/td> <td rowspan=\"2\" style=\"width:27.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\">elexacaftor 200 mg qd\/<br\/>   tezacaftor 100 mg qd\/<br\/>   ivacaftor 150 mg q12h<\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\">10600 (3350)<\/p> <\/td> <\/tr> <tr style=\"height:13.0pt\"> <td style=\"width:40.88%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 0in 0in 0in;height:13.0pt\" width=\"40%\"> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">Adult patients (\u226518 years)<\/p> <p class=\"MsoNormal\" style=\"margin-left:4.5pt;line-height:normal;page-break-after:   avoid\">n = 186<\/p> <\/td> <td style=\"width:31.84%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:13.0pt\" width=\"31%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\">12100 (4170)<\/p> <\/td> <\/tr> <\/table>","ID":"4bdd992f-19b4-403f-8eba-2495c7da80ce","Styles":"width:467.55pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"   Age group   Dose   Ivacaftor Mean (SD) AUC0-12h,ss (ng*h\/mL)     Adolescent patients (12 to <18 years)  n = 97   tezacaftor 100 mg qd\/    ivacaftor 150 mg q12h   11400 (5500)     Adult patients (\u2265 18 years) n = 389   11400 (4140)     Adolescent patients (12 to <18 years) n = 69   elexacaftor 200 mg qd\/   tezacaftor 100 mg qd\/   ivacaftor 150 mg q12h   10600 (3350)     Adult patients (\u226518 years) n = 186   12100 (4170)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6d4366ad-97d3-4cc5-82a4-641ab6dd9368","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p>","ID":"d39b0828-2d0c-48d3-803f-41d4d418c485","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"5.3     Preclinical safety data","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"46b59f17-910b-4734-8ec4-f6e38fc67555","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.<\/span><\/p>","ID":"e17d02b8-cd28-48e5-ba0e-657a623c8519","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d23e9431-587a-4375-be46-5c1b6e3400e7","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy and fertility<\/span><\/u><\/p>","ID":"e279325e-0291-4696-a106-3578fb2cc97d","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Pregnancy and fertility","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"2f979f74-53e1-4e53-8272-b8b4ec284dd6","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The No\u2011Observed\u2011Adverse\u2011Effect\u2011Level (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.<\/span><\/p>","ID":"fcd112a7-ebbc-402e-9798-fb38c798591b","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The No\u2011Observed\u2011Adverse\u2011Effect\u2011Level (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b3c3732d-6083-4671-a1d5-51908916ed4f","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Peri\u2011 and post\u2011natal development<\/span><\/u><\/p>","ID":"9be3fb4b-9f7b-4346-8795-80de80825c77","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Peri\u2011 and post\u2011natal development","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4ad7c8c0-5d45-4788-ac6f-12828bc5e9c9","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level of approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. <\/span><\/p>","ID":"1423478d-f8cf-4210-ad8f-ad50848ee284","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level of approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"eac5fcfe-5304-4527-ab40-8bfc0ff213c8","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile animal studies<\/span><\/u><\/p>","ID":"5e54f0ec-3df5-44c1-a728-87a3b932b66b","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Juvenile animal studies","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"610bdf58-67de-4d76-b4c7-fe3c004c30af","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7\u2011week old rats, nor in 3.5 to 5\u2011month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.<\/span><\/p>","ID":"9b66bfae-c9d9-4365-8424-662ffa0dd23f","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7\u2011week old rats, nor in 3.5 to 5\u2011month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"42af9b43-1ae1-4548-bfaa-5ff904d7a8f8","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"cd402dca-1ce8-4c09-9b5f-d0e5e7917aa7","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL PARTICULARS<\/span><\/h1>","ID":"fdb7756f-9af2-440d-8b1b-2c590e68d9bf","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"73184eed-8d1d-4430-9829-2f5935fa3ae3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p>","ID":"816dcbda-f362-4c3e-a8c6-2e676aece34c","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.1     List of excipients","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ad2e345e-9890-430d-9df5-e215050b7a26","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Tablet core<\/span><\/u><\/p>","ID":"ebbbda7b-9764-4ae9-b2c2-fc93776af56d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Tablet core","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"d15a0d56-6bc3-439c-bac9-13222509c373","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cellulose, microcrystalline<\/span><\/p>","ID":"88607957-1151-4ac8-98a9-6b87e4e52e99","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Cellulose, microcrystalline","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p>","ID":"d36f7cfe-1bdf-4353-9619-26488b489fc5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Lactose monohydrate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hypromellose acetate succinate<\/span><\/p>","ID":"fd691199-6cf6-4591-8f0f-ac65a45a1025","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Hypromellose acetate succinate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p>","ID":"eeb31213-8294-49f9-ab27-40752c6ffc22","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Croscarmellose sodium","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Sodium laurilsulfate (E487)<\/span><\/p>","ID":"628d1b5f-4e2f-4466-94a2-714d62c05360","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Sodium laurilsulfate (E487)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Silica, colloidal anhydrous<\/span><\/p>","ID":"157d5a90-796b-49cc-826f-2a6988eb7a96","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Silica, colloidal anhydrous","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Magnesium stearate<\/span><\/p>","ID":"16450f9d-fbc0-4439-b082-48803dd88725","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Magnesium stearate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\"> <\/span><\/p>","ID":"1b64cf2e-2222-4d87-977d-8de2ab1437b1","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"IT\">Tablet film coat<\/span><\/u><\/p>","ID":"3319df87-a52c-46c3-882e-8bf460940ab2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Tablet film coat","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"IT\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"31cc00e8-6238-47fb-b526-6dcf7706b459","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Polyvinyl alcohol<\/span><\/p>","ID":"7459c896-7597-4b24-bf36-fe689aba6091","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Polyvinyl alcohol","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Titanium dioxide (E171)<\/span><\/p>","ID":"5fe45619-d39a-4021-9083-db169c24595a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Titanium dioxide (E171)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PT\">Macrogol (PEG 3350)<\/span><\/p>","ID":"74924092-a771-4ec7-b2ac-2a3aaab02ae7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Macrogol (PEG 3350)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PT\">Talc<\/span><\/p>","ID":"2d2b3238-8c67-447e-8b9e-e91bef86ebe7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Talc","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PT\">Indigo carmine aluminium lake (E132)<\/span><\/p>","ID":"ed3c80e2-ddce-4fc5-a498-a8f62ee22f09","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Indigo carmine aluminium lake (E132)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Carnauba wax<\/p>","ID":"8ce94c72-6441-477f-b9aa-ff7806316b7d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Carnauba wax","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"ec3c8d88-c965-4f66-923c-709e80254530","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u>Printing ink<\/u><\/p>","ID":"753c4802-0489-4be6-b609-24d7bc6677e6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Printing ink","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"4be5b723-70b3-47c6-ae2d-92b84041e74d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Shellac<\/p>","ID":"051fd665-0f11-4ea8-a9f6-e0d14df5108c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Shellac","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Iron oxide black (E172)<\/p>","ID":"33595a10-3c3b-4b26-ba08-1050887a86e4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Iron oxide black (E172)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Propylene glycol (E1520)<\/span><\/p>","ID":"807d1d63-e71e-418e-8fd7-0f3b3275f5e2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Propylene glycol (E1520)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Ammonia solution, concentrated<\/span><\/p>","ID":"c8b66f7d-c387-4e72-87f6-08e747b7cd71","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Ammonia solution, concentrated","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\"> <\/span><\/p>","ID":"72112f2d-a8ed-45b2-add7-99f53bf711ce","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p>","ID":"53f9cbbc-66e8-426f-91ed-fdcdb4106dff","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.2     Incompatibilities","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"cb1ebb5d-7699-4c76-a276-c9fe6ed713ae","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p>","ID":"a6b90755-5ed7-4996-ae29-2ff91ebf64cf","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Not applicable.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"3ab53ef9-0b25-433a-b12b-f06adc58ac92","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p>","ID":"e575493c-8211-4c52-8016-2497308adbc6","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.3     Shelf life","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c6a96b79-35f2-4e95-be28-cb6206ac70bf","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">4 years.<\/span><\/p>","ID":"bd64ca46-9f7a-43ed-b8e6-b37edac1ca29","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4 years.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b4e6082e-7843-4dda-a22d-70c42a9d50ca","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p>","ID":"4d90c4e3-0ac7-418d-ad1e-86ecb227f72a","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.4     Special precautions for storage","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b1b69238-46ec-4a6e-b3b4-cab7f579e3f5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p>","ID":"5b164e14-eac9-42d2-b912-82bc9c7f2c1b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"This medicinal product does not require any special storage conditions.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"037ac863-fc43-48ee-8e50-ac5f7b8c13ed","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p>","ID":"874a4b23-94d0-4393-93cf-0d61a221984f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.5     Nature and contents of container","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ead7cf3b-cf4e-4767-a822-37244fa334a7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The film-coated tablets are packed in a thermoform (PolyChloroTriFluoroEthylene [PCTFE]\/foil) blister or a High-Density PolyEthylene (HDPE) bottle with <\/span><span lang=\"EN-GB\">a polypropylene child-resistant closure, foil-lined induction seal and molecular sieve<\/span><span lang=\"EN-GB\"> desiccant.<\/span><\/p>","ID":"60c2bc95-fbc1-4bd9-95fd-eb473dd9457c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The film-coated tablets are packed in a thermoform (PolyChloroTriFluoroEthylene [PCTFE]\/foil) blister or a High-Density PolyEthylene (HDPE) bottle with a polypropylene child-resistant closure, foil-lined induction seal and molecular sieve desiccant.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"23862e1b-bec2-4418-8bfc-9799452e99c0","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The following pack sizes are available:<\/span><\/p>","ID":"4d9585dc-6990-4803-af45-1a23f8e7c9de","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The following pack sizes are available:","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt; font-family:Symbol\">-<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Blister card pack containing 28 film\u2011coated tablets<\/span><\/p>","ID":"d868210d-cedd-496c-a426-09f8863a6f28","Styles":"margin-left:13.5pt;text-indent:-13.5pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"-      Blister card pack containing 28 film\u2011coated tablets","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:8.0pt; font-family:Symbol\">-<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Blister pack containing 56 film\u2011coated tablets<\/span><\/p>","ID":"b59478cf-1872-465c-bab5-05595aaeabd0","Styles":"margin-left:13.5pt;text-indent:-13.5pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"-      Blister pack containing 56 film\u2011coated tablets","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;line-height: normal\"><span lang=\"EN-GB\" style=\"font-size:8.0pt;font-family:Symbol\">-<span style='font:7.0pt \"Times New Roman\"'>      <\/span><\/span><span lang=\"EN-GB\">Bottle containing 56 film\u2011coated tablets<\/span><\/p>","ID":"4c8f677e-9224-4222-a477-c22654024fcb","Styles":"margin-left:13.5pt;text-indent:-13.5pt;line-height:\nnormal","Classes":"['MsoNormal']","Text":"-      Bottle containing 56 film\u2011coated tablets","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d2d430b1-400c-4953-93e3-1fc59923ecfa","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\">Not all pack sizes may be marketed<\/p>","ID":"91b2bfec-e7f9-493a-abe0-b7ae43c83822","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Not all pack sizes may be marketed","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"588d76e3-65e1-4cc6-971c-4cd50c7ba135","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.1pt;text-indent:-28.1pt;line-height: normal;page-break-after:avoid\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6    Special precautions for disposal and other handling<\/span><\/b><\/a><\/p>","ID":"959c4dc8-b7af-40c0-8a0b-06d636bd696a","Styles":"margin-left:28.1pt;text-indent:-28.1pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.6    Special precautions for disposal and other handling","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"0bcf1699-3b16-490f-9b16-1e903aa60a8c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<\/span><\/p>","ID":"6e174f30-f32d-415c-bc91-999a3db310cb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Any unused medicinal product or waste material should be disposed of in accordance with local requirements.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"338ab0b8-871c-4c2f-896d-f6dc6153d483","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9bd3e220-6979-49dc-836e-bb97609b53c8","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>7.       MARKETING AUTHORISATION HOLDER<\/span><\/h1>","ID":"9291bd0c-1ae9-4bca-aca9-5e7c6c0d7709","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4766ef25-dac7-4f75-a6c0-87a041ea71f2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p>","ID":"3a248fa7-afb2-4330-99fb-cc1108a3023c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Vertex Pharmaceuticals (Ireland) Limited","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p>","ID":"730ce75b-8e7f-47ac-804d-853fee4b07ce","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"28-32 Pembroke Street Upper","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p>","ID":"d5d17d95-64b5-480a-a197-27578025647b","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Dublin 2, D02 EK84","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p>","ID":"1809bc78-e0fe-4458-8a36-9872fb5f94c8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ireland","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1e0388ca-0c32-4023-b14e-b8cb235b88e3","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"40d580a6-16bb-44ff-ae71-d26cdb2f9f81","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/h1>","ID":"35185ff1-bb90-4925-a19c-d466ab7bf5d1","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"8.       MARKETING AUTHORISATION NUMBER(S)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d1ad4e6e-5994-4c44-a1af-bc0540fd9918","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/001<\/span><\/p>","ID":"8be09bd4-dcd3-4204-8968-1129d9ff2c36","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"EU\/1\/12\/782\/001","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/002<\/span><\/p>","ID":"df4bf3f4-4373-41da-bd2d-e803dc547565","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"EU\/1\/12\/782\/002","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/005<\/span><\/p>","ID":"029bfb7b-a8cc-4fe0-8b11-02b3a11cf92a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"EU\/1\/12\/782\/005","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e5b54fad-11db-4ddf-b4c3-c24e686f8b2e","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6089c389-03ab-4be8-8215-11e45be8edf1","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/h1>","ID":"1ea18b76-7e72-4a66-bd77-7b6469273c69","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e1921185-2c86-44e0-af6d-1aa83299f98c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of first authorisation: 23 July 2012<\/span><\/p>","ID":"42f22b1f-3d64-4785-9d6a-76ba5943cf4e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Date of first authorisation: 23 July 2012","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of latest renewal: 28 April 2017<\/span><\/p>","ID":"e034d91b-697f-440d-ab61-8a315da2ff55","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Date of latest renewal: 28 April 2017","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e0cc86db-c3d8-49c0-8c51-df5828645186","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"41764299-5976-4660-8eec-83e24a8a99ce","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>10.     DATE OF REVISION OF THE TEXT<\/span><\/h1>","ID":"50d89347-265e-43cf-88ac-3932940a0d0f","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5facab6b-604c-4dfb-9d2f-5eabda81f34b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>http:\/\/www.ema.europa.eu<\/u>.<\/span><\/p>","ID":"20b8976b-785b-40ff-b94d-b833a73881d0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Detailed information on this medicinal product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"3e2dc6ed-5f66-4758-9469-bdcdb0c1c4ec","Styles":"None","Classes":"None","Text":"","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"d867b4dc-5460-401a-bcd3-2c340b9bf436","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Text":" ","ParentId":"3e2dc6ed-5f66-4758-9469-bdcdb0c1c4ec"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"f385c361-b4b9-43fc-8281-ba725912d8e2","Styles":"page-break-before:always","Classes":"None","Text":"","ParentId":"d867b4dc-5460-401a-bcd3-2c340b9bf436"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b1b3dd52-53a5-44bf-aced-f5b6102e611d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b7a5bafb-5d72-4eed-a406-fb37605a24db","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/b><\/p>","ID":"8737419b-e6e5-4884-a95b-7d96dc09954c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ed64c72a-d66e-4476-bea6-2b8afb608ea4","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet<\/span><\/p>","ID":"564baf4e-8ee8-4f7c-b50e-efdc93065a31","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Kalydeco 25 mg granules in sachet","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet<\/span><\/p>","ID":"d049e78e-ed0e-4910-bd6b-5ff0be69f298","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Kalydeco 50 mg granules in sachet","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet<\/span><\/p>","ID":"a23dc9e2-3e21-4aff-b12d-5f29fee6455f","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Kalydeco 75 mg granules in sachet","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4cdf2fc4-6180-437f-84c8-3296e1151393","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1b3f2f00-6069-42a3-b067-2fe5ab71a5f0","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/h1>","ID":"4e826906-f3b8-4d6c-b5c5-a1ce58c8849a","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"2.       QUALITATIVE AND QUANTITATIVE COMPOSITION","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d0f1fd2d-6246-4f1b-a9d8-8721de3f6c84","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Kalydeco 25 mg granules in sachet<\/span><\/u><\/p>","ID":"eca32bec-a3ef-4e12-a070-d2fe15189008","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Kalydeco 25 mg granules in sachet","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"38d137af-481e-4d2f-85ae-2c3bbbb4aaa5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 25 mg of ivacaftor.<\/span><\/p>","ID":"b8e126ef-fe6f-4730-9b90-fce11fe9ea9e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each sachet contains 25 mg of ivacaftor.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"888d6e7d-1303-46be-9491-09440fdd4d2a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Excipient with known effect<\/span><\/i><\/p>","ID":"26dcb5a4-e446-47c0-974f-ded8a60b3333","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Excipient with known effect","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"f9faa24c-60b3-473b-813b-c3ed08d762e8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 36.6 mg of lactose monohydrate.<\/span><\/p>","ID":"0335fcce-4a66-4365-b8a2-864b39b663fd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each sachet contains 36.6 mg of lactose monohydrate.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"80dd9220-a29d-4619-af65-2e8c78ddba8f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Kalydeco 50 mg granules in sachet<\/span><\/u><\/p>","ID":"abf17175-3ac2-4313-993c-ee49555e6b2e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Kalydeco 50 mg granules in sachet","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"14621bfd-c02f-4f00-aeea-958763239947","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 50 mg of ivacaftor.<\/span><\/p>","ID":"0f3b1a6a-e0f4-4f18-9aba-c10be8aae464","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each sachet contains 50 mg of ivacaftor.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"0800f633-18ea-4c10-acfa-1bbc69ff6ab3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Excipient with known effect<\/span><\/i><\/p>","ID":"9ef28fd0-30fa-41e8-aa29-eee172b984bd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Excipient with known effect","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"21b570a7-3cec-4497-84f6-f4ee7d13e8f0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 73.2 mg of lactose monohydrate.<\/span><\/p>","ID":"c013aa96-5ed3-4a21-a248-e90a75233724","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each sachet contains 73.2 mg of lactose monohydrate.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"52c7cddc-f591-4aa2-b259-32e04742bd16","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Kalydeco 75 mg granules in sachet<\/span><\/u><\/p>","ID":"b4578e7e-8d37-4a49-8ba4-b0ba3d15f853","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Kalydeco 75 mg granules in sachet","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"260bc899-b132-4ec7-984f-0f628e5a5295","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 75 mg of ivacaftor.<\/span><\/p>","ID":"c806296e-48e4-4949-9c21-0b7900e841e6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each sachet contains 75 mg of ivacaftor.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"c4c4cd17-5d11-4e7c-a246-84cdb084c072","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Excipient with known effect<\/span><\/i><\/p>","ID":"26766f93-1540-4c73-9289-64fb0fbfe86a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Excipient with known effect","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"811e5bf7-77b0-4e5d-a85f-b827a15f102e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Each sachet contains 109.8 mg of lactose monohydrate.<\/span><\/p>","ID":"f5b7d203-05f0-4cd8-a2d1-ef2e5eed47ac","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Each sachet contains 109.8 mg of lactose monohydrate.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5178d913-32e8-4aad-ade5-64cc2c065ccf","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p>","ID":"5ccb4729-a2bd-405c-b811-f1f5ff7fae25","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"For the full list of excipients, see section 6.1.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2949741b-0114-4e72-9d62-58d9a42ea056","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"de147a2d-a14d-4e1b-9c4a-1d85c35a1b86","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>3.       PHARMACEUTICAL FORM<\/span><\/h1>","ID":"44b68e1e-f567-4395-8435-2f06920828d2","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"3.       PHARMACEUTICAL FORM","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9f91dcf4-a1ef-4390-ab81-44a2c34ebd40","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph; line-height:normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">Granules in sachet<\/span><\/p>","ID":"81c69728-099d-4c0e-b54f-63a575842b8a","Styles":"text-align:justify;text-justify:inter-ideograph;\nline-height:normal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Text":"Granules in sachet","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"55ba1c3e-a3fe-4279-b005-eccd30452c9b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">White to off\u2011white granules approximately 2 mm in diameter.<\/span><\/p>","ID":"6ad7e33f-b971-4dff-a6f1-51615bf1029a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"White to off\u2011white granules approximately 2 mm in diameter.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p>","ID":"e157cd6e-1eac-4ce1-8e93-96b305317d5f","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> <\/span><\/p>","ID":"0e290efc-e794-43cb-b357-3ea1da8b17a8","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif;text-transform:uppercase'>4.       <\/span><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>CLINICAL PARTICULARS<\/span><\/h1>","ID":"aa342841-8224-4f23-bc19-228588b9268d","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"4.       CLINICAL PARTICULARS","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6404d7c8-bf4d-4c4f-a8f5-cf3b24566514","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p>","ID":"6dfddd7d-834a-483d-8ae2-e901a2b2bc09","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.1     Therapeutic indications","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e399c0a9-e892-48a8-b5eb-e7077f49b2cf","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an <i>R117H CFTR<\/i> mutation or one of the following gating (class III) mutations in the <i>CFTR<\/i> gene: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N <\/i>or<i> S549R<\/i> (see sections 4.4 and 5.1).<\/span><\/p>","ID":"9297f549-9bab-4238-a3c1-ae3781d06884","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e5feea68-86db-46b9-8dfa-daad4a59885b","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.2     Posology and method of administration<\/span><\/b><\/p>","ID":"ee4bdf85-1653-42e2-963e-979f492394ff","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"4.2     Posology and method of administration","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"a65b6b78-f44b-412a-9d6f-9bd8db0e26eb","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. <\/span>If the patient's genotype is unknown, an <span lang=\"EN-GB\">accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in at least one allele of the <i>CFTR<\/i> gene (see section 4.1). The phase of the poly-T variant identified with the <i>R117H <\/i>mutation should be determined in accordance with local clinical recommendation.<\/span><\/p>","ID":"6c990a50-6317-4363-8ee6-e0ca478a5f82","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient's genotype is unknown, an accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in at least one allele of the CFTR gene (see section 4.1). The phase of the poly-T variant identified with the R117H mutation should be determined in accordance with local clinical recommendation.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"37084233-d4a9-402e-ab18-a3817819111b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"9a1cb0a3-2586-4a25-8747-60769a5dd3cb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Posology","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c875c030-5e92-41a8-bdfc-1de01da578e9","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Infants aged at least 4 months, toddlers, children, adolescents and adults should be dosed according to Table 1.<\/span><\/p>","ID":"f8c513ac-6b10-45e6-a283-70483a1da853","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Infants aged at least 4 months, toddlers, children, adolescents and adults should be dosed according to Table 1.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7a05b855-e191-495f-8350-51f20dde6795","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 1: Dosing recommendations for patients aged 4 months and older<\/span><\/b><\/p>","ID":"c60c2a61-27f0-477c-8913-e722e0c28961","Styles":"margin-bottom:6.0pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 1: Dosing recommendations for patients aged 4 months and older","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.0%;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Age<\/span><\/b><\/p> <\/td> <td style=\"width:21.68%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Weight<\/span><\/b><\/p> <\/td> <td style=\"width:36.18%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <\/td> <td style=\"width:20.46%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Total daily dose<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">4 months to less than 6 months<\/span><\/p> <\/td> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\">5 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">25 mg granules taken orally every 12 hours with fat-containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td rowspan=\"4\" style=\"width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">6 months and older<\/span><\/p> <\/td> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\">5 kg to   &lt; 7 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">25 mg granules taken orally every 12 hours with fat\u2011containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 7 kg to &lt; 14 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">50 mg granules taken orally every 12 hours with fat\u2011containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">100 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.85pt\"> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 14 kg to   &lt; 25 kg<\/span><\/p> <\/td> <td style=\"width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"36%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">75 mg granules taken orally every 12 hours with fat\u2011containing   food<\/span><\/p> <\/td> <td style=\"width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">150 mg<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.7pt\"> <td style=\"width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 25 kg<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:56.64%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">See Kalydeco   tablets SmPC for further details.<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"d966a1fb-9884-4655-8edc-64f2eb96596f","Styles":"width:99.0%;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"   Age   Weight   Dose   Total daily dose     4 months to less than 6 months   \u22655 kg   25 mg granules taken orally every 12 hours with fat-containing   food   50 mg     6 months and older   \u22655 kg to   < 7 kg   25 mg granules taken orally every 12 hours with fat\u2011containing   food   50 mg     \u2265 7 kg to < 14 kg   50 mg granules taken orally every 12 hours with fat\u2011containing   food   100 mg     \u2265 14 kg to   < 25 kg   75 mg granules taken orally every 12 hours with fat\u2011containing   food   150 mg     \u2265 25 kg   See Kalydeco   tablets SmPC for further details.   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span class=\"s10\"><span lang=\"EN-GB\"> <\/span><\/span><\/p>","ID":"fd880faf-bac2-43a8-829b-d104c65c01f3","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span class=\"s10\"><i><span lang=\"EN-GB\">Missed dose<\/span><\/i><\/span><\/p>","ID":"7034708c-d662-48ed-b08a-54cedcc2385a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Missed dose","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span class=\"s10\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/span><\/p>","ID":"2cbbbfa4-17ec-43ad-b0b0-ff3861a3b7fe","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span class=\"s10\"><span lang=\"EN-GB\">If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.<\/span><\/span><\/p>","ID":"1dde6e60-96f9-42fc-8196-e36eea906079","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"If 6 hours or less have passed since the missed morning or evening dose, the patient should take it as soon as possible and continue on the original schedule. If more than 6 hours have passed since the time the dose is usually taken, the patient should be told to wait until the next scheduled dose.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"5c009d51-770d-4ea6-98b3-fa448fa017f5","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">Concomitant use of CYP3A inhibitors<\/span><\/i><\/p>","ID":"eae82598-0d62-4009-91be-6e73d82d66eb","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Concomitant use of CYP3A inhibitors","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p>","ID":"b8d464ee-f467-4772-b849-9f5ad0b4e799","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">When co-administered with strong inhibitors of CYP3A in patients aged 6 months and older, the <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">ivacaftor dose should be reduced to one sachet (ivacaftor 25 mg for patients 5 kg to &lt; 7 kg; ivacaftor 50 mg for patients 7 kg to &lt; 14 kg; ivacaftor 75 mg for patients 14 kg to &lt; 25 kg) twice a week <\/span><span style=\"font-size:11.0pt\">(see sections 4.4 and 4.5).<\/span><\/p>","ID":"4290ac4b-90ea-4115-9fc4-b89115a34db7","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"When co-administered with strong inhibitors of CYP3A in patients aged 6 months and older, the ivacaftor dose should be reduced to one sachet (ivacaftor 25 mg for patients 5 kg to < 7 kg; ivacaftor 50 mg for patients 7 kg to < 14 kg; ivacaftor 75 mg for patients 14 kg to < 25 kg) twice a week (see sections 4.4 and 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"001155b7-3f45-45d3-9e3d-3891b1a90e68","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">When co-administered with moderate inhibitors of CYP3A in patients aged 6 months and older,<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> the ivacaftor dose is as above recommended but administered once daily <\/span><span style=\"font-size:11.0pt\">(see sections 4.4 and 4.5).<\/span><\/p>","ID":"dcd3bdc2-25de-4095-9c02-3a761d0fca59","Styles":"None","Classes":"['labeltext']","Text":"When co-administered with moderate inhibitors of CYP3A in patients aged 6 months and older, the ivacaftor dose is as above recommended but administered once daily (see sections 4.4 and 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"be179e7a-5deb-4671-b501-5c3651a4b2d9","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Due to the variability in maturation of the cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended when co-administered with moderate or strong inhibitors of CYP3A in patients aged 4 months to less than 6 months, unless the benefits outweigh the risks. In such cases, the recommended dose is one packet of 25 mg granules twice weekly or less frequently (see sections 4.4 and 4.5). Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2)<\/span><\/p>","ID":"3ac02dea-b37a-4521-9d9a-58291948b6da","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Due to the variability in maturation of the cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended when co-administered with moderate or strong inhibitors of CYP3A in patients aged 4 months to less than 6 months, unless the benefits outweigh the risks. In such cases, the recommended dose is one packet of 25 mg granules twice weekly or less frequently (see sections 4.4 and 4.5). Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ea914e34-3b35-48a9-9a5b-506a814f316d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"0e265109-6cc1-46a9-b5bd-a5126a312b47","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p>","ID":"9e55cf26-c500-4b3c-9bc3-3518195d3a9a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Special populations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"f30337bd-dc58-499e-923f-50e86db38fa6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"9e774490-af52-4833-991a-7d4626f04f65","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Renal impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"a046c579-97ab-4f6a-90f9-74082e36e6b5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.4 and 5.2).<\/span><\/p>","ID":"db0bc259-1c03-4a5a-98c9-46be86bbd098","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end\u2011stage renal disease (see sections 4.4 and 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"d878aca7-f396-4cd6-9ab9-89968e2d8df0","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span style=\"font-size:11.0pt\">Hepatic impairment<\/span><\/p>","ID":"6b400c5a-d531-45bd-b500-5a17972c142a","Styles":"None","Classes":"['labeltextheading']","Text":"Hepatic impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"04397619-280f-487e-9a06-92adba14bbc7","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustment is necessary for patients aged 6 months and older with mild hepatic impairment (Child\u2011Pugh Class A). For patients aged 6 months and older with moderate hepatic impairment (Child\u2011Pugh Class B), a <\/span><span style=\"font-size:11.0pt\">reduced dose of one sachet (ivacaftor 25 mg for patients 5 kg to &lt; 7 kg; ivacaftor 50 mg for patients 7 kg to &lt; 14 kg; ivacaftor 75 mg for patients 14 kg to &lt; 25 kg) once daily is recommended. There is no experience of the use of ivacaftor in patients aged 6 months and older with severe hepatic impairment (Child-Pugh Class C); therefore, its use is not recommended unless the benefits outweigh the risks. In such cases, the starting dose should be as above recommended, administered <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">every other day<\/span><span style=\"font-size:11.0pt\">. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).<\/span><\/p>","ID":"b5952151-667e-4edf-beee-5321dbcec0e6","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"No dose adjustment is necessary for patients aged 6 months and older with mild hepatic impairment (Child\u2011Pugh Class A). For patients aged 6 months and older with moderate hepatic impairment (Child\u2011Pugh Class B), a reduced dose of one sachet (ivacaftor 25 mg for patients 5 kg to < 7 kg; ivacaftor 50 mg for patients 7 kg to < 14 kg; ivacaftor 75 mg for patients 14 kg to < 25 kg) once daily is recommended. There is no experience of the use of ivacaftor in patients aged 6 months and older with severe hepatic impairment (Child-Pugh Class C); therefore, its use is not recommended unless the benefits outweigh the risks. In such cases, the starting dose should be as above recommended, administered every other day. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"6abe3719-aca8-48d9-8043-24783a4baf46","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">Due to variability in maturation of cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended in patients aged 4 months to less than 6 months with hepatic impairment, unless the benefits outweigh the risks. In such cases, the recommended dose is one sachet (ivacaftor 25 mg) once daily or less frequently. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).<\/span><\/p>","ID":"51820fc0-9bb7-4d55-ab4c-4176e258aab9","Styles":"None","Classes":"['labeltext']","Text":"Due to variability in maturation of cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended in patients aged 4 months to less than 6 months with hepatic impairment, unless the benefits outweigh the risks. In such cases, the recommended dose is one sachet (ivacaftor 25 mg) once daily or less frequently. Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"9ce421f4-2db5-49a5-be15-6c57cd132ae9","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"c4cbdbb2-105f-4c4a-8689-fcce033134b5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\"> <\/span><\/i><\/b><\/p>","ID":"d401da06-ea74-4f0b-97fd-8bb60f50af91","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">The safety and efficacy of ivacaftor in children aged less than 4 months have not been established. No data are available.<\/span><\/p>","ID":"b1ae7a60-4dc8-431b-8a0d-c2cee528e200","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"The safety and efficacy of ivacaftor in children aged less than 4 months have not been established. No data are available.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"467c5dc7-45c6-438a-9bd9-5ef70d4bee29","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\">Limited data are available in patients less than 6 years of age with an <i>R117H<\/i> mutation in the <i>CFTR<\/i> gene. Available data in patients aged 6 years and older are described in sections 4.8, 5.1 and 5.2.<\/span><\/p>","ID":"bb5f529e-7df6-4ade-959a-8f94cf206339","Styles":"None","Classes":"['labeltext']","Text":"Limited data are available in patients less than 6 years of age with an R117H mutation in the CFTR gene. Available data in patients aged 6 years and older are described in sections 4.8, 5.1 and 5.2.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"6caec2a7-fd35-4960-8043-f1f1ab18572b","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration <\/span><\/u><\/p>","ID":"10e44efd-5156-4cc0-8a2f-27110c7f5ac4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Method of administration ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"6bb41be9-b1a9-491b-8c65-a2647a97461c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">For oral use.<\/span><\/p>","ID":"55847383-4d99-444f-b8ef-064bbce5928d","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\nnone","Classes":"['MsoNormal']","Text":"For oral use.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4db36be1-2ea2-445a-b083-4bd8639aaaea","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Each sachet is for single use only.<\/span><\/p>","ID":"15148570-34c8-4e3a-9a24-eaf77ac5b5f7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":"Each sachet is for single use only.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"51c77c37-a9a5-448e-93f8-9cc7de734cd2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each sachet of granules should be mixed with 5 mL of age\u2011appropriate soft food or liquid and<\/span><span lang=\"EN-GB\"> completely and immediately consumed. <\/span>Food or liquid should be at room temperature or below. <span lang=\"EN-GB\">If not immediately consumed, the mixture has been shown to be stable for one hour and therefore should be ingested during this period. A fat\u2011containing meal or snack should be consumed just before or just after dosing.<\/span><\/p>","ID":"8bf519b5-dd42-4abd-899c-44497b0823ae","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Each sachet of granules should be mixed with 5 mL of age\u2011appropriate soft food or liquid and completely and immediately consumed. Food or liquid should be at room temperature or below. If not immediately consumed, the mixture has been shown to be stable for one hour and therefore should be ingested during this period. A fat\u2011containing meal or snack should be consumed just before or just after dosing.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"20bb3d50-f8a2-4f7b-bb78-6dd7b8f22bfd","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Food or drink containing grapefruit should be avoided during treatment (see section 4.5).<\/span><\/p>","ID":"0b9ea9b8-ffb8-4b40-8bd1-548e1dc9d086","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Food or drink containing grapefruit should be avoided during treatment (see section 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"55c6fbc1-d461-4192-a0d2-83b5d284e63d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.3       Contraindications<\/span><\/h2>","ID":"9afbdbe1-3264-4c35-9779-682d25529e25","Styles":"margin:0in","Classes":"None","Text":"4.3       Contraindications","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d9e65e10-41f2-4962-81e3-0e01b155e8f8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"4cbabd91-6da8-4dc8-84a6-247a52e5aa9e","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":"Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4dbdc084-e61e-4635-a64c-35cc18fe04cb","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.4       Special warnings and precautions for use<\/span><\/h2>","ID":"f9f7a093-ee8d-440b-af65-d42dae1521b8","Styles":"margin:0in","Classes":"None","Text":"4.4       Special warnings and precautions for use","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d55ee00b-8534-4ae3-b87a-791c3b4a18d3","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Only patients with CF who had a <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N<\/i> or <i>S549R<\/i> gating (class III) or <i>G970R<\/i> mutation in at least one allele of the <i>CFTR<\/i> gene were included in studies 1, 2, 5 and 7 (see section<\/span><span lang=\"EN-GB\"> 5.1).<\/span><\/p>","ID":"204da700-0591-4ee2-8cb3-1e8341506da7","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Only patients with CF who had a G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R gating (class III) or G970R mutation in at least one allele of the CFTR gene were included in studies 1, 2, 5 and 7 (see section 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6b4ac564-a75c-4b6c-9172-5c7d204d4253","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Less evidence of a positive effect of ivacaftor has been shown for patients with an <i>R117H-7T<\/i> mutation associated with less severe disease in study 6 (see section 5.1).<\/span><\/p>","ID":"e44eaeab-7c3b-44eb-9c69-df8e0dc83d57","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Less evidence of a positive effect of ivacaftor has been shown for patients with an R117H-7T mutation associated with less severe disease in study 6 (see section 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"12c53ff3-aa6e-4259-9f28-167ee18836cb","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In study 5, four patients with the <i>G970R<\/i> mutation were included. In three of four patients the change in the sweat chloride test was &lt; 5<\/span><span lang=\"EN-GB\"> mmol\/L and this group did not demonstrate a clinically relevant improvement in FEV<sub>1<\/sub> after 8 weeks of treatment. Clinical efficacy in patients with the <i>G970R<\/i> mutation of the <i>CFTR<\/i> gene could not be established (see section 5.1).<\/span><\/p>","ID":"0fa219c5-3661-44bd-acc7-0cee5a4cc02a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In study 5, four patients with the G970R mutation were included. In three of four patients the change in the sweat chloride test was < 5 mmol\/L and this group did not demonstrate a clinically relevant improvement in FEV1 after 8 weeks of treatment. Clinical efficacy in patients with the G970R mutation of the CFTR gene could not be established (see section 5.1).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"78897d09-9195-4081-ab38-c346d34533b7","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Efficacy results from a phase 2 study in patients with CF who are homozygous for the <i>F508del <\/i>mutation in the <i>CFTR<\/i> gene showed no statistically significant difference in FEV<sub>1<\/sub> over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.<\/span><\/p>","ID":"08ae96f5-6e0c-40be-8028-d8057734585c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Efficacy results from a phase 2 study in patients with CF who are homozygous for the F508del mutation in the CFTR gene showed no statistically significant difference in FEV1 over 16 weeks of ivacaftor treatment compared to placebo (see section 5.1). Therefore, use of ivacaftor as monotherapy in these patients is not recommended.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltextheading\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-style: normal\"> <\/span><\/p>","ID":"3e9db5fb-7abf-48d3-ad03-7f324dadc87e","Styles":"None","Classes":"['labeltextheading']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Effect on liver function tests<\/span><\/u><\/p>","ID":"20cb151f-a6bc-454e-a7a1-38265a1ade1c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Effect on liver function tests","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"17ff69bf-17e6-47b6-b939-2cf40f4fc4ab","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor monotherapy. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3<\/span><span style=\"font-size:11.0pt\"> <\/span><span style=\"font-size:11.0pt\">months during the first year of treatment and annually thereafter. <\/span><span style=\"font-size:11.0pt\">For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. <\/span><span style=\"font-size:11.0pt\">In the event of significant elevations of transaminases (e.g., patients with ALT or AST &gt; 5 x the upper limit of normal (ULN), or ALT or AST &gt; 3 x ULN with bilirubin &gt; 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).<\/span><\/p>","ID":"b9d11314-c72a-4559-b5ad-040359a9e838","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in subjects with CF. Transaminase elevations have been observed in some patients treated with ivacaftor monotherapy. Therefore, liver function tests are recommended for all patients prior to initiating ivacaftor, every 3 months during the first year of treatment and annually thereafter. For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. In the event of significant elevations of transaminases (e.g., patients with ALT or AST > 5 x the upper limit of normal (ULN), or ALT or AST > 3 x ULN with bilirubin > 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see section 4.8).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"52db60a7-f1fc-450f-9ec3-3ae64cefa2b2","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p>","ID":"8df837bf-6776-404c-a226-5688d3aa26f0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Hepatic impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"64b67fa4-d601-44d0-974e-26c1c7f59ddd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Use of ivacaftor is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks (see sections 4.2 and 5.2). No safety data are available in infants aged 4 to less than 12 months of age with moderate or severe hepatic impairment treated with ivacaftor.<\/span><\/p>","ID":"90dd13d1-ef3d-4e37-b7dc-43b58f532817","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Use of ivacaftor is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks (see sections 4.2 and 5.2). No safety data are available in infants aged 4 to less than 12 months of age with moderate or severe hepatic impairment treated with ivacaftor.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"cf591e8a-a211-4f55-88be-3a7383af6b4a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"5264a5b1-5f86-421b-b3b5-afaa0b757c84","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Renal impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"e49f2dfa-995e-47c0-91dd-df3ca95bff76","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Caution is recommended while using ivacaftor in patients with severe renal impairment or end\u2011stage renal disease (see sections 4.2 and 5.2).<\/span><\/p>","ID":"63bac87a-ee9e-44b5-a889-a1a2a1b4e9e1","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Caution is recommended while using ivacaftor in patients with severe renal impairment or end\u2011stage renal disease (see sections 4.2 and 5.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"3e33cad4-5027-4219-947b-c84e8f39511a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Patients after organ transplantation<\/span><\/u><\/p>","ID":"c8c2aaa2-7ffe-4533-abdf-5522d8bb1b2b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Patients after organ transplantation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"96aef81a-461c-483c-878a-f0db5de8867f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.<\/span><\/p>","ID":"e36d0163-a48c-4150-96bf-a8515ef8cf64","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with ciclosporin or tacrolimus.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c188e964-3bc1-4eda-8c15-c593e7ff7e14","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Interactions with medicinal products<\/span><\/u><\/p>","ID":"345ef143-3a3d-4c1f-b90f-3fb54df089ab","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Interactions with medicinal products","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"e58d3602-3bc0-4614-8758-d505cec5971d","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inducers<\/span><\/i><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"ad622e1b-d406-4cb6-b371-8efc616cf197","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"CYP3A inducers ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"6edbf18b-95fc-4358-b964-5447c9adb130","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Exposure to ivacaftor is significantly decreased by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">co-administration <\/span><span style=\"font-size:11.0pt\">of ivacaftor <\/span><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">with strong CYP3A inducers is not recommended<\/span><span style=\"font-size:11.0pt\"> (see section 4.5).<\/span><\/p>","ID":"c671e1cc-6546-44d9-ab60-165d0a5dda05","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Exposure to ivacaftor is significantly decreased by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, co-administration of ivacaftor with strong CYP3A inducers is not recommended (see section 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"054336b6-ac31-4856-ad80-c6b5ae3c99d8","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inhibitors <\/span><\/i><\/p>","ID":"7d5494bd-355d-4823-8d2b-f66ef754469b","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"CYP3A inhibitors ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p>","ID":"ec1bea6b-31ae-4e0e-bdce-92158fb886f4","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Exposure to ivacaftor is increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see sections 4.2 and 4.5). No safety data are available in infants aged 4 to less than 12 months of age who are treated with ivacaftor and moderate or strong CYP3A inhibitors (see sections 4.2 and 4.5).<\/span><\/p>","ID":"1e80728d-b336-4d71-9d9f-c2d56bb6be5a","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Exposure to ivacaftor is increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor must be adjusted when used concomitantly with strong or moderate CYP3A inhibitors (see sections 4.2 and 4.5). No safety data are available in infants aged 4 to less than 12 months of age who are treated with ivacaftor and moderate or strong CYP3A inhibitors (see sections 4.2 and 4.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"5ddcdd6d-15c3-47c8-9405-424cd3621b3b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population <\/span><\/u><\/p>","ID":"1547a73e-dcf9-4c9e-9e08-56996d699a20","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Paediatric population ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"00b6ae9a-81e1-4cf9-9aa7-6ff5cd502bb7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cases of non\u2011congenital lens opacities\/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow\u2011up ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment.<\/span><\/p>","ID":"a1f1bb5b-e91c-47e6-9639-16695ba398d2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Cases of non\u2011congenital lens opacities\/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow\u2011up ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"757e9da1-3bd1-4a74-a0b5-178acde8c647","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Lactose content<\/span><\/u><\/p>","ID":"38c05be9-ce08-4a37-ab9f-89bf0f3e8562","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Lactose content","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"23d6388a-e61b-4090-946f-8c752466099f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose\u2011galactose malabsorption should not take this medicine.<\/span><\/p>","ID":"528fd864-7d5b-4f96-8753-60c49d5d2a57","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose\u2011galactose malabsorption should not take this medicine.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"acfbd3ce-70a8-44b0-8d53-7b25a610208c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium content<\/span><\/u><\/p>","ID":"d5314052-8f35-4a89-80ae-bd665c3e7911","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Sodium content","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"345f567a-66f8-4949-90e1-8d8a8cc322b6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.<\/span><\/p>","ID":"6ff36b83-e7f0-41b6-a9c6-dfa2a85e3cf1","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9fd14403-e2a5-41e2-bec1-c57474af1e45","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.5pt;text-indent:-28.5pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Interaction with other medicinal products and other forms of interaction<\/span><\/b><\/p>","ID":"46394b10-9cba-4784-a75e-1be193fc018f","Styles":"margin-left:28.5pt;text-indent:-28.5pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.5          Interaction with other medicinal products and other forms of interaction","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"91544de8-251d-4829-9af5-2ab5464b49e8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P\u2011gp and a potential inhibitor of CYP2C9. <\/span><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> studies showed that ivacaftor is not a substrate for P\u2011gp. <\/span><\/p>","ID":"254bf947-15e6-4e94-8586-c34a114e6db9","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P\u2011gp and a potential inhibitor of CYP2C9. In vitro studies showed that ivacaftor is not a substrate for P\u2011gp. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b974b53e-6bb0-48cc-9ad3-ddff6e4433ea","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Medicinal products affecting the pharmacokinetics of ivacaftor<\/span><\/u><\/p>","ID":"04fee1e4-d94d-4885-8714-123c51e03056","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Medicinal products affecting the pharmacokinetics of ivacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5a2086fa-057d-4bca-b3de-d4cdcc246708","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A inducers<\/span><\/i><\/p>","ID":"be27bf90-7607-4365-905a-88b27bcd9578","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"CYP3A inducers","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"dd9cb75a-9efa-4712-9087-580d9bb20a55","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Co\u2011administration of ivacaftor with strong CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John\u2019s wort (<i>Hypericum perforatum<\/i>), is not recommended (see section 4.4).<\/span><\/p>","ID":"33cae9ce-d691-436d-8b08-cff044a915ab","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Co\u2011administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor. Co\u2011administration of ivacaftor with strong CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John\u2019s wort (Hypericum perforatum), is not recommended (see section 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"3eca8390-635b-4e96-9608-9e28501924ec","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers. <\/span><\/p>","ID":"dad5803f-2799-4567-8878-9ef4af9548f0","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":"No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"eab211fd-9b47-47eb-833d-db711e1c655b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\">CYP3A inhibitors<\/span><\/i><\/p>","ID":"d57262ca-f9a9-4869-8d8d-1406aa6e89ff","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"CYP3A inhibitors","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><i><span style=\"font-size: 11.0pt\"> <\/span><\/i><\/p>","ID":"2253f5b7-0d88-4bc1-8188-57f0ff25a12b","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor is a sensitive CYP3A substrate. Co\u2011administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the <\/span><span style=\"font-size:11.0pt\">ivacaftor dose <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">is recommended for co\u2011administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).<\/span><\/p>","ID":"69ece678-4fe3-4519-88bb-859fc1835f8a","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Ivacaftor is a sensitive CYP3A substrate. Co\u2011administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose is recommended for co\u2011administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see sections 4.2 and 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"e1465c91-229d-44d7-aee2-de7f5c17dffb","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the <\/span><span style=\"font-size:11.0pt\">ivacaftor dose is recommended <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).<\/span><\/p>","ID":"3fbe42f2-b66f-42d3-80d7-8cd58d715a19","Styles":"None","Classes":"['labeltext']","Text":"Co\u2011administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3\u2011fold and increased M1 to a lesser extent than ivacaftor. A reduction of the ivacaftor dose is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections 4.2 and 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"feff6881-afc6-44de-80a3-86b16a395684","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co-administration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (see section 4.2).<\/span><\/p>","ID":"697d2ddb-9c68-4ecf-8a35-aa735aece286","Styles":"None","Classes":"['labeltext']","Text":"Co-administration of ivacaftor with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with ivacaftor (see section 4.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"eaabe583-8f68-4f6b-b890-03b4f3914e15","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Potential for ivacaftor to interact with transporters<\/span><\/u><\/p>","ID":"fa0537a4-251f-4c27-a920-cf4812d1a47b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Potential for ivacaftor to interact with transporters","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"489a0a2f-e144-4990-9e37-ec3ef6f0fcff","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In vitro<\/span><\/i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in vitro<\/i>. Due to its high intrinsic permeability and low likelihood of being excreted intact, co\u2011administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1\u2011IVA, while any potential changes in M6\u2011IVA exposures are not expected to be clinically relevant. <\/span><\/p>","ID":"44349b1e-dd25-47a8-8bab-90afdd3b900d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"In vitro studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP in vitro. Due to its high intrinsic permeability and low likelihood of being excreted intact, co\u2011administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1\u2011IVA, while any potential changes in M6\u2011IVA exposures are not expected to be clinically relevant. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"791af876-de8d-45c3-a5ba-9255494da23a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Ciprofloxacin<\/span><\/i><\/p>","ID":"a2b5434f-891e-4b0e-b63c-054d9f30ce52","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ciprofloxacin","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"52307857-1cb9-4ac2-8b79-3fcf94ab30eb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">Co-administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor is co\u2011administered with ciprofloxacin.<\/span><\/p>","ID":"07cfed75-4e84-4d93-82ed-1c22adfb383f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Co-administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when ivacaftor is co\u2011administered with ciprofloxacin.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"1489000b-a73d-42e8-9ff4-25215398f9e9","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Medicinal products affected by ivacaftor<\/span><\/u><\/p>","ID":"d24c8b84-06c9-4333-8140-87be6a05d509","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Medicinal products affected by ivacaftor","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"d61baba5-39e6-4dd7-abcb-50eb0394b962","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and\/or P\u2011gp, and\/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.<\/span><\/p>","ID":"b7a874f4-8de8-4373-90c8-0a0ca25b2ba1","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and\/or P\u2011gp, and\/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"7613c72e-f99b-4c65-95fb-8e8d42944c39","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">CYP2C9 substrates<\/span><\/i><\/p>","ID":"8bfc8af5-a2a7-41bf-b935-26fd57a7f1a4","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"CYP2C9 substrates","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"3e289e3d-4f7d-4157-8612-5aa6eb16a79a","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during co\u2011administration of warfarin with ivacaftor. Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.<\/span><\/p>","ID":"a3d8be13-fe7d-41c7-9424-ac470f7d0d38","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during co\u2011administration of warfarin with ivacaftor. Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"4c12d4ed-6b22-4c82-b6da-07898f575d51","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Digoxin and other P\u2011gp substrates<\/span><\/i><\/p>","ID":"4f849112-946b-46e2-bb1f-53920287217a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Digoxin and other P\u2011gp substrates","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"294e4ae4-20f9-4f67-b175-0386253a167a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with digoxin, a sensitive P\u2011gp substrate, increased digoxin exposure by 1.3\u2011fold, consistent with weak inhibition of P\u2011gp by ivacaftor. Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of P\u2011gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly<\/span><span style=\"font-size:11.0pt\"> with<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> digoxin or other substrates of P\u2011gp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.<\/span><\/p>","ID":"7b04e6c9-bfdc-4f88-89d2-fc29f141a5a7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Co\u2011administration with digoxin, a sensitive P\u2011gp substrate, increased digoxin exposure by 1.3\u2011fold, consistent with weak inhibition of P\u2011gp by ivacaftor. Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of P\u2011gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly with digoxin or other substrates of P\u2011gp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"a309245d-75c9-40e9-aca9-d42d5d3e3960","Styles":"line-height:normal","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\">CYP3A substrates <\/span><\/i><\/p>","ID":"944bacee-a389-4f44-a564-3ebbf3bfa426","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"CYP3A substrates ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><\/i><\/p>","ID":"1ddcc9c5-b766-4d06-8a5e-61537be6a4d8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Co\u2011administration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5\u2011fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co-administered with ivacaftor. <\/span><\/p>","ID":"80de745b-c265-4933-b1ae-74ac19ff1f30","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Co\u2011administration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5\u2011fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co-administered with ivacaftor. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"29ad105d-819f-4c13-86e4-3dcff9fcfab3","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hormonal contraceptives<\/span><\/i><\/p>","ID":"190607a3-d20d-4bd1-84fd-1c7887a7bfb0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Hormonal contraceptives","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"9ce56887-d430-494a-ac8c-beed41ecf65a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoCommentText\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Ivacaftor has been studied with an oestrogen\/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive.<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Therefore, no dose adjustment of oral contraceptives is necessary.<\/span><\/p>","ID":"6bfcc4e1-ee80-4422-b015-dc49f372a2d8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoCommentText']","Text":"Ivacaftor has been studied with an oestrogen\/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral contraceptives is necessary.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"bf135d0a-82ab-412a-aef3-a016d2b47c4b","Styles":"margin:0in","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Paediatric population<\/span><\/u><\/p>","ID":"e1e5f756-e311-4491-8526-cea888c10302","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"9ac094cd-d5c3-4fa9-9457-f9082eaa7041","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size: 11.0pt\">Interaction studies have only been performed in adults.<i> <\/i><\/span><\/p>","ID":"29db7783-5ac6-43e2-a6e3-9a146f86fbce","Styles":"margin:0in;page-break-after:avoid","Classes":"None","Text":"Interaction studies have only been performed in adults. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p style=\"margin:0in\"><b><span style=\"font-size:11.0pt\"> <\/span><\/b><\/p>","ID":"962317fd-4be0-4e8d-a05c-b1b69da4438f","Styles":"margin:0in","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.6       Fertility, pregnancy and lactation<\/span><\/h2>","ID":"6e796b6a-35af-4d5a-b03e-8a8414285370","Styles":"margin:0in","Classes":"None","Text":"4.6       Fertility, pregnancy and lactation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7d948e30-002a-451f-a879-e7fe95fa7d65","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Pregnancy<\/span><\/u><\/p>","ID":"2cfc8191-d288-4afd-a413-718ebe17b706","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Pregnancy","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"0eb5e1d0-8a67-47d7-a135-3d3c5c3c290e","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women.<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\"> <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable avoid the use of ivacaftor during pregnancy.<\/span><\/p>","ID":"fcd8ab08-ffe6-4ea6-9549-f09c9b340fe5","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women. Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable avoid the use of ivacaftor during pregnancy.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"> <\/p>","ID":"710bd206-95e3-4ae6-9c0e-6f0317d3da44","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding<\/span><\/u><\/p>","ID":"30462769-8e49-4fc5-86bf-5d1526ff3961","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Breast\u2011feeding","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"7645a4c6-3085-49e6-9be3-c571973caf6d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">It is unknown whether ivacaftor and\/or its metabolites are excreted in human milk. <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Available pharmacokinetic data in animals have shown excretion of <\/span><span style=\"font-size:11.0pt\">ivacaftor into the milk of lactating female rats. <\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">As such, a risk to the newborns\/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue\/abstain from ivacaftor therapy taking into account the benefit of breast\u2011feeding for the child and the benefit of therapy for the woman.<\/span><\/p>","ID":"41a4c716-a366-47e7-b36a-07544247f432","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"It is unknown whether ivacaftor and\/or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of ivacaftor into the milk of lactating female rats. As such, a risk to the newborns\/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue\/abstain from ivacaftor therapy taking into account the benefit of breast\u2011feeding for the child and the benefit of therapy for the woman.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"> <\/p>","ID":"4d05513d-45b5-4083-960c-acb0a72ec5d2","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"3d8ccc63-fe0d-4f20-b0c3-6713a69da283","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":"Fertility","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormalIndent\" style=\"margin:0in;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"966be08b-5678-4c74-8b3d-ab0ec7cd8500","Styles":"margin:0in;page-break-after:avoid","Classes":"['MsoNormalIndent']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3)<\/span>.<\/p>","ID":"6cd960bf-5d1f-4d64-bb8d-d11c2a063586","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"bccb1cd2-3a35-4c6e-b17c-902139dcc65f","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use machines<\/span><\/b><\/p>","ID":"daa09aed-7b6f-463f-82f6-ff21aab9683e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.7     Effects on ability to drive and use machines","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c30f8589-5114-41df-b02c-66d942d34c54","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore, patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.<\/span><\/p>","ID":"09ef89e6-d852-4e86-9cbe-c97fd3ac3950","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore, patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"37318d33-0b02-4cac-a6f7-991bf1e12080","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/b><\/p>","ID":"2e2f483f-88e0-4511-ab08-e22e884c5dad","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"4.8     Undesirable effects","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"33d7b88d-4900-4047-98c0-991bae19fc35","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Summary of the safety profile<\/span><\/u><\/p>","ID":"acd7b6c8-24e4-43e1-aa34-f219aa701f5d","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Summary of the safety profile","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"63d59544-f600-4972-8239-6ce809193182","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The most common adverse reactions experienced by patients aged 6 years and older are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and bacteria in sputum (12.8%).<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">Transaminase elevations occurred in 12.8% of ivacaftor\u2011treated patients versus 11.5% of placebo-treated patients.<\/span><\/p>","ID":"0024b97e-471e-48b8-91c7-1b6e1dc5f4e4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The most common adverse reactions experienced by patients aged 6 years and older are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and bacteria in sputum (12.8%). Transaminase elevations occurred in 12.8% of ivacaftor\u2011treated patients versus 11.5% of placebo-treated patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"30e1f32f-cb2b-4354-8bf6-a02bda4253d4","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).<\/span><\/p>","ID":"3eb88d9a-7a90-4013-aaf9-b217a258d0cd","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2ce4f40c-dd0f-4c9a-a3bd-67f5a01a6061","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).<\/span><\/p>","ID":"de3b5a75-bc82-4906-9f58-c09e456f2550","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\"><u><span style=\"font-size:11.0pt\"><span style=\"text-decoration:  none\"> <\/span><\/span><\/u><\/p>","ID":"8cf8df76-8033-4a3e-a0ee-3c29057f8077","Styles":"None","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\">Tabulated list of adverse reactions<\/span><\/u><\/p>","ID":"01ed8015-8ffe-45ad-8609-3ffa56afe056","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"Tabulated list of adverse reactions","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><u><span style=\"font-size: 11.0pt\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"4c1c6562-e8f8-45c0-b279-39c57953835f","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Table 2 reflects the adverse reactions observed with ivacaftor in clinical trials (placebo\u2011controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. The frequency of adverse reactions is defined as follows: very common (\u2265 1\/10); common (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare (&lt; 1\/10,000); not known (cannot be estimated from the available data). <\/span><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<\/span><\/p>","ID":"fb2b3857-3dcd-4d89-b619-a0eb260bf704","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Table 2 reflects the adverse reactions observed with ivacaftor in clinical trials (placebo\u2011controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. The frequency of adverse reactions is defined as follows: very common (\u2265 1\/10); common (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare (< 1\/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"41165170-980a-464d-9077-873fbda1b66c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b>Table 2: Adverse reactions in ivacaftor\u2011treated patients aged 4 months and older<\/b><\/p>","ID":"b08ef0f2-18e6-4777-8ef9-a11c0ce9e61c","Styles":"margin-bottom:6.0pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 2: Adverse reactions in ivacaftor\u2011treated patients aged 4 months and older","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:95.28%;margin-left:5.45pt;border-collapse:collapse;border:none\" width=\"95%\"> <thead> <tr style=\"page-break-inside:avoid;height:12.55pt\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:12.55pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">System organ class<\/span><\/b><\/p> <\/td> <td style=\"width:33.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt\" valign=\"top\" width=\"33%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b>Adverse reactions<\/b><\/p> <\/td> <td style=\"width:33.72%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"NL-BE\">Frequency <\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td rowspan=\"3\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Infections and   infestations<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Upper   respiratory tract infection<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nasopharyngitis<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.35pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rhinitis <\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nervous system   disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Headache<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Dizziness<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td rowspan=\"6\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear and   labyrinth disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear discomfort<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tinnitus<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tympanic   membrane hyperaemia<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Vestibular   disorder<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ear congestion<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.15pt\"> <td rowspan=\"4\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory, thoracic and mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Oropharyngeal pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Nasal congestion<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:6.4pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Sinus congestion <\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:16.6pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharyngeal   erythema<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:18.75pt\"> <td rowspan=\"2\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gastrointestinal   disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Abdominal pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:18.75pt\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:18.75pt\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DA\">Hepatobiliary   disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Transaminase   elevations<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Skin and   subcutaneous tissue disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rash<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"5\" style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Reproductive   system and breast disorders<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Breast mass<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">common<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Breast   inflammation<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gynaecomastia<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple   disorder<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Nipple pain<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">uncommon<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:16.6pt\"> <td style=\"width:32.52%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"32%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Investigations<\/span><\/p> <\/td> <td style=\"width:33.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Bacteria in   sputum<\/span><\/p> <\/td> <td style=\"width:33.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.6pt\" valign=\"top\" width=\"33%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">very common<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"342ee491-425b-41e4-9168-cf3ba70d64b5","Styles":"width:95.28%;margin-left:5.45pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"    System organ class   Adverse reactions   Frequency       Infections and   infestations   Upper   respiratory tract infection   very common     Nasopharyngitis   very common     Rhinitis    common     Nervous system   disorders   Headache   very common     Dizziness   very common     Ear and   labyrinth disorders   Ear pain   common     Ear discomfort   common     Tinnitus   common     Tympanic   membrane hyperaemia   common     Vestibular   disorder   common     Ear congestion   uncommon     Respiratory, thoracic and mediastinal disorders   Oropharyngeal pain   very common     Nasal congestion   very common     Sinus congestion    common     Pharyngeal   erythema   common     Gastrointestinal   disorders   Abdominal pain   very common     Diarrhoea   very common     Hepatobiliary   disorders   Transaminase   elevations   very common     Skin and   subcutaneous tissue disorders   Rash   very common     Reproductive   system and breast disorders   Breast mass   common     Breast   inflammation   uncommon     Gynaecomastia   uncommon     Nipple   disorder   uncommon     Nipple pain   uncommon     Investigations   Bacteria in   sputum   very common   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7cd15bfa-093f-4855-bedf-41f3a818334e","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p>","ID":"4f07b063-e861-4eea-9fe2-753ed3ffd5af","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Description of selected adverse reactions","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"56d7c2c1-ac4d-497c-872e-5e6ef4d3f349","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Transaminase elevations<\/span><\/i><\/p>","ID":"f9e587ac-da61-4a6f-91d5-cbff17bc206e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Transaminase elevations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"a4f7a4d5-7af9-428a-95ca-b68d1c14511c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">During the 48\u2011week placebo\u2011controlled studies 1 and 2 in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5 or &gt; 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor-treated patients and 1.0%, 1.9% and 8.7% in placebo-treated patients, respectively. Two patients, one on placebo and one on ivacaftor, permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN. No ivacaftor\u2011treated patients experienced a transaminase elevation &gt; 3 x ULN associated with elevated total bilirubin &gt; 1.5 x ULN. In ivacaftor-treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations &gt; 5 x ULN. In all instances where dosing was interrupted for elevated transaminases and <\/span><span lang=\"EN-GB\">subsequently resumed, ivacaftor<\/span><span lang=\"EN-GB\"> dosing was able to be resumed successfully (see section 4.4).<\/span><\/p>","ID":"781f954b-2a61-4637-adbf-04d8d0ddb04c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"During the 48\u2011week placebo\u2011controlled studies 1 and 2 in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) > 8, > 5 or > 3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor-treated patients and 1.0%, 1.9% and 8.7% in placebo-treated patients, respectively. Two patients, one on placebo and one on ivacaftor, permanently discontinued treatment for elevated transaminases, each > 8 x ULN. No ivacaftor\u2011treated patients experienced a transaminase elevation > 3 x ULN associated with elevated total bilirubin > 1.5 x ULN. In ivacaftor-treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations > 5 x ULN. In all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"386da291-5085-489d-856b-3d96d5d8c5fb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor\/ivacaftor, the incidence of maximum transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor\/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor\/ivacaftor experienced a transaminase elevation &gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. <\/span><\/p>","ID":"cc03af3e-807d-4820-976f-dd017c891e87","Styles":"None","Classes":"['MsoNormal']","Text":"During the placebo controlled phase 3 studies (up to 24 weeks) of tezacaftor\/ivacaftor, the incidence of maximum transaminase (ALT or AST) > 8, > 5, or > 3 x ULN were 0.2%, 1.0%, and 3.4% in tezacaftor\/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%) on placebo permanently discontinued treatment for elevated transaminases. No patients treated with tezacaftor\/ivacaftor experienced a transaminase elevation >3 x ULN associated with elevated total bilirubin >2 x ULN. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"> <\/p>","ID":"fae3c894-0b86-4bf1-b93a-5ac9d2f172a9","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">During the 24-week, placebo-controlled, phase 3 study of ivacaftor\/tezacaftor\/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor\/tezacaftor\/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor treated patients and 4.0% in placebo-treated patients.<\/span><\/p>","ID":"e43308ba-ad6d-48f2-bf99-d936027981bb","Styles":"None","Classes":"['MsoNormal']","Text":"During the 24-week, placebo-controlled, phase 3 study of ivacaftor\/tezacaftor\/elexacaftor, these figures were 1.5%, 2.5%, and 7.9% in ivacaftor\/tezacaftor\/elexacaftor-treated patients and 1.0%, 1.5%, and 5.5% in placebo-treated patients. The incidence of adverse reactions of transaminase elevations was 10.9% in ivacaftor in a combination regimen with ivacaftor\/tezacaftor\/elexacaftor treated patients and 4.0% in placebo-treated patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c5e2e9d2-a4c7-4c10-ac45-09abe3ad07f6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"186a04eb-7528-4f32-b4d7-1161718324f5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"0fd72593-4c7e-4cf5-ae4f-876be184f2bf","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The safety data of ivacaftor were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, 19 patients between 12 months to less than 24 months of age, 34 patients between 2 to less than 6 years of age, 61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age.<\/span><\/p>","ID":"c3b76db0-cdc8-459e-886a-e811c02cb8ad","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The safety data of ivacaftor were evaluated in 6 patients between 4 months to less than 6 months of age, 11 patients between 6 months to less than 12 months of age, 19 patients between 12 months to less than 24 months of age, 34 patients between 2 to less than 6 years of age, 61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"f4bdcedd-7edf-4717-b183-31073ac34a58","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety profile is generally consistent among paediatric patients aged 4 months and older and is also consistent with adult patients.<\/span><\/p>","ID":"dab0af8f-20bd-4106-a3fe-13c967d30168","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The safety profile is generally consistent among paediatric patients aged 4 months and older and is also consistent with adult patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6a8acf3e-f4dd-4cdd-9200-995bf57e5d3d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients aged 6 to less than 24 months) are described in Table 3. <\/span><span lang=\"EN-GB\">In the placebo controlled studies, the incidence of transaminase elevations were similar between treatment with ivacaftor (15.0%) and placebo<\/span>(14.6%)<span lang=\"EN-GB\">Across all populations, <\/span>peak LFT <span lang=\"EN-GB\">elevations <\/span>returned to baseline levels following interruption, and in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4). Cases suggestive of positive rechallenge were observed. In study 7 <span lang=\"EN-GB\">ivacaftor was permanently discontinued in one patient. In study 8 <\/span><span lang=\"EN-GB\">no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).<\/span><\/p>","ID":"8b705ecb-b42a-4cd3-a956-c47dbc006d9f","Styles":"None","Classes":"['MsoNormal']","Text":"The incidence of transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12 years), study 7 (patients aged 2 to less than 6 years), and study 8 (patients aged 6 to less than 24 months) are described in Table 3. In the placebo controlled studies, the incidence of transaminase elevations were similar between treatment with ivacaftor (15.0%) and placebo(14.6%)Across all populations, peak LFT elevations returned to baseline levels following interruption, and in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4). Cases suggestive of positive rechallenge were observed. In study 7 ivacaftor was permanently discontinued in one patient. In study 8 no patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in either cohort (see section 4.4 for management of elevated transaminases).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"7937b6db-cf58-4675-81a2-23aeabce5311","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:12.0pt\"><b><span lang=\"EN-GB\">Table 3: Transaminase elevations in patients 4 months to &lt; 12 years treated with ivacaftor as monotherapy<\/span><\/b><\/p>","ID":"8b305eaf-cadc-4b68-bfb4-95366f852e7b","Styles":"margin-bottom:12.0pt","Classes":"['MsoNormal']","Text":"Table 3: Transaminase elevations in patients 4 months to < 12 years treated with ivacaftor as monotherapy","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"margin-left:6.85pt;border-collapse:collapse;border:none\"> <tr style=\"height:28.95pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td style=\"width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">n<\/span><\/b><\/p> <\/td> <td style=\"width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 3 x ULN <\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt;5 x ULN<\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">% of Patients &gt; 8 x ULN<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.0%   (6)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2.5%   (1)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2 to &lt;6 years<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14.7%   (5)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:14.35pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 to &lt;24 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">18<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.8%   (5)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11.1%   (2)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 to &lt;12 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">11<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">9.1%   (1)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.7pt\"> <td style=\"width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"161\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4 to &lt;6 months<\/span><\/p> <\/td> <td style=\"width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"66\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6<\/span><\/p> <\/td> <td style=\"width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" valign=\"top\" width=\"108\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.0%   (0)<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"a01f3659-55bf-4943-875e-73110fe83eb7","Styles":"margin-left:6.85pt;border-collapse:collapse;border:none","Classes":"['MsoTableGrid']","Text":"       n   % of Patients > 3 x ULN    % of Patients >5 x ULN   % of Patients > 8 x ULN     6 to <12 years   40   15.0%   (6)   2.5%   (1)   2.5%   (1)     2 to <6 years   34   14.7%   (5)   14.7%   (5)   14.7%   (5)     12 to <24 months   18   27.8%   (5)   11.1%   (2)   11.1%   (2)     6 to <12 months   11   9.1%   (1)   0.0%   (0)   0.0%   (0)     4 to <6 months   6   0.0%   (0)   0.0%   (0)   0.0%   (0)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"777d5dc9-9d1d-424f-8540-10b70070a94f","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","ID":"7f2d013f-4b32-4590-83e1-cd57428602a9","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Reporting of suspected adverse reactions","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"c823aae1-b73d-4345-957e-e1fa0187b2cc","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style=\"background: lightgrey\">the national reporting system listed in <\/span><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a>.<\/span><\/p>","ID":"551c2725-9f10-48bb-aaaf-37147966c3d1","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6a8a8284-2db0-479e-aaad-89e9590168ad","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">4.9       Overdose<\/span><\/h2>","ID":"76392377-2b37-4275-8160-6b11d22a91dc","Styles":"margin:0in","Classes":"None","Text":"4.9       Overdose","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\"> <\/span><\/p>","ID":"3d032d7e-e4fc-4898-a2e9-3be937b55b92","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"labeltext\" style=\"page-break-after:avoid\"><span style=\"font-size:11.0pt\">No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.<\/span><\/p>","ID":"3dd53205-0c5f-4475-bbbb-c8bba61ff2d8","Styles":"page-break-after:avoid","Classes":"['labeltext']","Text":"No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"fc301425-6a80-47e3-83c1-716bce2fc258","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"824e38e3-c4d3-40dd-bede-25b37cfb514e","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'>5.       PHARMACOLOGICAL PROPERTIES<\/span><\/h1>","ID":"fd106acb-ddd6-4bbd-b7ab-e57ed872e19a","Styles":"margin:0in","Classes":"None","Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"fd6fc170-9719-4a3a-8595-398b01e3c2d5","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.5pt;text-indent:-28.5pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1<span style='font:7.0pt \"Times New Roman\"'>          <\/span><\/span><\/b><b><span lang=\"EN-GB\">Pharmacodynamic properties<\/span><\/b><\/p>","ID":"74ff7b31-d77f-476d-934e-d1be2f7628e9","Styles":"margin-left:28.5pt;text-indent:-28.5pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"5.1          Pharmacodynamic properties","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"ecfe6856-19de-4e14-aefd-12a630f45299","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Other respiratory system products, ATC code: <\/span>R07AX02<\/p>","ID":"66246664-e078-4d91-a417-744a778794ca","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Pharmacotherapeutic group: Other respiratory system products, ATC code: R07AX02","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"83fdc275-f041-4c09-8fdf-83c4ed56d8fb","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"46d83c1d-8c78-4b85-b03e-33f24b649728","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Mechanism of action","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"60be59d0-b9ef-4af9-86bb-19d1108df8da","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is a potentiator of the CFTR protein, i.e., <i>in vitro<\/i> ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channel\u2011open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance). The <i>G970R <\/i>mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data). <\/span><\/p>","ID":"b892f9b3-fd82-43ee-89e6-c94e18e4927d","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channel\u2011open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance). The G970R mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b1d1af6f-f08a-42c5-a807-6c76beecb08c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to <i>in vivo <\/i>pharmacodynamic response (e.g., sweat chloride) or clinical benefit. <\/span><span lang=\"EN-GB\">The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.<\/span><\/p>","ID":"c96330ac-96bd-433e-a384-0b45a1c4c508","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In vitro responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to in vivo pharmacodynamic response (e.g., sweat chloride) or clinical benefit. The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"d63af4fa-e84a-425b-9182-5fe45ef63b62","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Pharmacodynamic effects<\/span><\/u><\/p>","ID":"d73a670e-9167-4378-91d7-0453d2b6ec91","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Pharmacodynamic effects","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"3caee4be-e919-4b32-bcf9-75c7ae468051","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In studies 1 and 2 in patients with the <i>G551D <\/i>mutation in one allele of the <i>CFTR<\/i> gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was \u201148 mmol\/L [95% CI \u201151, \u201145] and \u201154 mmol\/L [95% CI \u201162, \u201147], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.<\/span><\/p>","ID":"7fac761a-9056-4acd-a18b-43ce6162bb8e","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"In studies 1 and 2 in patients with the G551D mutation in one allele of the CFTR gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was \u201148 mmol\/L [95% CI \u201151, \u201145] and \u201154 mmol\/L [95% CI \u201162, \u201147], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"8a4fb798-d814-47fb-876e-0b804cb7f48f","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 5, part 1 in patients who had a non-<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of \u201149 mmol\/L (95% CI \u201157, \u201141) through 8 weeks of treatment. However, in patients with the <i>G970R<\/i>\u2011<i>CFTR<\/i> mutation, the mean (SD) absolute change in sweat chloride at week 8 was \u20116.25 (6.55) mmol\/L. Similar results to part 1 were seen in part 2 of the study. At the 4\u2011week follow\u2011up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre\u2011treatment levels.<\/span><\/p>","ID":"041baadd-2dcd-4a70-be4c-efce1855c044","Styles":"None","Classes":"['MsoNormal']","Text":"In study 5, part 1 in patients who had a non-G551D gating mutation in the CFTR gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of \u201149 mmol\/L (95% CI \u201157, \u201141) through 8 weeks of treatment. However, in patients with the G970R\u2011CFTR mutation, the mean (SD) absolute change in sweat chloride at week 8 was \u20116.25 (6.55) mmol\/L. Similar results to part 1 were seen in part 2 of the study. At the 4\u2011week follow\u2011up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre\u2011treatment levels.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c4c8846a-1634-4a9d-8991-8ffb4eb69298","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 6 in patients aged 6 years or older with CF who had an <i>R117H<\/i> mutation in the <i>CFTR<\/i> gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was \u201124 mmol\/L (95% CI \u201128, \u201120). In subgroup analyses by age, the treatment difference was \u201121.87 mmol\/L (95% CI: \u201126.46, \u201117.28) in patients aged 18 years or older, and \u201127.63 mmol\/L (95% CI: \u201137.16, \u201118.10) in patients aged 6\u201111 years. Two patients 12 to 17 years of age were enrolled in this study.<\/span><\/p>","ID":"67887747-274f-42c4-a27c-2982dcdaf01e","Styles":"None","Classes":"['MsoNormal']","Text":"In study 6 in patients aged 6 years or older with CF who had an R117H mutation in the CFTR gene, the treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment was \u201124 mmol\/L (95% CI \u201128, \u201120). In subgroup analyses by age, the treatment difference was \u201121.87 mmol\/L (95% CI: \u201126.46, \u201117.28) in patients aged 18 years or older, and \u201127.63 mmol\/L (95% CI: \u201137.16, \u201118.10) in patients aged 6\u201111 years. Two patients 12 to 17 years of age were enrolled in this study.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9bcff221-a858-418b-ac95-f4221b3e35e0","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 7 in patients aged 2 to less than 6 years with a gating mutation on at least 1 allele of the <i>CFTR<\/i> gene administered either 50 mg or 75 mg of ivacaftor twice daily, the mean absolute change from baseline in sweat chloride was \u201147 mmol\/L (95% CI \u201158, \u201136) at week 24.<\/span><\/p>","ID":"ec62c741-ac4f-4980-ab67-6a8d08a69c8b","Styles":"None","Classes":"['MsoNormal']","Text":"In study 7 in patients aged 2 to less than 6 years with a gating mutation on at least 1 allele of the CFTR gene administered either 50 mg or 75 mg of ivacaftor twice daily, the mean absolute change from baseline in sweat chloride was \u201147 mmol\/L (95% CI \u201158, \u201136) at week 24.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"59bfecc2-3ca8-475f-b422-719b14b6779b","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In study 8 in patients with CF aged less than 24 months, the mean absolute change from baseline in sweat chloride was -65.1 mmol\/L (95% CI \u201174.1, \u201156.0) at week 24. Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.<\/span><\/p>","ID":"a004ca99-153f-40f1-9130-3a547a3076d7","Styles":"None","Classes":"['MsoNormal']","Text":"In study 8 in patients with CF aged less than 24 months, the mean absolute change from baseline in sweat chloride was -65.1 mmol\/L (95% CI \u201174.1, \u201156.0) at week 24. Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"74288923-3fd9-4c08-8d7a-40ba8f1b0b73","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Clinical efficacy and safety<\/span><\/u><\/p>","ID":"76ef90c3-5376-4081-8d39-ad0ce9e3ebc7","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Clinical efficacy and safety","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"e6f52346-bfde-44ad-87d9-3f3536aa893a","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 1 and 2: studies in patients with CF with G551D gating mutations<\/span><\/i><\/p>","ID":"634a9a7f-3d40-43a6-883d-a1304420ac82","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 1 and 2: studies in patients with CF with G551D gating mutations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5628ec9f-b43c-4cdf-861f-a6701aaca9ea","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The efficacy of ivacaftor has been evaluated in two phase 3 randomised, double\u2011blind, placebo\u2011controlled, multi\u2011centre studies of clinically stable patients with CF who had the <i>G551D<\/i> mutation in the <i>CFTR<\/i> gene on at least 1 allele and had FEV<sub>1<\/sub> <\/span><span style=\"font-family: SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 40% predicted.<\/span><\/p>","ID":"51ffdd92-c5cd-48f5-8fd2-349d78ba7a22","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"The efficacy of ivacaftor has been evaluated in two phase 3 randomised, double\u2011blind, placebo\u2011controlled, multi\u2011centre studies of clinically stable patients with CF who had the G551D mutation in the CFTR gene on at least 1 allele and had FEV1 \u2265 40% predicted.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9fa8736c-e0a5-47b2-9b6d-8d499b203b37","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.<\/span><\/p>","ID":"65644b92-fa50-47ee-8910-5446a9b4f069","Styles":"None","Classes":"['MsoNormal']","Text":"Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"a500ac05-ee7d-4094-bf60-c5311c104de5","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the <i>F508del<\/i> mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol\/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV<sub>1<\/sub> was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).<\/span><\/p>","ID":"1627f375-21ba-4aa7-af7d-fdcef983b1f0","Styles":"None","Classes":"['MsoNormal']","Text":"Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the F508del mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol\/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV1 was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"f22047dc-b3c5-4fb2-8a99-9be41140409a","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the <i>F508del<\/i> mutation in the second allele. At baseline, mean predicted FEV<sub>1<\/sub> was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV<sub>1<\/sub> less than 70% predicted at baseline.<\/span><\/p>","ID":"4b39c241-ed86-48e9-874a-14ee50858b3a","Styles":"None","Classes":"['MsoNormal']","Text":"Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the F508del mutation in the second allele. At baseline, mean predicted FEV1 was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV1 less than 70% predicted at baseline.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"07b3ba63-1512-4908-841a-4cfadec480ed","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV<sub>1<\/sub> through 24 weeks of treatment.<\/span><\/p>","ID":"d13bb0c5-4219-40bd-a4b7-2744ec5e9fdd","Styles":"None","Classes":"['MsoNormal']","Text":"The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV1 through 24 weeks of treatment.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9a31e507-9786-44f5-9bff-02bc440e3c4f","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV<sub>1<\/sub> (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV<sub>1<\/sub> were rapid in onset (day 15) and durable through 48 weeks.<\/span><\/p>","ID":"47465489-406e-4f57-8ddf-f3c2ffe30b33","Styles":"None","Classes":"['MsoNormal']","Text":"The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV1 from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV1 from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV1 (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV1 were rapid in onset (day 15) and durable through 48 weeks.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1a071d34-5205-4421-874a-f858aa8df19d","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1<\/sub> from baseline through week 24 in patients with baseline predicted FEV<sub>1 <\/sub>greater than 90% in study 2 was 6.9 percentage points (\u20113.8, 17.6).<\/span><\/p>","ID":"a409ab45-e8cf-4a33-948e-cbc4fa5343f7","Styles":"None","Classes":"['MsoNormal']","Text":"The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV1 from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV1 from baseline through week 24 in patients with baseline predicted FEV1 greater than 90% in study 2 was 6.9 percentage points (\u20113.8, 17.6).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c470caeb-6b00-43e7-8d9c-2ddf77dcd88f","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The results for clinically relevant secondary endpoints are shown in Table 4.<\/span><\/p>","ID":"e4573401-51ff-49be-b35e-1cfa6c895926","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The results for clinically relevant secondary endpoints are shown in Table 4.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4a6cac00-99dd-4083-9c64-3e62c4276fc3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 4: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2<\/span><\/b><\/p>","ID":"9ffbd714-49bb-437f-bcd2-a89c28859566","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Table 4: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.82%;margin-left:5.45pt;border-collapse:collapse\" width=\"98%\"> <thead> <tr style=\"height:10.5pt\"> <td rowspan=\"2\" style=\"width:27.12%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"bottom\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Endpoint<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:34.82%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"34%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:38.06%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"38%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:28.25pt\"> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:14.64%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <td style=\"width:20.18%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Treatment difference<sup>a<\/sup><\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <td style=\"width:17.88%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt\" valign=\"bottom\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;    page-break-after:avoid\"><b><i><span lang=\"EN-GB\">P <\/span><\/i><span lang=\"EN-GB\">value<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in CFQ-R<\/span><\/b><sup><span lang=\"EN-GB\">b<\/span><\/sup><b><span lang=\"EN-GB\"> respiratory domain score   (points)<\/span><\/b><sup><span lang=\"EN-GB\">c<\/span><\/sup><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(4.7, 11.4)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">6.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.4, 13.5)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1092<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Through week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8.6<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(5.3, 11.9)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">5.1<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(\u20111.6, 11.8)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.1354<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Relative risk of pulmonary exacerbation<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.40<\/span><sup><span lang=\"EN-GB\">d<\/span><\/sup><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0016<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:9.95pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Through week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.46<sup>d<\/sup><\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0012<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">NA<\/span><\/p> <\/td> <\/tr> <tr style=\"height:10.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in body weight (kg)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.85pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.8, 3.7)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.9<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.9, 2.9)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0004<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week   48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.7<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.1)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">2.8<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(1.3, 4.2)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0002<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.5pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean absolute change from baseline in BMI (kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 24<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.94<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.62, 1.26)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.81<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.34, 1.28)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0008<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At week 48<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.93<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.48, 1.38)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">1.09<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.51, 1.67)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0003<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.05pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mean change from baseline in z\u2011scores<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2011for\u2011age   z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.04, 0.62)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.0260<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.39<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.24, 0.53)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <tr style=\"height:18.3pt\"> <td style=\"width:27.12%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"27%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">BMI\u2011for\u2011age z\u2011score at week 48<sup>e<\/sup><\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.002, 0.65)<\/span><\/p> <\/td> <td style=\"width:14.64%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.0490<\/span><\/p> <\/td> <td style=\"width:20.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"20%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">0.45<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">(0.26, 0.65)<\/span><\/p> <\/td> <td style=\"width:17.88%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt\" valign=\"top\" width=\"17%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><span lang=\"EN-GB\">&lt; 0.0001<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"6b85c4b1-2553-4502-abc5-0ed0438ce692","Styles":"width:98.82%;margin-left:5.45pt;border-collapse:collapse","Classes":"['MsoNormalTable']","Text":"    Endpoint   Study 1   Study 2     Treatment differencea (95% CI)   P value   Treatment differencea (95% CI)   P value      Mean absolute change from baseline in CFQ-Rb respiratory domain score   (points)c     Through week   24   8.1 (4.7, 11.4)   < 0.0001   6.1 (\u20111.4, 13.5)   0.1092     Through week   48   8.6 (5.3, 11.9)   < 0.0001   5.1 (\u20111.6, 11.8)   0.1354     Relative risk of pulmonary exacerbation     Through week 24   0.40d   0.0016   NA   NA     Through week 48   0.46d   0.0012   NA   NA     Mean absolute change from baseline in body weight (kg)     At week   24   2.8 (1.8, 3.7)   < 0.0001   1.9 (0.9, 2.9)   0.0004     At week   48   2.7 (1.3, 4.1)   0.0001   2.8 (1.3, 4.2)   0.0002     Mean absolute change from baseline in BMI (kg\/m2)     At week 24   0.94 (0.62, 1.26)   < 0.0001   0.81 (0.34, 1.28)   0.0008     At week 48   0.93 (0.48, 1.38)   < 0.0001   1.09 (0.51, 1.67)   0.0003     Mean change from baseline in z\u2011scores     Weight\u2011for\u2011age   z\u2011score at week 48e   0.33 (0.04, 0.62)   0.0260   0.39 (0.24, 0.53)   < 0.0001     BMI\u2011for\u2011age z\u2011score at week 48e   0.33 (0.002, 0.65)   0.0490   0.45 (0.26, 0.65)   < 0.0001   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">CI: confidence interval; NA: not analysed due to low incidence of events <\/span><\/p>","ID":"4995fb1e-77a6-453f-b6f8-2409887087c6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"CI: confidence interval; NA: not analysed due to low incidence of events ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">a<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment difference = effect of ivacaftor \u2013 effect of placebo<\/span><\/p>","ID":"e12142e6-8b4d-4408-9310-2aa8942fd2a0","Styles":"margin-left:.2in;text-indent:-.2in;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"a     Treatment difference = effect of ivacaftor \u2013 effect of placebo","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">b<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     CFQ-R: Cystic Fibrosis Questionnaire-Revised is a disease-specific, health-related quality-of-life measure for CF.<\/span><\/p>","ID":"6eb47098-0fc1-422c-a9b7-1bff474f7728","Styles":"margin-left:.2in;text-indent:-.2in;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"b     CFQ-R: Cystic Fibrosis Questionnaire-Revised is a disease-specific, health-related quality-of-life measure for CF.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">c<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Study 1 data were pooled from CFQ-R for adults\/adolescents and CFQ-R for children 12 to 13 years of age; Study 2 data were obtained from CFQ-R for children 6 to 11 years of age.<\/span><\/p>","ID":"c1942264-0396-4c6b-9541-aa9783f08978","Styles":"margin-left:.2in;text-indent:-.2in;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"c     Study 1 data were pooled from CFQ-R for adults\/adolescents and CFQ-R for children 12 to 13 years of age; Study 2 data were obtained from CFQ-R for children 6 to 11 years of age.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">d<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Hazard ratio for time to first pulmonary exacerbation<\/span><\/p>","ID":"89467739-9299-4a0a-ae92-9dc9f17dfa7e","Styles":"margin-left:.2in;text-indent:-.2in;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"d     Hazard ratio for time to first pulmonary exacerbation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">e<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     In subjects under 20 years of age (CDC growth charts)<\/span><\/p>","ID":"8127b3f6-afd6-48e3-a4a0-8aec4c250af6","Styles":"margin-left:.2in;text-indent:-.2in;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"e     In subjects under 20 years of age (CDC growth charts)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"a05af3ad-7336-4ca5-bb93-f884f03d03f6","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 5: study in patients with CF with non-G551D gating mutations<\/span><\/i><\/p>","ID":"042f1f64-e1cd-4e52-bee6-6d2114511c44","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 5: study in patients with CF with non-G551D gating mutations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"f2bef065-8cc2-4585-90cb-32634b2afe9a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 5 was a phase 3, two\u2011part, randomised, double\u2011blind, placebo-controlled, crossover study (part 1) followed by a 16\u2011week open\u2011label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a <i>G970R<\/i> or non\u2011<i>G551D<\/i> gating mutation in the <i>CFTR<\/i> gene (<i>G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P<\/i> or<i> G1349D<\/i>).<\/span><\/p>","ID":"9e66599b-84f0-403b-b3fa-0f994535f9ed","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 5 was a phase 3, two\u2011part, randomised, double\u2011blind, placebo-controlled, crossover study (part 1) followed by a 16\u2011week open\u2011label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a G970R or non\u2011G551D gating mutation in the CFTR gene (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"cbac2b6d-8ad7-42f4-a899-6e7b92aee269","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat-containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4- to 8\u2011week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to the part 1 placebo\/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor\/placebo treatment sequence.<\/span><\/p>","ID":"668fe9a9-232c-45de-a4f8-b51d15b4d4c5","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat-containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4- to 8\u2011week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to the part 1 placebo\/ivacaftor treatment sequence and 16 weeks for patients randomised to part 1 ivacaftor\/placebo treatment sequence.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5ec0e8b0-9950-4a3e-acd4-ef107e761b8b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Thirty-nine patients (mean age 23 years) with baseline FEV<sub>1<\/sub> <\/span><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">40% predicted (mean FEV<sub>1<\/sub> 78% predicted [range: 43% to 119%]) were enrolled. Sixty\u2011two percent (24\/39) of them carried the <i>F508del<\/i>-<i>CFTR<\/i> mutation in the second allele. A total of 36 patients continued into part 2 (18 per treatment sequence).<\/span><\/p>","ID":"dddda5d4-6f16-4ca1-9d81-0686aa0e3390","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Thirty-nine patients (mean age 23 years) with baseline FEV1 \u2265 40% predicted (mean FEV1 78% predicted [range: 43% to 119%]) were enrolled. Sixty\u2011two percent (24\/39) of them carried the F508del-CFTR mutation in the second allele. A total of 36 patients continued into part 2 (18 per treatment sequence).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"ca250fb0-b00a-4912-9066-6d4c49cc2f15","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part 1 of study 5, the mean FEV<sub>1<\/sub> percent predicted at baseline in placebo-treated patients was 79.3% while in ivacaftor\u2011treated patients this value was 76.4%. The mean overall post\u2011baseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week 8 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 7.5% in the ivacaftor period and \u20113.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) <\/span><span lang=\"EN-GB\">(P &lt; 0.0001).<\/span><\/p>","ID":"ca65874d-02d7-4419-9cc7-edeb3f2f2a0f","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In part 1 of study 5, the mean FEV1 percent predicted at baseline in placebo-treated patients was 79.3% while in ivacaftor\u2011treated patients this value was 76.4%. The mean overall post\u2011baseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week 8 in percent predicted FEV1 (primary efficacy endpoint) was 7.5% in the ivacaftor period and \u20113.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P < 0.0001).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b3ff2e3a-0a51-4264-b847-96a0b4558431","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQ\u2011R through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV<sub>1<\/sub> at week 8) is shown in Table 5. Based on clinical (percent predicted FEV<sub>1<\/sub>) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the <i>G970R<\/i> mutation could not be established.<\/span><\/p>","ID":"eecd34e3-366c-4f01-882b-25ce9f54f8e1","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQ\u2011R through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV1 at week 8) is shown in Table 5. Based on clinical (percent predicted FEV1) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the G970R mutation could not be established.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2714f533-4ccd-4b92-a223-467f37138b7b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Table 5: Effect of ivacaftor for efficacy variables in the overall population and for specific <i>CFTR<\/i> mutations<\/span><\/b><\/p>","ID":"ce77f16f-2b60-421e-a27a-182ff5a58c2b","Styles":"margin-bottom:6.0pt;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Table 5: Effect of ivacaftor for efficacy variables in the overall population and for specific CFTR mutations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:454.0pt;margin-left:5.35pt;border-collapse:collapse;border:none\" width=\"605\"> <tr> <td colspan=\"2\" style=\"width:147.75pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"197\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change in percent   predicted FEV<sub>1<\/sub><\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:152.5pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"203\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">BMI<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">(kg\/m<sup>2<\/sup>)<\/span><\/b><\/p> <\/td> <td style=\"width:153.75pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">CFQ-R respiratory domain score   (points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:147.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"197\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Through week 8<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:152.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"203\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">At week 8<\/span><\/b><\/p> <\/td> <td style=\"width:153.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Through week 8<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"5\" style=\"width:454.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\"> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">All patients (N = 39)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (95% CI) change from baseline ivacaftor vs.   placebo-treated patients:<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:147.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"197\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.7 (7.3, 14.1)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:152.5pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"203\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.66 (0.34, 0.99)<\/span><\/p> <\/td> <td style=\"width:153.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"205\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.6 (4.5, 14.7)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"5\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Patients grouped under mutation types (n)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Results shown as mean (minimum, maximum) change from baseline for   ivacaftor-treated patients <br\/>   at week 8*:<\/span><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td rowspan=\"2\" style=\"width:18.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"bottom\" width=\"18%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">Mutation (n)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">Absolute change in sweat chloride   (mmol\/L)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">Absolute change in percent predicted   FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:13.4pt\"> <td colspan=\"2\" style=\"width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">At week 8<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.4pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><b><span lang=\"EN-GB\">At week 8<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:88.5pt\"> <td style=\"width:18.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:88.5pt\" valign=\"top\" width=\"18%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><i><span lang=\"PT\">G1244E<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G1349D<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G178R<\/span><\/i><span lang=\"PT\"> (5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G551S<\/span><\/i><span lang=\"PT\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"PT\">G970R<sup>#<\/sup><\/span><\/i><span lang=\"PT\"> (4)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"EN-GB\">S1251N <\/span><\/i><span lang=\"EN-GB\">(8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"EN-GB\">S1255P<\/span><\/i><span lang=\"EN-GB\"> (2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><i><span lang=\"EN-GB\">S549N<\/span><\/i><span lang=\"EN-GB\"> (6)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   text-autospace:none\"><i><span lang=\"EN-GB\">S549R<\/span><\/i><span lang=\"EN-GB\">   (4)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:40.52%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:88.5pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-55 (-75, -34)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-80 (-82, -79)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-53 (-65, -35)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-68<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-6 (-16, -2)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-54 (-84, -7)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-78 (-82, -74)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-74 (-93, -53)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">-61<span style=\"position:relative;top:-3.0pt\">\u2020\u2020<\/span> (-71, -54)<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:40.8%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:88.5pt\" valign=\"top\" width=\"40%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">20 (3, 36)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">8 (-1, 18)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">3<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">3 (-1, 5)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9 (-20, 21)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">3 (-1, 8)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">11 (-2, 20)<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">5 (-3, 13)<\/span><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"113\"><\/td> <td style=\"border:none\" width=\"123\"><\/td> <td style=\"border:none\" width=\"123\"><\/td> <td style=\"border:none\" width=\"123\"><\/td> <td style=\"border:none\" width=\"124\"><\/td> <\/tr> <\/table>","ID":"9890cb38-4d19-415e-8024-ac00b1c34073","Styles":"width:454.0pt;margin-left:5.35pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"   Absolute change in percent   predicted FEV1   BMI (kg\/m2)   CFQ-R respiratory domain score   (points)     Through week 8   At week 8   Through week 8     All patients (N = 39) Results shown as mean (95% CI) change from baseline ivacaftor vs.   placebo-treated patients:     10.7 (7.3, 14.1)   0.66 (0.34, 0.99)   9.6 (4.5, 14.7)     Patients grouped under mutation types (n) Results shown as mean (minimum, maximum) change from baseline for   ivacaftor-treated patients    at week 8*:     Mutation (n)   Absolute change in sweat chloride   (mmol\/L)   Absolute change in percent predicted   FEV1 (percentage points)     At week 8   At week 8     G1244E (5) G1349D (2) G178R (5) G551S (2) G970R# (4) S1251N (8) S1255P (2) S549N (6) S549R   (4)   -55 (-75, -34) -80 (-82, -79) -53 (-65, -35) -68\u2020 -6 (-16, -2) -54 (-84, -7) -78 (-82, -74) -74 (-93, -53) -61\u2020\u2020 (-71, -54)   8 (-1, 18) 20 (3, 36) 8 (-1, 18) 3\u2020 3 (-1, 5) 9 (-20, 21) 3 (-1, 8) 11 (-2, 20) 5 (-3, 13)          ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Statistical testing was not performed due to small numbers for individual mutations.<\/span><\/p>","ID":"9125f494-b0b0-4cec-9132-85b66661a871","Styles":"margin-left:.2in;text-indent:-.2in;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"*     Statistical testing was not performed due to small numbers for individual mutations.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Reflects results from the one patient with the <i>G551S<\/i> mutation with data at the 8-week time point.<\/span><\/p>","ID":"88235f82-2433-4222-9949-8ebb4332224b","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"\u2020     Reflects results from the one patient with the G551S mutation with data at the 8-week time point.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">    n = 3 for the analysis of absolute change in sweat chloride.<\/span><\/p>","ID":"0c2bce0c-81ca-4ea0-af1a-521cab915c95","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"\u2020\u2020    n = 3 for the analysis of absolute change in sweat chloride.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal; page-break-after:avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">#        <\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface<\/span><\/p>","ID":"1071677c-b9b1-49de-b05d-da2673bc787d","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal;\npage-break-after:avoid","Classes":"['MsoNormal']","Text":"#        Causes a splicing defect resulting in little-to-no CFTR protein at the cell surface","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ece894c6-4bc5-49a5-be9e-9d4010364bd7","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> following 16 weeks (patients randomised to the ivacaftor\/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the follow\u2011up visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1 <\/sub>from<sub> <\/sub>part 2 week 16 was \u20115.9% (9.4%). For patients randomised to the placebo\/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV<sub>1<\/sub> after the additional 16 weeks of treatment with ivacaftor. At the follow up visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> from part 2 week 16 was \u20117.4% (5.5%).<\/span><\/p>","ID":"805a5c28-0fca-4ce1-9635-dba8822ae328","Styles":"None","Classes":"['MsoNormal']","Text":"In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV1 following 16 weeks (patients randomised to the ivacaftor\/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the follow\u2011up visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV1 from part 2 week 16 was \u20115.9% (9.4%). For patients randomised to the placebo\/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV1 after the additional 16 weeks of treatment with ivacaftor. At the follow up visit 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV1 from part 2 week 16 was \u20117.4% (5.5%).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5c4be41e-f981-436b-95ab-0dfa4941d6ae","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 3: study in patients with CF with the F508del mutation in the CFTR gene<\/span><\/i><\/p>","ID":"0ad4e36e-26ed-41fe-8e04-8e421db101d4","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 3: study in patients with CF with the F508del mutation in the CFTR gene","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"25bc61c9-f883-4b47-9da3-c014a7ee9345","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Study 3 (part A) was a 16\u2011week, 4:1 randomised, double\u2011blind, placebo\u2011controlled, parallel\u2011group phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the <i>F508del<\/i> mutation in the <i>CFTR<\/i> gene and who had FEV<sub>1<\/sub> \u2265 40% predicted.<\/span><\/p>","ID":"0ca16ce6-8fd7-4692-974c-5d6c1b5c5316","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 3 (part A) was a 16\u2011week, 4:1 randomised, double\u2011blind, placebo\u2011controlled, parallel\u2011group phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF age 12 years and older who were homozygous for the F508del mutation in the CFTR gene and who had FEV1 \u2265 40% predicted.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"58dd536f-eb71-449e-9751-88024fc73b9e","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The mean absolute change from baseline through week 16 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and \u20110.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI \u20110.6, 4.1); this difference was not statistically significant (P = 0.15).<\/span><\/p>","ID":"6223a076-ccd7-4cec-8544-426e495baef1","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The mean absolute change from baseline through week 16 in percent predicted FEV1 (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and \u20110.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI \u20110.6, 4.1); this difference was not statistically significant (P = 0.15).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"51e9ceb6-c575-4ead-8fb1-e6fe90f4e4f2","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 4: open-label extension study<\/span><\/i><\/p>","ID":"2e0f9e4a-d85c-4a55-b2ed-f0dae7ac6e97","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 4: open-label extension study","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"a0081686-24dd-41cd-95b9-d510d19d610f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">In study 4, patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo\/ivacaftor group and at least 144 weeks for patients in the ivacaftor\/ivacaftor group.<\/span><\/p>","ID":"62ee0de7-b847-4425-909b-8af5f8f90ab7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"In study 4, patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo\/ivacaftor group and at least 144 weeks for patients in the ivacaftor\/ivacaftor group.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"a0991163-3a16-4bb3-8ffa-26793264f753","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One hundred and forty\u2011four (144) patients from study 1 were rolled over in study 4, 67 in the placebo\/ivacaftor group and 77 in the ivacaftor\/ivacaftor group. Forty\u2011eight (48) patients from study 2 were rolled over in study 4, 22 in the placebo\/ivacaftor group and 26 in the ivacaftor\/ivacaftor group.<\/span><\/p>","ID":"bad58480-cb45-4ba2-b768-f1c8cfd8bffa","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"One hundred and forty\u2011four (144) patients from study 1 were rolled over in study 4, 67 in the placebo\/ivacaftor group and 77 in the ivacaftor\/ivacaftor group. Forty\u2011eight (48) patients from study 2 were rolled over in study 4, 22 in the placebo\/ivacaftor group and 26 in the ivacaftor\/ivacaftor group.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c820c5c9-bb79-4938-9601-519e5912cf7b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Table<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">6 shows the results of the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> for both groups of patients. For patients in the placebo\/ivacaftor group baseline percent predicted FEV<sub>1<\/sub> is that of study 4 while for patients in the ivacaftor\/ivacaftor group the baseline value is that of studies<\/span><span lang=\"EN-GB\"> <\/span><span lang=\"EN-GB\">1 and 2.<\/span><\/p>","ID":"f78a3f81-487d-41d3-8a02-969d39ec4797","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Table 6 shows the results of the mean (SD) absolute change in percent predicted FEV1 for both groups of patients. For patients in the placebo\/ivacaftor group baseline percent predicted FEV1 is that of study 4 while for patients in the ivacaftor\/ivacaftor group the baseline value is that of studies 1 and 2.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"4038b770-2b08-40a7-adb0-75b5fea0ed97","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 6: Effect of ivacaftor on percent predicted FEV<\/span><\/b><sub><span lang=\"EN-GB\">1<\/span><\/sub><b><span lang=\"EN-GB\"> in study 4<\/span><\/b><\/p>","ID":"91f045c4-81f8-4131-a0fd-42657a697252","Styles":"margin-bottom:6.0pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 6: Effect of ivacaftor on percent predicted FEV1 in study 4","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:5.4pt;border-collapse:collapse;border:none\"> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"24%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Original study and treatment group<\/span><\/b><\/p> <\/td> <td rowspan=\"2\" style=\"width:27.72%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Duration of ivacaftor treatment (weeks)<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:47.56%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"47%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change from baseline in   percent predicted FEV<sub>1 <\/sub>(percentage points)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">N<\/span><\/b><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Mean (SD)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 1<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">77<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (8.3)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">72<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.4 (10.8)<\/span><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">67<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20111.2 (7.8)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">55<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">9.5 (11.2)<\/span><\/p> <\/td> <\/tr> <tr> <td colspan=\"4\" style=\"width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Study 2<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Ivacaftor<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">48<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">26<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.2 (15.7)<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">144<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">25<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.3 (12.4)<\/span><\/p> <\/td> <\/tr> <tr> <td rowspan=\"2\" style=\"width:24.72%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"24%\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <\/td> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0<sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">22<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u20110.6 (10.1)<sup><span style=\"position:relative;top:-3.0pt\">\u2020<\/span><\/sup><\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:27.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"27%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">96<\/span><\/p> <\/td> <td style=\"width:14.86%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"14%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">21<\/span><\/p> <\/td> <td style=\"width:32.7%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"32%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">10.5 (11.5)<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"c2cd2488-6f20-4438-ac6b-92611956500e","Styles":"margin-left:5.4pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"   Original study and treatment group   Duration of ivacaftor treatment (weeks)   Absolute change from baseline in   percent predicted FEV1 (percentage points)     N   Mean (SD)     Study 1     Ivacaftor   48*   77   9.4 (8.3)     144   72   9.4 (10.8)     Placebo   0*   67   \u20111.2 (7.8)\u2020     96   55   9.5 (11.2)     Study 2     Ivacaftor   48*   26   10.2 (15.7)     144   25   10.3 (12.4)     Placebo   0*   22   \u20110.6 (10.1)\u2020     96   21   10.5 (11.5)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Treatment occurred during blinded, controlled, 48-week phase 3 study.<\/span><\/p>","ID":"060356c5-816b-4d93-8b65-c09e43f15684","Styles":"margin-left:.2in;text-indent:-.2in","Classes":"['MsoNormal']","Text":"*     Treatment occurred during blinded, controlled, 48-week phase 3 study.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:.2in;text-indent:-.2in;line-height:normal\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Change from prior study baseline after 48 weeks of placebo treatment.<\/span><\/p>","ID":"34e5bafb-1699-448f-9075-41012b3b01b6","Styles":"margin-left:.2in;text-indent:-.2in;line-height:normal","Classes":"['MsoNormal']","Text":"\u2020     Change from prior study baseline after 48 weeks of placebo treatment.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ba3d6cc6-cb29-4179-a45f-05d745e36b83","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">When the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> is compared from study 4 baseline for patients in the ivacaftor\/ivacaftor group (n<\/span><span lang=\"EN-GB\"> = <\/span><span lang=\"EN-GB\">72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV<sub>1<\/sub> was 0.0% (9.05), while for patients in the ivacaftor\/ivacaftor group (n<\/span><span lang=\"EN-GB\"> = <\/span><span lang=\"EN-GB\">25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor\/ivacaftor group maintained the improvement seen at <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 of the initial study (<\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 0 through <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48) in percent predicted FEV<sub>1<\/sub> through <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 144. There were no additional improvements in study 4 (<\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 through <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 144).<\/span><\/p>","ID":"ffcaa985-1744-4e5c-afe3-490f410ab102","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"When the mean (SD) absolute change in percent predicted FEV1 is compared from study 4 baseline for patients in the ivacaftor\/ivacaftor group (n = 72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV1 was 0.0% (9.05), while for patients in the ivacaftor\/ivacaftor group (n = 25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor\/ivacaftor group maintained the improvement seen at week 48 of the initial study (day 0 through week 48) in percent predicted FEV1 through week 144. There were no additional improvements in study 4 (week 48 through week 144).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"714ecd81-7601-4fe3-b7be-0948403b1fc0","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">For patients in the placebo\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events\/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events\/year across <\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 1 to <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48, and 0.67 events\/year across <\/span><span lang=\"EN-GB\">weeks<\/span><span lang=\"EN-GB\"> 48 to 96). For patients in the ivacaftor\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events\/year across <\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 1 to <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events\/year across <\/span><span lang=\"EN-GB\">day<\/span><span lang=\"EN-GB\"> 1 to <\/span><span lang=\"EN-GB\">week<\/span><span lang=\"EN-GB\"> 48 and 0.77 events\/year across <\/span><span lang=\"EN-GB\">weeks<\/span><span lang=\"EN-GB\"> 48 to 96.<\/span><\/p>","ID":"d2d0af6c-c482-4b67-819e-735a41f8f940","Styles":"None","Classes":"['MsoNormal']","Text":"For patients in the placebo\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events\/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events\/year across day 1 to week 48, and 0.67 events\/year across weeks 48 to 96). For patients in the ivacaftor\/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events\/year across day 1 to week 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events\/year across day 1 to week 48 and 0.77 events\/year across weeks 48 to 96.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"60a2285f-be89-4086-bb00-7802ef08ab35","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For patients who rolled over from study 2 the number of events was, overall, low.<\/span><\/p>","ID":"5dd6739a-3216-442c-887b-14937de7d54d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"For patients who rolled over from study 2 the number of events was, overall, low.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"7db3bee4-3b09-407d-b099-0935594a404c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i>Study 6: study in patients with CF with an R117H mutation in the CFTR gene<\/i><\/p>","ID":"c446dba9-0bd3-4f40-bd8e-4ce37b11f25c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 6: study in patients with CF with an R117H mutation in the CFTR gene","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i> <\/i><\/p>","ID":"5c4b47cd-327c-40f2-8070-6bea3e310d34","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\">Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the <i>F508del<\/i> mutation in the second allele. The confirmed <i>R117H <\/i>poly\u2011T variant was <i>5T <\/i>in 38 patients<i> <\/i>and <i>7T <\/i>in 16 patients. At baseline, mean predicted FEV<sub>1<\/sub> was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV<sub>1<\/sub> (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI \u20111.1, 5.4).<\/p>","ID":"0ca3cb8c-3ae1-4462-bc6c-eb96da958e93","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 6 evaluated 69 patients who were 6 years of age or older; 53 (76.8%) patients had the F508del mutation in the second allele. The confirmed R117H poly\u2011T variant was 5T in 38 patients and 7T in 16 patients. At baseline, mean predicted FEV1 was 73% (range: 32.5% to 105.5%) and mean age was 31 years (range: 6 to 68 years). The mean absolute change from baseline through week 24 in percent predicted FEV1 (primary efficacy endpoint) was 2.57 percentage points in the ivacaftor group and 0.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 2.1 percentage points (95% CI \u20111.1, 5.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"> <\/p>","ID":"b3df19d3-a2a5-4525-aef5-bf2fc944b911","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\">A pre\u2011planned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV<sub>1<\/sub> through week 24 of 4.5 percentage points in the ivacaftor group versus \u20110.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).<\/p>","ID":"b9159d51-3ab4-4e39-a136-e62ee35e3005","Styles":"None","Classes":"['MsoNormal']","Text":"A pre\u2011planned subgroup analysis was conducted in patients 18 years and older (26 patients on placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in percent predicted FEV1 through week 24 of 4.5 percentage points in the ivacaftor group versus \u20110.46 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 5.0 percentage points (95% CI 1.1, 8.8).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"> <\/p>","ID":"e759300b-beef-4f59-9be5-3113adae6b68","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\">In a subgroup analysis in patients with a confirmed <i>R117H\u20115T <\/i>genetic variant, the difference in the mean absolute change from baseline through week<span lang=\"EN-GB\"> <\/span>24 in percent predicted FEV<sub>1<\/sub> between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed <i>R117H\u20117T <\/i>genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI \u20118.1, 8.5).<\/p>","ID":"4922e1d3-f3ac-49b0-98f2-2dcf5d937356","Styles":"None","Classes":"['MsoNormal']","Text":"In a subgroup analysis in patients with a confirmed R117H\u20115T genetic variant, the difference in the mean absolute change from baseline through week 24 in percent predicted FEV1 between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a confirmed R117H\u20117T genetic variant, the treatment difference between ivacaftor and placebo was 0.2% (95% CI \u20118.1, 8.5).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"59fb28ec-6c38-41b1-9b9d-1d8d06ec7b3e","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQ\u2011R respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).<\/span><\/p>","ID":"3d97cee6-fb9d-479a-9b43-eca406e3d111","Styles":"None","Classes":"['MsoNormal']","Text":"For secondary efficacy variables, no treatment differences were observed for ivacaftor versus placebo in absolute change from baseline in BMI at week 24 or time to first pulmonary exacerbation. Treatment differences were observed in absolute change in CFQ\u2011R respiratory domain score through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from baseline in sweat chloride (see Pharmacodynamic effects).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"49ae0743-068c-4edc-ab70-59102cf1a7d9","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 7: study in paediatric patients <\/span><span lang=\"EN-GB\">with CF <\/span><\/i><i><span lang=\"EN-GB\">aged 2 to less than 6<\/span><span lang=\"EN-GB\"> years with G551D or another gating mutation<\/span><\/i><\/p>","ID":"cedb56bd-56f4-4d7c-894f-17cc37726033","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 7: study in paediatric patients with CF aged 2 to less than 6 years with G551D or another gating mutation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"0e285e68-0939-4031-b1f0-6736124a1d2a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetic profile, safety and efficacy of ivacaftor in 34 patients aged 2 to less than 6 years with CF who had a <i>G551D<\/i>, <i>G1244E<\/i>, <i>G1349D<\/i>,<i> G178R<\/i>,<i> G551S<\/i>,<i> S1251N<\/i>,<i> S1255P<\/i>,<i> S549N<\/i> or<i> S549R<\/i><i> <\/i>mutation in the <i>CFTR<\/i> gene were assessed in a 24\u2011week uncontrolled study with ivacaftor (patients weighing less than 14 kg received ivacaftor 50 mg and patients weighing 14 kg or more received ivacaftor 75 mg). Ivacaftor was administered orally every 12 hours with fat\u2011containing food in addition to their prescribed CF therapies.<\/span><\/p>","ID":"9bf3f52c-f0c9-46a8-b750-456792fbecd3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The pharmacokinetic profile, safety and efficacy of ivacaftor in 34 patients aged 2 to less than 6 years with CF who had a G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R mutation in the CFTR gene were assessed in a 24\u2011week uncontrolled study with ivacaftor (patients weighing less than 14 kg received ivacaftor 50 mg and patients weighing 14 kg or more received ivacaftor 75 mg). Ivacaftor was administered orally every 12 hours with fat\u2011containing food in addition to their prescribed CF therapies.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e5a1f3d6-f231-4b7e-869a-8498209902e0","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients in study 7 were aged 2 to less than 6 years (mean age 3 years). Twenty\u2011six patients out of the 34 enrolled (76.5%) had a <i>CFTR<\/i> genotype <i>G551D\/F508del<\/i> with only 2 patients with a non\u2011<i>G551D<\/i> mutation (<i>S549N<\/i>). The mean (SD) sweat chloride at baseline (n = 25) was 97.88 mmol\/L (14.00). The mean (SD) faecal elastase\u20111 value at baseline (n = 27) was 28 \u00b5g\/g (95).<\/span><\/p>","ID":"9e46d69c-c235-4140-aecb-8358c0b81f29","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Patients in study 7 were aged 2 to less than 6 years (mean age 3 years). Twenty\u2011six patients out of the 34 enrolled (76.5%) had a CFTR genotype G551D\/F508del with only 2 patients with a non\u2011G551D mutation (S549N). The mean (SD) sweat chloride at baseline (n = 25) was 97.88 mmol\/L (14.00). The mean (SD) faecal elastase\u20111 value at baseline (n = 27) was 28 \u00b5g\/g (95).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"5f4ce444-c0be-4875-b661-d35ec4e4dd31","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary endpoint of safety was evaluated through week 24 (see section 4.8). Secondary and exploratory efficacy endpoints evaluated were absolute change from baseline in sweat chloride through 24 weeks of treatment, absolute change from baseline in weight, body mass index (BMI) and stature (supported by weight, BMI and stature z-scores) at 24 weeks of treatment, and measures of pancreatic function such as faecal elastase\u20111. Data on percent predicted FEV<sub>1<\/sub> (exploratory endpoint) were available for 3 patients in the ivacaftor 50 mg group and 17 patients in the 75 mg dosing group.<\/span><\/p>","ID":"2fccbcdc-fc40-4b86-a03b-7de3f8d04868","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The primary endpoint of safety was evaluated through week 24 (see section 4.8). Secondary and exploratory efficacy endpoints evaluated were absolute change from baseline in sweat chloride through 24 weeks of treatment, absolute change from baseline in weight, body mass index (BMI) and stature (supported by weight, BMI and stature z-scores) at 24 weeks of treatment, and measures of pancreatic function such as faecal elastase\u20111. Data on percent predicted FEV1 (exploratory endpoint) were available for 3 patients in the ivacaftor 50 mg group and 17 patients in the 75 mg dosing group.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/s><\/p>","ID":"df7e3100-a197-461a-9297-f3c47c814ec8","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The mean (SD) overall (both ivacaftor dosing groups combined) absolute change from baseline in BMI at week 24 was 0.32 kg\/m<sup>2<\/sup> (0.54) and the mean (SD) overall change in BMI\u2011for\u2011age z\u2011score was 0.37 (0.42). The mean (SD) overall change in stature-for-age z-score was \u20110.01 (0.33). The mean (SD) overall change from baseline in faecal elastase\u20111 (n = 27) was 99.8 \u00b5g\/g (138.4). Six patients with initial levels below 200 \u00b5g\/g achieved, at week 24, a level of \u2265 200 \u00b5g\/g. The mean (SD) overall change in percent predicted FEV<sub>1 <\/sub>from baseline at week 24 (exploratory endpoint) was 1.8 (17.81).<\/span><\/p>","ID":"c0705afe-7c7c-4ba1-9ee8-59a5c79e36b2","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The mean (SD) overall (both ivacaftor dosing groups combined) absolute change from baseline in BMI at week 24 was 0.32 kg\/m2 (0.54) and the mean (SD) overall change in BMI\u2011for\u2011age z\u2011score was 0.37 (0.42). The mean (SD) overall change in stature-for-age z-score was \u20110.01 (0.33). The mean (SD) overall change from baseline in faecal elastase\u20111 (n = 27) was 99.8 \u00b5g\/g (138.4). Six patients with initial levels below 200 \u00b5g\/g achieved, at week 24, a level of \u2265 200 \u00b5g\/g. The mean (SD) overall change in percent predicted FEV1 from baseline at week 24 (exploratory endpoint) was 1.8 (17.81).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"3b428690-a8cf-4c0a-80d9-65278f6f1a70","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Study 8: study in paediatric patients <\/span><span lang=\"EN-GB\">with CF <\/span><\/i><i><span lang=\"EN-GB\">aged less than 24 months<\/span><\/i><\/p>","ID":"02d7f5a7-9c96-4c23-a54f-fc29468256e2","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Study 8: study in paediatric patients with CF aged less than 24 months","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"dc7153cd-c5cf-43c9-878f-61d3ee3a603d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetic profile, safety, and efficacy of ivacaftor in patients with CF aged 6 months to less than 24 months were assessed in a completed cohort of patients in an on-going 24\u2011week, open\u2011label, phase 3 clinical study in patients aged less than 24 months (study 8).<\/span><\/p>","ID":"e6df8eb6-e7e9-41fe-978b-cf3677f6ca2d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The pharmacokinetic profile, safety, and efficacy of ivacaftor in patients with CF aged 6 months to less than 24 months were assessed in a completed cohort of patients in an on-going 24\u2011week, open\u2011label, phase 3 clinical study in patients aged less than 24 months (study 8).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1f810259-fff5-4517-8008-08459914bd0c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Part B of study 8 enrolled 19 patients aged 12 months to less than 24 months (mean age 15.2 months at baseline), with 18 patients completing the 24\u2011week treatment period, 11 patients aged 6 months to less than 12 months (mean age 9.0 months at baseline) with all 11 patients completing the 24\u2011week treatment period, and 6 patients aged 4 months to less than 6 months (mean age 4.5 months at baseline) with all 6 patients completing the 24\u2011week treatment period. Patients received ivacaftor 25 mg, 50 mg or 75 mg according to their age and weight at each study visit (see section 4.2). Ivacaftor was administered orally every 12 hours with fat<\/span><span lang=\"EN-GB\" style='font-family:\"MS Mincho\"'>\u2011<\/span><span lang=\"EN-GB\">containing food. Patients continued on their prescribed standard\u2011of\u2011care CF therapies.<\/span><\/p>","ID":"80efddad-ca94-404b-9de9-75843d938566","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Part B of study 8 enrolled 19 patients aged 12 months to less than 24 months (mean age 15.2 months at baseline), with 18 patients completing the 24\u2011week treatment period, 11 patients aged 6 months to less than 12 months (mean age 9.0 months at baseline) with all 11 patients completing the 24\u2011week treatment period, and 6 patients aged 4 months to less than 6 months (mean age 4.5 months at baseline) with all 6 patients completing the 24\u2011week treatment period. Patients received ivacaftor 25 mg, 50 mg or 75 mg according to their age and weight at each study visit (see section 4.2). Ivacaftor was administered orally every 12 hours with fat\u2011containing food. Patients continued on their prescribed standard\u2011of\u2011care CF therapies.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2064be38-fa07-45ef-ba03-1390f6140629","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In part B of study 8 the primary endpoint of safety was evaluated through 24 weeks (see section 4.8). Secondary endpoints were evaluation of pharmacokinetics and the absolute change from baseline in sweat chloride through 24 weeks of treatment (see Pharmacodynamic effects). Tertiary endpoints included efficacy measures such as faecal elastase\u20111 and growth parameters.<\/span><\/p>","ID":"2e2fb5fc-ae8f-4503-aa6c-40d22e9d0a31","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In part B of study 8 the primary endpoint of safety was evaluated through 24 weeks (see section 4.8). Secondary endpoints were evaluation of pharmacokinetics and the absolute change from baseline in sweat chloride through 24 weeks of treatment (see Pharmacodynamic effects). Tertiary endpoints included efficacy measures such as faecal elastase\u20111 and growth parameters.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"216f4037-647b-4d31-b2a4-23e107aa6f5d","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For patients aged 4 months to less than 24 months, with both baseline and week 24 values available, mean (SD) weight\u2011for\u2011age, length\u2011for\u2011age, and weight\u2011for\u2011length z\u2011scores are provided in Table 7.<\/span><\/p>","ID":"8a1c82fb-9765-4d8c-9aef-a955e7b9dd6e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"For patients aged 4 months to less than 24 months, with both baseline and week 24 values available, mean (SD) weight\u2011for\u2011age, length\u2011for\u2011age, and weight\u2011for\u2011length z\u2011scores are provided in Table 7.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"797d66c4-8432-4e32-bafa-9660294a21a9","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after: avoid\"><b><span lang=\"EN-GB\">Table 7: Effect of ivacaftor on growth parameters in patients aged 4 months to less than 24 months with baseline and week 24 values<\/span><\/b><\/p>","ID":"6b7af72b-e02f-4ef3-bc9f-e88e14e98059","Styles":"margin-top:0in;margin-right:0in;margin-bottom:6.0pt;\nmargin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Table 7: Effect of ivacaftor on growth parameters in patients aged 4 months to less than 24 months with baseline and week 24 values","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableGrid1\" style=\"border-collapse:collapse;border:none\" width=\"601\"> <tr> <td rowspan=\"2\" style=\"width:126.9pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Parameter<\/span><\/b><\/p> <\/td> <td rowspan=\"2\" style=\"width:.75in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Number of patients<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:1.75in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"168\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Baseline<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:2.0in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" width=\"192\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\">Absolute change at week 24<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Mean<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(SD)<\/span><\/b><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Median<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(min, max)<\/span><\/b><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Mean<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(SD)<\/span><\/b><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Median<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">(min, max)<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2013for\u2011age   z\u2011score<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">35<\/span><\/p> <\/td> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.17 (0.85)<\/span><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.20<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-1.92, 1.79]<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.33<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.53)<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.26<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-0.54, 1.63]<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Length\u2011for\u2011age   z\u2011score<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.06 (1.03) <\/span><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.12<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-1.99, 2.79]<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.32<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">(0.92)<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">0.47<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">[-1.81, 3.38]<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:126.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"169\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Weight\u2011for\u2011length   z\u2011score<\/span><\/p> <\/td> <td style=\"width:.75in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">34<\/span><\/p> <\/td> <td style=\"width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"78\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.24 (1.01)<\/span><\/p> <\/td> <td style=\"width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"90\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.26<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">[-1.72, 2.16]<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.24<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">(0.98)<\/span><\/p> <\/td> <td style=\"width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"96\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">0.29<\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">[-2.04, 2.22]<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"ece6b9df-a2cc-422d-b305-1a29855323d0","Styles":"border-collapse:collapse;border:none","Classes":"['TableGrid1']","Text":"   Parameter   Number of patients   Baseline     Absolute change at week 24       Mean (SD)   Median (min, max)   Mean (SD)   Median (min, max)     Weight\u2013for\u2011age   z\u2011score   35   0.17 (0.85)   0.20 [-1.92, 1.79]   0.33 (0.53)   0.26 [-0.54, 1.63]     Length\u2011for\u2011age   z\u2011score   34   0.06 (1.03)    0.12 [-1.99, 2.79]   0.32 (0.92)   0.47 [-1.81, 3.38]     Weight\u2011for\u2011length   z\u2011score   34   0.24 (1.01)   0.26 [-1.72, 2.16]   0.24 (0.98)   0.29 [-2.04, 2.22]   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e425828c-ace8-40d3-a731-45078d1ecdf5","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients aged 4 months to less than 24 months, with both baseline and week 24 values available, 18 patients were pancreatic insufficient at baseline (defined as faecal elastase-1 &lt; 200 \u00b5g\/g) with mean (SD) faecal elastase\u20111 values at baseline and week 24 of 25.5 \u00b5g\/g (27.6) and 253.6 \u00b5g\/g (128.3), respectively (mean [SD] absolute change 228.41 \u00b5g\/g [128.3]). Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.<\/span><\/p>","ID":"603e413c-4c32-4c99-9678-3934f52886bb","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"In patients aged 4 months to less than 24 months, with both baseline and week 24 values available, 18 patients were pancreatic insufficient at baseline (defined as faecal elastase-1 < 200 \u00b5g\/g) with mean (SD) faecal elastase\u20111 values at baseline and week 24 of 25.5 \u00b5g\/g (27.6) and 253.6 \u00b5g\/g (128.3), respectively (mean [SD] absolute change 228.41 \u00b5g\/g [128.3]). Results were consistent in the 12 months to less than 24 months, 6 months to less than 12 months, and 4 months to less than 6 months age cohorts.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6fd8d660-4240-4cd1-961a-8cbf39da7e49","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"3ae8ecfb-28dd-4515-89cb-fa9fdc102027","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"4faf99d9-7b09-4976-940c-d55fc42478e1","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).<\/span><\/p>","ID":"bff34a4d-bb69-4e2b-822b-396eefced6b0","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The European Medicines Agency has deferred the obligation to submit the results of studies with Kalydeco in one or more subsets of the paediatric population in cystic fibrosis (see section 4.2 for information on paediatric use).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"759b52fc-7a38-4bcf-9698-e2564fb87942","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">5.2       Pharmacokinetic properties<\/span><\/h2>","ID":"27452606-8212-43ef-8a57-b62a8a9056b3","Styles":"margin:0in","Classes":"None","Text":"5.2       Pharmacokinetic properties","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"cd128299-ab0f-4790-8cf5-29d23fe94feb","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.<\/p>","ID":"925205d3-8e5b-4275-a33d-48718460a1a4","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"ab280543-dd8f-4fe1-9d55-c46af198f691","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\">After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (\u00b1 SD) for AUC and C<sub>max<\/sub> were 10600 (5260) ng*hr\/mL and 768 (233) ng\/mL, respectively. After every 12\u2011hour dosing, steady-state plasma concentrations of ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.<\/p>","ID":"e19b1f9b-6b44-4d21-9d1b-7ddafe8542cc","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (\u00b1 SD) for AUC and Cmax were 10600 (5260) ng*hr\/mL and 768 (233) ng\/mL, respectively. After every 12\u2011hour dosing, steady-state plasma concentrations of ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ca1874f2-d1e4-4de8-ac22-a0473cf073a4","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"d40db35f-953b-4fd9-9aa4-b8406df10fbe","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Absorption","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"910e46cc-a971-4a4f-bbd1-ed0e41c958b3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food the exposure of ivacaftor increased approximately 2.5- to 4\u2011fold. Therefore, ivacaftor should be administered with fat\u2011containing food. The median (range) t<sub>max <\/sub>is approximately 4.0 (3.0; 6.0) hours in the fed state.<\/span><\/p>","ID":"146cff4a-5412-4d77-b7ed-e43fba90e20e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food the exposure of ivacaftor increased approximately 2.5- to 4\u2011fold. Therefore, ivacaftor should be administered with fat\u2011containing food. The median (range) tmax is approximately 4.0 (3.0; 6.0) hours in the fed state.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"683cd26a-5cfc-4ec5-a648-d20f11f4b8d5","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ivacaftor granules (2 x 75<\/span><span lang=\"EN-GB\"> mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0-\u221e<\/sub> and 0.918 (0.750, 1.12) for C<sub>max<\/sub>. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.<\/span><\/p>","ID":"dd8792af-9809-4ffc-9ac3-d782a29036b4","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Ivacaftor granules (2 x 75 mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC0-\u221e and 0.918 (0.750, 1.12) for Cmax. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b433ca64-93ec-439b-b499-2985b1c95e2d","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"41d8de25-d104-4754-a301-5d2b9974de9a","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"Distribution","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after: avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"5b364d72-9888-462f-9b39-6979561caced","Styles":"margin-right:-.1pt;line-height:normal;page-break-after:\navoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1\u2011acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor 150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (\u00b1 SD) apparent volume of distribution was 353 L (122) .<\/span><\/p>","ID":"ea71df30-7761-4646-9932-4f561aaa34a9","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1\u2011acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells. After oral administration of ivacaftor 150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (\u00b1 SD) apparent volume of distribution was 353 L (122) .","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"8ce61592-0ab2-4ab2-84cd-15c6ab161380","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"37acfd54-b39a-4b2b-b73b-2eb4f7403c93","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Biotransformation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/i><\/p>","ID":"6ce2fe1e-6b6d-4ebb-bc89-41565c0db90a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor is extensively metabolised in humans. <i>In vitro<\/i> and <i>in vivo<\/i> data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one\u2011sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one\u2011fiftieth the potency of ivacaftor and is not considered pharmacologically active.<\/span><\/p>","ID":"01fcd015-c514-4b82-ad21-1d12fe6db36e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor is extensively metabolised in humans. In vitro and in vivo data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one\u2011sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one\u2011fiftieth the potency of ivacaftor and is not considered pharmacologically active.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"380f1661-7c9e-4838-84be-6cae68173da5","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The effect of the CYP3A4*22 heterozygous genotype on ivacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose adjustment of ivacaftor is considered necessary. The effect of CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.<\/span><\/p>","ID":"8cf09edf-0753-4404-bd7b-1f17562e7123","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The effect of the CYP3A4*22 heterozygous genotype on ivacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose adjustment of ivacaftor is considered necessary. The effect of CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><u><span style=\"text-decoration:none\"> <\/span><\/u><\/p>","ID":"12ba17da-ccb9-4d4d-9202-90e01fe23719","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"4f53eead-8e55-45ec-ab12-b00a22ec28f8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Elimination","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"55f91c41-3251-45bf-b57b-b950324e3d99","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half\u2011life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL\/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (\u00b1SD) CL\/F for a single 150 mg dose was 17.3 (8.4) L\/hr in healthy subjects.<\/span><\/p>","ID":"32c5a643-f5fc-4ac9-b0a3-67933df8119c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half\u2011life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL\/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (\u00b1SD) CL\/F for a single 150 mg dose was 17.3 (8.4) L\/hr in healthy subjects.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"00d1df90-4a18-4d41-bf58-0048e2cd7808","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Linearity\/non\u2011linearity<\/span><\/u><\/p>","ID":"14970cc6-51e5-4ac3-9434-ec8b5881a084","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Linearity\/non\u2011linearity","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"162e5e14-c2d9-4318-9348-ac86aa218426","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.<\/span><\/p>","ID":"5646b898-78f0-4ed0-9fab-646fd1245779","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 25 mg to 250 mg.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9bd6ced4-0a54-4e1c-8362-2401044257ab","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p>","ID":"065a6ed4-5abe-46fd-9cb2-dde7456653fd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Special populations","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"a51b2186-6568-446f-81c3-dcbc76e2756d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"be2205ad-4d75-4fa2-b2d5-c76afc233986","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Hepatic impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"fe8e1386-72fe-4d7c-99e3-0de84d9be66f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had similar ivacaftor C<sub>max<\/sub> (mean [\u00b1 SD] of 735 [331] ng\/mL) but an approximately two-fold increase in ivacaftor AUC<sub>0-<\/sub><\/span><sub><span style=\"font-family:SimSun\">\u221e<\/span><\/sub><span lang=\"EN-GB\"> (mean [\u00b1 SD] of 16800 [6140] ng*hr\/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady-state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady-state C<sub>min<\/sub> values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. Based on these results, a modified regimen of Kalydeco monotherapy is recommended for patients with moderate hepatic impairment (see section 4.2)<\/span><\/p>","ID":"3d0f3681-2873-4fdd-a327-0f6737764f3c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had similar ivacaftor Cmax (mean [\u00b1 SD] of 735 [331] ng\/mL) but an approximately two-fold increase in ivacaftor AUC0-\u221e (mean [\u00b1 SD] of 16800 [6140] ng*hr\/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady-state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady-state Cmin values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. Based on these results, a modified regimen of Kalydeco monotherapy is recommended for patients with moderate hepatic impairment (see section 4.2)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"88302fd0-1dc1-48ad-84cf-f65f1941975b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor have not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. The use of Kalydeco in patients with severe hepatic impairment is therefore not recommended unless the benefits outweigh the risks (see section 4.2 and section 4.4).<\/span><\/p>","ID":"b2b604ae-0d22-4305-8617-0d76145bbf3a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"The impact of severe hepatic impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of ivacaftor have not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment. The use of Kalydeco in patients with severe hepatic impairment is therefore not recommended unless the benefits outweigh the risks (see section 4.2 and section 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c33ca8ec-d76a-4851-a4ce-b561540c352a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No dose adjustment is considered necessary for patients with mild hepatic impairment.<\/span><\/p>","ID":"4ab7e69c-398d-4d00-876c-1b3b85b9e03f","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"No dose adjustment is considered necessary for patients with mild hepatic impairment.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6163e1d6-be80-413e-a9a1-bdbd87f17102","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"566fff0d-f833-4a29-b465-4b90f3d75cd3","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Renal impairment","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"e803e842-20b3-41af-807b-bd56325a5c9e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment. In a human pharmacokinetic study, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). <\/span><\/p>","ID":"0d4289a0-cad5-4c37-b42b-c7f4c77a0053","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment. In a human pharmacokinetic study, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"125dab15-cad3-4f77-bb72-e981e1602362","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No dose adjustments are recommended for mild and moderate renal impairment. However, caution is recommended when administering ivacaftor to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end-stage renal disease (see sections 4.2 and 4.4).<\/span><\/p>","ID":"33ad6df2-47c1-4f12-9bff-ec31c17d3665","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"No dose adjustments are recommended for mild and moderate renal impairment. However, caution is recommended when administering ivacaftor to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL\/min) or end-stage renal disease (see sections 4.2 and 4.4).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"0da4a5ae-5440-46ba-b96f-08da4c2ad742","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Race<\/span><\/i><\/p>","ID":"3b4a0fa5-c333-4186-98ce-9150a09e33d7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Race","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"4d7174bb-09b1-4ae3-9399-84e185e5f83e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.<\/span><\/p>","ID":"3eaa3764-53c7-4ecd-b689-8c19cc58a27e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Race had no clinically meaningful effect on the PK of ivacaftor in white (n = 379) and non-white (n = 29) patients based on a population PK analysis.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"336707e4-ef26-4a70-8639-f93d625dc256","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Gender<\/span><\/i><\/p>","ID":"a3da4d55-6349-4a14-85d4-70ed8c50d9af","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Gender","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"b75a9215-a03c-4b48-8e76-5dc1224e978c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The pharmacokinetic parameters of ivacaftor are similar in males and females.<\/span><\/p>","ID":"6f4d3500-9fbd-434e-98cf-bc07c1df0ab6","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"The pharmacokinetic parameters of ivacaftor are similar in males and females.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"3903cd92-ef17-4da2-8810-834c409bf04a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly<\/span><\/i><\/p>","ID":"384e79fb-dc92-4f31-baa4-6d2dec856e79","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Elderly","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"088574e0-786c-4338-b76d-9c8bcbd1da3d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Clinical studies of ivacaftor as monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.<\/span><\/p>","ID":"ec4b8e76-245b-4367-88cf-39da3466951c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Clinical studies of ivacaftor as monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"161e57bd-a104-4c56-8fdd-e8160d363cef","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","ID":"2d3229cd-1d91-421f-86ab-818e19c7f43f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Paediatric population","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"911643fc-2b16-4495-81a1-f5838494c50d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 8. <\/span><\/p>","ID":"c4dff552-4d18-4c66-ae3e-02554ac94cfa","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 8. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1ebc78f5-52f3-4454-9885-0a53c9c8f5e2","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt;line-height:normal\"><b><span lang=\"EN-GB\">Table 8: Mean (SD) ivacaftor exposure by age group<\/span><\/b><\/p>","ID":"7fa457c4-b257-4494-9d21-36c46f54c4f5","Styles":"margin-bottom:6.0pt;line-height:normal","Classes":"['MsoNormal']","Text":"Table 8: Mean (SD) ivacaftor exposure by age group","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:99.66%;margin-left:5.45pt;border-collapse:collapse;border:none\" width=\"99%\"> <thead> <tr style=\"height:13.7pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"56%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Age group<\/span><\/b><\/p> <\/td> <td style=\"width:15.24%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <\/td> <td style=\"width:12.34%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">C<sub>min, ss<\/sub> (ng\/mL)<\/span><\/b><\/p> <\/td> <td style=\"width:15.68%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"PT\">AUC<\/span><sub><span lang=\"EN-GB\">\u03c4<\/span><\/sub><\/b><b><sub><span lang=\"PT\">,ss<\/span><\/sub><\/b><b><span lang=\"PT\"> (ng*h\/mL)<\/span><\/b><\/p> <\/td> <\/tr> <\/thead> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">4 months to less than 6 months (<\/span><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\">5 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">25 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">371 (183)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6480 (2520)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 months to less than 12 months   (5 kg to &lt; 7 kg) <sup>*<\/sup><\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">25 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">336<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">5410<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6 months to less than 12 months   (7 kg to &lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">508 (252)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9140 (4200)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 months to less than   24 months (7 kg to &lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">440 (212)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9050 (3050)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12 months to less than   24 months (<\/span><span style=\"font-family:SimSun\">\u2265<\/span><span lang=\"EN-GB\"> 14 kg to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">451 (125)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9600 (1800)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2- to 5-year-olds (&lt; 14 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">50 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">577 (317)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10500 (4260)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2- to 5-year-olds (\u2265 14 kg   to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">629 (296)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">11300 (3820)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6- to 11-year-olds <sup>\u2020<\/sup> (\u2265 14 kg   to &lt; 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">75 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">641 (329)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10760 (4470)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">6- to 11-year-olds <sup>\u2020<\/sup> (\u2265 25 kg)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">150 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">958 (546)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">15300 (7340)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">12- to 17-year-olds<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">150 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">564 (242)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">9240 (3420)<\/span><\/p> <\/td> <\/tr> <tr style=\"height:15.15pt\"> <td style=\"width:56.74%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"56%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Adults (\u2265 18 years old)<\/span><\/p> <\/td> <td style=\"width:15.24%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">150 mg q12h<\/span><\/p> <\/td> <td style=\"width:12.34%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">701 (317)<\/span><\/p> <\/td> <td style=\"width:15.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.15pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\"><span lang=\"EN-GB\">10700 (4100)<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"b10af115-fcc7-4919-8c40-6c963ae35b97","Styles":"width:99.66%;margin-left:5.45pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Text":"    Age group   Dose   Cmin, ss (ng\/mL)   AUC\u03c4,ss (ng*h\/mL)      4 months to less than 6 months (\u22655 kg)   25 mg q12h   371 (183)   6480 (2520)     6 months to less than 12 months   (5 kg to < 7 kg) *   25 mg q12h   336   5410     6 months to less than 12 months   (7 kg to < 14 kg)   50 mg q12h   508 (252)   9140 (4200)     12 months to less than   24 months (7 kg to < 14 kg)   50 mg q12h   440 (212)   9050 (3050)     12 months to less than   24 months (\u2265 14 kg to < 25 kg)   75 mg q12h   451 (125)   9600 (1800)     2- to 5-year-olds (< 14 kg)   50 mg q12h   577 (317)   10500 (4260)     2- to 5-year-olds (\u2265 14 kg   to < 25 kg)   75 mg q12h   629 (296)   11300 (3820)     6- to 11-year-olds \u2020 (\u2265 14 kg   to < 25 kg)   75 mg q12h   641 (329)   10760 (4470)     6- to 11-year-olds \u2020 (\u2265 25 kg)   150 mg q12h   958 (546)   15300 (7340)     12- to 17-year-olds   150 mg q12h   564 (242)   9240 (3420)     Adults (\u2265 18 years old)   150 mg q12h   701 (317)   10700 (4100)   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*<\/span><\/sup><sup>       <\/sup><span style=\"font-size:9.0pt\">Values based on data from a single patient; standard deviation not reported.<\/span><\/p>","ID":"8df78ae5-b7ef-4687-8c34-df41f6752b80","Styles":"margin-left:13.5pt;text-indent:-13.5pt;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"*       Values based on data from a single patient; standard deviation not reported.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid\"><sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;position:relative; top:-3.0pt\">\u2020<\/span><\/sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">     Exposures in 6\u2011 to 11\u2011year\u2011olds are predictions based on simulations from the population PK model using data obtained for this age group.<\/span><\/p>","ID":"c0c2da4c-a637-4865-aa3b-c4a2eea62c2d","Styles":"margin-left:13.5pt;text-indent:-13.5pt;page-break-after:\navoid","Classes":"['MsoNormal']","Text":"\u2020     Exposures in 6\u2011 to 11\u2011year\u2011olds are predictions based on simulations from the population PK model using data obtained for this age group.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"13e3bcae-b786-489f-812d-42544d4c1a97","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p>","ID":"3565991d-a0f4-465d-9ee4-716488509d1a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"5.3     Preclinical safety data","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"26ce039f-3aa4-4786-9b13-df6460393d11","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.<\/span><\/p>","ID":"118fa9a8-b75f-46a4-b69c-04d596fb62f5","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e4c3e1ee-7ef6-4f46-be17-53bfd4d0ed80","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy and fertility<\/span><\/u><\/p>","ID":"871561ad-5c2c-44b5-8551-f46f0f393407","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Pregnancy and fertility","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\"> <\/span><\/i><\/p>","ID":"1ce6c9c0-8240-4978-8148-c3534bb2f4d7","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The No\u2011Observed\u2011Adverse\u2011Effect\u2011Level (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.<\/span><\/p>","ID":"1ef9801e-29d7-4761-9f7f-d099d4912c5d","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The No\u2011Observed\u2011Adverse\u2011Effect\u2011Level (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b3abc227-915a-4991-a9df-d6abb6d04fdc","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Peri\u2011 and post\u2011natal development<\/span><\/u><\/p>","ID":"c7ad7d16-8109-4f58-896c-f230c6990a98","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Peri\u2011 and post\u2011natal development","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"6e2f45ee-1ec8-4b69-a9bd-54cb92a25153","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. <\/span><\/p>","ID":"0f96b353-b353-459d-93fb-ae20db90d2e1","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD. ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"7e8421bd-75b6-4c6b-a9be-8e12afa60346","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile animal studies<\/span><\/u><\/p>","ID":"4b821700-20f1-48a5-82f5-5d5bdea4258c","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Juvenile animal studies","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"2b6c8abc-d85e-49f2-ae32-165e5ed3cb20","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7\u2011week old rats, nor in 3.5 to 5\u2011month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.<\/span><\/p>","ID":"4321bd93-9047-4811-92c0-ccbafccf5eb3","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7\u2011week old rats, nor in 3.5 to 5\u2011month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2f48614e-0bbb-4881-8d19-bd8fc8710955","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"ad92bcbf-d142-4a02-bd0c-ef84dba82e0b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>6.       PHARMACEUTICAL PARTICULARS<\/span><\/h1>","ID":"6566b3ee-4dec-4019-a659-482503f414c5","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d6bc8893-983d-44d4-aa5a-98df9da992c7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p>","ID":"cc21730d-8de8-48bc-ab69-75eb69e59792","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.1     List of excipients","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"fd55a059-866c-4537-bc2e-cd7974e5c801","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Silica, colloidal anhydrous<\/span><\/p>","ID":"7c19ed78-32bd-48ad-a76f-e7e0b1a8a4e0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Silica, colloidal anhydrous","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p>","ID":"dca7bacd-3676-4aee-8354-5b4a9aca9b81","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Croscarmellose sodium","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hypromellose acetate succinate<\/span><\/p>","ID":"b8e832ac-f672-4025-8fa6-2fc071a65f79","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Hypromellose acetate succinate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p>","ID":"ffe2db2c-b4f4-4eb3-bdda-2083fbb61706","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Lactose monohydrate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Magnesium stearate<\/span><\/p>","ID":"4df0582a-0e26-41c0-aaff-1aac02cc789f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Magnesium stearate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Mannitol<\/span><\/p>","ID":"fbfe507c-0eaf-473d-9898-60b1641fa3ee","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Mannitol","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Sucralose<\/span><\/p>","ID":"01eaac5d-0860-4280-92ed-0665900babfe","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Sucralose","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"IT\">Sodium laurilsulfate (E487)<\/span><\/p>","ID":"0cedd643-9548-4b90-8975-43e93a3652b9","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Sodium laurilsulfate (E487)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"IT\"> <\/span><\/p>","ID":"422d96a5-1e68-4e78-9db5-9726dc33200a","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p>","ID":"30585059-dc0e-44fa-9800-de9708921354","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.2     Incompatibilities","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"bd7d2f7d-d910-4d8c-8955-c31e847632a5","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p>","ID":"0bc93625-1f85-49bd-a9da-28158084eca9","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Not applicable.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"86f1e477-1284-4e42-af91-61fabf30afff","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h2 style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">6.3       Shelf life<\/span><\/h2>","ID":"bc53d897-ccac-46e7-975f-02c3d3e0e682","Styles":"margin:0in","Classes":"None","Text":"6.3       Shelf life","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"2ca8042d-93b0-44dd-ad3a-629f0ac3c6a7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"a0733571-83a1-43a3-be70-1820dadeb49e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"3 years.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1de49469-5ec8-4234-9051-51ff1bc90361","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Once mixed, the mixture has been shown to be stable for one hour.<\/span><\/p>","ID":"49310076-e29f-4f5f-a641-da311cd22475","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Once mixed, the mixture has been shown to be stable for one hour.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"9cb4569a-f3ce-4109-86a7-63c824ad2e91","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p>","ID":"59deb138-19bd-4bbf-a856-d929dd38d437","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.4     Special precautions for storage","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"1068fdcc-8a4e-417b-9b88-9593e4d69f47","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">This medicinal product does not require any special storage conditions.<\/span><\/p>","ID":"eb2de3e5-4393-40f9-8dc8-11df9b84398e","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"This medicinal product does not require any special storage conditions.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"d1798e78-10f1-4a7e-bdeb-c58d9eaeb763","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p>","ID":"3b6b5f2c-b037-460c-9854-34c7cb692d10","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.5     Nature and contents of container","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\"> <\/span><\/b><\/p>","ID":"e8a29761-155f-43c3-bd32-4fb8abfefdc9","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace: none\"><span lang=\"EN-GB\">The granules are packed in a Biaxially Oriented Polyethylene Terephthalate\/Polyethylene\/Foil\/Polyethylene (BOPET\/PE\/Foil\/PE) sachet.<\/span><\/p>","ID":"366481ed-cbe0-4c09-b7cb-78cc6a7b733e","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\nnone","Classes":"['MsoNormal']","Text":"The granules are packed in a Biaxially Oriented Polyethylene Terephthalate\/Polyethylene\/Foil\/Polyethylene (BOPET\/PE\/Foil\/PE) sachet.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"137cef46-0184-4de3-ba76-1f756abce99a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pack size of 56 sachets (contains 4 individual wallets with 14 sachets per wallet)<\/span><\/p>","ID":"b289373b-c36a-4280-871d-e82f1576cac9","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Pack size of 56 sachets (contains 4 individual wallets with 14 sachets per wallet)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"49a932b2-5f0c-4fb7-8dcb-2d82befc37b9","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and other handling<\/span><\/b><\/p>","ID":"268b4c40-94a4-42fe-bcc2-b8f1c48b455a","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"6.6     Special precautions for disposal and other handling","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"e3e56e54-a0b7-4309-8ae7-3130298a7dab","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<\/span><\/p>","ID":"9f9e6c72-13b1-4bf4-8a56-219f9ade9e4f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Any unused medicinal product or waste material should be disposed of in accordance with local requirements.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"6882bba0-962f-4bca-8826-37bebfea899e","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"60cd5d7c-96b4-4e3d-a67f-d4d6bfd54da0","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>7.       MARKETING AUTHORISATION HOLDER<\/span><\/h1>","ID":"8a167cb8-8bf9-499f-83a1-384240251001","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"f3fef4f5-32be-4b32-a934-277f33951e3b","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vertex Pharmaceuticals (Ireland) Limited<\/span><\/p>","ID":"b93e8412-8d93-4830-9bb7-aa71aca3ad53","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Vertex Pharmaceuticals (Ireland) Limited","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">28-32 Pembroke Street Upper<\/span><\/p>","ID":"8f57722c-0beb-4e79-b0f3-74b7b31576a1","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"28-32 Pembroke Street Upper","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 2, D02 EK84<\/span><\/p>","ID":"5d63ce60-4c8a-4359-ab6c-dc0e110d9e85","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Dublin 2, D02 EK84","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Ireland<\/span><\/p>","ID":"ddc82cb1-87ab-40b2-a16b-0130b9c5634f","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":"Ireland","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"08ae4e65-b853-4502-9df5-dfd7ac45e112","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"fbf42db5-6b5e-4588-a760-f133a5713a01","Styles":"page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/h1>","ID":"144cda72-ce43-4a23-90f8-ba759dac37bb","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"8.       MARKETING AUTHORISATION NUMBER(S)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"603744d5-20f5-4e64-aa97-26360e63c230","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/003<\/span><\/p>","ID":"1f521a66-11fd-4fae-808c-211a04c6d2e0","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"EU\/1\/12\/782\/003","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/004<\/span><\/p>","ID":"049102d8-6158-4fb7-8424-0080900a789c","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"EU\/1\/12\/782\/004","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU\/1\/12\/782\/006<\/span><\/p>","ID":"993bfa67-7ebf-4669-95b0-6429bdfb94e8","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"EU\/1\/12\/782\/006","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"55f348ca-66ff-4807-9249-d9e632ff6a15","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"c524994a-763e-4f18-8954-69350a90c273","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/h1>","ID":"eabc71e6-3348-493e-ba06-df550cb31b5d","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"60467a7a-2077-4d4c-be14-32e13f6a3920","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of first authorisation: 23 July 2012<\/span><\/p>","ID":"5278c462-5463-4c42-91bf-01cb42c6faea","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Date of first authorisation: 23 July 2012","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of latest renewal: 28 April 2017<\/span><\/p>","ID":"21db1ab6-c208-4407-acac-0bcd22c29dbd","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Text":"Date of latest renewal: 28 April 2017","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"8615e36d-d979-4dfe-8f6c-021a81d49f73","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"0bdebf50-3c67-4e1c-b4c9-a5ff5b261f20","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<h1 style=\"margin:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size: 11.0pt;font-family:\"Times New Roman\",serif'>10.     DATE OF REVISION OF THE TEXT<\/span><\/h1>","ID":"2b477db2-0d72-4b2d-8235-2a05b84f1f8c","Styles":"margin:0in;line-height:normal","Classes":"None","Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"50103762-feaa-43f3-8be4-e6e89810f7b7","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>http:\/\/www.ema.europa.eu.<\/u><\/span><\/p>","ID":"6da4c29b-7bcc-496c-b0c7-2e7d4ee70413","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Text":"Detailed information on this medicinal product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/u>","ID":"d0644418-b7f1-4c91-89d7-ed8ee3c72795","Styles":"None","Classes":"None","Text":"","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"662387c2-8541-4974-8802-500f57b4edc2","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Text":" ","ParentId":"d0644418-b7f1-4c91-89d7-ed8ee3c72795"}]